LIPOCALIN FUSION PARTNERS

Abstract

Methods and systems for producing fusion proteins and peptides are disclosed. Fusion proteins and peptides created using the methods are also provided. Also provided are methods of using the fusion proteins and peptides produced according to the present disclosure.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application is a continuation of U.S. patent application Ser. No. 14/651,175, filed Jun. 10, 2015, which is a National Phase Application based on International Patent Application No. PCT/US2013/074215, filed Dec. 10, 2013, which claims priority to U.S. Provisional Patent Application Nos. 61/735,516, filed Dec. 10, 2012 and 61/794,685, filed Mar. 15, 2013, all of which are incorporated herein by reference in their entirety as if fully set forth herein.

BACKGROUND OF THE INVENTION

[0003] Efforts toward drug discovery continue to use vast technical and financial resources to identify and develop new and useful drugs. Unfortunately, finding new drugs has continued to be difficult. For example, development of less damaging, more precisely targeted cancer therapies is essential. But even after decades of research, scientists still struggle to identify therapeutic compounds with the right mix of medicinal and cancer-targeting properties which not only reduce the likelihood that a therapeutic compound could serve as a treatment strategy but creates a need for successful methods of surgical resection.

[0004] A wide variety of types of compounds have been studied and pursued for a large breadth of therapeutic purposes. For example, small chemical molecules and larger biologics (e.g., antibodies) have been used for a plethora of therapeutic applications with varied success. Some smaller peptides have also been shown to be useful as drugs, e.g., by virtue of their natural potency.

[0005] A lack of methods for rapid and efficient production of peptides and proteins for clinical applications has limited the discovery of peptides and proteins that might serve as therapeutic compounds. Creating fusions of peptides, protein domains, or proteins, to a different protein to enhance production of peptides and proteins has been explored in bacterial expression systems, e.g., E. coli gene expression. However, bacterial protein expression systems are generally limited due to errors in protein folding efficiency. Thus, there is still a need for methods enabling the rapid and efficient production of peptides, protein domains, and proteins.

SUMMARY OF THE INVENTION

[0006] The present invention relates to methods for the production of siderocalin fusion proteins. In various aspects, the present invention relates to the fusion proteins produced according to those methods. In certain apsects, the fusion protein is cleaved, thereby producing a peptide according to the present disclosure. The present invention further relates to methods for producing a fusion protein, the methods comprising expressing, in a cell, a fusion protein, the fusion protein comprising a peptide or protein domain and a lipocalin protein, thereby producing the fusion protein. In some embodiments, the present invention further relates to a method of producing a peptide, the method comprising: expressing, in a cell, a fusion protein comprising a peptide and a lipocalin protein; and separating the peptide from the lipocalin protein, thereby producing the peptide.

[0007] In some embodiments, the present invention relates to a composition of a fusion protein, the composition comprising; a peptide or protein domain, and; a lipocalin protein. In some embodiments, the present invention further relates to a composition comprising a peptide library, the peptide library further comprising a plurality of peptides lacking at least one native lysine residue. The present invention further relates to a composition comprising a fusion protein comprising a peptide and a lipocalin protein.

INCORPORATION BY REFERENCE

[0008] All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.

BRIEF DESCRIPTION OF THE DRAWINGS

[0009] The novel features of the invention are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings of which:

[0010] FIG. 1 provides a gel image showing a variety of scaffolds, in accordance with an embodiment of the present invention.

[0011] FIG. 2 shows an example method of producing peptide libraries, in accordance with an embodiment of the present invention.

[0012] FIG. 3 depicts an example fusion system that can be used to make knottins (e.g., bubble protein), in accordance with an embodiment of the present invention.

[0013] FIG. 4 shows analysis of a large peptide library using mass spectrometry, in accordance with an embodiment of the present invention.

[0014] FIG. 5 shows an example method of using siderocalin fusions to express knottin variants, in accordance with an embodiment of the present invention.

[0015] FIG. 6 depicts SDS-PAGE analysis of expressing knottin scaffolds, in accordance with embodiments of the present invention.

[0016] FIGS. 7A and 7B provide a schematic of pooled library production, in accordance with an embodiment of the present invention. FIG. 7B shows an expanded view of FIG. 7A.

[0017] FIG. 8 describes representative sequencing data from a cloned knottin library, in accordance with an embodiment of the present invention.

[0018] FIG. 9 shows SDS-PAGE analysis of 3000-member knottin libraries, in accordance with embodiments of the present invention.

[0019] FIG. 10 shows a generalized process for manufacturing knottins, in accordance with an aspect of the present disclosure.

[0020] FIG. 11 shows a generalized process for manufacturing knottins, in accordance with an aspect of the present disclosure.

[0021] FIG. 12 a generalized process for manufacturing knottins, in accordance with an aspect of the present disclosure. According to this aspect, cleavage occurs at the furin-knottin interface.

[0022] FIG. 13 shows examples of knottins made with the Daedalus system and corresponding SDS PAGE analyses in accordance with an aspect of the present disclosure. The Daedalus system is desribed in Bandaranayake A. D., et al., Nucleic Acids Res. (2011) 39(21):e143.

[0023] FIG. 14 shows the alignment of Scn sequences from 18 species. The alignment shows a high level of sequence conservation between the 18 species with recognizable orthologs. Positions with an asterisk are possible sites for ligand binding. Correnti, C. & Strong, R. K. (2013) `Iron sequestration in immunity` In Metals in Cells; Encyclopedia of Inorganic and Bioinorganic Chemistry. (Culotta, V. & Scott, R. A., eds.) John Wley & Sons, pp. 349-59

[0024] FIG. 15 depicts a 3D model of super-stable Scn in accordance with an aspect of the present disclosure. In this form of Scn, a second disulfide bond was engineered in order to secure the N-terminus and increase thermal stability.

[0025] FIG. 16 shows a schematic of a generic Scn fusion that can be used in various aspects of the present disclosure. The native signal peptide was been removed and an exogenous sFLAG and HIS tag were added to facilitate purification. These modifications are optionally present in various aspects of the disclosure.

[0026] FIG. 17 depicts a schematic of a light chain antibody fusion with Scn and corresponding SDS PAGE analysis according to an aspect of the present disclosure.

[0027] FIG. 18 shows the SDS PAGE analysis comparing the expression of a Scn fusion with a cytoplasmic enzyme, HMOX1, both before and after cleavage according to an aspect of the present dislcosure.

[0028] FIG. 19 depicts the expression of a Scn fusion with a cytoplasmic viral protein Adv2 and the corresponding SDS PAGE analysis according to one aspect of the present disclosure.

[0029] FIG. 20 depicts the expression of a Scn fusion with an extracellular viral glycoprotein HIV gp120 and the corresponding SDS PAGE analysis according to one aspect of the present disclosure.

[0030] FIG. 21 depicts the expression of a Scn fusion with a knottin protein, Imperatoxin, and the corresponding SDS PAGE analysis according to one aspect of the present disclosure.

[0031] FIG. 22 depicts the expression of a Scn fusion with a small subdomain (i.e., Kringle domain) of the extracellular tyrosine kinase receptor ROR1 and corresponding SDS PAGE analysis according to one aspect of the present disclosure.

[0032] FIG. 23 depicts the expression of a Scn fusion with heptameric and trimeric subdomains and corresponding SDS PAGE analysis according to one aspect of the present disclosure.

[0033] FIG. 24 depicts the expression of an ExFABP fusion with a knottin and corresponding SDS PAGE analysis according to one aspect of the present disclosure. ExFABP is another functional Scn. According to the present disclosure, this construct can be used in a periplasmic bacterial system to secret a variety of client proteins.

[0034] FIG. 25 depicts the crystal structure of Scn with a Th ligand.

[0035] FIG. 26 depicts a captured fluorescent siderophore. The left frame depicts a size-exclusion purification of the protein siderophore complex. The right frame is a schematic.

DETAILED DESCRIPTION OF THE INVENTION

[0036] The methods and systems of the present disclosure relate to fusion proteins and methods of producing them. According to certain aspects, the peptides produced using the present methods can be used as components of drug discovery platforms. In some aspects, the methods relate to creating a fusion of a first protein, or of a peptide, that has potential therapeutic value, with a second protein such that the second protein enhances production and folding of the first protein by an expression system. In some aspects, after expression and purification of the fusion protein, the fusion protein is cleaved such that the first protein and the second protein are separate proteins. In some aspects, the second protein may be a lipocalin. For example, the second protein may be a specific lipocalin such as siderocalin.

Conjugates

[0037] In some aspects, the present invention includes fusion proteins, peptides, or conjugates thereof as described herein. For example, some or all of the fusion proteins or peptides can be conjugated to a moiety selected to modify a property of the peptides.

[0038] In certain aspects, the present invention includes fusion proteins or peptides conjugated at the N-terminus to hydrophobic (e.g., lipophilic) moieties. All or some of the fusion proteins or peptides of the present disclosure can be lacking internal lysines, e.g., to avoid conjugation at the internal lysine positions, thereby allowing conjugation to the amino terminus of the peptide. In some embodiments, the attachment of a hydrophobic moiety to the N-terminus can be used to extend half-life of the fusion protein or peptide of the present disclosure. In some embodiments, simple carbon chains (e.g., by myristoylation and/or palmitylation) can be conjugated to the fusion proteins or peptides. In some aspects, the simple carbon chains may render the fusion proteins or peptides easily separable from the unconjugated material. For example, methods that may be used to separate the fusion proteins or peptides from the unconjugated material include, but are not limited to, solvent extraction and reverse phase chromatography. The lipophilic moieties can extend half-life through reversible binding to serum albumin. In certain embodiments, attachment of a near infrared dye to the N-terminus of the fusion protein or peptide can also be performed to allow for tracing of the conjugated fusion protein or peptide. In certain embodiments, attachment of a near infrared dye to a lysine of the peptide can also be performed to allow for tracing of the conjugated peptide. An antibody to the dye can further allow the dye to fill a dual role of both a tracking marker and a retrieval handle. The conjugated fusion proteins or peptides can also be conjugated to other moieties that can serve other roles, such as providing an affinity handle (e.g., biotin) for retrieval of the peptides from tissues or fluids.

[0039] Other modifications can be used. For example, the fusion proteins, peptides, or conjugates thereof can include post-translational modifications (e.g., methylation and/or amidation). In some embodiments, the fusion proteins or peptides of the present disclosure can be conjugated to other moieties that, e.g., can modify or effect changes to the properties of the peptides. The conjugated moieties can, e.g., be lipophilic moieties that extend half-life of the peptides through reversible binding to serum albumin. In some embodiments, the lipophilic moiety can be cholesterol or a cholesterol derivative including cholestenes, cholestanes, cholestadienes and oxysterols. In some embodiments, the peptides can be conjugated to myristic acid (tetradecanoic acid) or a derivative thereof.

[0040] In some embodiments, the fusion proteins or peptides of the present disclosure can be conjugated to detectable labels to enable tracking detecting or visualizing of the bio-distribution of a conjugated peptide. The detectable labels can be fluorescent labels (e.g., fluorescent dyes). In certain embodiments, the fluorescent label can have emission characteristics that are desired for a particular application. For example, the fluorescent label can be a fluorescent dye that has a emission wavelength maximum between a range of 500 nm to 1100 nm, between a range of 600 nm to 1000 nm, between a range of 600 to 800 nm, between a range of 650 nm to 850 nm, between a range of 700 nm to 800 nm, between a range of 720 to 780 nm, or between a range of 720 to 750 nm. For example, under certain conditions, cyanine 5.5 can have an emission maximum around 695 nm, IRdye 800 can have an emission maximum around 800 nm, and indocyanine green can have an emission maximum around 820 nm. One of ordinary skill in the art will appreciate the various dyes that can be used as detectable labels and that have the emission characteristics above.

[0041] As used herein, the term "detectable label" means a tag or modification that can be attached to a small chemical molecule, peptide, protein, or a fragment or a portion thereof such that the small chemical molecule, peptide, protein, or a fragment thereof is recognizable using a device, apparatus or method that permits the detection of the tag or modification.

[0042] In some aspects, the detectable label is a fluorescent dye. Non limiting examples of fluorescent dyes that could be used as a conjugating molecule in the present disclosure include rhodamine, rhodol, fluorescein, thiofluorescein, aminofluorescein, carboxyfluorescein, chlorofluorescein, methylfluorescein, sulfofluorescein, aminorhodol, carboxyrhodol, chlororhodol, methylrhodol, sulforhodol; aminorhodamine, carboxyrhodamine, chlororhodamine, methylrhodamine, sulforhodamine, and thiorhodamine, cyanine, indocarbocyanine, oxacarbocyanine, thiacarbocyanine, merocyanine, a cyanine dye (e.g., cyanine 2, cyanine 3, cyanine 3.5, cyanine 5, cyanine 5.5, cyanine 7), oxadiazole derivatives, pyridyloxazole, nitrobenzoxadiazole, benzoxadiazole, pyrene derivatives, cascade blue, oxazine derivatives, Nile red, Nile blue, cresyl violet, oxazine 170, acridine derivatives, proflavin, acridine orange, acridine yellow, arylmethine derivatives, xanthene dyes, sulfonated xanthenes dyes, Alexa Fluors (e.g., Alexa Fluor 594, Alexa Fluor 633, Alexa Fluor 647, Alexa Fluor 700), auramine, crystal violet, malachite green, tetrapyrrole derivatives, porphyrin, phtalocyanine, and bilirubin. In some embodiments, the dyes can be near-infrared dyes including, e.g., Cy5.5, IRdye 800, DyLight 750 or indocyanine green (ICG). In some embodiments, near infrared dyes can include cyanine dyes (e.g., cyanine 2, cyanine 3, cyanine 3.5, cyanine 5, cyanine 5.5, cyanine 7). In certain embodiments, the detectable label can include xanthene dyes or sulfonated xanthenes dyes, such as Alexa Fluors (e.g., Alexa Fluor 594, Alexa Fluor 633, Alexa Fluor 647, Alexa Fluor 700). If an antibody to the dye could be found the conjugated dyes could be used both as a tracking, detecting or visualizing marker and as a retrieval handle.

[0043] The fusion proteins or peptides of the present invention can also be conjugated to biotin. In addition of extension of half-life, biotin could also act as an affinity handle for retrieval of the peptides from tissues or other locations. In one embodiment, the peptides can be conjugated, e.g., to a biotinidase resistant biotin with a PEG linker (e.g., NHS-dPEG.sub.4-Biotinidase resistant biotin). In some embodiments, fluorescent biotin conjugates that can act both as a detectable label and an affinity handle can be used. Non limiting examples of commercially available fluorescent biotin conjugates include Atto 425-Biotin, Atto 488-Biotin, Atto 520-Biotin, Atto-550 Biotin, Atto 565-Biotin, Atto 590-Biotin, Atto 610-Biotin, Atto 620-Biotin, Atto 655-Biotin, Atto 680-Biotin, Atto 700-Biotin, Atto 725-Biotin, Atto 740-Biotin, fluorescein biotin, biotin-4-fluorescein, biotin-(5-fluorescein) conjugate, and biotin-B-phycoerythrin, alexa fluor 488 biocytin, alexa flour 546, alexa fluor 549, lucifer yellow cadaverine biotin-X, Lucifer yellow biocytin, Oregon green 488 biocytin, biotin-rhodamine and tetramethylrhodamine biocytin. In some other examples, the conjugates could include chemiluminescent compounds, colloidal metals, luminescent compounds, enzymes, radioisotopes, and paramagnetic labels.

[0044] In some aspects, the fusion proteins and peptides of the present invention can be conjugated to vitamins or other molecules typically found in foods that are absorbed into the bloodstream from the stomach, small intestine, or colon. Examples include, but are not limited to, vitamin A, vitamin C, vitamin B2, vitamin B3, vitamin B6, vitamin B12, vitamin D, vitamin E, vitamin K. The goal of these conjugations is to improve oral bioavailability or absorption of the peptide from the gastrointestinal system.

[0045] In some instances, selected series of amino acids that appear to help certain peptides cross biologic barriers such as the gastrointestinal tract, the blood brain barrier, the cell membrane, the nuclear membrane can be identified and genetically or physically grafted onto other peptides for the purpose of helping the new peptide cross the same biologic barriers. In other cases, the same approach might be used to graft sequences onto peptides that would prevent the new peptide from crossing certain biological barriers. For example, a drug could be modified in this manner to prevent BBB penetration and thus reduce the likelihood of central nervous system side effects.

[0046] In certain embodiments, the fluorescent label can have emission characteristics that are desired for a particular application. For example, the fluorescent label can be a fluorescent dye that has a emission wavelength maximum between a range of 500 nm to 1100 nm, between a range of 600 nm to 1000 nm, between a range of 600 to 800 nm, between a range of 650 nm to 850 nm, between a range of 700 nm to 800 nm, between a range of 720 to 780 nm, or between a range of 720 to 750 nm. One of ordinary skill in the art will appreciate the various dyes that can be used as detectable labels and that have the emission characteristics above. For example, under certain conditions, cyanine 5.5 can have an emission maximum around 695 nm, IRdye can have an emission maximum around 800 nm, and indocyanine green can have an emission maximum around 820 nm.

[0047] Non-limiting examples of fluorescent dyes that could be used as a conjugating molecule in the present disclosure include rhodamine, rhodol, fluorescein, thiofluorescein, am inofluorescein, carboxyfluorescein, chlorofluorescein, methylfluorescein, sulfofluorescein, aminorhodol, carboxyrhodol, chlororhodol, methylrhodol, sulforhodol; aminorhodamine, carboxyrhodamine, chlororhodamine, methylrhodamine, sulforhodamine, and thiorhodamine, cyanine, indocarbocyanine, oxacarbocyanine, thiacarbocyanine, merocyanine, oxadiazole derivatives, pyridyloxazole, nitrobenzoxadiazole, benzoxadiazole, pyrene derivatives, cascade blue, oxazine derivatives, Nile red, Nile blue, cresyl violet, oxazine 170, acridine derivatives, proflavin, acridine orange, acridine yellow, arylmethine derivatives, auramine, crystal violet, malachite green, tetrapyrrole derivatives, porphyrin, phtalocyanine, and bilirubin. In some embodiments, the detectable label can include near-infrared dyes, such as, but not limited to, Cy5.5, indocyanine green (ICG), DyLight 750 or IRdye 800. In some embodiments, near infrared dyes can include a cyanine dye (e.g., cyanine 2, cyanine 3, cyanine 3.5, cyanine 5, cyanine 5.5, cyanine 7). In certain embodiments, the detectable label can include xanthene dyes or sulfonated xanthenes dyes, such as Alexa Fluors (e.g., Alexa Fluor 594, Alexa Fluor 633, Alexa Fluor 647, Alexa Fluor 700). In addition, if an antibody to the dyes can be identified, then conjugated dyes could be used both as a tracking, detecting or visualizing marker and as a retrieval handle.

[0048] Other modifications to fusion proteins, peptides, or conjugates thereof of the present disclosure can be used. For example, the fusion proteins or peptides of the present disclosure can include post-translational modifications (e.g., methylation and/or amidation), which can affect, e.g., serum half-life. In some embodiments, the fusion proteins or peptides can be conjugated to other moieties that, e.g., can modify or effect changes to the properties of the peptides. The conjugated moieties can, e.g., be lipophilic moieties that extend half-life of the peptides through reversible binding to serum albumin. In some embodiments, simple carbon chains (e.g., by myristoylation) can be conjugated to the peptides. In some embodiments, the lipophilic moiety can be cholesterol or a cholesterol derivative including cholestenes, cholestanes, cholestadienes and oxysterols. In some embodiments, the peptides can be conjugated to myristic acid (tetradecanoic acid) or a derivative thereof.

[0049] The fusion proteins or peptides of the present disclosure can also be conjugated to other moieties that can serve other roles, such as providing an affinity handle (e.g., biotin) for retrieval of the peptides from tissues or fluids. For example, the peptides of the present invention can also be conjugated to biotin. In addition to extension of half-life, biotin could also act as an affinity handle for retrieval of the peptides from tissues or other locations. In some embodiments, fluorescent biotin conjugates that can act both as a detectable label and an affinity handle can be used. Non limiting examples of commercially available fluorescent biotin conjugates include Atto 425-Biotin, Atto 488-Biotin, Atto 520-Biotin, Atto-550 Biotin, Atto 565-Biotin, Atto 590-Biotin, Atto 610-Biotin, Atto 620-Biotin, Atto 655-Biotin, Atto 680-Biotin, Atto 700-Biotin, Atto 725-Biotin, Atto 740-Biotin, fluorescein biotin, biotin-4-fluorescein, biotin-(5-fluorescein) conjugate, and biotin-B-phycoerythrin, Alexa fluor 488 biocytin, Alexa flour 546, Alexa Fluor 549, lucifer yellow cadaverine biotin-X, Lucifer yellow biocytin, Oregon green 488 biocytin, biotin-rhodamine and tetramethylrhodamine biocytin. In some other examples, the conjugates could include chemiluminescent compounds, colloidal metals, luminescent compounds, enzymes, radioisotopes, and paramagnetic labels.

Methods of Making Fusion Proteins and Peptides

[0050] In yet another aspect, the present invention includes methods for making fusion proteins or peptides according to the present disclosure.

[0051] In some embodiments, the present invention includes methods of making fusion proteins or peptides according to the present disclosure. As described further herein, the present invention includes scaffolds that can be used as a starting point for generating fusion proteins or peptides according to the present disclosure. These scaffolds as well as a large diversity of scaffold variants can be made using several different approaches. In some aspects, the fusion proteins or peptides according to the present disclosure can be produced using peptide synthesis techniques generally well known in the art. Conventional oligonucleotide synthesis techniques (e.g., chip-based oligonucleotide synthesis) can also be used. In some instances, the synthetic approaches can be combined with a variety of expression systems. In one example embodiment, particular residue positions in a scaffold can be targeted for random mutagenesis using degenerate codons to generate a diverse set of DNAs that can be made using, e.g., chip-based oligonucleotide synthesis and can code for a large library of scaffold variants.

[0052] In some embodiments, the molecules coding for the scaffolds and scaffold variants can be expressed in various expression systems, and can, in some embodiments, be combined as part of a fusion system. The DNA molecules encoding the scaffolds and scaffold variants, e.g., can be combined with fusion systems that can be expressed in several different cell types, e.g., 293 HEK or E. coli. Fusions for 293 HEK cells, e.g., can include but are not limited to, IgK leader sequences and/or secreted fusion proteins, such as siderocalin, lipocalin 2, and human serum albumin.

[0053] In some embodiments, the peptides described herein (e.g., knotted peptides) can be expressed as fusions with lipocalin proteins. In one aspect, the present invention includes a method for producing a peptide that can include expressing, in a cell, a fusion protein including a peptide (e.g., a knotted peptide) and a lipocalin protein. The method can further include separating the peptide from the lipocalin protein, thereby producing the peptide (e.g., the knotted peptide). The present invention further includes compositions of the fusion protein including the lipocalin protein and the peptide (e.g., the knotted peptide). This fusion system offers a variety of advantages for producing peptides (e.g., knotted-peptides) over traditional fusion systems. By way of background, and not to be limiting in any way, the lipocalins are a class of proteins that can have a conserved fold characterized by an eight-stranded beta barrel with a flanking alpha helix. The expression levels of lipocalin proteins, like Lcn2, NGAL and Siderocalin, in mammalian cells equal or surpass many other fusion systems, including Fc fusions. The present invention relates to methods for producing a fusion protein, the methods comprising expressing, in a cell, a fusion protein, the fusion protein comprising a peptide or protein domain and a lipocalin protein, thereby producing the fusion protein. In some embodiments, the methods further comprise separating the peptide or protein domain from the lipocalin protein, thereby producing a peptide or protein domain. In certain embodiments, the peptide or protein domain is an antibody fragment. In certain embodiments, the antibody is trastuzumab, infliximab, adalimumab, OKT3, or Fc.

[0054] In some embodiments, the peptide or protein domain is human heme oxygenase 1 or murine heme oxygenase 1. In some embodiments, the fusion protein further comprises a cleavage site. In certain embodiments, the cleavage site is a furin cleavage site, a trypsin cleavage site or a TEV cleavage site. In some embodiments, the separating of the peptide or protein domain from the lipocalin protein results from cleavage at the cleavage site in the fusion protein. In certain embodiments, the separating of the peptide or protein domain from the lipocalin protein occurs following secretion of the fusion protein from a cell. In certain embodiments, the cell is a mammalian cell.

[0055] The present invention relates to methods of producing a peptide, the method comprising: expressing, in a cell, a fusion protein comprising a peptide and a lipocalin protein; and separating the peptide from the lipocalin protein, thereby producing the peptide. In some embodiments, the peptide is separated from the lipocalin protein by proteolysis or by cleavage of a furin cleavage site in the fusion protein such that the peptide is cleaved from the lipocalin protein upon secretion from the cell. In certain embodiments, the cell is a mammalian cell. In some embodiments, the peptide is produced at a concentration less than about 200 mg/liter.

[0056] In some embodiments, the present invention relates to compositions comprising a fusion protein comprising a peptide and a lipocalin protein. In some embodiments, the peptide comprises a knotted peptide. In some embodiments, the knotted-peptide is selected from the group consisting of chymotrypsin inhibitor, hefutoxin, bubble protein, the C-terminal domain of midkine, potato carboxypeptidase inhibitor, and epiregulin. In certain embodiments, the lipocalin protein is siderocalin. In certain embodiments, the knotted-peptide includes at least two disulfide bonds

[0057] The peptides described herein (e.g., knotted peptides) can be expressed using a variety of lipocalin proteins. As used herein, the term "lipocalin" refers to a protein as defined in "Structure and sequence relationships in the lipocalins and related proteins", Darren R. Flower, Anthony C. T. North, Teresa K. Attwood, Protein Science (1993) 2:5, 753-761. Lipocalins may include, but are not limited to, the numbered lipocalins (e.g., Lcn2 (also NGAL, Siderocalin, 24p3), and the like, chicken Ex-FABP and quail Q86.

[0058] In various apsects of the present disclosure, siderocalin is used as a secretion partner. As used herein, the term "siderocalin" refers to a lipocalin that is capable of binding a small chelator. In some aspects, a chelator may be natural or engineered. In some aspects, siderocalin binds to siderophores and ferric siderophore complexes. For example, a siderocalin can be, but is not limited to, a siderocalin or Ex-FABP. As used herein, the term "Siderocalin," (as a proper noun), refers to the orthologous family of proteins related to the human archetype Siderocalin.

[0059] Siderocalin advantageously can be used for the secretion of a variety of peptides, proteins, and protein domains, including intracellular peptides, proteins, and peptide domains when used as a secretion partner.

[0060] Siderocalin is useful as a fusion partner for larger proteins because, e.g., of the small size of siderocalin relative to larger proteins (the mature protein is 178 amino acids and has a molecular weight of 20547 Da). Also, a C87S mutation in siderocalin can prevent dimerization and yields pure monomeric fusion protein (see Goetz, D. H., et al. `The Neutrophil Lipocalin NGAL is a Bacteriostatic Agent that Interferes with Siderophore-mediated Iron Acquisition` Molecular Cell (2002) 10: 1033-43). A single intramolecular disulfide bond present in siderocalin increases its stability. Also, siderocalin only has a single N-linked glycosylation site, which involves correct processing in the ER before secretion. In some aspects, the peptides can also be expressed as fusion peptides with Murine SCN (also known as 24p3), which also works very well as a secretion partner. Other homologs can also be used. In addition, the peptides (e.g., knotted peptides) provided herein can also be expressed as fusion systems with the other members of the lipocalin family including Lcn1, Lcn6, Lcn8, Lcn9, Lcn10, Lcn12, Lcn15. In some embodiments, the peptide comprises a disulfide knotted-peptide. In certain embodiments, the knotted-peptide is PMP-D2, potato carboxypeptidase, huwentoxin, imperatoxin, epiregulin, midkine, bubble protein or conotoxin CVIC. In other embodiments, the peptide comprises a knottin. In some embodiments, the lipocalin protein comprises siderocalin. In some embodiments, the lipocalin protein is siderocalin. In certain embodiments, the lipocalin protein is human siderocalin, murine siderocalin, chicken Ex-FABP, or quail Q86.

[0061] In some embodiments, the expression of peptides (e.g., knotted peptides) as fusions with SCN can be utilized with an endogenously cleaving SCN, with RARYKR right after the CIDG, and an exogenously cleaved one, with ENLYFQ in that position. The former can be cleaved by the mammalian cells during protein export (e.g., by furin), and the free SCN and knotted peptide can be secreted into surrounding media. ENLYFQ is a tobacco etch virus (TEV) protease site, which is not found endogenously in mammalian cells. The constructs in this system can be secreted as fusions, allowing for the knotted peptide to be cleaved off later by adding exogenous TEV protease. This can be useful for recovering the knottins. In some embodiments, purification "handles" such as poly-histidine or poly-arginine can be added to the SCN and subsequently removed by proteolysis. In addition to the knotted peptides, these fusion systems can also used for difficult-to-express proteins of medical interest such as chemokines, interleukins, and peptide hormones.

[0062] In some embodiments, the peptide comprises a knotted-peptide. In certain embodiments, the knotted-peptide is selected from the group consisting of chymotrypsin inhibitor, hefutoxin, bubble protein, the C-terminal domain of midkine, and epiregulin. In some embodiments, the lipocalin protein comprises siderocalin.

[0063] The lipocalin fusions (e.g., siderocalin and/or Lcn2 fused with a knotted peptide) can be used in several ways different ways. It could be used to increase the size of the target protein (for example a potential therapeutic) in order to increase its half-life. It could be used to secrete the target protein where the target protein is naturally expressed in the cytoplasm. SCN also has unique ligand specificity and tightly binds catecholate siderophores (bacterial iron chelators). This opens the possibility of loading the SCN fusion with specific ligands, such as a chemotherapeutic or radioactive reagent or some type or a compound that has beneficial properties. SCN, when loaded with siderophores and iron, has a deep red color that can aid in chromatography or other purification steps.

[0064] The lipocalin fusions of the present disclosure (e.g., SCN fused with HO-1) can be used in a variety of ways. For example, fusions can be used to increase the size of the target protein (e.g., a potential therapeutic) in order to increase its biological half-life. Fusions can be used to secrete the target protein where the target protein is naturally expressed in the cytoplasm. Fusions can also be used to target the fusion partner protein to specific locations to maximize therapeutic effects. SCN also has unique ligand specificity, tightly binding catecholate siderophores (bacterial iron chelators), and has kidney protective effects. Combining SCN with other kidney protective agents, like HO-1, which could generate synergistic functional effects. This also opens the possibility of loading the SCN fusion with specific ligands, such as radioactive metal atoms (e.g. .sup.55Fe or Th) to allow in vivo tracking or specific cytotoxic activities. In addition to several other advantages, the lipocalin fusion systems can be used to make large amounts of protein over relatively short time frames. In some embodiments, the amount of peptide obtained can be less than about 10 mg/L, less than about 20 mg/L, less than about 40 mg/L, less than about 50 mg/L, less than about 100 mg/L, less than about 150 mg/L, less than about 180 mg/L, or less than about 200 mg/L. In some embodiments, the amount of peptide obtained can be between about 10 mg/L and 200 mg/L, between about 50 mg/L and 200 mg/L, between about 100 mg/L and 200 mg/L, and between about 150 mg/L and 200 mg/Lln some embodiments, the peptide is produced at a concentration less than about 500 mg/liter, less than about 400 mg/liter, less than about 300 mg/liter, less than about 200 mg/liter, less than about 100 mg/liter, or less than about 50 mg/liter.

[0065] In other embodiments, some of the peptides described herein can be expressed in a variety of ways known in the literature. For example, the peptides are expressed in bacterial systems including E. Coli, corynebacterium, and pseudomonas fluoresceins. Expression platforms for E. coli can include periplasmic expression or cytoplasmic expression. For periplasmic expression, fusions can include pelB, dsbA, and ExFABP fusion. The peptides can also be expressed in insect cell systems and eukaryotic systems including mammalian systems.

[0066] In some aspects, the peptides disclosed herein can be introduced by transfection, a technique that involves introduction of foreign DNA into the nucleus of the eukaryotic cells. In some aspects, the peptides can be synthesized by transient transfection (DNA does not integrate with the genome of the eukaryotic cells, but the genes are expressed for 24-96 hours). Various methods can be used to introduce the foreign DNA into the host cells, and transfection can be achieved by chemical-based means including by the calcium phosphate, by dendrimers, by liposomes, and by the use of cationic polymers. Non-chemical methods of transfection include electroporation, sono-poration, optical transfection, protoplast fusion, impalefection, and hydrodynamic delivery. In some embodiments, transfection can be achieved by particle-based methods including gene gun where the DNA is coupled to a nanoparticle of an inert solid which is then "shot" directly into the target cell's nucleus. Other particle-based transfection methods include magnet assisted transfection and impalefection.

[0067] DNA can also be introduced into cells using virus as a carrier (viral transduction) using reteroviruses or lentiviruses. In some embodiments, the peptides of the present invention can be prepared using a Daedalus expression system. Ashok D. Bandaranayake et al., Nucleic Acids Res. 2011 November; 39(21): e143, which is incorporated herein by reference in its entirety. This technique may also be combined with a serum free mammalian culture system. And, it is also possible to express tagless proteins, which can be purified in a single size exclusion step directly from the media, at high levels.

[0068] In one aspect, the present invention provides a method of making hundreds to thousands or more of peptide variants at high levels. Conventional methods of making knotted peptides can be limited in that activity of knotted peptides can depend on proper folding of the peptides. There has been limited success in making knotted peptides that fold properly during manufacture. The present invention overcomes these problems with other techniques known in the art. FIG. 2 shows an example method for making the peptide libraries of the present invention. As shown, viruses can be produced by packaging of specific oligonucleotides sequences, transferring the sequences to the viruses, and expressing the peptides. Recovery and scale up of the peptides can be conducted, and then the sample can be purified and assayed. The process can be conducted efficiently (e.g., in three weeks) and large amounts of peptide can be produced (e.g., 200 mg/liter). In some instances, purification by chromatography may not be needed due to the purity of manufacture according the methods described herein.

[0069] In an example embodiment, the present invention includes fusion proteins of a knotted peptide fused to siderocalin via a cleavable linker. FIG. 3 shows an example fusion system that can be used to make the knotted peptide libraries. As shown, the fusion system includes a sequence including an IgK SP, sFLAG, HIS, siderocalin, TEV, and the knotted peptide sequence of interest. In some embodiments, these fusions can be combined with the Daedalus expression systems. Ashok D. Bandaranayake et al., Nucleic Acids Res. 2011 November; 39(21): e143, which is incorporated herein by reference in its entirety. A lentivirus can be used to gain rapid, stable expression in HEK293 cells, a human kidney cell line. The siderocalin can be highly expressed in this system and, e.g., serves to help the knotted peptide to be expressed as well. The nature of the cleavable linker allows the fusion to be cleaved as the protein is being expressed or later via an exogenously added protease. The siderocalin fusion partner can, e.g., be a generalizable expression enhancement system for any difficult-to-express protein, can be used as a tag to increase the size of a smaller peptide, and/or to improve a peptide's serum half-life (e.g., by increasing the size of the final fusion protein above the glomerular filtration limit. In some embodiments, the fusion protein further comprises at least one of an IgK starter sequence, a sFLAG, a HIS, and a TEV. In certain embodiments, the fusion protein comprises the following construct: IgK SP-sFLAG-HIS-siderocalin-TEP-peptide. In some embodiments, the peptide comprises a knotted-peptide.

[0070] Although HEK293 cells are robust and used for general protein expression, the lentivirus can infect a wide variety of cells. Combining this with a system that allows proteins to be cleaved as they are expressed enables a set of powerful assays that rely upon the secreted peptide to act in an autocrine or paracrine manner (i.e., they act on the cell that is secreting them or on nearby cells). An example of this would be to infect cancer target cells with a library of peptide-expressing lentiviruses and then screen those cells by flow cytometry for those that showed signs of apoptosis (e.g., Annexin V expression). The cells showing signs of apoptotic stress could be sorted out and the viruses sequenced, essentially looking for cells that were expressing a peptide that was inducing apoptosis in an autocrine fashion. A related set of screens could be done in a diffusion-limited matrix (e.g., soft agar), where peptide-expressing cells were mixed with target cells and the agar limited diffusion of the peptide. Areas of target cell death would be an indication of an active secreted peptide. Screens done in this manner could employ very large libraries, as the deconvolution would be as simple as sequencing the gene from which the peptide came.

[0071] In some embodiments, the present invention can include methods for producing knottins such that the knottin protein can remain tethered to the surface of the mammalian cell for use in conventional binding screens (e.g., those in which the target molecule is tethered to a column or beads and candidate drugs are identified by affinity to the target). In contrast to other known methods (e.g., phage or yeast display), the methods described herein use fusion systems (e.g., a siderocalin system of the present invention) to express libraries of peptides that have been designed according to the "rules" described above (e.g., ratio of acid/basic amino acids in a peptide) and that can be established through the in vivo drug discovery process and/or that have already been prescreened for specific biophysical and pharmacological properties. In these methods, e.g., all DNA sequences and protein products are already known and have already been validated (e.g., the peptides all fold properly and have improved serum half lives). The methods of present invention are in direct contrast to other known display technologies where the displayed proteins are not known and previously validated, and instead have their sequences randomized (using mutagenic oligonucleotides and degenerate NNN codons) yielding libraries of immense size (generally greater than 10.sup.7), where many of the proteins do not fold properly due to deleterious mutations.

Methods of Making Knotted Peptides and Related Compositions

[0072] The fusion systems of the present disclosure can be used in various aspects for the production of peptides, knottins, and cytoplasmic and secreted proteins. In some aspects, the methods and compositions described herein include fusion of target proteins and/or peptides to lipocalin such that lipocalin facilitates the expression and secretion of the target protein by a cell. For example, lipocalins have a conserved fold characterized by an eight-stranded beta barrel with a flanking alpha helix and supports a versatile scaffold. In some aspects, lipocalin fusion protein systems result in greater fusion protein expression in mammalian cells compared to systems without the use of a lipocalin fusion protein. For example, lipocalin fusion protein systems result in less than 0.5 times greater, 1 times greater, 2 times greater, 3 times greater, 4 times greater, 5 times greater, 6 times greater, 7 times greater, 8 times greater, 9 times greater, 10 times greater, 11 times greater, 12 times greater, 13 times greater, 14 times greater, 15 times greater, 16 times greater, 17 times greater, 18 times greater, 19 times greater, 20 times greater, 25 times greater, 30 times greater, 35 times greater, 40 times greater, 45 times greater, 50 times greater, 55 times greater, 60 times greater, 65 times greater, 70 times greater, 75 times greater, 80 times greater, 85 times greater, 90 times greater, 95 times greater, 100 times greater, 200 times greater, 300 times greater, 400 times greater, 500 times greater, 600 times greater, 700 times greater, 800 times greater, 900 times greater, or 1000 times fusion protein expression in mammalian cells compared to systems lacking the lipocalin fusion protein.

[0073] In some aspects, lipocalin (e.g., SCN) may be used as a fusion partner to stabilize proteins or peptides of interest as immunogens. In aspects, the species from which the lipocalin sequence is derived is different than the recipient species. In some aspects, the species from which the lipocalin sequence is derived is the same as the recipient species.

[0074] SCN, and related proteins, when used as a secretion partner advantageously improve the production of secreted proteins and peptides. Moreover, SCN, and related proteins, advantageously are small, thereby improving their bioavailability. For example, the mature protein is 178 amino acids and has a molecular weight of 20547 Da. SCN has a single intramolecular disulfide bond, which increases its stability and a single N-linked glycosylation site.

[0075] In some aspects, at least one of the amino acids in the native sequence of lipocalin 2 (SCN) may be substituted for a non-native amino acid. In some aspects, the mutations may be generated to prevent SCN from dimerizing. For example, one SCN protein may dimerize with another SCN protein at cysteine residues or one SCN protein may dimerize with different proteins at cysteine residues. For example, generating a C87S mutation in SCN may prevent dimerization at a cysteine residue (see Goetz, D. H., et al., `The Neutrophil Lipocalin NGAL is a Bacteriostatic Agent that Interferes with Siderophore-mediated Iron Acquisition` Molecular Cell (2002) 10: 1033-43).

[0076] In some aspects, at least one of the amino acids in the native sequence of the non-human lipocalin protein orthologous to the human SCN may be substituted for a non-native amino acid. For example, non-human orthologs of the human lipocalin protein that may be used with the methods and compositions described herein include, but are not limited to, murine Lcn2 (e.g., 24p3), Lcn1, Lcn6, Lcn8, Lcn9, Lcn10, Lcn12 and Lcn15 (see FIG. 14). In some aspects, the mutations may be generated to prevent non-human lipocalin protein orthologous to the human SCN from dimerizing. For example, one non-human lipocalin protein orthologous to the human SCN protein may dimerize with another non-human lipocalin protein orthologous to the human SCN protein at cysteine residues or one non-human lipocalin protein orthologous to the human SCN protein may dimerize with a different protein at cysteine residues. For example, generating a mutation at a site orthologous to the C87S mutation in human lipocalin protein may prevent dimeraizaiton at a cysteine residue (see Goetz, D. H., et al., `The Neutrophil Lipocalin NGAL is a Bacteriostatic Agent that Interferes with Siderophore-mediated Iron Acquisition` Molecular Cell (2002) 10: 1033-43).

[0077] In an exemplary aspect, a lipocalin fusion protein may contain the following protein sequence:

TABLE-US-00001 MPLGLLWLGLALLGALHAQAQDSTSDLIPAPPLSKVPLQQNFQDNQFQGK WYVVGLAGNAILREDKDPQKMYATIYELKEDKSYNVTSVLFRKKKCDYWI RTFVPGCQPGEFTLGNIKSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNR EYFKITLYGRTKELTSELKENFIRFSKSLGLPENHIVFPVPIDQCIDG

In this sequence, the annotations indicate, a signal peptide, glycosylation site, disulfide bond and the C87S mutation.

[0078] In some aspects, fusion of a protein or peptide of interest to lipocalin may improve the biological properties of the target protein (e.g., a potential therapeutic). For example, fusion of a protein or peptide of interest to lipocalin may increase the half-life of the protein or peptide of interest by increasing the size of the overall protein. For example, the increased size of the protein may prevent glomerular filtration of the protein or peptide of interest. In some aspects, fusions of small proteins, such as antibody fragments, exhibit decreased glomerular filtration. These effects are observed with both enzymes and Fab antibody fragments. In some embodiments, the fusion protein further comprises a peptide selected from the group consisting of: an IgK starter sequence, a sFLAG, a HIS, siderocalin, a TEV and the knotted peptide sequence of interest. In certain embodiments, the fusion protein comprises the following construct: IgK SP-sFLAG-HIS-siderocalin-TEV-peptide. In some embodiments, the knotted-peptide includes at least two disulfide bonds.

[0079] In some embodiments, the fusion protein further comprises at least one of an IgK starter sequence, a sFLAG, a HIS, and a TEV. In certain embodiments, the fusion protein comprises the following construct: IgK SP-sFLAG-HIS-siderocalin-TEV-peptide. In some embodiments, the fusion protein is generated by direct fusion of each subunit to the adjacent subunits. In certain embodiments, the composition further comprises a linker sequence between the peptide or protein domain and the lipocalin protein. In some embodiments, the peptide comprises a knotted-peptide.

[0080] In some embodiments, the fusion protein further comprises at least one of an IgK starter sequence, a sFLAG, a HIS, and a TEV. In certain embodiments, the fusion protein comprises the following construct: IgK SP-sFLAG-HIS-siderocalin-TEV-peptide. In other embodiments, the peptide comprises a knotted-peptide

[0081] In some aspects, fusion of the protein or peptide of interest to lipocalin may enhance the purification of the protein or peptide of interest after production. For example, the protein or peptide of interest fused to lipocalin may be produced from a protein expression system (e.g., fusion protein expression system). For example, proteins or peptides of interest may be retained in a compartment of a cell during production if proteins or peptides of interest are not fused to lipocalin.

[0082] In some aspects, SCN has protective properties in vivo that are imparted to a fusion partner as the basis of in vivo therapeutics fusion partners. In some aspects, these therapeutics can be stabilized for use as immunogens, matching the species donating the lipocalin sequence to that of the recipient species to focus elicited immune responses to the fusion partner. SCN also has unique ligand specificity and tightly binds siderophores (ferric iron chelators).

[0083] The methods and compositions described herein include fusion proteins of a protein or peptide of interest coupled to SCN and a SCN ligand. In some aspects, the ligands for SCN may include, but are not limited to, a siderophore or an organizing metal. In some aspects, fusion proteins including the SCN ligands may be coupled to a fluorphore. For example, the coupling may be covalently coupled. In some aspects, fusion proteins including the SCN ligands may be coupled to a luminescent siderophore. In some aspects, the luminescent siderophore may include a metal complex.

[0084] In some aspects, the addition of SCN ligands to the fusion proteins could be used to detect or localize the target protein, or target peptide, of the fusion protein. For example, the detection and localization could be performed either in vitro or in vivo. In some aspects, the addition of SCN ligands to the fusion proteins could be used to purify fusion proteins from mixtures. For example, an SCN ligand (e.g., a siderophore/metal complex) could be contacted with at least one purification resin metal other than, including but not limited to, aluminum, gadolinium, indium, vanadium, plutonium or thorium, and any related isotopes.

[0085] In some aspects, the addition of SCN ligands to the fusion proteins could be used for the delivery of radionuclides to a target tissue. In some aspects, the addition of SCN ligands to the fusion proteins could be used to deliver iron to a target. In addition, SCN bound to siderophores and iron can be a dark red color. For example, the dark red color can be combined with methods and compositions of chromatography or other steps in a method of purification.

[0086] In an exemplary aspect, a self-cleaving SCN isoform may be added to a peptide or protein of interest to generate a fusion protein. For example, the self-cleaving SCN isoform may contain the RARYKR amino acid sequence immediately following the CIDG amino acid sequence. In this case, the RARYKR sequence may be cleaved by an endogenous enzyme to the cells of the protein expression system (e.g., the mammalian cells) during export of the fusion protein. For example, furin may cleave the RARYKR sequence. In this case, SCN and the peptide or protein of interest may be free and located in the extracellular space.

[0087] In an exemplary aspect, an exogenously cleaved SCN isoform may be added to a peptide or protein of interest to generate a fusion protein. For example, the exogenously cleaved SCN isoform may contain the ENLYFQ amino acid sequence immediately following the CIDG amino acid sequence. In this case, the ENLYFQ sequence may be cleaved by an exogenous enzyme to the cells of the protein expression system (e.g., the mammalian cells) during export or after export of the fusion protein. For example, a tobacco etch protease may cleave the ENLYFQ site.

[0088] In some aspects, the fusion proteins may be secreted from the cells of the protein expression system (e.g., the mammalian cells) as fusion proteins. In this case, the peptide or protein of interest may be cleaved from the SCN protein by TEV protease. For example, the TEV protease may be added to the cells of the protein expression system (e.g., the mammalian cells) or added after removal of the fusion protein from the cells.

[0089] In some aspects, the SCN peptide may be modified to include compounds for purification or isolation. In some aspects, the compounds may be an amino acid or more than one amino acid. For example, the compounds may be poly-histidine or poly-arginine and may be located between Lcn2 and a signal peptide in the fusion protein. In some aspects, the compounds may be removed from Lcn2 using an enzyme or proteolysis.

[0090] The present invention relates to compositions comprising a peptide library, the peptide library further comprising a plurality of peptides lacking at least one native lysine residue. In some embodiments, the peptides are conjugated to an adaptor molecule. In certain embodiments, the adaptor molecule is a peptide. In some embodiments, the peptide has a unique signature determined by mass spectroscopy.

Methods of Use

[0091] The fusion proteins, peptides, or conjugates thereof of the present disclosure can be used for a variety of other applications, such as therapeutic and/or diagnostic applications. In some embodiments, the fusion proteins, peptides, or conjugates thereof of the present disclosure can be used for methods of treating diseases. In some embodiments, the fusion proteins, peptides, or conjugates thereof of the present disclosure can be used to deliver drugs to, e.g., tumors in the brain of a subject.

[0092] The present invention also provides compositions for administering the fusion proteins, peptides, or conjugates thereof described herein to a subject to facilitate diagnostic and/or therapeutic applications.

[0093] In certain embodiments, the compositions can include a pharmaceutically acceptable excipient. Pharmaceutical excipients useful in the present invention include, but are not limited to, binders, fillers, disintegrants, lubricants, coatings, sweeteners, flavors and colors. One of skill in the art will recognize that other pharmaceutical excipients are useful in the present invention. The term "pharmaceutical composition" as used herein includes, e.g., solid and/or liquid dosage forms such as tablet, capsule, pill and the like.

[0094] The fusion proteins, peptides, or conjugates thereof of the present disclosure may be administered by any suitable technique available in the art, e.g., as compositions. For example, they can be administered as frequently as necessary, including hourly, daily, weekly or monthly. The fusion proteins, peptides, or conjugates thereof, can be utilized in the methods of the invention can be, e.g., administered at dosages that may be varied depending upon the requirements of the method being employed. The fusion proteins, peptides, or conjugates thereof described herein can be administered to the subject in a variety of ways, including parenterally, subcutaneously, intravenously, intratracheally, intranasally, intradermally, intramuscularly, colonically, rectally, urethrally or intraperitoneally. In some embodiments, the pharmaceutical compositions can be administered parenterally, intravenously, intramuscularly or orally. In some embodiments, the fusion proteins, peptides, or conjugates thereof of the present disclosure, can be administered systemically. In some embodiments, the compositions can be administered intratumorally and/or intranodally, such as delivery to a subject's lymph node(s). In certain embodiments, administration can include enteral administration including oral administration, rectal administration, and administration by gastric feeding tube or duodenal feeding tube. Administration can also be including intravenous injection, intra-arterial injection, intra-muscular injection, intracerebral, intracerebroventricular or subcutaneous (under the skin) administration. In some embodiments, administration can be achieved by topical means including epicutaneous (application to skin) and inhalation.

[0095] The oral agents comprising fusion proteins, peptides, or conjugates thereof of the present disclosure can be in any suitable form for oral administration, such as liquid, tablets, capsules, or the like. The oral formulations can be further coated or treated to prevent or reduce dissolution in stomach. The compositions of the present invention can be administered to a subject using any suitable methods known in the art. Suitable formulations for use in the present invention and methods of delivery are generally well known in the art. For example, the fusion proteins, peptides, or conjugates thereof of the present disclosure can be formulated as pharmaceutical compositions with a pharmaceutically acceptable diluent, carrier or excipient. The compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions including pH adjusting and buffering agents, tonicity adjusting agents, wetting agents and the like, such as, for example, sodium acetate, sodium lactate, sodium chloride, potassium chloride, calcium chloride, sorbitan monolaurate, triethanolamine oleate, etc.

[0096] As used herein, a "subject" is a human or non-human animal. In some embodiments, a subject can include, but is not limited to, a mouse, a rat, a rabbit, a human, or other animal. In another embodiment, a subject is a human, such as a human having or at risk of having a cancer. In some embodiments, a subject or biological source may be suspected of having or being at risk for having a disease, disorder or condition, including a malignant disease, disorder or condition (e.g., cancer). In certain embodiments, a subject or biological source may be suspected of having or being at risk for having a hyperproliferative disease (e.g., carcinoma, sarcoma), and in certain other embodiments of this disclosure a subject or biological source may be known to be free of a risk or presence of such disease, disorder, or condition.

[0097] "Treatment," "treating" or "ameliorating" refers to either a therapeutic treatment or prophylactic/preventative treatment. A treatment is therapeutic if at least one symptom of disease (e.g., a hyperproliferative disorder, such as cancer) in an individual receiving treatment improves or a treatment may delay worsening of a progressive disease in an individual, or prevent onset of additional associated diseases (e.g., metastases from cancer).

[0098] A "therapeutically effective amount (or dose)" or "effective amount (or dose)" of a composition including fusion proteins, peptides, or conjugates thereof of the present disclosure, refers to that amount of compound sufficient to result in amelioration of one or more symptoms of the disease being in a statistically significant manner. When referring to an individual active ingredient, administered alone, a therapeutically effective dose refers to that ingredient alone (e.g., a fusion proteins, peptides, or conjugates thereof of the present disclosure). When referring to a combination, a therapeutically effective dose refers to combined amounts of the active ingredients that result in the therapeutic effect, whether administered serially or simultaneously (in the same formulation or in separate formulations).

[0099] The term "pharmaceutically acceptable" refers to molecular entities and compositions that do not produce allergic or other serious adverse reactions when administered to a subject using routes well known in the art.

[0100] A "patient in need" or "subject in need" refers to a patient or subject at risk of, or suffering from, a disease, disorder or condition (e.g., cancer) that is amenable to treatment or amelioration with a fusion proteins, peptides, or conjugates thereof of the present disclosure described herein.

[0101] In some embodiments, the fusion proteins, peptides, or conjugates thereof of the present disclosure can further include other agents to facilitate treatment. For example, a fusion proteins, peptides, or conjugates thereof of the present disclosure can further include cytotoxic agents (e.g., mitotic inhibitors), toxins, antisense nucleotides, cancer treatment drugs (e.g., alkylating agents), nucleotide drugs, anti-metabolites, metabolic modulators, radiosensitizers, peptide therapeutics, peptide-drug conjugates, radionuclides, or a combination thereof.

[0102] Cytotoxic agents can include drugs that can be used to treat cancer, e.g., by inhibiting cell proliferation. Some example cytotoxic agents can include, e.g., the vinca alkaloids, mitomycins, bleomycins, cytotoxic nucleosides, taxanes, and epothilones, Members of those classes include, for example, doxorubicin, carminomycin, daunorubicin, aminopterin, methotrexate, methopterin, dichloromethotrexate, mitomycin C, porfiromycin, 5-fluorouracil, 6-mercaptopurine, gemcitabine, cytosine arabinoside, podophyllotoxin or podo-phyllotoxin derivatives, such as etoposide, etoposide phosphate or teniposide, melphalan, vinblastine, vincristine, leurosidine, vindesine, leurosine, paclitaxel and therapeutically effective analogs and derivatives of the same. Other useful antineoplastic agents include estramustine, cisplatin, carboplatin, cyclophosphamide, bleomycin, gemcitibine, ifosamide, melphalan, hexamethyl melamine, thiotepa, cytarabin, idatrexate, trimetrexate, dacarbazine, L-asparaginase, camptothecin, CPT-11, topotecan, ara-C, bicalutamide, flutamide, leuprolide, pyridobenzoindole derivatives, interferons and interleukins.

[0103] Suitable metabolic modulators can include, but are not limited to, lonidamine, dichloroacetate, alpha-tocopheryl succinate, methyl jasmonate, betulinic acid, and resveratrol

[0104] Radiosensitizers are known to increase the sensitivity of cancerous cells to the toxic effects of electromagnetic radiation, e.g., x-rays. Examples of x-ray activated radiosensitizers include, but are not limited to, metronidazole, misonidazole, desmethylmisonidazole, pimonidazole, etanidazole, nimorazole, mitomycin C, RSU 1069, SR 4233, E09, RB 6145, nicotinamide, 5-bromodeoxyuridine (BUdR), 5-iododeoxyuridine (I UdR), bromodeoxycytidine, fluorodeoxyuridine (FudR), hydroxyurea, cisplatin, and therapeutically effective analogs and derivatives of the same.

[0105] In some embodiments, the fusion proteins, peptides, or conjugates thereof of the present disclosure can include radionuclides and/or complexed radionuclides. Suitable radionuclides can include, but are not limited to, Sc-47, Ga-67, Y-90, Ag-111, In-111, Sm-153, Tb-166, Lu-177, Bi-213, Ac-225, Cu-64, Cu-67, Pd-109, Ag-111, Re-186, Re-188, Pt-197, Bi-212, Bi-213, Pb-212 or Ra-223.

[0106] In certain embodiments, the present invention can include treating diseases, disorders, and/or conditions, such as gliomas, astrocytomas medulloblastomas, choroids plexus carcinomas, ependymomas, other brain tumors, neuroblastoma, head and neck cancer, lung cancer, breast cancer, intestinal cancer, pancreatic cancer, liver cancer, kidney cancer, sarcomas, osteosarcoma, rhabdomyosarcoma, Ewing's sarcoma, carcinomas, melanomas, ovarian cancer, cervical cancer, lymphoma, thyroid cancer, anal cancer, colo-rectal cancer, endometrial cancer, germ cell tumors, laryngeal cancer, multiple myeloma, prostate cancer, retinoblastoma, gastric cancer, testicular cancer, and Wilm's tumor. In some embodiments, the methods can including treating a disease, disorder and/or condition including a glioma, a skin cancer, a lung cancer, a lymphoma, a medulloblastoma, a prostate cancer, a pancreatic cancer, or a combination thereof. In certain embodiments, the methods can be used to treat breast and mammary cancers, colon, skin, lung, lymphoma, glioma, medulloblastoma prostate, pancreatic cancers, oral squamous cell carcinoma, and/or hemangiopericytoma.

[0107] The present invention further includes methods of administering a fusion proteins, peptides, or conjugates thereof of the present disclosure. For example, in one aspect, the present invention includes a method comprising a step of administering an effective dose of a fusion proteins, peptides, or conjugates thereof of the present disclosure or a composition including fusion proteins, peptides, or conjugates thereof of the present disclosure to a subject with a tumor such that the peptide selectively targets tumor tissue over normal tissue.

[0108] The methods can further include facilitating surgical removal of cancerous tissue (e.g., a tumor) in a subject. For example, the present invention can include a method comprising administering an effective dose of fusion proteins, peptides, or conjugates thereof of the present disclosure or a composition including fusion proteins, peptides, or conjugates thereof of the present disclosure to a subject with cancerous tissue (e.g., a tumor) such that the peptide selectively targets cancerous tissue (e.g., tumor tissue) over normal tissue. The methods can include imaging the cancerous tissue by, e.g., detecting the tissue that shows elevated binding of the peptides, thereby indicating the location of the cancerous tissue. Identification of the location can provide a step of surgically removing the cancerous tissue from the subject. The surgically removing can include, e.g., intraoperative visualization of the cancerous tissue as identified by binding of the fusion proteins, peptides, or conjugates thereof of the present disclosure.

[0109] The present invention also provides compositions for administering fusion proteins, peptides, or conjugates thereof of the present disclosure to a subject to facilitate diagnostic and/or therapeutic applications. In certain embodiments, the compositions can include a pharmaceutically acceptable excipient. Pharmaceutical excipients useful in the present invention include, but are not limited to, binders, fillers, disintegrants, lubricants, coatings, sweeteners, flavors and colors. One of skill in the art will recognize that other pharmaceutical excipients are useful in the present invention. The term "pharmaceutical composition" as used herein includes, e.g., solid and/or liquid dosage forms such as tablet, capsule, pill and the like.

[0110] The fusion proteins, peptides, or conjugates thereof of the present disclosure can be administered as frequently as necessary, including hourly, daily, weekly or monthly. The fusion proteins, peptides, or conjugates thereof of the present disclosure utilized in the methods of the invention can be, e.g., administered at dosages that may be varied depending upon the requirements of the method being employed. The fusion proteins, peptides, or conjugates thereof of the present disclosure can be administered to the subject in a variety of ways, including parenterally, subcutaneously, intravenously, intratracheally, intranasally, intradermally, intramuscularly, colonically, rectally, urethrally or intraperitoneally. In some embodiments, the pharmaceutical compositions can be administered parenterally, intravenously, intramuscularly or orally. In some embodiments, the compositions can be administered intratumorally and/or intranodally, such as delivery to a subject's lymph node(s). In certain embodiments, administration can include enteral administration including oral administration, rectal administration, and administration by gastric feeding tube or duodenal feeding tube. Administration can also be including intravenous injection, intra-arterial injection, intra-muscular injection, intracerebral, intracerebroventricular or subcutaneous (under the skin) administration.

[0111] The oral agents comprising peptides or protein fusions described herein can be in any suitable form for oral administration, such as liquid, tablets, capsules, or the like. The oral formulations can be further coated or treated to prevent or reduce dissolution in stomach. The compositions of the present invention can be administered to a subject using any suitable methods known in the art. Suitable formulations for use in the present invention and methods of delivery are generally well known in the art. For example, the peptides or fusion proteins described herein can be formulated as pharmaceutical compositions with a pharmaceutically acceptable diluent, carrier or excipient. The compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions including pH adjusting and buffering agents, tonicity adjusting agents, wetting agents and the like, such as, for example, sodium acetate, sodium lactate, sodium chloride, potassium chloride, calcium chloride, sorbitan monolaurate, triethanolamine oleate, etc.

[0112] The present invention further includes functional assays of fusion proteins, peptides, or conjugates thereof of the present disclosure. The capacity of fusion proteins, peptides, or conjugates thereof of the present disclosure, to bind to tumor or cancerous tissue can be assayed by in vitro binding, ex vivo imaging, animal models, and other assays known in the art and as previously described. See, for example, US Patent Publication Number US20080279780 and WO 2011/142858, both of which are incorporated by reference herein for the description of functional assays to detect and measure binding to tumor cells and tumor tissue.

[0113] One skilled in the art will be knowledgeable about animal models that are useful for measuring the in vivo activity of fusion proteins, peptides, or conjugates thereof of the present disclosure. For example, the National Cancer Institute maintains a database of specific cancer models. See the "Cancer Models Database" at the National Cancer Institute website. All animals are handled in strict accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals. ND2:SmoA1 medulloblastoma mice, TRAMP prostate cancer mice and Apc.sup.1638N intestinal adenoma and adenocarcinoma mice have been previously described. See, Fodde, R., et al., A targeted chain-termination mutation in the mouse Apc gene results in multiple intestinal tumors. Proc. Natl. Acad. Sci. U.S.A., 1994. 91(19): p. 8969-73; Greenberg, N. M., et al., Prostate cancer in a transgenic mouse. Proc. Natl. Acad. Sci. U.S.A., 1995. 92(8): p. 3439-43; Kaplan-Lefko, P. J., et al., Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model. Prostate, 2003. 55(3): p. 219-37; Hallahan, A. R., et al., The SmoA1 mouse model reveals that notch signaling is critical for the growth and survival of sonic hedgehog-induced medulloblastomas. Cancer Res., 2004. 64(21): p. 7794-800; each expressly incorporated herein by reference in its entirety.

[0114] The fusion proteins, peptides, and conjugates therof generated and produced by the methods and systems described herein can be used for a range of applications. For example, the proteins and peptides can be used for therapeutic and/or diagnostic purposes. Some example uses include, but are not limited to, conjugating the fusion proteins or peptides to radiolabels and/or fluorescent molecules for bioimaging, linking the peptides to cytotoxic agents, using the peptides for in vitro diagnostics for biochemical assays, as well as, e.g., for veterinary uses, insecticides, antibiotics, herbicides, antifreeze compositions, and antivenoms.

[0115] As will be appreciated by one of ordinary skill in the art, the fusion proteins and peptides described herein can be tailored for a wide range of targets (e.g., therapeutic targets). In some embodiments, the targets are associated with a variety of diseases or disorders. Some targets, for example, can include but are not limited to glypican-2 (GPC2), protocadherin (1.quadrature.(PCDHA1), Ca.sub.v2.2, K.sub.v1.3, Na.sub.v1.2, NaV1.1, NaV1.7, NaV1.8, CIC-3, nAChR, NMDA-R, NPRA, GLP-1R, .quadrature..sub.1B-AR, NT-R-1, ACE, NET mTor, cMet, VEGF/VEGFR, c-Kit, PDGF/PDGFR, PI3K, HER2, EGFR, Orai1, CD47, Raf, NF.quadrature.B, Bromodomains, HATS, HDAC, LDH, IDH2, CD22, MIC, c-Myc, n-Myc, PHFSA, BUB1B, Bcl-2, k-Ras, Notch1, p53, .alpha.5.beta.3, NKG2D, CTLA4/CD28, and/or Mcl-1.

[0116] The present invention also provides compositions for administering the fusion peptides, peptides, or conjugates thereof according to the present disclosure to a subject to facilitate diagnostic and/or therapeutic applications. In certain embodiments, the compositions can include a pharmaceutically acceptable excipient. Pharmaceutical excipients useful in the present invention include, but are not limited to, binders, fillers, disintegrants, lubricants, coatings, sweeteners, flavors and colors. One of skill in the art will recognize that other pharmaceutical excipients are useful in the present invention. The term "pharmaceutical composition" as used herein includes, e.g., solid and/or liquid dosage forms such as tablet, capsule, pill and the like.

[0117] The fusion peptides, peptides, or conjugates thereof according to the present disclosure can be administered as frequently as necessary, including hourly, daily, weekly or monthly. The fusion peptides, peptides, or conjugates thereof according to the present disclosure utilized in the methods of the invention can be, e.g., administered at dosages that may be varied depending upon the requirements of the method being employed. The fusion peptides, peptides, or conjugates thereof according to the present disclosure can be administered to the subject in a variety of ways, including parenterally, subcutaneously, intravenously, intratracheally, intranasally, intradermally, intramuscularly, colonically, rectally, urethrally or intraperitoneally. In some embodiments, the pharmaceutical compositions can be administered parenterally, intravenously, intramuscularly or orally. In some embodiments, the fusion peptides, peptides, or conjugates thereof according to the present disclosure can be administered systemically. In some embodiments, the compositions can be administered intratumorally and/or intranodally, such as delivery to a subject's lymph node(s). In certain embodiments, administration can include enteral administration including oral administration, rectal administration, and administration by gastric feeding tube or duodenal feeding tube. Administration can also be including intravenous injection, intra-arterial injection, intra-muscular injection, intracerebral, intracerebroventricular or subcutaneous (under the skin) administration. In some embodiments, administration can be achieved by topical means including epicutaneous (application to skin) and inhalation.

[0118] The oral agents comprising a fusion peptides, peptides, or conjugates thereof according to the present disclosure described herein can be in any suitable form for oral administration, such as liquid, tablets, capsules, or the like. The oral formulations can be further coated or treated to prevent or reduce dissolution in stomach. The compositions of the present invention can be administered to a subject using any suitable methods known in the art. Suitable formulations for use in the present invention and methods of delivery are generally well known in the art. For example, the fusion peptides, peptides, or conjugates thereof according to the present disclosure can be formulated as pharmaceutical compositions with a pharmaceutically acceptable diluent, carrier or excipient. The compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions including pH adjusting and buffering agents, tonicity adjusting agents, wetting agents and the like, such as, for example, sodium acetate, sodium lactate, sodium chloride, potassium chloride, calcium chloride, sorbitan monolaurate, triethanolamine oleate, etc.

EXEMPLARY ASPECTS

Example 1

Expressing Peptide Constructs for Knottin Generation

[0119] This example describes a method for expressing peptide constructs in culture and greatly facilitating their development, particularly as drugs.

[0120] As shown in FIG. 5, the various knottins can be expressed, e.g., in a lentivirus expression-based method that can include packaging, transfer, and then expression followed by isolation and/or purification of the expressed knottin peptides. Several coding constructs can be used. In this example, the encoding of the knottin peptides included a polynucleotide construct including IgK SP-sFLAG-HIS-Siderocalin-TEV-Knottin. Specific sequences of some example constructs are disclosed in the "SEQUENCE" section below. FIG. 6 shows gel data of a number of example knottins that were made according to the method described in FIG. 5. As shown, chymotrypsin inhibitor (CTI), epiregulin (EPI), hefutoxin (HTX), bubble protein (BUB), potato carboxypeptidase inhibitor (PCI) were properly folded.

[0121] FIG. 9 shows a schematic describing production of a pooled library of knottins. In this example, sequences of thousands of knottins can be encoded in an oligonucleotide pool (1) and selectively amplified using unique primer pairs (2). DNA sublibraries can be cloned into the expression vector, which results in the knottin variants that can, e.g., have unique parental mass signatures and unique tryptic fragment mass signatures that can be resolvable using current techniques, such as mass spectroscopy.

[0122] FIG. 8 includes example knottin variants that describe representative sequencing from a cloned knottin library. The sequences show raw sequencing data from a single round of library cloning. The sequence portions highlighted in grey are full length knottin variants, and the errors in oligonucleotide synthesis can explain the truncated and extended peptide sequences.

[0123] Using the methods described in this example, variants of several knottin scaffolds were generated and analyzed. FIG. 9 shows an SDS-PAGE analysis of 3000 member knottin libraries for, e.g., hefutoxin, knottin and chymotrypsin inhibitor. Each column of the SDS-PAGE gel shows a purified sample of a pool of 3000 knottin protein variants run under native and reducing conditions. The migration shift between the paired bands indicates disulfide formation.

[0124] Four scaffolds were selected for the generation of defined libraries: hefutoxin, CTI, knottin, and epiregulin. A list of target amino acid sequences was generated in silico such that every member of each library would have a tryptic fragment with a unique mass; mutations were selected to be structurally adjacent in order to generate binding epitopes. The cysteines were not mutated, and lysine was specifically avoided in order to make N-terminal conjugation unambiguous. 3000 variants of each scaffold were generated, and each scaffold was flanked by a unique set of PCR primer sites so that each of the four sublibraries could be amplified independently. All constructs had an N-terminal BamHI site and a C-terminal NotI site, and following PCR amplification of each sublibrary from the pool of 12000 oligonucleotides, each sublibrary was restriction digested and cloned into cut parental vector (both the furin-cleaved and TEV-cleaved versions) as an SCN fusion protein using standard techniques. HEK293 cells were transfected with this plasmid library as well as the accessory plasmids needed for Daedalus expression, and the virus in the media harvested 3-4 days later. Virus was concentrated by centrifugation and used to infect HEK293 cells for protein production using standard procedures. We have found that the TEV-cleavable construct is technically easier to handle when producing libraries because it allows for facile recovery of the fusion by IMAC on nickel resin. Following IMAC, the fusion protein was dialyzed into PBS and allowed to cleave overnight with 6.times.His tagged TEV protease, and the SCN and protease were subsequently removed by running the material through nickel resin again. The flow-through containing the cleaved peptide libraries was further purified and buffer exchanged by size exclusion chromatography (SEC) into 10 mM ammonium formate, and the fractions containing the peptides were pooled and lyophilized.

[0125] There were two approaches taken to cloning, Seamless Cloning (Invitrogen) and restriction/ligation based methods. Seamless cloning was employed for making single constructs, typically using synthesized "gBlocks" from IDT. The manufacturer's instructions were followed. Restriction/ligation methods were standard and were used for cloning libraries as follows: the pooled oligonucleotides from CustomArray were subjected to PCR in order to amplify the relevant sublibrary. The amplified pool was agarose gel purified and cleaned of agarose using a Qiagen column. The purified fragment was digested with FaastDigest (Fermentas) BamHI and NotI and ligated into the parental vector which had been cut with the same two restriction endonucleases. Singleton clones were sequence verified, and 48 members of each library were sequenced in order to verify library quality.

[0126] The cloned knottin or library was cotransfected into HEK293 cells and media was collected as described ("Daedalus: A Robust, Turnkey Platform for Rapid Production of Decigram Quantities of Active Recombinant Proteins in Human Cell Lines Using Novel Lentiviral Vectors." Bandaranayake A. D., et al., Nucleic Acids Res. (2011) 39(21):e143). Fusion protein was isolated using nickel IMAC and cleaved with recombinant TEV protease. Excess siderocalin was removed via size exclusion chromatography, a process which also allowed the buffer to be switched to 10 mM ammonium formate. The knottin containing fractions were then lyophilized. Proper folding and peptide uniformity was demonstrated via SEC chromatography, reverse-phase HPLC, mass spectrometry, and a gel shift in reduced versus non-reduced samples in SDS-PAGE.

[0127] Conjugation to palmitic acid, ICG, or biotinidase-resistant biotin was performed using a 3-10 fold excess of commercially available, activated ester conjugate in PBS. Acetonitrile was added when there were solubility problems. The final material was purified by RP-HPLC for singletons, and excess conjugate was removed from libraries by dialysis.

Example 2

Fusion Protein Systems

[0128] This example describes expression systems for the efficient production of various peptides, including knotted peptides. Advantageously, the peptides produced according to these methods are secreted and stable.

[0129] Siderocalin can be used according to the present disclosure for construction of a Scn-peptide fusion, which can be secreted and cleaved for the efficient production of excreted peptides. FIG. 24 depicts the crystal structure of Scn with a Th ligand.

[0130] FIG. 14 shows the alignment of Scn sequences from 18 species. The alignment shows a high level of sequence conservation between the 18 species with recognizable orthologs. Positions with an asterisk are possible cites for ligand binding.

[0131] FIG. 15 depicts a 3D model of super-stable Scn in accordance with an aspect of the present disclosure. In this form of Scn, a second disulfide bond was engineered in order to secure the N-terminus and increase thermal stability.

[0132] FIGS. 10-12 depict various manufacturing methods according to the present disclosure, which enable the efficient production of knottin peptides. FIG. 10 depicts the elements of the siderocalin fusion protein and use thereof for the production of knottin peptides. In this example, the knottin is secreted as a fusion protein to the siderocalin. The IgK signal peptide is derived from the mouse Light Chain IgG. The sFLAG is the short FLAG (DYKDE) for enhanced cleavage of the signal peptide relative to the long FLAG signal peptide. The His is a histidine tag (HHHHHH) and TEV is the tobacco etch virus protease site (ENLYFQ). According to this method, and as depicted in FIG. 12, the fusion protein is secreted, followed by cleavage and isolation. IgK SP is Murine IgK light chain signal peptide, sFLAG: Shortened FLAG epitope, HIS: 6.times. histidine tag, TEV: Tobacco Etch Virus Protease recognition site and Furin--furin cleavage site with BamHI site.

[0133] FIG. 10 depicts the elements of the siderocalin fusion protein and the use thereof for the production of knottin peptides. In this example, the knottin is secreted as a fusion protein to HIS-tagged siderocalin. The HIS tag is six histidines (HHHHHH) that will reversibly bind nickel and is therefore a useful purification tag for Immobilized Metal Chromatography (IMAC). Following isolation of the fusion protein by IMAC, the fusion is cleaved with TEV protease and the cleaved siderocalin removed by another round of IMAC, leaving pure knottin.

[0134] FIG. 11 depicts the elements of the siderocalin fusion protein and use thereof for the production of knottin peptides. This method includes the secretion of a siderocalin fusion with concomitant, intracellular cleavage at the Furin-His junction and purification by IMAC. The HIS tag can then be removed from the knottin with TEV protease. The secretion method depicted in FIG. 11 utilizes the same restriction sites as the method depicted in FIG. 10.

[0135] FIG. 12 depicts the elements of a system for the secretion of cleaved knottin peptides. The siderocalin in this case is present during translation but is cleaved off by intracellular furin during protein. The secretion method depicted in FIG. 12 utilizes the same restriction sites as the method depicted in FIG. 10.

[0136] FIG. 16 shows a schematic of a generic Scn fusion that can be used in various aspects of the present disclosure. The native signal peptide was removed and an exogenous sFLAG and HIS tag were added to facilitate purification. These modifications are optionally present in various aspects of the disclosure.

[0137] FIG. 13 depicts exemplary knottins made using the Daedalus system and the corresponding SDS PAGE analyses in accordance with an aspect of the present disclosure. The Dadalus system is desribed in Bandaranayake A. D., et al., Nucleic Acids Res. (2011) 39(21):e143. SDS PAGE analyses were performed under reducing (left) and non-reducing (right) conditions. As shown in FIG. 13, a number of challenging peptides can be produced according to the presently described methods.

[0138] FIG. 17 depicts a schematic of a light chain antibody fusion with Scn and a corresponding SDS PAGE analysis according to an aspect of the present disclosure. The Scn fusion enables the generation of Fab fragments that have an increased molecular weight (.about.75 kDa) and improved serum half-life. The addition of the Scn moiety also enables the delivery of an exogenous ligand through the Scn ligand binding site. Also depicted is the SDS PAGE analysis under non-reducing and reducing conditions of a construct according to one aspect of the present disclosure.

[0139] FIG. 18 shows the SDS PAGE analysis comparing the expression of a Scn fusion with a cytoplasmic enzyme, HMOX1, both before and after cleavage according to an aspect of the present dislcosure. By cleaving the fusion protein as shown in FIG. 18, it is demonstrated that the HMOX1 protein is stable even after separation from Scn. This result further suggests that, using the presently described methods, it is possible to express enzymes in a mammalian cell culture system where they are secreted out of the cell.

[0140] FIG. 19 depicts the expression of a Scn fusion with a cytoplasmic viral protein Adv2 and the corresponding SDS PAGE analysis according to one aspect of the present disclosure. By cleaving the fusion protein as shown in FIG. 19, it is demonstrated that the Adv2 protein is stable even after separation from Scn. This result further suggests that, using the presently described methods, it is possible to express difficult viral proteins in a mammalian cell culture system where they are secreted out of the cell. Additionally this fusion protein has further utility because it can be used to raise antibodies against the viral antigen in rats, mice or rabbits using the corresponding Scn ortholog.

[0141] FIG. 20 depicts the expression of a Scn fusion with an extracellular viral glycoprotein HIV gp120 and the corresponding SDS PAGE analysis according to one aspect of the present disclosure. The results in FIG. 20 demonstrate that stabilized glycoproteins can be expressed according to one aspect of the present disclosure. Additionally this fusion protein has further utility because it can be used to raise antibodies against the viral antigen in rats, mice or rabbits using the corresponding Scn ortholog.

[0142] FIG. 21 depicts the expression of a Scn fusion with a knottin protein, Imperatoxin, and the corresponding SDS PAGE analysis according to one aspect of the present disclosure. The results in FIG. 21 show that the knottin protein, Imperatoxin, is stable even after separation from Scn. These results show that knottins can be expressed in a mammalian cell culture system where they are secreted out of the cell according to an aspect of the present disclosure. Although knottins are known to be incredibly difficult to secrete in a properly folded state, the results of FIG. 21 demonstrates that it is possible to do so using the presently described methods. Additionally, this fusion protein has further utility because it can be used to raise antibodies against the viral antigen in rats, mice or rabbits using the corresponding Scn ortholog.

[0143] FIG. 22 depicts the expression of a Scn fusion with a small subdomain (i.e., Kringle domain) of the extracellular tyrosine kinase receptor ROR1 and corresponding SDS PAGE analysis according to one aspect of the present disclosure. The results in FIG. 22 show that the Kringle domain failed to express when alone, while it was successfully expressed as part of a Scn fusion. These results show that the Kringle domain of the extracellular tyrosine kinase receptor ROR1 can be efficiently prepared according to one aspect of the present dislcosure. Additionally, this fusion protein has further utility because it can be used to raise antibodies against the viral antigen in rats, mice or rabbits using the corresponding Scn ortholog.

[0144] FIG. 23 depicts the expression of a Scn fusion with heptameric and trimeric subdomains and corresponding SDS PAGE analysis according to one aspect of the present disclosure. As demonstrated in FIG. 23, the presently described methods enable the expression of multimeric protein constructs in a mammalian cell culture system, where the proteins are secreted out of the cell.

[0145] FIG. 24 depicts the expression of an ExFABP fusion with a knottin and corresponding SDS PAGE analysis according to one aspect of the present disclosure. ExFABP is another functional Scn. According to the present disclosure, this construct can be used in a periplasmic bacterial system to secret a variety of client proteins.

[0146] While preferred embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention. It is intended that the following claims define the scope of the invention and that methods and structures within the scope of these claims and their equivalents be covered thereby.

TABLE-US-00002 SEQUENCES The following are DNA and/or amino acid sequences of genes of interest and constructs identified herein. Construction of parental construct for seamless cloning: IgK-SF-H6-GGS-Icn2C-GGS-ENLYFQ-GG-PARENTAL for Xho/Bam cut from pUC57 and ligation into pCVL SEQ ID NO: 1- GACTGAGTCGCCCGCTCGAGACCATGGAGACAGACACACTCCTGCTATGGGTACTGCTGC TCTGGGTTCCAGGTTCCACTGGTGACTACAAGGACGAGCATCACCATCATCACCATGGTG GAAGCCAGGACTCCACCTCAGACCTGATCCCAGCCCCACCTCTGAGCAAGGTCCCTCTGC AGCAGAACTTCCAGGACAACCAATTCCAGGGGAAGTGGTATGTGGTAGGCCTGGCAGGGA ATGCAATTCTCAGAGAAGACAAAGACCCGCAAAAGATGTATGCCACCATCTATGAGCTGAA AGAAGACAAGAGCTACAATGTCACCTCCGTCCTGTTTAGGAAAAAGAAGTGTGACTACTGG ATCAGGACTTTTGTTCCAGGTTGCCAGCCCGGCGAGTTCACGCTGGGCAACATTAAGAGTT ACCCTGGATTAACGAGTTACCTCGTCCGAGTGGTGAGCACCAACTACAACCAGCATGCTAT GGTGTTCTTCAAGAAAGTTTCTCAAAACAGGGAGTACTTCAAGATCACCCTCTACGGGAGA ACCAAGGAGCTGACTTCGGAACTAAAGGAGAACTTCATCCGCTTCTCCAAATCTCTGGGCC TCCCTGAAAACCACATCGTCTTCCCTGTCCCAATCGACCAGTGTATCGACGGCGGAGGTA GCGAAAACCTGTATTTTCAGGGAGGCGGCCGCTAAGGATCCCGGACCGCCTCTCC NotI cut is AACCTGTATTTTCAGGGAGGC - GCTAAGGATCCCGGACCGCCTCTCC Fusion protein Sequences - original set of 10 - cloned into NotI cut parent above by seamless cloning: IgK-SF-H6-GGS-Icn2C-GGS-ENLYFQ-GG-BubbleProtein SEQ ID NO: 2- GACTGAGTCGCCCGCTCGAGACCATGGAGACAGACACACTCCTGCTATGGGTACTGCTGC TCTGGGTTCCAGGTTCCACTGGTGACTACAAGGACGAGCATCACCATCATCACCATGGTG GAAGCCAGGACTCCACCTCAGACCTGATCCCAGCCCCACCTCTGAGCAAGGTCCCTCTGC AGCAGAACTTCCAGGACAACCAATTCCAGGGGAAGTGGTATGTGGTAGGCCTGGCAGGGA ATGCAATTCTCAGAGAAGACAAAGACCCGCAAAAGATGTATGCCACCATCTATGAGCTGAA AGAAGACAAGAGCTACAATGTCACCTCCGTCCTGTTTAGGAAAAAGAAGTGTGACTACTGG ATCAGGACTTTTGTTCCAGGTTGCCAGCCCGGCGAGTTCACGCTGGGCAACATTAAGAGTT ACCCTGGATTAACGAGTTACCTCGTCCGAGTGGTGAGCACCAACTACAACCAGCATGCTAT GGTGTTCTTCAAGAAAGTTTCTCAAAACAGGGAGTACTTCAAGATCACCCTCTACGGGAGA ACCAAGGAGCTGACTTCGGAACTAAAGGAGAACTTCATCCGCTTCTCCAAATCTCTGGGCC TCCCTGAAAACCACATCGTCTTCCCTGTCCCAATCGACCAGTGTATCGACGGCGGAGGTA GCGAAAACCTGTATTTTCAGGGAGGCGATACCTGCGGCAGCGGCTATAATGTGGATCAG CGTCGTACCAATAGCGGCTGCAAAGCGGGCAATGGCGATCGTCATTTTTGCGGCTGCGA TCGTACCGGCGTGGTGGAATGCAAAGGCGGCAAATGGACCGAAGTGCAGGATTGCGGC AGCAGCAGCTGCAAAGGCACCAGCAATGGCGGCGCGACCTGCTAATGCTAAGGATCCC GGA SEQ ID NO: 3- atggagacagacacactcctgctatgggtactgctgctctgggttccaggttccactggt M E T D T L L L W V L L L W V P G S T G gactacaaggacgagcatcaccatcatcaccatggtggaagccaggactccacctcagac D Y K D E H H H H H H G G S Q D S T S D ctgatcccagccccacctctgagcaaggtccctctgcagcagaacttccaggacaaccaa L I P A P P L S K V P L Q Q N F Q D N Q ttccaggggaagtggtatgtggtaggcctggcagggaatgcaattctcagagaagacaaa F Q G K W Y V V G L A G N A I L R E D K gacccgcaaaagatgtatgccaccatctatgagctgaaagaagacaagagctacaatgtc D P Q K M Y A T I Y E L K E D K S Y N V acctccgtcctgtttaggaaaaagaagtgtgactactggatcaggacttttgttccaggt T S V L F R K K K C D Y W I R T F V P G tgccagcccggcgagttcacgctgggcaacattaagagttaccctggattaacgagttac C Q P G E F T L G N I K S Y P G L T S Y ctcgtccgagtggtgagcaccaactacaaccagcatgctatggtgttcttcaagaaagtt L V R V V S T N Y N Q H A M V F F K K V tctcaaaacagggagtacttcaagatcaccctctacgggagaaccaaggagctgacttcg S Q N R E Y F K I T L Y G R T K E L T S gaactaaaggagaacttcatccgcttctccaaatctctgggcctccctgaaaaccacatc E L K E N F I R F S K S L G L P E N H I gtcttccctgtcccaatcgaccagtgtatcgacggcggaggtagcgaaaacctgtatttt V F P V P I D Q C I D G G G S E N L Y F cagggaggcgatacctgcggcagcggctataatgtggatcagcgtcgtaccaatagcggc Q G G D T C G S G Y N V D Q R R T N S G tgcaaagcgggcaatggcgatcgtcatttttgcggctgcgatcgtaccggcgtggtggaa C K A G N G D R H F C G C D R T G V V E tgcaaaggcggcaaatggaccgaagtgcaggattgcggcagcagcagctgcaaaggcacc C K G G K W T E V Q D C G S S S C K G T agcaatggcggcgcgacctgc S N G G A T C IgK-SF-H6-GGS-Icn2C-GGS-ENLYFQ-GG-Attractin SEQ ID NO: 4- GACTGAGTCGCCCGCTCGAGACCATGGAGACAGACACACTCCTGCTATGGGTACTGCTGC TCTGGGTTCCAGGTTCCACTGGTGACTACAAGGACGAGCATCACCATCATCACCATGGTG GAAGCCAGGACTCCACCTCAGACCTGATCCCAGCCCCACCTCTGAGCAAGGTCCCTCTGC AGCAGAACTTCCAGGACAACCAATTCCAGGGGAAGTGGTATGTGGTAGGCCTGGCAGGGA ATGCAATTCTCAGAGAAGACAAAGACCCGCAAAAGATGTATGCCACCATCTATGAGCTGAA AGAAGACAAGAGCTACAATGTCACCTCCGTCCTGTTTAGGAAAAAGAAGTGTGACTACTGG ATCAGGACTTTTGTTCCAGGTTGCCAGCCCGGCGAGTTCACGCTGGGCAACATTAAGAGTT ACCCTGGATTAACGAGTTACCTCGTCCGAGTGGTGAGCACCAACTACAACCAGCATGCTAT GGTGTTCTTCAAGAAAGTTTCTCAAAACAGGGAGTACTTCAAGATCACCCTCTACGGGAGA ACCAAGGAGCTGACTTCGGAACTAAAGGAGAACTTCATCCGCTTCTCCAAATCTCTGGGCC TCCCTGAAAACCACATCGTCTTCCCTGTCCCAATCGACCAGTGTATCGACGGCGGAGGTA GCGAAAACCTGTATTTTCAGGGAGGCGATCAGAATTGCGATATTGGCAATATTACCAGCC AGTGCCAGATGCAGCATAAAAATTGCGAAGATGCGAATGGCTGCGATACCATTATTGAA GAATGCAAAACCAGCATGGTGGAACGTTGCCAGAATCAGGAATTTGAAAGCGCGGCGG GCAGCACCACCCTGGGCCCGCAGTAATGCTAAGGATCCCGGA SEQ ID NO: 5- atggagacagacacactcctgctatgggtactgctgctctgggttccaggttccactggt M E T D T L L L W V L L L W V P G S T G gactacaaggacgagcatcaccatcatcaccatggtggaagccaggactccacctcagac D Y K D E H H H H H H G G S Q D S T S D ctgatcccagccccacctctgagcaaggtccctctgcagcagaacttccaggacaaccaa L I P A P P L S K V P L Q Q N F Q D N Q ttccaggggaagtggtatgtggtaggcctggcagggaatgcaattctcagagaagacaaa F Q G K W Y V V G L A G N A I L R E D K gacccgcaaaagatgtatgccaccatctatgagctgaaagaagacaagagctacaatgtc D P Q K M Y A T I Y E L K E D K S Y N V acctccgtcctgtttaggaaaaagaagtgtgactactggatcaggacttttgttccaggt T S V L F R K K K C D Y W I R T F V P G tgccagcccggcgagttcacgctgggcaacattaagagttaccctggattaacgagttac C Q P G E F T L G N I K S Y P G L T S Y ctcgtccgagtggtgagcaccaactacaaccagcatgctatggtgttcttcaagaaagtt L V R V V S T N Y N Q H A M V F F K K V tctcaaaacagggagtacttcaagatcaccctctacgggagaaccaaggagctgacttcg S Q N R E Y F K I T L Y G R T K E L T S gaactaaaggagaacttcatccgcttctccaaatctctgggcctccctgaaaaccacatc E L K E N F I R F S K S L G L P E N H I gtcttccctgtcccaatcgaccagtgtatcgacggcggaggtagcgaaaacctgtatttt V F P V P I D Q C I D G G G S E N L Y F cagggaggcgatcagaattgcgatattggcaatattaccagccagtgccagatgcagcat Q G G D Q N C D I G N I T S Q C Q M Q H aaaaattgcgaagatgcgaatggctgcgataccattattgaagaatgcaaaaccagcatg K N C E D A N G C D T I I E E C K T S M gtggaacgttgccagaatcaggaatttgaaagcgcggcgggcagcaccaccctgggcccg V E R C Q N Q E F E S A A G S T T L G P cag Q IgK-SF-H6-GGS-Icn2C-GGS-ENLYFQ-GG-Hefutoxin SEQ ID NO: 6- GACTGAGTCGCCCGCTCGAGACCATGGAGACAGACACACTCCTGCTATGGGTACTGCTGC TCTGGGTTCCAGGTTCCACTGGTGACTACAAGGACGAGCATCACCATCATCACCATGGTG GAAGCCAGGACTCCACCTCAGACCTGATCCCAGCCCCACCTCTGAGCAAGGTCCCTCTGC AGCAGAACTTCCAGGACAACCAATTCCAGGGGAAGTGGTATGTGGTAGGCCTGGCAGGGA ATGCAATTCTCAGAGAAGACAAAGACCCGCAAAAGATGTATGCCACCATCTATGAGCTGAA AGAAGACAAGAGCTACAATGTCACCTCCGTCCTGTTTAGGAAAAAGAAGTGTGACTACTGG ATCAGGACTTTTGTTCCAGGTTGCCAGCCCGGCGAGTTCACGCTGGGCAACATTAAGAGTT ACCCTGGATTAACGAGTTACCTCGTCCGAGTGGTGAGCACCAACTACAACCAGCATGCTAT GGTGTTCTTCAAGAAAGTTTCTCAAAACAGGGAGTACTTCAAGATCACCCTCTACGGGAGA ACCAAGGAGCTGACTTCGGAACTAAAGGAGAACTTCATCCGCTTCTCCAAATCTCTGGGCC TCCCTGAAAACCACATCGTCTTCCCTGTCCCAATCGACCAGTGTATCGACGGCGGAGGTA GCGAAAACCTGTATTTTCAGGGAGGCGGCCATGCGTGCTATCGTAATTGCTGGCGTGAAG GCAATGATGAAGAAACCTGCAAAGAACGTTGCTAATGCTAAGGATCCCGGACCGCC SEQ ID NO: 7- atggagacagacacactcctgctatgggtactgctgctctgggttccaggttccactggt M E T D T L L L W V L L L W V P G S T G gactacaaggacgagcatcaccatcatcaccatggtggaagccaggactccacctcagac D Y K D E H H H H H H G G S Q D S T S D ctgatcccagccccacctctgagcaaggtccctctgcagcagaacttccaggacaaccaa L I P A P P L S K V P L Q Q N F Q D N Q ttccaggggaagtggtatgtggtaggcctggcagggaatgcaattctcagagaagacaaa F Q G K W Y V V G L A G N A I L R E D K gacccgcaaaagatgtatgccaccatctatgagctgaaagaagacaagagctacaatgtc D P Q K M Y A T I Y E L K E D K S Y N V acctccgtcctgtttaggaaaaagaagtgtgactactggatcaggacttttgttccaggt T S V L F R K K K C D Y W I R T F V P G tgccagcccggcgagttcacgctgggcaacattaagagttaccctggattaacgagttac C Q P G E F T L G N I K S Y P G L T S Y ctcgtccgagtggtgagcaccaactacaaccagcatgctatggtgttcttcaagaaagtt L V R V V S T N Y N Q H A M V F F K K V tctcaaaacagggagtacttcaagatcaccctctacgggagaaccaaggagctgacttcg S Q N R E Y F K I T L Y G R T K E L T S

gaactaaaggagaacttcatccgcttctccaaatctctgggcctccctgaaaaccacatc E L K E N F I R F S K S L G L P E N H I gtcttccctgtcccaatcgaccagtgtatcgacggcggaggtagcgaaaacctgtatttt V F P V P I D Q C I D G G G S E N L Y F cagggaggcggccatgcgtgctatcgtaattgctggcgtgaaggcaatgatgaagaaacc Q G G G H A C Y R N C W R E G N D E E T tgcaaagaacgttgc C K E R C IgK-SF-H6-GGS-Icn2C-GGS-ENLYFQ-GG-Hanatoxin SEQ ID NO: 8- GACTGAGTCGCCCGCTCGAGACCATGGAGACAGACACACTCCTGCTATGGGTACTGCTGC TCTGGGTTCCAGGTTCCACTGGTGACTACAAGGACGAGCATCACCATCATCACCATGGTG GAAGCCAGGACTCCACCTCAGACCTGATCCCAGCCCCACCTCTGAGCAAGGTCCCTCTGC AGCAGAACTTCCAGGACAACCAATTCCAGGGGAAGTGGTATGTGGTAGGCCTGGCAGGGA ATGCAATTCTCAGAGAAGACAAAGACCCGCAAAAGATGTATGCCACCATCTATGAGCTGAA AGAAGACAAGAGCTACAATGTCACCTCCGTCCTGTTTAGGAAAAAGAAGTGTGACTACTGG ATCAGGACTTTTGTTCCAGGTTGCCAGCCCGGCGAGTTCACGCTGGGCAACATTAAGAGTT ACCCTGGATTAACGAGTTACCTCGTCCGAGTGGTGAGCACCAACTACAACCAGCATGCTAT GGTGTTCTTCAAGAAAGTTTCTCAAAACAGGGAGTACTTCAAGATCACCCTCTACGGGAGA ACCAAGGAGCTGACTTCGGAACTAAAGGAGAACTTCATCCGCTTCTCCAAATCTCTGGGCC TCCCTGAAAACCACATCGTCTTCCCTGTCCCAATCGACCAGTGTATCGACGGCGGAGGTA GCGAAAACCTGTATTTTCAGGGAGGCGAATGCCGTTATCTGTTTGGCGGCTGCAAAACCA CCAGCGATTGCTGCAAACATCTGGGCTGCAAATTTCGTGATAAATATTGCGCGTGGGATT TTACCTTTAGCTAATGCTAAGGATCCCGGA SEQ ID NO: 9- atggagacagacacactcctgctatgggtactgctgctctgggttccaggttccactggt M E T D T L L L W V L L L W V P G S T G gactacaaggacgagcatcaccatcatcaccatggtggaagccaggactccacctcagac D Y K D E H H H H H H G G S Q D S T S D ctgatcccagccccacctctgagcaaggtccctctgcagcagaacttccaggacaaccaa L I P A P P L S K V P L Q Q N F Q D N Q ttccaggggaagtggtatgtggtaggcctggcagggaatgcaattctcagagaagacaaa F Q G K W Y V V G L A G N A I L R E D K gacccgcaaaagatgtatgccaccatctatgagctgaaagaagacaagagctacaatgtc D P Q K M Y A T I Y E L K E D K S Y N V acctccgtcctgtttaggaaaaagaagtgtgactactggatcaggacttttgttccaggt T S V L F R K K K C D Y W I R T F V P G tgccagcccggcgagttcacgctgggcaacattaagagttaccctggattaacgagttac C Q P G E F T L G N I K S Y P G L T S Y ctcgtccgagtggtgagcaccaactacaaccagcatgctatggtgttcttcaagaaagtt L V R V V S T N Y N Q H A M V F F K K V tctcaaaacagggagtacttcaagatcaccctctacgggagaaccaaggagctgacttcg S Q N R E Y F K I T L Y G R T K E L T S gaactaaaggagaacttcatccgcttctccaaatctctgggcctccctgaaaaccacatc E L K E N F I R F S K S L G L P E N H I gtcttccctgtcccaatcgaccagtgtatcgacggcggaggtagcgaaaacctgtatttt V F P V P I D Q C I D G G G S E N L Y F cagggaggcgaatgccgttatctgtttggcggctgcaaaaccaccagcgattgctgcaaa Q G G E C R Y L F G G C K T T S D C C K catctgggctgcaaatttcgtgataaatattgcgcgtgggattttacctttagc H L G C K F R D K Y C A W D F T F S IgK-SF-H6-GGS-Icn2C-GGS-ENLYFQ-GG-ChymotrypsinInhibitor SEQ ID NO: 10- GACTGAGTCGCCCGCTCGAGACCATGGAGACAGACACACTCCTGCTATGGGTACTGCTGC TCTGGGTTCCAGGTTCCACTGGTGACTACAAGGACGAGCATCACCATCATCACCATGGTG GAAGCCAGGACTCCACCTCAGACCTGATCCCAGCCCCACCTCTGAGCAAGGTCCCTCTGC AGCAGAACTTCCAGGACAACCAATTCCAGGGGAAGTGGTATGTGGTAGGCCTGGCAGGGA ATGCAATTCTCAGAGAAGACAAAGACCCGCAAAAGATGTATGCCACCATCTATGAGCTGAA AGAAGACAAGAGCTACAATGTCACCTCCGTCCTGTTTAGGAAAAAGAAGTGTGACTACTGG ATCAGGACTTTTGTTCCAGGTTGCCAGCCCGGCGAGTTCACGCTGGGCAACATTAAGAGTT ACCCTGGATTAACGAGTTACCTCGTCCGAGTGGTGAGCACCAACTACAACCAGCATGCTAT GGTGTTCTTCAAGAAAGTTTCTCAAAACAGGGAGTACTTCAAGATCACCCTCTACGGGAGA ACCAAGGAGCTGACTTCGGAACTAAAGGAGAACTTCATCCGCTTCTCCAAATCTCTGGGCC TCCCTGAAAACCACATCGTCTTCCCTGTCCCAATCGACCAGTGTATCGACGGCGGAGGTA GCGAAAACCTGTATTTTCAGGGAGGCGAAATTAGCTGCGAACCGGGCAAAACCTTTAAAG ATAAATGCAATACCTGCCGTTGCGGCGCGGATGGCAAAAGCGCGGCGTGCACCCTGAA AGCGTGCCCGAATCAGTAATGCTAAGGATCCCGGA SEQ ID NO: 11- atggagacagacacactcctgctatgggtactgctgctctgggttccaggttccactggt M E T D T L L L W V L L L W V P G S T G gactacaaggacgagcatcaccatcatcaccatggtggaagccaggactccacctcagac D Y K D E H H H H H H G G S Q D S T S D ctgatcccagccccacctctgagcaaggtccctctgcagcagaacttccaggacaaccaa L I P A P P L S K V P L Q Q N F Q D N Q ttccaggggaagtggtatgtggtaggcctggcagggaatgcaattctcagagaagacaaa F Q G K W Y V V G L A G N A I L R E D K gacccgcaaaagatgtatgccaccatctatgagctgaaagaagacaagagctacaatgtc D P Q K M Y A T I Y E L K E D K S Y N V acctccgtcctgtttaggaaaaagaagtgtgactactggatcaggacttttgttccaggt T S V L F R K K K C D Y W I R T F V P G tgccagcccggcgagttcacgctgggcaacattaagagttaccctggattaacgagttac C Q P G E F T L G N I K S Y P G L T S Y ctcgtccgagtggtgagcaccaactacaaccagcatgctatggtgttcttcaagaaagtt L V R V V S T N Y N Q H A M V F F K K V tctcaaaacagggagtacttcaagatcaccctctacgggagaaccaaggagctgacttcg S Q N R E Y F K I T L Y G R T K E L T S gaactaaaggagaacttcatccgcttctccaaatctctgggcctccctgaaaaccacatc E L K E N F I R F S K S L G L P E N H I gtcttccctgtcccaatcgaccagtgtatcgacggcggaggtagcgaaaacctgtatttt V F P V P I D Q C I D G G G S E N L Y F cagggaggcgaaattagctgcgaaccgggcaaaacctttaaagataaatgcaatacctgc Q G G E I S C E P G K T F K D K C N T C cgttgcggcgcggatggcaaaagcgcggcgtgcaccctgaaagcgtgcccgaatcag R C G A D G K S A A C T L K A C P N Q IgK-SF-H6-GGS-Icn2C-GGS-ENLYFQ-GG-ToxinK SEQ ID NO: 12- GACTGAGTCGCCCGCTCGAGACCATGGAGACAGACACACTCCTGCTATGGGTACTGCTGC TCTGGGTTCCAGGTTCCACTGGTGACTACAAGGACGAGCATCACCATCATCACCATGGTG GAAGCCAGGACTCCACCTCAGACCTGATCCCAGCCCCACCTCTGAGCAAGGTCCCTCTGC AGCAGAACTTCCAGGACAACCAATTCCAGGGGAAGTGGTATGTGGTAGGCCTGGCAGGGA ATGCAATTCTCAGAGAAGACAAAGACCCGCAAAAGATGTATGCCACCATCTATGAGCTGAA AGAAGACAAGAGCTACAATGTCACCTCCGTCCTGTTTAGGAAAAAGAAGTGTGACTACTGG ATCAGGACTTTTGTTCCAGGTTGCCAGCCCGGCGAGTTCACGCTGGGCAACATTAAGAGTT ACCCTGGATTAACGAGTTACCTCGTCCGAGTGGTGAGCACCAACTACAACCAGCATGCTAT GGTGTTCTTCAAGAAAGTTTCTCAAAACAGGGAGTACTTCAAGATCACCCTCTACGGGAGA ACCAAGGAGCTGACTTCGGAACTAAAGGAGAACTTCATCCGCTTCTCCAAATCTCTGGGCC TCCCTGAAAACCACATCGTCTTCCCTGTCCCAATCGACCAGTGTATCGACGGCGGAGGTA GCGAAAACCTGTATTTTCAGGGAGGCGTGTGCCGTGATTGGTTTAAAGAAACCGCGTGCC GTCATGCGAAAAGCCTGGGCAATTGCCGTACCAGCCAGAAATATCGTGCGAATTGCGCG AAAACCTGCGAACTGTGCTAATGCTAAGGATCCCGGA SEQ ID NO: 13- atggagacagacacactcctgctatgggtactgctgctctgggttccaggttccactggt M E T D T L L L W V L L L W V P G S T G gactacaaggacgagcatcaccatcatcaccatggtggaagccaggactccacctcagac D Y K D E H H H H H H G G S Q D S T S D ctgatcccagccccacctctgagcaaggtccctctgcagcagaacttccaggacaaccaa L I P A P P L S K V P L Q Q N F Q D N Q ttccaggggaagtggtatgtggtaggcctggcagggaatgcaattctcagagaagacaaa F Q G K W Y V V G L A G N A I L R E D K gacccgcaaaagatgtatgccaccatctatgagctgaaagaagacaagagctacaatgtc D P Q K M Y A T I Y E L K E D K S Y N V acctccgtcctgtttaggaaaaagaagtgtgactactggatcaggacttttgttccaggt T S V L F R K K K C D Y W I R T F V P G tgccagcccggcgagttcacgctgggcaacattaagagttaccctggattaacgagttac C Q P G E F T L G N I K S Y P G L T S Y ctcgtccgagtggtgagcaccaactacaaccagcatgctatggtgttcttcaagaaagtt L V R V V S T N Y N Q H A M V F F K K V tctcaaaacagggagtacttcaagatcaccctctacgggagaaccaaggagctgacttcg S Q N R E Y F K I T L Y G R T K E L T S gaactaaaggagaacttcatccgcttctccaaatctctgggcctccctgaaaaccacatc E L K E N F I R F S K S L G L P E N H I gtcttccctgtcccaatcgaccagtgtatcgacggcggaggtagcgaaaacctgtatttt V F P V P I D Q C I D G G G S E N L Y F cagggaggcgtgtgccgtgattggtttaaagaaaccgcgtgccgtcatgcgaaaagcctg Q G G V C R D W F K E T A C R H A K S L ggcaattgccgtaccagccagaaatatcgtgcgaattgcgcgaaaacctgcgaactgtgc G N C R T S Q K Y R A N C A K T C E L C IgK-SF-H6-GGS-Icn2C-GGS-ENLYFQ-GG-EGFepiregulinCore SEQ ID NO: 14- GACTGAGTCGCCCGCTCGAGACCATGGAGACAGACACACTCCTGCTATGGGTACTGCTGC TCTGGGTTCCAGGTTCCACTGGTGACTACAAGGACGAGCATCACCATCATCACCATGGTG GAAGCCAGGACTCCACCTCAGACCTGATCCCAGCCCCACCTCTGAGCAAGGTCCCTCTGC AGCAGAACTTCCAGGACAACCAATTCCAGGGGAAGTGGTATGTGGTAGGCCTGGCAGGGA ATGCAATTCTCAGAGAAGACAAAGACCCGCAAAAGATGTATGCCACCATCTATGAGCTGAA AGAAGACAAGAGCTACAATGTCACCTCCGTCCTGTTTAGGAAAAAGAAGTGTGACTACTGG ATCAGGACTTTTGTTCCAGGTTGCCAGCCCGGCGAGTTCACGCTGGGCAACATTAAGAGTT ACCCTGGATTAACGAGTTACCTCGTCCGAGTGGTGAGCACCAACTACAACCAGCATGCTAT GGTGTTCTTCAAGAAAGTTTCTCAAAACAGGGAGTACTTCAAGATCACCCTCTACGGGAGA ACCAAGGAGCTGACTTCGGAACTAAAGGAGAACTTCATCCGCTTCTCCAAATCTCTGGGCC TCCCTGAAAACCACATCGTCTTCCCTGTCCCAATCGACCAGTGTATCGACGGCGGAGGTA GCGAAAACCTGTATTTTCAGGGAGGCGTGAGCATTACCAAATGCAGCAGCGATATGAATG GCTATTGCCTGCATGGCCAGTGCATTTATCTGGTGGATATGAGCCAGAATTATTGCCGTT GCGAAGTGGGCTATACCGGCGTGCGTTGCGAACATTTTTTTCTGTAATGCTAAGGATCCC

GGA SEQ ID NO: 15- atggagacagacacactcctgctatgggtactgctgctctgggttccaggttccactggt M E T D T L L L W V L L L W V P G S T G gactacaaggacgagcatcaccatcatcaccatggtggaagccaggactccacctcagac D Y K D E H H H H H H G G S Q D S T S D ctgatcccagccccacctctgagcaaggtccctctgcagcagaacttccaggacaaccaa L I P A P P L S K V P L Q Q N F Q D N Q ttccaggggaagtggtatgtggtaggcctggcagggaatgcaattctcagagaagacaaa F Q G K W Y V V G L A G N A I L R E D K gacccgcaaaagatgtatgccaccatctatgagctgaaagaagacaagagctacaatgtc D P Q K M Y A T I Y E L K E D K S Y N V acctccgtcctgtttaggaaaaagaagtgtgactactggatcaggacttttgttccaggt T S V L F R K K K C D Y W I R T F V P G tgccagcccggcgagttcacgctgggcaacattaagagttaccctggattaacgagttac C Q P G E F T L G N I K S Y P G L T S Y ctcgtccgagtggtgagcaccaactacaaccagcatgctatggtgttcttcaagaaagtt L V R V V S T N Y N Q H A M V F F K K V tctcaaaacagggagtacttcaagatcaccctctacgggagaaccaaggagctgacttcg S Q N R E Y F K I T L Y G R T K E L T S gaactaaaggagaacttcatccgcttctccaaatctctgggcctccctgaaaaccacatc E L K E N F I R F S K S L G L P E N H I gtcttccctgtcccaatcgaccagtgtatcgacggcggaggtagcgaaaacctgtatttt V F P V P I D Q C I D G G G S E N L Y F cagggaggcgtgagcattaccaaatgcagcagcgatatgaatggctattgcctgcatggc Q G G V S I T K C S S D M N G Y C L H G cagtgcatttatctggtggatatgagccagaattattgccgttgcgaagtgggctatacc Q C I Y L V D M S Q N Y C R C E V G Y T ggcgtgcgttgcgaacatttttttctg G V R C E H F F L IgK-SF-H6-GGS-Icn2C-GGS-ENLYFQ-GG-Circulin SEQ ID NO: 16- GACTGAGTCGCCCGCTCGAGACCATGGAGACAGACACACTCCTGCTATGGGTACTGCTGC TCTGGGTTCCAGGTTCCACTGGTGACTACAAGGACGAGCATCACCATCATCACCATGGTG GAAGCCAGGACTCCACCTCAGACCTGATCCCAGCCCCACCTCTGAGCAAGGTCCCTCTGC AGCAGAACTTCCAGGACAACCAATTCCAGGGGAAGTGGTATGTGGTAGGCCTGGCAGGGA ATGCAATTCTCAGAGAAGACAAAGACCCGCAAAAGATGTATGCCACCATCTATGAGCTGAA AGAAGACAAGAGCTACAATGTCACCTCCGTCCTGTTTAGGAAAAAGAAGTGTGACTACTGG ATCAGGACTTTTGTTCCAGGTTGCCAGCCCGGCGAGTTCACGCTGGGCAACATTAAGAGTT ACCCTGGATTAACGAGTTACCTCGTCCGAGTGGTGAGCACCAACTACAACCAGCATGCTAT GGTGTTCTTCAAGAAAGTTTCTCAAAACAGGGAGTACTTCAAGATCACCCTCTACGGGAGA ACCAAGGAGCTGACTTCGGAACTAAAGGAGAACTTCATCCGCTTCTCCAAATCTCTGGGCC TCCCTGAAAACCACATCGTCTTCCCTGTCCCAATCGACCAGTGTATCGACGGCGGAGGTA GCGAAAACCTGTATTTTCAGGGAGGCGGCATTCCGTGCGGCGAAAGCTGCGTGTGGATT CCGTGCATTAGCGCGGCGCTGGGCTGCAGCTGCAAAAATAAAGTGTGCTATCGTAATTA ATGCTAAGGATCCCGGA SEQ ID NO: 17- atggagacagacacactcctgctatgggtactgctgctctgggttccaggttccactggt M E T D T L L L W V L L L W V P G S T G gactacaaggacgagcatcaccatcatcaccatggtggaagccaggactccacctcagac D Y K D E H H H H H H G G S Q D S T S D ctgatcccagccccacctctgagcaaggtccctctgcagcagaacttccaggacaaccaa L I P A P P L S K V P L Q Q N F Q D N Q ttccaggggaagtggtatgtggtaggcctggcagggaatgcaattctcagagaagacaaa F Q G K W Y V V G L A G N A I L R E D K gacccgcaaaagatgtatgccaccatctatgagctgaaagaagacaagagctacaatgtc D P Q K M Y A T I Y E L K E D K S Y N V acctccgtcctgtttaggaaaaagaagtgtgactactggatcaggacttttgttccaggt T S V L F R K K K C D Y W I R T F V P G tgccagcccggcgagttcacgctgggcaacattaagagttaccctggattaacgagttac C Q P G E F T L G N I K S Y P G L T S Y ctcgtccgagtggtgagcaccaactacaaccagcatgctatggtgttcttcaagaaagtt L V R V V S T N Y N Q H A M V F F K K V tctcaaaacagggagtacttcaagatcaccctctacgggagaaccaaggagctgacttcg S Q N R E Y F K I T L Y G R T K E L T S gaactaaaggagaacttcatccgcttctccaaatctctgggcctccctgaaaaccacatc E L K E N F I R F S K S L G L P E N H I gtcttccctgtcccaatcgaccagtgtatcgacggcggaggtagcgaaaacctgtatttt V F P V P I D Q C I D G G G S E N L Y F cagggaggcggcattccgtgcggcgaaagctgcgtgtggattccgtgcattagcgcggcg Q G G G I P C G E S C V W I P C I S A A ctgggctgcagctgcaaaaataaagtgtgctatcgtaat L G C S C K N K V C Y R N IgK-SF-H6-GGS-Icn2C-GGS-ENLYFQ-GG-Brazzein SEQ ID NO: 18- GACTGAGTCGCCCGCTCGAGACCATGGAGACAGACACACTCCTGCTATGGGTACTGCTGC TCTGGGTTCCAGGTTCCACTGGTGACTACAAGGACGAGCATCACCATCATCACCATGGTG GAAGCCAGGACTCCACCTCAGACCTGATCCCAGCCCCACCTCTGAGCAAGGTCCCTCTGC AGCAGAACTTCCAGGACAACCAATTCCAGGGGAAGTGGTATGTGGTAGGCCTGGCAGGGA ATGCAATTCTCAGAGAAGACAAAGACCCGCAAAAGATGTATGCCACCATCTATGAGCTGAA AGAAGACAAGAGCTACAATGTCACCTCCGTCCTGTTTAGGAAAAAGAAGTGTGACTACTGG ATCAGGACTTTTGTTCCAGGTTGCCAGCCCGGCGAGTTCACGCTGGGCAACATTAAGAGTT ACCCTGGATTAACGAGTTACCTCGTCCGAGTGGTGAGCACCAACTACAACCAGCATGCTAT GGTGTTCTTCAAGAAAGTTTCTCAAAACAGGGAGTACTTCAAGATCACCCTCTACGGGAGA ACCAAGGAGCTGACTTCGGAACTAAAGGAGAACTTCATCCGCTTCTCCAAATCTCTGGGCC TCCCTGAAAACCACATCGTCTTCCCTGTCCCAATCGACCAGTGTATCGACGGCGGAGGTA GCGAAAACCTGTATTTTCAGGGAGGCCAGGATAAATGCAAAAAAGTGTATGAAAATTATC CGGTGAGCAAATGCCAGCTGGCGAATCAGTGCAATTATGATTGCAAACTGGATAAACAT GCGCGTAGCGGCGAATGCTTTTATGATGAAAAACGTAATCTGCAGTGCATTTGCGATTAT TGCGAATATTAATGCTAAGGATCCCGGA SEQ ID NO: 19- atggagacagacacactcctgctatgggtactgctgctctgggttccaggttccactggt M E T D T L L L W V L L L W V P G S T G gactacaaggacgagcatcaccatcatcaccatggtggaagccaggactccacctcagac D Y K D E H H H H H H G G S Q D S T S D ctgatcccagccccacctctgagcaaggtccctctgcagcagaacttccaggacaaccaa L I P A P P L S K V P L Q Q N F Q D N Q ttccaggggaagtggtatgtggtaggcctggcagggaatgcaattctcagagaagacaaa F Q G K W Y V V G L A G N A I L R E D K gacccgcaaaagatgtatgccaccatctatgagctgaaagaagacaagagctacaatgtc D P Q K M Y A T I Y E L K E D K S Y N V acctccgtcctgtttaggaaaaagaagtgtgactactggatcaggacttttgttccaggt T S V L F R K K K C D Y W I R T F V P G tgccagcccggcgagttcacgctgggcaacattaagagttaccctggattaacgagttac C Q P G E F T L G N I K S Y P G L T S Y ctcgtccgagtggtgagcaccaactacaaccagcatgctatggtgttcttcaagaaagtt L V R V V S T N Y N Q H A M V F F K K V tctcaaaacagggagtacttcaagatcaccctctacgggagaaccaaggagctgacttcg S Q N R E Y F K I T L Y G R T K E L T S gaactaaaggagaacttcatccgcttctccaaatctctgggcctccctgaaaaccacatc E L K E N F I R F S K S L G L P E N H I gtcttccctgtcccaatcgaccagtgtatcgacggcggaggtagcgaaaacctgtatttt V F P V P I D Q C I D G G G S E N L Y F cagggaggccaggataaatgcaaaaaagtgtatgaaaattatccggtgagcaaatgccag Q G G Q D K C K K V Y E N Y P V S K C Q ctggcgaatcagtgcaattatgattgcaaactggataaacatgcgcgtagcggcgaatgc L A N Q C N Y D C K L D K H A R S G E C ttttatgatgaaaaacgtaatctgcagtgcatttgcgattattgcgaatat F Y D E K R N L Q C I C D Y C E Y SEQ ID NO: 20- atggagacagacacactcctgctatgggtactgctgctctgggttccaggttccactggt M E T D T L L L W V L L L W V P G S T G gactacaaggacgagcatcaccatcatcaccatggtggaagccaggactccacctcagac D Y K D E H H H H H H G G S Q D S T S D ctgatcccagccccacctctgagcaaggtccctctgcagcagaacttccaggacaaccaa L I P A P P L S K V P L Q Q N F Q D N Q ttccaggggaagtggtatgtggtaggcctggcagggaatgcaattctcagagaagacaaa F Q G K W Y V V G L A G N A I L R E D K gacccgcaaaagatgtatgccaccatctatgagctgaaagaagacaagagctacaatgtc D P Q K M Y A T I Y E L K E D K S Y N V acctccgtcctgtttaggaaaaagaagtgtgactactggatcaggacttttgttccaggt T S V L F R K K K C D Y W I R T F V P G tgccagcccggcgagttcacgctgggcaacattaagagttaccctggattaacgagttac C Q P G E F T L G N I K S Y P G L T S Y ctcgtccgagtggtgagcaccaactacaaccagcatgctatggtgttcttcaagaaagtt L V R V V S T N Y N Q H A M V F F K K V tctcaaaacagggagtacttcaagatcaccctctacgggagaaccaaggagctgacttcg S Q N R E Y F K I T L Y G R T K E L T S gaactaaaggagaacttcatccgcttctccaaatctctgggcctccctgaaaaccacatc E L K E N F I R F S K S L G L P E N H I gtcttccctgtcccaatcgaccagtgtatcgacggcggaggtagcgaaaacctgtatttt V F P V P I D Q C I D G G G S E N L Y F cagggaggcatgtgcatgccgtgctttaccaccgatcatcagatggcgcgtaaatgcgat Q G G M C M P C F T T D H Q M A R K C D gattgctgcggcggcaaaggccgtggcaaatgctatggcccgcagtgcctgtgccgt D C C G G K G R G K C Y G P Q C L C R Construction of parental construct for BamH1/NotI cloning: IgK-SF-H6-GGS-Icn2C-GGS-ENLYFQ-GS-PARENTAL SEQ ID NO: 21- GACTGAGTCGCCCGCTCGAGACCATGGAGACAGACACACTCCTGCTATGGGTACTGCTGC TCTGGGTTCCAGGTTCCACTGGTGACTACAAGGACGAGCATCACCATCATCACCATGGTG GAAGCCAGGACTCCACCTCAGACCTGATCCCAGCCCCACCTCTGAGCAAGGTCCCTCTGC AGCAGAACTTCCAGGACAACCAATTCCAGGGGAAGTGGTATGTGGTAGGCCTGGCAGGGA ATGCAATTCTCAGAGAAGACAAAGACCCGCAAAAGATGTATGCCACCATCTATGAGCTGAA AGAAGACAAGAGCTACAATGTCACCTCCGTCCTGTTTAGGAAAAAGAAGTGTGACTACTGG ATCAGGACTTTTGTTCCAGGTTGCCAGCCCGGCGAGTTCACGCTGGGCAACATTAAGAGTT ACCCTGGATTAACGAGTTACCTCGTCCGAGTGGTGAGCACCAACTACAACCAGCATGCTAT GGTGTTCTTCAAGAAAGTTTCTCAAAACAGGGAGTACTTCAAGATCACCCTCTACGGGAGA

ACCAAGGAGCTGACTTCGGAACTAAAGGAGAACTTCATCCGCTTCTCCAAATCTCTGGGCC TCCCTGAAAACCACATCGTCTTCCCTGTCCCAATCGACCAGTGTATCGACGGCGGAGGTA GCGAAAACCTGTATTTTCAGGGATCCTAATGTTGGCCATGATGTTAGGCGGCCGCTAAGGA TCCCGGA BamHI site: GGATCC NotI site: GCGGCCGC A BamHI site adds "GS" before a knottin. This construct can be used for cloning libraries. Construction of parental construct for furin cleavage, BamHI/NotI cloning can include an idealized furin cut site is RARYKRS-RARYKRGS can be used for a Bam HI site. IgK-SF-H6-GGS-Icn2C-GGS-furin-GS-PARENTAL SEQ ID NO: 22- GACTGAGTCGCCCGCTCGAGACCATGGAGACAGACACACTCCTGCTATGGGTACTGCTGC TCTGGGTTCCAGGTTCCACTGGTGACTACAAGGACGAGCATCACCATCATCACCATGGTG GAAGCCAGGACTCCACCTCAGACCTGATCCCAGCCCCACCTCTGAGCAAGGTCCCTCTGC AGCAGAACTTCCAGGACAACCAATTCCAGGGGAAGTGGTATGTGGTAGGCCTGGCAGGGA ATGCAATTCTCAGAGAAGACAAAGACCCGCAAAAGATGTATGCCACCATCTATGAGCTGAA AGAAGACAAGAGCTACAATGTCACCTCCGTCCTGTTTAGGAAAAAGAAGTGTGACTACTGG ATCAGGACTTTTGTTCCAGGTTGCCAGCCCGGCGAGTTCACGCTGGGCAACATTAAGAGTT ACCCTGGATTAACGAGTTACCTCGTCCGAGTGGTGAGCACCAACTACAACCAGCATGCTAT GGTGTTCTTCAAGAAAGTTTCTCAAAACAGGGAGTACTTCAAGATCACCCTCTACGGGAGA ACCAAGGAGCTGACTTCGGAACTAAAGGAGAACTTCATCCGCTTCTCCAAATCTCTGGGCC TCCCTGAAAACCACATCGTCTTCCCTGTCCCAATCGACCAGTGTATCGACGGCGGAGGTA GCcgcgcgcgctataaacgcGGATCCTAATGTTGGCCATGATGTTAGGCGGCCGCTAAGGATCCC GGA IgK-SF-H6-GGS-Icn2C-GGS-ENLYFQ-GS-MIDKINE SEQ ID NO: 23- GACTGAGTCGCCCGCTCGAGACCATGGAGACAGACACACTCCTGCTATGGGTACTGCTGC TCTGGGTTCCAGGTTCCACTGGTGACTACAAGGACGAGCATCACCATCATCACCATGGTG GAAGCCAGGACTCCACCTCAGACCTGATCCCAGCCCCACCTCTGAGCAAGGTCCCTCTGC AGCAGAACTTCCAGGACAACCAATTCCAGGGGAAGTGGTATGTGGTAGGCCTGGCAGGGA ATGCAATTCTCAGAGAAGACAAAGACCCGCAAAAGATGTATGCCACCATCTATGAGCTGAA AGAAGACAAGAGCTACAATGTCACCTCCGTCCTGTTTAGGAAAAAGAAGTGTGACTACTGG ATCAGGACTTTTGTTCCAGGTTGCCAGCCCGGCGAGTTCACGCTGGGCAACATTAAGAGTT ACCCTGGATTAACGAGTTACCTCGTCCGAGTGGTGAGCACCAACTACAACCAGCATGCTAT GGTGTTCTTCAAGAAAGTTTCTCAAAACAGGGAGTACTTCAAGATCACCCTCTACGGGAGA ACCAAGGAGCTGACTTCGGAACTAAAGGAGAACTTCATCCGCTTCTCCAAATCTCTGGGCC TCCCTGAAAACCACATCGTCTTCCCTGTCCCAATCGACCAGTGTATCGACGGCGGAGGTA GCGAAAACCTGTATTTTCAGAGCGATTGCAAATATAAATTTGAAAACTGGGGCGCGTGCGA TGGCGGCACCGGCACCAAAGTGCGCCAGGGCACCCTGAAAAAAGCGCGCTATAACGCGC AGTGCCAGGAAACCATTCGCGTGACCAAACCGTGCTAATGCTGGATCCCGGACCGCCTCT CC SEQ ID NO: 24- atggagacagacacactcctgctatgggtactgctgctctgggttccaggttccactggt M E T D T L L L W V L L L W V P G S T G gactacaaggacgagcatcaccatcatcaccatggtggaagccaggactccacctcagac D Y K D E H H H H H H G G S Q D S T S D ctgatcccagccccacctctgagcaaggtccctctgcagcagaacttccaggacaaccaa L I P A P P L S K V P L Q Q N F Q D N Q ttccaggggaagtggtatgtggtaggcctggcagggaatgcaattctcagagaagacaaa F Q G K W Y V V G L A G N A I L R E D K gacccgcaaaagatgtatgccaccatctatgagctgaaagaagacaagagctacaatgtc D P Q K M Y A T I Y E L K E D K S Y N V acctccgtcctgtttaggaaaaagaagtgtgactactggatcaggacttttgttccaggt T S V L F R K K K C D Y W I R T F V P G tgccagcccggcgagttcacgctgggcaacattaagagttaccctggattaacgagttac C Q P G E F T L G N I K S Y P G L T S Y ctcgtccgagtggtgagcaccaactacaaccagcatgctatggtgttcttcaagaaagtt L V R V V S T N Y N Q H A M V F F K K V tctcaaaacagggagtacttcaagatcaccctctacgggagaaccaaggagctgacttcg S Q N R E Y F K I T L Y G R T K E L T S gaactaaaggagaacttcatccgcttctccaaatctctgggcctccctgaaaaccacatc E L K E N F I R F S K S L G L P E N H I gtcttccctgtcccaatcgaccagtgtatcgacggcggaggtagcgaaaacctgtatttt V F P V P I D Q C I D G G G S E N L Y F cagagcgattgcaaatataaatttgaaaactggggcgcgtgcgatggcggcaccggcacc Q S D C K Y K F E N W G A C D G G T G T aaagtgcgccagggcaccctgaaaaaagcgcgctataacgcgcagtgccaggaaaccatt K V R Q G T L K K A R Y N A Q C Q E T I cgcgtgaccaaaccgtgc R V T K P C IgK-SF-H6-GGS-Icn2C-GGS-ENLYFQ-GG-Violacin A SEQ ID NO: 25- GACTGAGTCGCCCGCTCGAGACCATGGAGACAGACACACTCCTGCTATGGGTACTGCTGC TCTGGGTTCCAGGTTCCACTGGTGACTACAAGGACGAGCATCACCATCATCACCATGGTG GAAGCCAGGACTCCACCTCAGACCTGATCCCAGCCCCACCTCTGAGCAAGGTCCCTCTGC AGCAGAACTTCCAGGACAACCAATTCCAGGGGAAGTGGTATGTGGTAGGCCTGGCAGGGA ATGCAATTCTCAGAGAAGACAAAGACCCGCAAAAGATGTATGCCACCATCTATGAGCTGAA AGAAGACAAGAGCTACAATGTCACCTCCGTCCTGTTTAGGAAAAAGAAGTGTGACTACTGG ATCAGGACTTTTGTTCCAGGTTGCCAGCCCGGCGAGTTCACGCTGGGCAACATTAAGAGTT ACCCTGGATTAACGAGTTACCTCGTCCGAGTGGTGAGCACCAACTACAACCAGCATGCTAT GGTGTTCTTCAAGAAAGTTTCTCAAAACAGGGAGTACTTCAAGATCACCCTCTACGGGAGA ACCAAGGAGCTGACTTCGGAACTAAAGGAGAACTTCATCCGCTTCTCCAAATCTCTGGGCC TCCCTGAAAACCACATCGTCTTCCCTGTCCCAATCGACCAGTGTATCGACGGCGGAGGTA GCGAAAACCTGTATTTTCAGGGAGGCAGCGCCATCAGCTGCGGCGAGACCTGCTTCAAGT TCAAGTGCTACACCCCCAGATGCAGCTGCAGCTACCCCGTGTGCAAGTAAGCTAAGGATC CCGGACCGCC SEQ ID NO: 26- atggagacagacacactcctgctatgggtactgctgctctgggttccaggttccactggt M E T D T L L L W V L L L W V P G S T G gactacaaggacgagcatcaccatcatcaccatggtggaagccaggactccacctcagac D Y K D E H H H H H H G G S Q D S T S D ctgatcccagccccacctctgagcaaggtccctctgcagcagaacttccaggacaaccaa L I P A P P L S K V P L Q Q N F Q D N Q ttccaggggaagtggtatgtggtaggcctggcagggaatgcaattctcagagaagacaaa F Q G K W Y V V G L A G N A I L R E D K gacccgcaaaagatgtatgccaccatctatgagctgaaagaagacaagagctacaatgtc D P Q K M Y A T I Y E L K E D K S Y N V acctccgtcctgtttaggaaaaagaagtgtgactactggatcaggacttttgttccaggt T S V L F R K K K C D Y W I R T F V P G tgccagcccggcgagttcacgctgggcaacattaagagttaccctggattaacgagttac C Q P G E F T L G N I K S Y P G L T S Y ctcgtccgagtggtgagcaccaactacaaccagcatgctatggtgttcttcaagaaagtt L V R V V S T N Y N Q H A M V F F K K V tctcaaaacagggagtacttcaagatcaccctctacgggagaaccaaggagctgacttcg S Q N R E Y F K I T L Y G R T K E L T S gaactaaaggagaacttcatccgcttctccaaatctctgggcctccctgaaaaccacatc E L K E N F I R F S K S L G L P E N H I gtcttccctgtcccaatcgaccagtgtatcgacggcggaggtagcgaaaacctgtatttt V F P V P I D Q C I D G G G S E N L Y F cagggaggcagcgccatcagctgcggcgagacctgcttcaagttcaagtgctacaccccc Q G G S A I S C G E T C F K F K C Y T P agatgcagctgcagctaccccgtgtgcaag R C S C S Y P V C K IgK-SF-H6-GGS-Icn2C-GGS-ENLYFQ-GG-Lambda Toxin SEQ ID NO: 27- GACTGAGTCGCCCGCTCGAGACCATGGAGACAGACACACTCCTGCTATGGGTACTGCTGC TCTGGGTTCCAGGTTCCACTGGTGACTACAAGGACGAGCATCACCATCATCACCATGGTG GAAGCCAGGACTCCACCTCAGACCTGATCCCAGCCCCACCTCTGAGCAAGGTCCCTCTGC AGCAGAACTTCCAGGACAACCAATTCCAGGGGAAGTGGTATGTGGTAGGCCTGGCAGGGA ATGCAATTCTCAGAGAAGACAAAGACCCGCAAAAGATGTATGCCACCATCTATGAGCTGAA AGAAGACAAGAGCTACAATGTCACCTCCGTCCTGTTTAGGAAAAAGAAGTGTGACTACTGG ATCAGGACTTTTGTTCCAGGTTGCCAGCCCGGCGAGTTCACGCTGGGCAACATTAAGAGTT ACCCTGGATTAACGAGTTACCTCGTCCGAGTGGTGAGCACCAACTACAACCAGCATGCTAT GGTGTTCTTCAAGAAAGTTTCTCAAAACAGGGAGTACTTCAAGATCACCCTCTACGGGAGA ACCAAGGAGCTGACTTCGGAACTAAAGGAGAACTTCATCCGCTTCTCCAAATCTCTGGGCC TCCCTGAAAACCACATCGTCTTCCCTGTCCCAATCGACCAGTGTATCGACGGCGGAGGTA GCGAAAACCTGTATTTTCAGGGAGGCGTGTGCTGCGGCTACAAGCTGTGCCACCCCTGCT AAGCTAAGGATCCCGGACC SEQ ID NO: 28- atggagacagacacactcctgctatgggtactgctgctctgggttccaggttccactggt M E T D T L L L W V L L L W V P G S T G gactacaaggacgagcatcaccatcatcaccatggtggaagccaggactccacctcagac D Y K D E H H H H H H G G S Q D S T S D ctgatcccagccccacctctgagcaaggtccctctgcagcagaacttccaggacaaccaa L I P A P P L S K V P L Q Q N F Q D N Q ttccaggggaagtggtatgtggtaggcctggcagggaatgcaattctcagagaagacaaa F Q G K W Y V V G L A G N A I L R E D K gacccgcaaaagatgtatgccaccatctatgagctgaaagaagacaagagctacaatgtc D P Q K M Y A T I Y E L K E D K S Y N V acctccgtcctgtttaggaaaaagaagtgtgactactggatcaggacttttgttccaggt T S V L F R K K K C D Y W I R T F V P G tgccagcccggcgagttcacgctgggcaacattaagagttaccctggattaacgagttac C Q P G E F T L G N I K S Y P G L T S Y ctcgtccgagtggtgagcaccaactacaaccagcatgctatggtgttcttcaagaaagtt L V R V V S T N Y N Q H A M V F F K K V tctcaaaacagggagtacttcaagatcaccctctacgggagaaccaaggagctgacttcg S Q N R E Y F K I T L Y G R T K E L T S gaactaaaggagaacttcatccgcttctccaaatctctgggcctccctgaaaaccacatc E L K E N F I R F S K S L G L P E N H I

gtcttccctgtcccaatcgaccagtgtatcgacggcggaggtagcgaaaacctgtatttt V F P V P I D Q C I D G G G S E N L Y F cagggaggcgtgtgctgcggctacaagctgtgccacccctgc Q G G V C C G Y K L C H P C IgK-SF-H6-GGS-Icn2C-GGS-ENLYFQ-GG-Lambda Toxin NG SEQ ID NO: 29- GACTGAGTCGCCCGCTCGAGACCATGGAGACAGACACACTCCTGCTATGGGTACTGCTGC TCTGGGTTCCAGGTTCCACTGGTGACTACAAGGACGAGCATCACCATCATCACCATGGTG GAAGCCAGGACTCCACCTCAGACCTGATCCCAGCCCCACCTCTGAGCAAGGTCCCTCTGC AGCAGAACTTCCAGGACAACCAATTCCAGGGGAAGTGGTATGTGGTAGGCCTGGCAGGGA ATGCAATTCTCAGAGAAGACAAAGACCCGCAAAAGATGTATGCCACCATCTATGAGCTGAA AGAAGACAAGAGCTACAATGTCACCTCCGTCCTGTTTAGGAAAAAGAAGTGTGACTACTGG ATCAGGACTTTTGTTCCAGGTTGCCAGCCCGGCGAGTTCACGCTGGGCAACATTAAGAGTT ACCCTGGATTAACGAGTTACCTCGTCCGAGTGGTGAGCACCAACTACAACCAGCATGCTAT GGTGTTCTTCAAGAAAGTTTCTCAAAACAGGGAGTACTTCAAGATCACCCTCTACGGGAGA ACCAAGGAGCTGACTTCGGAACTAAAGGAGAACTTCATCCGCTTCTCCAAATCTCTGGGCC TCCCTGAAAACCACATCGTCTTCCCTGTCCCAATCGACCAGTGTATCGACGGCGGAGGTA GCGAAAACCTGTATTTTCAGGGAGGCAACGGCGTGTGCTGCGGCTACAAGCTGTGCCACC CCTGCTAAGCTAAGGATCCCGGACC SEQ ID NO: 30- atggagacagacacactcctgctatgggtactgctgctctgggttccaggttccactggt M E T D T L L L W V L L L W V P G S T G gactacaaggacgagcatcaccatcatcaccatggtggaagccaggactccacctcagac D Y K D E H H H H H H G G S Q D S T S D ctgatcccagccccacctctgagcaaggtccctctgcagcagaacttccaggacaaccaa L I P A P P L S K V P L Q Q N F Q D N Q ttccaggggaagtggtatgtggtaggcctggcagggaatgcaattctcagagaagacaaa F Q G K W Y V V G L A G N A I L R E D K gacccgcaaaagatgtatgccaccatctatgagctgaaagaagacaagagctacaatgtc D P Q K M Y A T I Y E L K E D K S Y N V acctccgtcctgtttaggaaaaagaagtgtgactactggatcaggacttttgttccaggt T S V L F R K K K C D Y W I R T F V P G tgccagcccggcgagttcacgctgggcaacattaagagttaccctggattaacgagttac C Q P G E F T L G N I K S Y P G L T S Y ctcgtccgagtggtgagcaccaactacaaccagcatgctatggtgttcttcaagaaagtt L V R V V S T N Y N Q H A M V F F K K V tctcaaaacagggagtacttcaagatcaccctctacgggagaaccaaggagctgacttcg S Q N R E Y F K I T L Y G R T K E L T S gaactaaaggagaacttcatccgcttctccaaatctctgggcctccctgaaaaccacatc E L K E N F I R F S K S L G L P E N H I gtcttccctgtcccaatcgaccagtgtatcgacggcggaggtagcgaaaacctgtatttt V F P V P I D Q C I D G G G S E N L Y F cagggaggcaacggcgtgtgctgcggctacaagctgtgccacccctgc Q G G N G V C C G Y K L C H P C IgK-SF-H6-GGS-Icn2C-GGS-ENLYFQ-GG-Potato Carboxypeptidase Inhibitor SEQ ID NO: 31- GACTGAGTCGCCCGCTCGAGACCATGGAGACAGACACACTCCTGCTATGGGTACTGCTGC TCTGGGTTCCAGGTTCCACTGGTGACTACAAGGACGAGCATCACCATCATCACCATGGTG GAAGCCAGGACTCCACCTCAGACCTGATCCCAGCCCCACCTCTGAGCAAGGTCCCTCTGC AGCAGAACTTCCAGGACAACCAATTCCAGGGGAAGTGGTATGTGGTAGGCCTGGCAGGGA ATGCAATTCTCAGAGAAGACAAAGACCCGCAAAAGATGTATGCCACCATCTATGAGCTGAA AGAAGACAAGAGCTACAATGTCACCTCCGTCCTGTTTAGGAAAAAGAAGTGTGACTACTGG ATCAGGACTTTTGTTCCAGGTTGCCAGCCCGGCGAGTTCACGCTGGGCAACATTAAGAGTT ACCCTGGATTAACGAGTTACCTCGTCCGAGTGGTGAGCACCAACTACAACCAGCATGCTAT GGTGTTCTTCAAGAAAGTTTCTCAAAACAGGGAGTACTTCAAGATCACCCTCTACGGGAGA ACCAAGGAGCTGACTTCGGAACTAAAGGAGAACTTCATCCGCTTCTCCAAATCTCTGGGCC TCCCTGAAAACCACATCGTCTTCCCTGTCCCAATCGACCAGTGTATCGACGGCGGAGGTA GCGAAAACCTGTATTTTCAGGGAGGCcagcagcatgcggatccgatttgcaacaaaccgtgcaaaacccatgat- g attgcagcggcgcgtggttttgccaggcgtgctggaacagcgcgcgcacctgcggcccgtatgtgggcTAATGC- TAAGGAT CCCGGACCG SEQ ID NO: 32- atggagacagacacactcctgctatgggtactgctgctctgggttccaggttccactggt M E T D T L L L W V L L L W V P G S T G gactacaaggacgagcatcaccatcatcaccatggtggaagccaggactccacctcagac D Y K D E H H H H H H G G S Q D S T S D ctgatcccagccccacctctgagcaaggtccctctgcagcagaacttccaggacaaccaa L I P A P P L S K V P L Q Q N F Q D N Q ttccaggggaagtggtatgtggtaggcctggcagggaatgcaattctcagagaagacaaa F Q G K W Y V V G L A G N A I L R E D K gacccgcaaaagatgtatgccaccatctatgagctgaaagaagacaagagctacaatgtc D P Q K M Y A T I Y E L K E D K S Y N V acctccgtcctgtttaggaaaaagaagtgtgactactggatcaggacttttgttccaggt T S V L F R K K K C D Y W I R T F V P G tgccagcccggcgagttcacgctgggcaacattaagagttaccctggattaacgagttac C Q P G E F T L G N I K S Y P G L T S Y ctcgtccgagtggtgagcaccaactacaaccagcatgctatggtgttcttcaagaaagtt L V R V V S T N Y N Q H A M V F F K K V tctcaaaacagggagtacttcaagatcaccctctacgggagaaccaaggagctgacttcg S Q N R E Y F K I T L Y G R T K E L T S gaactaaaggagaacttcatccgcttctccaaatctctgggcctccctgaaaaccacatc E L K E N F I R F S K S L G L P E N H I gtcttccctgtcccaatcgaccagtgtatcgacggcggaggtagcgaaaacctgtatttt V F P V P I D Q C I D G G G S E N L Y F cagggaggccagcagcatgcggatccgatttgcaacaaaccgtgcaaaacccatgatgat Q G G Q Q H A D P I C N K P C K T H D D tgcagcggcgcgtggttttgccaggcgtgctggaacagcgcgcgcacctgcggcccgtat C S G A W F C Q A C W N S A R T C G P Y gtgggctaa V G Anti-CD3-STa bispecific The anti-CD3 is an OKT3 variant from the C-terminus of patent 7635462. It is supposed to work as either N- or C- terminal. SEQ ID NO: 33- GSDIKLQQSGAELARPGASVKMSCKTSGYTFTRYTMHWVKQRPGQGLEWIGYINPSRGYTNY NQKFKDKATLTTDKSSSTAYMQLSSLTSEDSAVYYCARYYDDHYCLDYWGQGTTLTVSSVEG GSGGSGGSGGSGGVDDIQLTQSPAIMSASPGEKVTMTCRASSSVSYMNVVYQQKSGTSPKR WIYDTSKVASGVPYRFSGSGSGTSYSLTISSMEAEDAATYYCQQWSSNPLTFGAGTKLELKGG GGSNSSNYCCELCCNPACTGCY This is designed to be dropped into the Bam/Not cut library vector as a TEV-cleavable siderocalin fusion: SEQ ID NO: 34- ACCTGTATTTTCAGGGATCCgatattaaactgcagcagagcggcgcggaactggcgcgcccgggcgcgagcgtg- aa aatgagctgcaaaaccagcggctatacctttacccgctataccatgcattgggtgaaacagcgcccgggccagg- gcctggaatgga ttggctatattaacccgagccgcggctataccaactataaccagaaatttaaagataaagcgaccctgaccacc- gataaaagcagc agcaccgcgtatatgcagctgagcagcctgaccagcgaagatagcgcggtgtattattgcgcgcgctattatga- tgatcattattgcctg gattattggggccagggcaccaccctgaccgtgagcagcgtggaaggcggcagcggcggcagcggcggcagcgg- cggcagcg gcggcgtggatgatattcagctgacccagagcccggcgattatgagcgcgagcccgggcgaaaaagtgaccatg- acctgccgcgc gagcagcagcgtgagctatatgaactggtatcagcagaaaagcggcaccagcccgaaacgctggatttatgata- ccagcaaagtg gcgagcggcgtgccgtatcgctttagcggcagcggcagcggcaccagctatagcctgaccattagcagcatgga- agcggaagatg cggcgacctattattgccagcagtggagcagcaacccgctgacctttggcgcgggcaccaaactggaactgaaa- ggcggcggcgg cagcaacagcagcaactattgctgcgaactgtgctgcaacccggcgtgcaccggctgctatTAATGCGGCCGCT- CATCA CCATTAATC Parental cloning construct 1 for downstream fusions: IgK-sFLAG-H6-GGS-humanScn-GGS-ENLYFQ-GG-NotI SEQ ID NO: 35- CTCGAGACCATGGAGACAGACACACTCCTGCTATGGGTACTGCTGCTCTGGGTTCCAGGT TCCACTGGTGACTACAAGGACGAGCATCACCATCATCACCATGGTGGAAGCCAGGACTCC ACCTCAGACCTGATCCCAGCCCCACCTCTGAGCAAGGTCCCTCTGCAGCAGAACTTCCA GGACAACCAATTCCAGGGGAAGTGGTATGTGGTAGGCCTGGCAGGGAATGCAATTCTCA GAGAAGACAAAGACCCGCAAAAGATGTATGCCACCATCTATGAGCTGAAAGAAGACAA GAGCTACAATGTCACCTCCGTCCTGTTTAGGAAAAAGAAGTGTGACTACTGGATCAGGA CTTTTGTTCCAGGTTGCCAGCCCGGCGAGTTCACGCTGGGCAACATTAAGAGTTACCCTG GATTAACGAGTTACCTCGTCCGAGTGGTGAGCACCAACTACAACCAGCATGCTATGGTG TTCTTCAAGAAAGTTTCTCAAAACAGGGAGTACTTCAAGATCACCCTCTACGGGAGAACC AAGGAGCTGACTTCGGAACTAAAGGAGAACTTCATCCGCTTCTCCAAATCTCTGGGCCTC CCTGAAAACCACATCGTCTTCCCTGTCCCAATCGACCAGTGTATCGACGGCGGAGGTAG CGAAAACCTGTATTTTCAGGGAGGCGGCCGC Parental cloning construct 2 for downstream fusions: IgK-sFLAG-H6-GGS-humanScnC87S-GGS-ENLYFQ-GS-STUFFER SEQ ID NO: 36- ATGGAGACAGACACACTCCTGCTATGGGTACTGCTGCTCTGGGTTCCAGGT TCCACTGGTGACTACAAGGACGAGCATCACCATCATCACCATGGTGGAAGCCAGGACTCC ACCTCAGACCTGATCCCAGCCCCACCTCTGAGCAAGGTCCCTCTGCAGCAGAACTTCCA GGACAACCAATTCCAGGGGAAGTGGTATGTGGTAGGCCTGGCAGGGAATGCAATTCTCA GAGAAGACAAAGACCCGCAAAAGATGTATGCCACCATCTATGAGCTGAAAGAAGACAA GAGCTACAATGTCACCTCCGTCCTGTTTAGGAAAAAGAAGTGTGACTACTGGATCAGGA CTTTTGTTCCAGGTTCCCAGCCCGGCGAGTTCACGCTGGGCAACATTAAGAGTTACCCTG GATTAACGAGTTACCTCGTCCGAGTGGTGAGCACCAACTACAACCAGCATGCTATGGTG TTCTTCAAGAAAGTTTCTCAAAACAGGGAGTACTTCAAGATCACCCTCTACGGGAGAACC AAGGAGCTGACTTCGGAACTAAAGGAGAACTTCATCCGCTTCTCCAAATCTCTGGGCCTC CCTGAAAACCACATCGTCTTCCCTGTCCCAATCGACCAGTGTATCGACGGCGGAGGTAG CGAAAACCTGTATTTTCAGGGATCCATGTACGGTCTTAAGGGACCCGACATTTACAAAGGA

GTTTACCAATTTAAGTCAGTGGAGTTTGATATGTCACATCTGAACCTGACCATGCCCAACGC ATGTTCAGCCAACAACTCCCACCATTACATCAGTATGGGGACTTCTGGACTAGAATTGACC TTCACCAATGATTCCATCATCAGTCACAACTTTTGCAATCTGACCTCTGCCTTCAACAAAAA GACCTTTGACCACACACTCATGAGTATAGTTTCGAGCCTACACCTCAGTATCAGAGGGAAC TCCAACTATAAGGCAGTATCCTGCGACTTCAACAATGGCATAACCATCCAATACAACTTGAC ATTCTCAGATCGACAAAGTGCTCAGAGCCAGTGTAGAACCTTCAGAGGTAGAGTCCTAGAT ATGTTTAGAACTGCCTTCGGGGGGAAATACATGAGGAGTGGCTGGGGCTGGACAGGCTCA GATGGCAAGACCACCTGGTGTAGCCAGACGAGTTACCAATACCTGATTATACAAAATAGAA CCTGGGAAAACCACTGCACATATGCAGGTCCTTTTGGGATGTCCAGGATTCTCCTTTCCCA AGAGAAGACTAAGTTCTTCACTAGGAGACTGGTGCCCAGGGGCAGCGGCCTGAACGACAT CTTCGAGGCCCAGAAGATCGAGTGGCACGAGTAATGCGGCCGCTCATCACCATTAATCAT CACCATTAATCGGACCG Parental cloning construct 3 for light chain fusions: LightChain-GRGGSGGS-humanScnC87S SEQ ID NO: 37- CTCGAGACCATGGATTTCCAGGTGCAGATTTTTAGCTTTCTGCTGATTTCCGCTTCCGTGAT TATGAGCCGAGGCGACATTGTGATGACCCAGGCAGCTCCTAGCGTGCCAGTCACCCCAGG AGAGTCAGTGAGCATCTCCTGCAGAAGTACTAAGTCACTGCTGCACAGCAACGGCAATAC CTACCTGTATTGGTTCCTGCAGAGACCTGGGCAGTCCCCACAGAGGCTGATCTACTATATG AGTAACCTGGCATCAGGAGTGCCTGACAGGTTCAGCGGACGAGGCAGCGGCACTGATTTT ACCCTGCGGATTTCTAGAGTGGAGGCAGAAGACGCCGGCGTCTACTATTGCATGCAGAGT CTGGAGTACCCTTATACTTTCGGCGGGGGAACCAAACTGGAAATCAAGAGGGCCGATGCC GCTCCAACCGTGTCCATTTTTCCCCCTAGCTCCGAGCAGCTGACATCTGGCGGGGCTAGT GTGGTCTGTTTCCTGAACAATTTTTACCCAAAGGACATCAACGTGAAATGGAAGATTGATG GAAGTGAAAGGCAGAACGGCGTCCTGAATTCATGGACAGACCAGGATAGCAAAGACTCCA CTTATTCTATGTCTAGTACCCTGACACTGACTAAGGATGAGTACGAACGCCACAATTCTTAT ACATGCGAGGCAACTCATAAAACCTCTACAAGTCCCATCGTGAAGAGCTTTAACCGAAATG AATGCGGCCGCGGAGGCTCCGGAGGCTCCCAGGACTCAACAAGCGATCTGATTCCAGCC CCACCCCTGAGCAAAGTGCCCCTGCAGCAGAACTTCCAGGACAATCAGTTTCAGGGCAA GTGGTACGTGGTCGGGCTGGCTGGAAACGCAATCCTGCGGGAGGACAAAGATCCCCAG AAGATGTACGCCACTATCTACGAGCTGAAAGAAGACAAGTCATACAATGTGACCAGCGT CCTGTTCCGCAAGAAAAAGTGTGATTATTGGATCAGAACATTCGTGCCCGGCTCCCAGC CTGGGGAGTTTACTCTGGGGAATATTAAGTCCTACCCTGGACTGACCTCTTATCTGGTGC GAGTGGTCTCTACAAACTACAATCAGCATGCTATGGTGTTCTTTAAAAAGGTCAGCCAGA ACCGGGAGTACTTTAAAATCACCCTGTATGGCAGAACCAAAGAACTGACAAGCGAGCTG AAGGAAAATTTCATTCGCTTTTCCAAGTCTCTGGGGCTGCCAGAGAATCATATTGTGTTC CCAGTCCCCATTGACCAGTGTATTGACGGGTGAGGATCC Super stable ScnC87S humanScn-I8C-N39C-C87S SEQ ID NO: 38- CTCGAGATGCCCCTGGGCCTGCTGTGGCTGGGCCTGGCCCTGCTGGGCGCCCTGCACG CCCAGGCCCAGGACTCCACCTCAGACCTGTGTCCAGCCCCACCTCTGAGCAAGGTCCCT CTGCAGCAGAACTTCCAGGACAACCAATTCCAGGGGAAGTGGTATGTGGTAGGCCTGGC AGGGTGTGCAATTCTCAGAGAAGACAAAGACCCGCAAAAGATGTATGCCACCATCTATG AGCTGAAAGAAGACAAGAGCTACAATGTCACCTCCGTCCTGTTTAGGAAAAAGAAGTGT GACTACTGGATCAGGACTTTTGTTCCAGGTTCCCAGCCGGGCGAGTTCACGCTGGGCAA CATTAAGAGTTACCCTGGATTAACGAGTTACCTCGTCCGAGTGGTGAGCACCAACTACAA CCAGCATGCTATGGTGTTCTTCAAGAAAGTTTCTCAAAACAGGGAGTACTTCAAGATCAC CCTCTACGGGAGAACCAAGGAGCTGACTTCGGAACTAAAGGAGAACTTCATCCGCTTCT CCAAATCTCTGGGCCTCCCTGAAAACCACATCGTCTTCCCTGTCCCAATCGACCAGTGTA TCGACGGCGGATCC Homosapiens SEQ ID NO: 39- QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQKMYATIYELKEDKS YNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIKSYPGLTSYLVRVVSTNYNQHAMVFFKKV SQNREYFKITLYGRTKELTSELKENFIRFSKSLGLPENHIVFPVPIDQCIDG Pantroglodytes SEQ ID NO: 40- QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQKMYATIYELKEDKS YNVTSVLFRKKKCDYWIRTFVPGRQPGEFTLGNIKSYPGLTSYLVRVVSTNYNQHAMVFFKKV SQNREYFKITLYGRTKELTSELQENFIRFSKSLGLPENHIVFPVPIDQCIDG Canisfamiliaris SEQ ID NO: 41- QDSTPSLIPAPPPLKVPLQPDFQHDQFQGKWYVTGIAGNILKKEGHGQLKMYTTTYELKDDQSY NVTSTLLRNERCDYWNRDFVPSFQPGQFSLGDIQLYPGVQSYLVQVVATNYNQYALVYFRKV YKSQEYFKITLYGRTKELPLELKKEFIRFAKSIGLTEDHIIFPVPIDQCIDE Bostaurus SEQ ID NO: 42- RSSSSRLLRAPPLSRIPLQPNFQADQFQGKWYTVGVAGNAIKKEEQDPLKMYSSNYELKEDGS YNVTSILLKDDLCDYWIRTFVPSSQPGQFTLGNIKSYRGIRSYTVRVVNTDYNQFAIVYFKKVQR KKTYFKITLYGRTKELTPEVRENFINFAKSLGLTDDHIVFTVPIDRCIDDQ Musmusculus SEQ ID NO: 43- QDSTQNLIPAPSLLTVPLQPDFRSDQFRGRWYVVGLAGNAVQKKTEGSFTMYSTIYELQENNS YNVTSILVRDQDQGCRYWIRTFVPSSRAGQFTLGNMHRYPQVQSYNVQVATTDYNQFAMVFF RKTSENKQYFKITLYGRTKELSPELKERFTRFAKSLGLKDDNIIFSVPTDQCIDN Rattusnorvegicus SEQ ID NO: 44- QDSTQNLIPAPPLISVPLQPGFWTERFQGRWFVVGLAANAVQKERQSRFTMYSTIYELQEDNS YNVTSILVRGQGCRYWIRTFVPSSRPGQFTLGNIHSYPQIQSYDVQVADTDYDQFAMVFFQKT SENKQYFKVTLYGRTKGLSDELKERFVSFAKSLGLKDNNIVFSVPTDQCIDN Macacamulatta SEQ ID NO: 45- QDSSSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLSGNAVGRKDEAPLKMYATIYELKEDKS YNVTSILFRKEKCDYWIRTFVPGSQPGEFTLGNIQNHPGLTSYVVRVVSTNYKQYAMVFFKKVS QNKEYFKITLYGRTKELTSELKENFIRFSKSLGLPENHIVFSVPIDQCING Tursiopstruncatus SEQ ID NO: 46- QDSTPNLIPAPPLFRVPLQPNFQPDQFQGKWYIVGLAGNAFKKEKQGQFKMYATTYELKEDRS YNVTSALLRGKTQRCDHWIRTFVPSSRPGQFTLGNIKGFPGVQSYTVRVATTNYNQFAIVYFKK VYKNQEYFKTTLYGRTKELTPQLKENFIHFAKSLGLTDEYILFPVPIDKCIDDQ Gorillagorilla SEQ ID NO: 47- QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQKMYATIYELKEDKS YNVTSVLFREKAQKCDYWIRTFVPGSQPGEFTLGNIKSYPGLTSYLVRVVSTNYNQHAMVFFK KVSQNREYFKITLYGRTKELTSELKENFIRFSKSLGLPENHIVFPVPIDQCIDG Procaviacapensis SEQ ID NO: 48- QEPTPTLIPAPPLSSIPLKPNFHNDKFQGKWYVVGVAGNAITKEKDPSLMYTTTYELRDDGSYN VTSTQFREKINCTHWTRTFVPTSQPGQFSLGNIDKYPHLSSYTVRVTATNYNYFAIVYFKKVSK NQEYFKTTLYKRIKKLTHGLKKHFIQFAKSLGLPDNHITFLVPTDRCIDDA Callithrixjacchus SEQ ID NO: 49- QDSPSPLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAIRREDQDSLKMYATIYELKEDKS YNVTSVLFRKAQKCDYWIRTFVPSSRPGEFKLGNIESHPGLTSYIVRVVNTDYKQHAMVFFMKA SHNRKYFKVTLYGRTKELTSDLKENFTSFSKSLGLTENHIIFPVPIDQCIDG Microcebusmurinus SEQ ID NO: 50- QDSKEKLIPAPPLLRVPLQPDFQDDQFRETSWPRGSKMKETPAGSRDAGTGWATTYELKDHS YNVTSTLLRQNGKCDYWIRTFVLTSQPGQFALGNINRYPGIQSYTVRVVTTNYNQFAIVFFKKV SENKEYFKTTLYGRTKELPPELKENFIRFAKSLGLTEDHIIYPVPIDQCIDD SEQ ID NO: 51- QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAIRREDKDSQKMYATIYELKEDKS YNVTSVLFRKKKCDYWIRTFVPGSQPGEFTLGNTKGYPGLTSYLVRVVSTNYNQYAMVFFKKV SQNREYFKITLYGRTKELTSELKENFIRFSKSLGLPENHIVFPAPIDQCIDG Ochotonaprinceps SEQ ID NO: 52- QELTTDLIPVPSLRKIHVQKNFQSDQFQGKWYVVGLAGNNIHNSDQEHQQMYSTTYELKEDGS YNVTSTLLRQRNQQCDHWIRTFVPGSKLGHFNLGNIKSYPTLKSYLIRVVTTDYNQFAIVFFRKV YKNNKKFFKIVLYGRTKELSPELRGRFTSFAKTLGLTDNHIVFPAPIGQCIDD Loxodontaafricana SEQ ID NO: 53- QTHSPTLIPAPPLLRVPLQPDFQDDKFQGKWYVIGLAGNAVEKKEQGQFKMYTTTYELKEDGS YNVTSTLLQEDGKCSYWIRTFVPSFQPGQFNLGNIKNFPGLQSYTVRVTATNYNQFAIVFFKKV SKNGEYFKTTLYGRTKELTPELKERFIRFAKSLGLSDHIIFPVPIDRCIDD Oryctolaguscuniculus SEQ ID NO: 54- QDPTPKLIPAPSLRRVPLQRNFQDEQFQGKWYVVGLAGNAVQKREEGQEPMYSTTYELNEDR SFNVTSTLLRDQRCDHWIRTFVPTSRPGQYNLGNIKSYPGVKNYIVRVVATDYSQYAMMFFRK GSRNKQFFKTTLYGRTKELSPELRERFTRFAKSLGLPDDRIVFPTPIDQCIDD Murine Scn construct for downstream viral fusions: IgK-H6-murineScn-StrepII-GGGGS-E7.16 gi|29468134|gb|AAO85409.1|AF402678_2 E7 [HPV16] SEQ ID NO: 55- CTCGAGACCATGGAGACCGACACGCTCTTGTTGTGGGTTCTCTTGTTGTGGGTGCCTGGG TCTACAGGCGACCACCACCATCATCACCACCTCGTTCCTAGAGGCAGCCAGGATAGTAC CCAGAATCTTATCCCAGCACCATCTTTGCTCACAGTACCATTGCAACCCGACTTTCGGTC TGATCAATTTCGGGGACGCTGGTACGTGGTTGGACTGGCCGGCAATGCTGTACAGAAAA AAACAGAGGGCAGTTTCACCATGTACTCAACAATCTATGAGCTCCAAGAGAATAATAGTT ACAACGTTACCTCCATCTTGGTGAGGGACCAGGATCAGGGATGTCGCTACTGGATTCGG ACATTCGTACCAAGTTCTCGGGCCGGTCAGTTTACTCTGGGCAACATGCACAGGTATCCC CAAGTTCAATCTTACAACGTGCAGGTGGCGACTACCGACTACAACCAATTCGCTATGGTG TTCTTCCGCAAAACAAGCGAGAACAAGCAGTATTTTAAAATCACTCTGTACGGTAGAACT AAGGAGCTGAGCCCTGAACTTAAGGAGCGGTTCACCAGATTCGCTAAGTCCCTGGGACT GAAGGATGATAATATAATCTTTTCCGTCCCCACCGATCAGTGTATCGATAATTCAGCTTG

GTCACATCCCCAGTTCGAGAAAGGAGGCGGTGGATCCATGCATGGCGACACTCCGACCCT GCACGAATACATGCTGGACCTGCAGCCCGAAACCACTGACCTGTATTGTTACGAGCAACTC AACGATTCTAGCGAGGAGGAGGACGAGATCGATGGACCGGCAGGCCAGGCCGAACCAGA CCGCGCACATTATAACATTGTTACCTTCTGTTGCAAATGTGATTCAACTCTTAGACTTTGTG TCCAGAGTACACACGTGGACATCCGCACCCTGGAAGATCTGCTGATGGGAACTCTGGGTA TCGTGTGTCCTATATGTAGCCAGAAACCCTGACGGACCG SEQ ID NO: 56- METDTLLLWVLLLWVPGSTGDHHHHHHLVPRGSQDSTQNLIPAPSLLTVPLQPDFRSDQFRG RWYVVGLAGNAVQKKTEGSFTMYSTIYELQENNSYNVTSILVRDQDQGCRYWIRTFVPSSRA GQFTLGNMHRYPQVQSYNVQVATTDYNQFAMVFFRKTSENKQYFKITLYGRTKELSPELKER FTRFAKSLGLKDDNIIFSVPTDQCIDN IgK-H6-murineScn-StrepII-GGGGS-E6.16 gi|4927720|gb|AAD33252.1|AF125673_1 E6 [HPV16] SEQ ID NO: 57- CTCGAGACCATGGAGACCGACACGCTCTTGTTGTGGGTTCTCTTGTTGTGGGTGCCTGGG TCTACAGGCGACCACCACCATCATCACCACCTCGTTCCTAGAGGCAGCCAGGATAGTAC CCAGAATCTTATCCCAGCACCATCTTTGCTCACAGTACCATTGCAACCCGACTTTCGGTC TGATCAATTTCGGGGACGCTGGTACGTGGTTGGACTGGCCGGCAATGCTGTACAGAAAA AAACAGAGGGCAGTTTCACCATGTACTCAACAATCTATGAGCTCCAAGAGAATAATAGTT ACAACGTTACCTCCATCTTGGTGAGGGACCAGGATCAGGGATGTCGCTACTGGATTCGG ACATTCGTACCAAGTTCTCGGGCCGGTCAGTTTACTCTGGGCAACATGCACAGGTATCCC CAAGTTCAATCTTACAACGTGCAGGTGGCGACTACCGACTACAACCAATTCGCTATGGTG TTCTTCCGCAAAACAAGCGAGAACAAGCAGTATTTTAAAATCACTCTGTACGGTAGAACT AAGGAGCTGAGCCCTGAACTTAAGGAGCGGTTCACCAGATTCGCTAAGTCCCTGGGACT GAAGGATGATAATATAATCTTTTCCGTCCCCACCGATCAGTGTATCGATAATTCAGCTTG GTCACATCCCCAGTTCGAGAAAGGAGGCGGTGGATCCATGCACCAGAAGAGAACCGCCAT GTTCCAGGAcCCaCAAGAGCGGCCCCGGAAACTGCCCCAACTGTGCACTGAATTGCAGAC CACCATCCACGACATCATTTTGGAATGTGTCTACTGTAAGCAGCAGCTCCTCAGGCGAGAG GTGTATGACTTCGCCTTCCGGGATTTGTGTATTGTCTACAGGGATGGTAATCCCTATGCCG TTTGTGATAAGTGCCTGAAATTTTATAGCAAGATCAGCGAGTACCGACATTACTGTTACAGC GTTTATGGAACAACATTGGAGCAGCAGTACAACAAACCTCTTTGCGACCTCCTGATTCGCT GCATCAACTGCCAGAAGCCCCTGTGCCCCGAAGAGAAACAAAGGCATTTGGATAAGAAGC AGAGGTTCCACAACATCCGCGGTCGCTGGACGGGGCGCTGCATGAGTTGCTGCAGGAGT TCCCGCACTCGGCGCGAGACCCAACTCTGACGGACCGCCTCTCCCTCCC IgK-H6-murineScn-StrepII-GGGGS-E6.18 gi|30172005|gb|AAP20594.1| E6 protein [HPV18] SEQ ID NO: 58- CTCGAGACCATGGAGACCGACACGCTCTTGTTGTGGGTTCTCTTGTTGTGGGTGCCTGGG TCTACAGGCGACCACCACCATCATCACCACCTCGTTCCTAGAGGCAGCCAGGATAGTAC CCAGAATCTTATCCCAGCACCATCTTTGCTCACAGTACCATTGCAACCCGACTTTCGGTC TGATCAATTTCGGGGACGCTGGTACGTGGTTGGACTGGCCGGCAATGCTGTACAGAAAA AAACAGAGGGCAGTTTCACCATGTACTCAACAATCTATGAGCTCCAAGAGAATAATAGTT ACAACGTTACCTCCATCTTGGTGAGGGACCAGGATCAGGGATGTCGCTACTGGATTCGG ACATTCGTACCAAGTTCTCGGGCCGGTCAGTTTACTCTGGGCAACATGCACAGGTATCCC CAAGTTCAATCTTACAACGTGCAGGTGGCGACTACCGACTACAACCAATTCGCTATGGTG TTCTTCCGCAAAACAAGCGAGAACAAGCAGTATTTTAAAATCACTCTGTACGGTAGAACT AAGGAGCTGAGCCCTGAACTTAAGGAGCGGTTCACCAGATTCGCTAAGTCCCTGGGACT GAAGGATGATAATATAATCTTTTCCGTCCCCACCGATCAGTGTATCGATAATTCAGCTTG GTCACATCCCCAGTTCGAGAAAGGAGGCGGTGGATCCATGGCCAGATTTGAAGACCCCAC AAGGCGCCCCTATAAACTGCCGGATCTTTGCACCGAACTGAATACTAGCCTGCAAGATATT GAGATTACCTGCGTGTACTGTAAAACGGTGCTCGAATTGACCGAGGTTTTTGAGTTCGCAT TCAAGGACCTGTTTGTTGTATATCGCGATTCCATCCCGCACGCAGCTTGCCATAAATGCAT TGACTTTTACTCCCGGATACGCGAGCTGCGACACTATAGTGATAGCGTGTACGGCGATACA CTTGAGAAGCTTACCAACACCGGTCTGTACAATCTTCTGATTCGGTGTTTGAGGTGCCAGA AGCCGCTCAACCCAGCTGAGAAACTGCGGCATCTGAACGAAAAAAGAAGATTCCACAACAT TGCTGGCCACTACAGGGGCCAGTGCCATTCTTGTTGTAATAGAGCAAGGCAGGAGCGGCT GCAACGGCGGCGCGAGACCCAGGTATGACGGACCGCCTCTCCCTCCC IgK-H6-murineScn-StrepII-GGGGS-E7.18 gi|285804409|gb|ADC35717.1| E7 [HPV 18] SEQ ID NO: 59- CTCGAGACCATGGAGACCGACACGCTCTTGTTGTGGGTTCTCTTGTTGTGGGTGCCTGGG TCTACAGGCGACCACCACCATCATCACCACCTCGTTCCTAGAGGCAGCCAGGATAGTAC CCAGAATCTTATCCCAGCACCATCTTTGCTCACAGTACCATTGCAACCCGACTTTCGGTC TGATCAATTTCGGGGACGCTGGTACGTGGTTGGACTGGCCGGCAATGCTGTACAGAAAA AAACAGAGGGCAGTTTCACCATGTACTCAACAATCTATGAGCTCCAAGAGAATAATAGTT ACAACGTTACCTCCATCTTGGTGAGGGACCAGGATCAGGGATGTCGCTACTGGATTCGG ACATTCGTACCAAGTTCTCGGGCCGGTCAGTTTACTCTGGGCAACATGCACAGGTATCCC CAAGTTCAATCTTACAACGTGCAGGTGGCGACTACCGACTACAACCAATTCGCTATGGTG TTCTTCCGCAAAACAAGCGAGAACAAGCAGTATTTTAAAATCACTCTGTACGGTAGAACT AAGGAGCTGAGCCCTGAACTTAAGGAGCGGTTCACCAGATTCGCTAAGTCCCTGGGACT GAAGGATGATAATATAATCTTTTCCGTCCCCACCGATCAGTGTATCGATAATTCAGCTTG GTCACATCCCCAGTTCGAGAAAGGAGGCGGTGGATCCATGCACGGACCTAAAGCAACACT CCAGGACATCGTCCTGCATTTGGAACCACAAAACGAAATACCCGTGGACCTTTTGTGTCAC GAACAGCTTTCAGATTCTGAGGAAGAGAATGATGAAATCGACGGTGTCAACCACCAGCATC TCCCCGCTAGGCGGGCAGAACCCCAGCGCCACACAATGCTGTGCATGTGTTGCAAATGCG AAGCTCGAATTGAACTCGTGGTTGAGTCCTCCGCGGACGACTTGAGGGCATTCCAGCAAC TGTTCCTCAACACACTGAGCTTTGTCTGTCCTTGGTGCGCTAGTCAGCAGTGACGGACCGC CTCTCCCTCCC IgK-H6-murineScn-StrepII-GGGGS- E6.33 gi|218931423|gb|ACL12326.1| E6 [HPV 33] SEQ ID NO: 60- CTCGAGACCATGGAGACCGACACGCTCTTGTTGTGGGTTCTCTTGTTGTGGGTGCCTGGG TCTACAGGCGACCACCACCATCATCACCACCTCGTTCCTAGAGGCAGCCAGGATAGTAC CCAGAATCTTATCCCAGCACCATCTTTGCTCACAGTACCATTGCAACCCGACTTTCGGTC TGATCAATTTCGGGGACGCTGGTACGTGGTTGGACTGGCCGGCAATGCTGTACAGAAAA AAACAGAGGGCAGTTTCACCATGTACTCAACAATCTATGAGCTCCAAGAGAATAATAGTT ACAACGTTACCTCCATCTTGGTGAGGGACCAGGATCAGGGATGTCGCTACTGGATTCGG ACATTCGTACCAAGTTCTCGGGCCGGTCAGTTTACTCTGGGCAACATGCACAGGTATCCC CAAGTTCAATCTTACAACGTGCAGGTGGCGACTACCGACTACAACCAATTCGCTATGGTG TTCTTCCGCAAAACAAGCGAGAACAAGCAGTATTTTAAAATCACTCTGTACGGTAGAACT AAGGAGCTGAGCCCTGAACTTAAGGAGCGGTTCACCAGATTCGCTAAGTCCCTGGGACT GAAGGATGATAATATAATCTTTTCCGTCCCCACCGATCAGTGTATCGATAATTCAGCTTG GTCACATCCCCAGTTCGAGAAAGGAGGCGGTGGATCCATGTTCCAAGACACTGAGGAGAA GCCACGCACGCTGCACGATCTGTGCCAGGCCCTTGAGACTACCATCCATAACATCGAGCT CCAGTGTGTCGAATGCAGGAATCCTCTTCAGCGGAGCGAGGTGTACGATTTTGCCTTCGC GGACCTGACGGTGGTCTACCGGGAAGGTAACCCATTCGGGATTTGCAAGCTGTGTCTCAG ATTTCTTAGTAAGATAAGTGAATACCGGCACTACAACTATTCAGTTTACGGTCACACTCTGG AACAGACCGTGAACAAACCCCTGAACGAGATCCTCATTCGATGTATCATCTGTCAGAGACC TCTCTGTCCGCGCGAAAAGAAGAGGCACGTCGACCTGAATAAGCGATTTCATAATATCTCT GGACGGTGGGCGGGGCGCTGTGCAGCCTGTTGGAGATCCCGGAGACGGGAAACAGCTCT TTGACGGACCGCCTCTCCCTCCC IgK-H6-murineScn-StrepII-GGGGS-E7.33 gi|218931424|gb|ACL12327.1| E7 [HPV 33] SEQ ID NO: 61- CTCGAGACCATGGAGACCGACACGCTCTTGTTGTGGGTTCTCTTGTTGTGGGTGCCTGGG TCTACAGGCGACCACCACCATCATCACCACCTCGTTCCTAGAGGCAGCCAGGATAGTAC CCAGAATCTTATCCCAGCACCATCTTTGCTCACAGTACCATTGCAACCCGACTTTCGGTC TGATCAATTTCGGGGACGCTGGTACGTGGTTGGACTGGCCGGCAATGCTGTACAGAAAA AAACAGAGGGCAGTTTCACCATGTACTCAACAATCTATGAGCTCCAAGAGAATAATAGTT ACAACGTTACCTCCATCTTGGTGAGGGACCAGGATCAGGGATGTCGCTACTGGATTCGG ACATTCGTACCAAGTTCTCGGGCCGGTCAGTTTACTCTGGGCAACATGCACAGGTATCCC CAAGTTCAATCTTACAACGTGCAGGTGGCGACTACCGACTACAACCAATTCGCTATGGTG TTCTTCCGCAAAACAAGCGAGAACAAGCAGTATTTTAAAATCACTCTGTACGGTAGAACT AAGGAGCTGAGCCCTGAACTTAAGGAGCGGTTCACCAGATTCGCTAAGTCCCTGGGACT GAAGGATGATAATATAATCTTTTCCGTCCCCACCGATCAGTGTATCGATAATTCAGCTTG GTCACATCCCCAGTTCGAGAAAGGAGGCGGTGGATCCATGCGGGGACATGAACCTACTCT GAAGGAGTACGTCCTGGACCTTTACCCGGAGCCGACAGATCTTTACTGTTACGAGCAATTG TCTGACTCCAGCGACGAGGATGAGGGCCTTGACAGACCTGATGGCCAGGCTCAGCCAGC TACTGCCGATTATTATATCGTTACGTGTTGTCACACCTGCAACACAACCGTAAGGTTGTGTG TGAACTCCACCGCCAGTGACTTGAGAACGATACAACAACTCCTCATGGGCACTGTCAATAT CGTCTGTCCTACATGTGCTCAGCTGCTGACGGACCGCCTCTCCCTCCC IgK-H6-murineScn-StrepII-GGGGS-E6.45 gi|145968371|gb|ABP99896.1| E6 [HPV45] SEQ ID NO: 62- CTCGAGACCATGGAGACCGACACGCTCTTGTTGTGGGTTCTCTTGTTGTGGGTGCCTGGG TCTACAGGCGACCACCACCATCATCACCACCTCGTTCCTAGAGGCAGCCAGGATAGTAC CCAGAATCTTATCCCAGCACCATCTTTGCTCACAGTACCATTGCAACCCGACTTTCGGTC TGATCAATTTCGGGGACGCTGGTACGTGGTTGGACTGGCCGGCAATGCTGTACAGAAAA AAACAGAGGGCAGTTTCACCATGTACTCAACAATCTATGAGCTCCAAGAGAATAATAGTT ACAACGTTACCTCCATCTTGGTGAGGGACCAGGATCAGGGATGTCGCTACTGGATTCGG ACATTCGTACCAAGTTCTCGGGCCGGTCAGTTTACTCTGGGCAACATGCACAGGTATCCC CAAGTTCAATCTTACAACGTGCAGGTGGCGACTACCGACTACAACCAATTCGCTATGGTG TTCTTCCGCAAAACAAGCGAGAACAAGCAGTATTTTAAAATCACTCTGTACGGTAGAACT

AAGGAGCTGAGCCCTGAACTTAAGGAGCGGTTCACCAGATTCGCTAAGTCCCTGGGACT GAAGGATGATAATATAATCTTTTCCGTCCCCACCGATCAGTGTATCGATAATTCAGCTTG GTCACATCCCCAGTTCGAGAAAGGAGGCGGTGGATCCATGGCCAGGTTCGATGATCCCAC CCAGCGACCCTATAAGTTGCCCGATCTCTGCACAGAACTTAACACTAGCTTGCAGGACGTA AGCATTGCATGTGTTTACTGTAAAGCTACGCTGGAGCGAACCGAGGTGTACCAATTCGCCT TCAAAGACTTGTTCATCGTGTATAGAGACTGTATCGCTTATGCCGCCTGCCACAAATGCATA GACTTTTACAGCAGGATCAGGGAATTGAGGTACTATTCCAACTCAGTCTATGGAGAAACGC TGGAGAAGATAACTAACACTGAGCTTTATAACCTCCTGATTCGCTGCCTCCGGTGTCAGAA GCCACTGAATCCTGCCGAAAAGAGACGCCATCTGAAGGACAAGCGGCGCTTTCATAGCAT TGCAGGACAGTACAGAGGCCAATGTAATACTTGCTGTGACCAAGCACGCCAAGAAAGGCT CAGGAGAAGGAGAGAGACACAGGTGTGACGGACCGCCTCTCCCTCCC IgK-H6-murineScn-StrepII-GGGGS-E7.45 gi|145968372|gb|ABP99897.1| E7 [HPV 45] SEQ ID NO: 63- CTCGAGACCATGGAGACCGACACGCTCTTGTTGTGGGTTCTCTTGTTGTGGGTGCCTGGG TCTACAGGCGACCACCACCATCATCACCACCTCGTTCCTAGAGGCAGCCAGGATAGTAC CCAGAATCTTATCCCAGCACCATCTTTGCTCACAGTACCATTGCAACCCGACTTTCGGTC TGATCAATTTCGGGGACGCTGGTACGTGGTTGGACTGGCCGGCAATGCTGTACAGAAAA AAACAGAGGGCAGTTTCACCATGTACTCAACAATCTATGAGCTCCAAGAGAATAATAGTT ACAACGTTACCTCCATCTTGGTGAGGGACCAGGATCAGGGATGTCGCTACTGGATTCGG ACATTCGTACCAAGTTCTCGGGCCGGTCAGTTTACTCTGGGCAACATGCACAGGTATCCC CAAGTTCAATCTTACAACGTGCAGGTGGCGACTACCGACTACAACCAATTCGCTATGGTG TTCTTCCGCAAAACAAGCGAGAACAAGCAGTATTTTAAAATCACTCTGTACGGTAGAACT AAGGAGCTGAGCCCTGAACTTAAGGAGCGGTTCACCAGATTCGCTAAGTCCCTGGGACT GAAGGATGATAATATAATCTTTTCCGTCCCCACCGATCAGTGTATCGATAATTCAGCTTG GTCACATCCCCAGTTCGAGAAAGGAGGCGGTGGATCCATGCACGGCCCACAGGCAACCC TGCAAGAGATCGTGCTGCATCTCGAACCACAGAATGAATTGGACCCTGTGGATCTGCTGTG TTACGAGCAGCTCTCTGAAAGCGAAGAGGAGAATGACGAGGCCGACGGCGTGTCTCATGC ACAGCTGCCTGCTCGCCGGGCCGAACCTCAGCGACACAAAATTCTGTGCGTGTGCTGCAA ATGCGACGGCCGCATAGAGCTGACGGTAGAATCATCAGCCGACGATCTGCGAACTCTTCA ACAACTCTTCCTGAGCACGCTCAGCTTCGTGTGTCCTTGGTGTGCTACAAATCAGTGACGG ACCGCCTCTCCCTCCC IgK-H6-murineScn-StrepII-GGGGS-E6.31 gi|l48727550|gb|ABR08438.1| E6 protein [HPV31] SEQ ID NO: 64- CTCGAGACCATGGAGACCGACACGCTCTTGTTGTGGGTTCTCTTGTTGTGGGTGCCTGGG TCTACAGGCGACCACCACCATCATCACCACCTCGTTCCTAGAGGCAGCCAGGATAGTAC CCAGAATCTTATCCCAGCACCATCTTTGCTCACAGTACCATTGCAACCCGACTTTCGGTC TGATCAATTTCGGGGACGCTGGTACGTGGTTGGACTGGCCGGCAATGCTGTACAGAAAA AAACAGAGGGCAGTTTCACCATGTACTCAACAATCTATGAGCTCCAAGAGAATAATAGTT ACAACGTTACCTCCATCTTGGTGAGGGACCAGGATCAGGGATGTCGCTACTGGATTCGG ACATTCGTACCAAGTTCTCGGGCCGGTCAGTTTACTCTGGGCAACATGCACAGGTATCCC CAAGTTCAATCTTACAACGTGCAGGTGGCGACTACCGACTACAACCAATTCGCTATGGTG TTCTTCCGCAAAACAAGCGAGAACAAGCAGTATTTTAAAATCACTCTGTACGGTAGAACT AAGGAGCTGAGCCCTGAACTTAAGGAGCGGTTCACCAGATTCGCTAAGTCCCTGGGACT GAAGGATGATAATATAATCTTTTCCGTCCCCACCGATCAGTGTATCGATAATTCAGCTTG GTCACATCCCCAGTTCGAGAAAGGAGGCGGTGGATCCATGTTCAAAAACCCGGCTGAGAG ACCGCGGAAGTTGCACGAGCTCTCATCCGCGCTGGAAATACCTTATGATGAGCTTCGCTT GAATTGTGTGTACTGCAAAGGCCAGCTCACTGAGACCGAAGTACTTGATTTTGCCTTTACT GACCTGACAATCGTCTATAGAGACGACACTCCACACGGGGTCTGTACAAAATGTCTGCGGT TTTATAGTAAAGTGAGCGAATTCCGGTGGTATCGCTATTCAGTGTATGGAACCACATTGGA GAAACTCACTAACAAAGGTATCTGTGACCTGCTGATCAGGTGCATAACTTGTCAGAGGCCG CTCTGCCCCGAGGAGAAGCAGCGCCACCTGGATAAGAAGAAGAGATTCCACAACATTGGA GGCAGATGGACAGGCCGGTGCATTGCTTGTTGGCGCAGGCCAAGAACCGAGACCCAAGT TTGACGGACCGCCTCTCCCTCCC IgK-H6-murineScn-StrepII-GGGGS-E7.31 gi|338969947|gb|AEJ33624.1| E7, partial [HPV31] SEQ ID NO: 65- CTCGAGACCATGGAGACCGACACGCTCTTGTTGTGGGTTCTCTTGTTGTGGGTGCCTGGG TCTACAGGCGACCACCACCATCATCACCACCTCGTTCCTAGAGGCAGCCAGGATAGTAC CCAGAATCTTATCCCAGCACCATCTTTGCTCACAGTACCATTGCAACCCGACTTTCGGTC TGATCAATTTCGGGGACGCTGGTACGTGGTTGGACTGGCCGGCAATGCTGTACAGAAAA AAACAGAGGGCAGTTTCACCATGTACTCAACAATCTATGAGCTCCAAGAGAATAATAGTT ACAACGTTACCTCCATCTTGGTGAGGGACCAGGATCAGGGATGTCGCTACTGGATTCGG ACATTCGTACCAAGTTCTCGGGCCGGTCAGTTTACTCTGGGCAACATGCACAGGTATCCC CAAGTTCAATCTTACAACGTGCAGGTGGCGACTACCGACTACAACCAATTCGCTATGGTG TTCTTCCGCAAAACAAGCGAGAACAAGCAGTATTTTAAAATCACTCTGTACGGTAGAACT AAGGAGCTGAGCCCTGAACTTAAGGAGCGGTTCACCAGATTCGCTAAGTCCCTGGGACT GAAGGATGATAATATAATCTTTTCCGTCCCCACCGATCAGTGTATCGATAATTCAGCTTG GTCACATCCCCAGTTCGAGAAAGGAGGCGGTGGATCCATGCGGGGTGAGACACCAACTCT TCAGGATTATGTTCTGGATCTGCAGCCAGAGGCCACAGATCTGCACTGTTACGAGCAATTG CCTGATTCCAGCGACGAGGAGGATGTCATCGATAGCCCTGCTGGGCAGGCCAAGCCAGA CACTTCAAATTACAACATTGTAACGTTTTGTTGTCAGTGCGAATCCACCCTCAGGCTTTGCG TCCAGAGCACTCAGGTTGACATTCGAATACTCCAGGAGCTGTTGATGGGGAGCTTTGGAAT CGTGTGCCCAAATTGTAGTACACGACTGTGACGGACCGCCTCTCCCTCCC IgK-H6-murineScn-StrepII-GGGGS-E6.58 gi|425892429|gb|AFY09749.1| E6 [HPV 58] SEQ ID NO: 66- CTCGAGACCATGGAGACCGACACGCTCTTGTTGTGGGTTCTCTTGTTGTGGGTGCCTGGG TCTACAGGCGACCACCACCATCATCACCACCTCGTTCCTAGAGGCAGCCAGGATAGTAC CCAGAATCTTATCCCAGCACCATCTTTGCTCACAGTACCATTGCAACCCGACTTTCGGTC TGATCAATTTCGGGGACGCTGGTACGTGGTTGGACTGGCCGGCAATGCTGTACAGAAAA AAACAGAGGGCAGTTTCACCATGTACTCAACAATCTATGAGCTCCAAGAGAATAATAGTT ACAACGTTACCTCCATCTTGGTGAGGGACCAGGATCAGGGATGTCGCTACTGGATTCGG ACATTCGTACCAAGTTCTCGGGCCGGTCAGTTTACTCTGGGCAACATGCACAGGTATCCC CAAGTTCAATCTTACAACGTGCAGGTGGCGACTACCGACTACAACCAATTCGCTATGGTG TTCTTCCGCAAAACAAGCGAGAACAAGCAGTATTTTAAAATCACTCTGTACGGTAGAACT AAGGAGCTGAGCCCTGAACTTAAGGAGCGGTTCACCAGATTCGCTAAGTCCCTGGGACT GAAGGATGATAATATAATCTTTTCCGTCCCCACCGATCAGTGTATCGATAATTCAGCTTG GTCACATCCCCAGTTCGAGAAAGGAGGCGGTGGATCCATGTTTCAGGACGCTGAGGAGAA GCCCAGAACTCTGCACGATCTGTGTCAGGCCTTGGAGACGTCTGTGCATAAAATTGAGCTT AAATGTGTCGAATGTAAGAAGACACTCCAGCGCAGCGAAGTTTATGACTTCGTGTTCGCGG ATCTGAGAATCGTGTATCGGGACGGCAACCCTTTTGCTGTTTGCAAGGTTTGCCTTAGGCT CCTGTCCAAAATTAGCGAGTACCGCCACTATAACTACTCTCTCTACGGTGATACTCTCGAG CAAACACTGAAGAAGTGCTTGAACGAGATCCTGATTAGATGCATCATTTGTCAAAGGCCAC TTTGTCCACAGGAGAAGAAGAGGCACGTGGACCTGAATAAGCGCTTTCATAACATCTCTGG CAGATGGACAGGCCGATGCGCTGTATGTTGGCGCCCACGGAGAAGGCAAACCCAGGTGT GACGGACCGCCTCTCCCTCCC IgK-H6-murineScn-StrepII-GGGGS-E7.58 gi|414090989|gb|AFW98384.1| E7 [HPV 58] SEQ ID NO: 67- CTCGAGACCATGGAGACCGACACGCTCTTGTTGTGGGTTCTCTTGTTGTGGGTGCCTGGG TCTACAGGCGACCACCACCATCATCACCACCTCGTTCCTAGAGGCAGCCAGGATAGTAC CCAGAATCTTATCCCAGCACCATCTTTGCTCACAGTACCATTGCAACCCGACTTTCGGTC TGATCAATTTCGGGGACGCTGGTACGTGGTTGGACTGGCCGGCAATGCTGTACAGAAAA AAACAGAGGGCAGTTTCACCATGTACTCAACAATCTATGAGCTCCAAGAGAATAATAGTT ACAACGTTACCTCCATCTTGGTGAGGGACCAGGATCAGGGATGTCGCTACTGGATTCGG ACATTCGTACCAAGTTCTCGGGCCGGTCAGTTTACTCTGGGCAACATGCACAGGTATCCC CAAGTTCAATCTTACAACGTGCAGGTGGCGACTACCGACTACAACCAATTCGCTATGGTG TTCTTCCGCAAAACAAGCGAGAACAAGCAGTATTTTAAAATCACTCTGTACGGTAGAACT AAGGAGCTGAGCCCTGAACTTAAGGAGCGGTTCACCAGATTCGCTAAGTCCCTGGGACT GAAGGATGATAATATAATCTTTTCCGTCCCCACCGATCAGTGTATCGATAATTCAGCTTG GTCACATCCCCAGTTCGAGAAAGGAGGCGGTGGATCCATGCGGGGGAATAACCCCACCCT GCGCGAGTACATTCTTGACCTGCACCCAGAGCCTACGGATCTGTTTTGTTACGAACAACTG TGCGACTCCTCCGACGAGGATGAGATCGGGCTGGATGGCCCAGACGGGCAGGCACAGCC TGCTACAGCTAACTACTATATTGTGACATGTTGCTACACATGCGGAACGACGGTCAGACTG TGCATTAATAGCACTGCCACAGACGTGCGGACCCTGCAGCAACTGCTCATGGGGACCTGC ACTATTGTGTGTCCTTCATGTGCGCAGCAATGACGGACCGCCTCTCCCTCCC Human Scn construct for downstream viral fusions: IgK-sFLAG-H6-GGS-humanScn-GGS-ENLYFQ-GG-Adv2E3/19K SEQ ID NO: 68- METDTLLLWVLLLWVPGSTGDYKDEHHHHHHGGSQDSTSDLIPAPPLSKVPLQQNFQDNQF QGKWYVVGLAGNAILREDKDPQKMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGSQP GEFTLGNIKSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTSELKENFI RFSKSLGLPENHIVFPVPIDQCIDGGGSENLYFQGGAKKVEFKEPACNVTFKSEANECTTLIKC TTEHEKLIIRHKDKIGKYAVYAIWQPGDTNDYNVTVFQGENRKTFMYKFPFYEMCDITMYMSKQ YKLW IgK-sFLAG-H6-GGS-humanScn-GGS-ENLYFQ-GG-SF162gp120 SEQ ID NO: 69- METDTLLLWVLLLWVPGSTGDYKDEHHHHHHGGSQDSTSDLIPAPPLSKVPLQQNFQDNQF QGKWYVVGLAGNAILREDKDPQKMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGSQP GEFTLGNIKSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTSELKENFI RFSKSLGLPENHIVFPVPIDQCIDGGGSENLYFQGGWVTVYYGVPVWKEATTTLFCASDAKAY DTEVHNVWATHACVPTDPNPQEIVLENVTENFNMWKNNMVEQMHEDIISLWDQSLKPCVKLT PLCVTLHCTNLKNATNTKSSNWKEMDRGEIKNCSFKVTTSIRNKMQKEYALFYKLDVVPIDNDN

TSYKLINCNTSVITQACPKVSFEPIPIHYCAPAGFAILKCNDKKFNGSGPCTNVSTVQCTHGIRPV VSTQLLLNGSLAEEGVVIRSENFTDNAKTIIVQLKESVEINCTRPNNNTRKSITIGPGRAFYATGDI IGDIRQAHCNISGEKWNNTLKQIVTKLQAQFGNKTIVFKQSSGGDPEIVMHSFNCGGEFFYCNS TQLFNSTWNNTIGPNNTNGTITLPCRIKQIINRWQEVGKAMYAPPIRGQIRCSSNITGLLLTRDG GKEISNTTEIFRPGGGDMRDNWRSELYKYKVVKIEPLGVAPTKAKRRVVQQGLNDIFEAQKIEW HE IgK-sFLAG-H6-GGS-humanScn-GGS-ENLYFQ-GG-QH0692gp120 SEQ ID NO: 70- METDTLLLWVLLLWVPGSTGDYKDEHHHHHHGGSQDSTSDLIPAPPLSKVPLQQNFQDNQF QGKWYVVGLAGNAILREDKDPQKMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGSQP GEFTLGNIKSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTSELKENFI RFSKSLGLPENHIVFPVPIDQCIDGGGSENLYFQGGWVTVYYGVPVWKEATTTLFCASDAKAY ETEKHNVWATHACVPTDPNPQEVVLGNVTENFNMWKNNMVEQMHEDIISLWDESLKPCVKLT PLCVTLNCTDEVKTSYANKTSNETYKTSNETFGEIKNCSFSVPTGIKDKVQNVYALFYKLDVIPID DNNNSSKNNNGSYSSYRLINCNTSVITQACPKVSFEPIPIHYCAPAGFAILKCNNKTFNGTGPCT NVSTVQCTHGIRPVVSTQLLLNGSLAEEEVVIRSENFTNNAKTIIVHLKKSVEINCTRPGNNTRKS IHIGPGRAFYATGDIIGDIRQAHCNLSSVQWNDTLKQIVIKLGEQFGTNKTIAFNQSSGGDPEIVM HSFNCGGEFFYCNTTQLFNSTWEFHGNWTRSNFTESNSTTITLPCRIKQIVNMWQEVGKAMY APPIRGQIRCSSNITGLLLTRDGGVNGTRETFRPGGGDMRDNWRSELYKYKVVKIEPLGVAPT KAKRRVVQGLNDIFEAQKIEWHE Human Scn construct for downstream peptide fusions: IgK-sFLAG-H6-GGS-humanScn-GGS-ENLYFQ-GG-ITPR-1 SEQ ID NO: 71- METDTLLLWVLLLWVPGSTGDYKDEHHHHHHGGSQDSTSDLIPAPPLSKVPLQQNFQDNQF QGKWYVVGLAGNAILREDKDPQKMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGSQP GEFTLGNIKSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTSELKENFI RFSKSLGLPENHIVFPVPIDQCIDGGGSENLYFQGGSKCRVFNTTERDEQGSKVNDFFQQTED LYNEMKWQK IgK-sFLAG-H6-GGS-humanScn-GGS-ENLYFQ-GG-ITPR-2 SEQ ID NO: 72- METDTLLLWVLLLWVPGSTGDYKDEHHHHHHGGSQDSTSDLIPAPPLSKVPLQQNFQDNQF QGKWYVVGLAGNAILREDKDPQKMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGSQP GEFTLGNIKSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTSELKENFI RFSKSLGLPENHIVFPVPIDQCIDGGGSENLYFQGGPPHELTEEEKQQILHSEEFLSFFDHSTRI VERALSE IdK-sFLAG-H6-GGS-humanScn-GGS-ENLYFQ-GG-ITPR-3 SEQ ID NO: 73- METDTLLLWVLLLWVPGSTGDYKDEHHHHHHGGSQDSTSDLIPAPPLSKVPLQQNFQDNQF QGKWYVVGLAGNAILREDKDPQKMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGSQP GEFTLGNIKSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTSELKENFI RFSKSLGLPENHIVFPVPIDQCIDGGGSENLYFQGGPPPRCISTNKCTAPEVENAIRVPGNRSF FSLTEIVR IgK-sFLAG-H6-GGS-humanScn-GGS-ENLYFQ-GG-ITPR-4 SEQ ID NO: 74- METDTLLLWVLLLWVPGSTGDYKDEHHHHHHGGSQDSTSDLIPAPPLSKVPLQQNFQDNQFQ GKWYVVGLAGNAILREDKDPQKMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGSQPGE FTLGNIKSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTSELKENFIRFS KSLGLPENHIVFPVPIDQCIDGGGSENLYFQGGTERDEQGSKINDFFLRSEDLFNEMNWQKKL RAQPVL IgK-sFLAG-H6-GGS-humanScn-GGS-ENLYFQ-GG-ITPR-5 SEQ ID NO: 75- METDTLLLWVLLLWVPGSTGDYKDEHHHHHHGGSQDSTSDLIPAPPLSKVPLQQNFQDNQF QGKWYVVGLAGNAILREDKDPQKMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGSQP GEFTLGNIKSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTSELKENFI RFSKSLGLPENHIVFPVPIDQCIDGGGSENLYFQGGLTEETKHRLFTTTEQDEQGSKVSDFFDQ SSFLHNEM IgK-sFLAG-H6-GGS-humanScn-GGS-ENLYFQ-GG-ITPR-8 SEQ ID NO: 76- METDTLLLWVLLLWVPGSTGDYKDEHHHHHHGGSQDSTSDLIPAPPLSKVPLQQNFQDNQF QGKWYVVGLAGNAILREDKDPQKMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGSQP GEFTLGNIKSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTSELKENFI RFSKSLGLPENHIVFPVPIDQCIDGGGSENLYFQGGGAQPPFDAQSPLDSQPQPSGQPWNFH ASTSWYWRQS Human Scn construct for downstream HMOX1 fusions: IgK-5FLAG-H6-GGS-humanScn-GGS-ENLYFQ-GG-human HMOX1 SEQ ID NO: 77- METDTLLLWVLLLWVPGSTGDYKDEHHHHHHGGSQDSTSDLIPAPPLSKVPLQQNFQDNQF QGKWYVVGLAGNAILREDKDPQKMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGSQP GEFTLGNIKSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTSELKENFI RFSKSLGLPENHIVFPVPIDQCIDGGGSENLYFQGGMERPQPDSMPQDLSEALKEATKEVHTQ AENAEFMRNFQKGQVTRDGFKLVMASLYHIYVALEEEIERNKESPVFAPVYFPEELHRKAALEQ DLAFWYGPRWQEVIPYTPAMQRYVKRLHEVGRTEPELLVAHAYTRYLGDLSGGQVLKKIAQKA LDLPSSGEGLAFFTFPNIASATKFKQLYRSRMNSLEMTPAVRQRVIEEAKTAFLLNIQLFEELQE LLTHDTKDQSPSRAPGLRQRASNKVQDSAPVETPRGKPPLNTRSQA IgK-sFLAG-H6-GGS-humanScn-GGS-ENLYFQ-GG-murineHMOX1 SEQ ID NO: 78- METDTLLLWVLLLWVPGSTGDYKDEHHHHHHGGSQDSTSDLIPAPPLSKVPLQQNFQDNQF QGKWYVVGLAGNAILREDKDPQKMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGSQP GEFTLGNIKSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTSELKENFI RFSKSLGLPENHIVFPVPIDQCIDGGGSENLYFQGGMERPQPDSMPQDLSEALKEATKEVHIQ AENAEFMKNFQKGQVSREGFKLVMASLYHIYTALEEEIERNKQNPVYAPLYFPEELHRRAALEQ DMAFWYGPHWQEIIPCTPATQHYVKRLHEVGRTHPELLVAHAYTRYLGDLSGGQVLKKIAQKA MALPSSGEGLAFFTFPNIDSPTKFKQLYRARMNTLEMTPEVKHRVTEEAKTAFLLNIELFEELQV MLTEEHKDQSPSQMASLRQRPASLVQDTAPAETPRGKPQISTSSSQ* humanScn-humanHMOX1 (Second Generation) SEQ ID NO: 79- MPLGLLWLGLALLGALHAQAQDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAI LREDKDPQKMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGSQPGEFTLGNIKSYPGLT SYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTSELKENFIRFSKSLGLPENHIVF PVPIDQCIDGGGSENLYFQGGGMERPQPDSMPQDLSEALKEATKEVHT QAENAEFMRNFQKGQVTRDGFKLVMASLYHIYVALEEEIERNKESPVFAPVYFPEELHRKAALE QDLAFWYGPRWQEVIPYTPAMQRYVKRLHEVGRTEPELLVAHAYTRYLGDLSGGQVLKKIAQ KALDLPSSGEGLAFFTFPNIASATKFKQLYRSRMNSLEMTPAVRQRVIEEAKTAFLLNIQLFEEL QELLTHDTKDQSPSRAPGLRQRASNKVQDSAPVETPRGKPPLNTRSQAGGLVPRGSHHHHH H humanScn-cTHAP4 SEQ ID NO: 80- MPLGLLWLGLALLGALHAQAQDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAI LREDKDPQKMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGSQPGEFTLGNIKSYPGLT SYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTSELKENFIRFSKSLGLPENHIVF PVPIDQCIDGGGSENLYFQGGGPPKMNPVVEPLSWMLGTWLSDPPGAG TYPTLQPFQYLEEVHISHVGQPMLNFSFNSFHPDTRKPMHRECGFIRLKPDTNKVAFVSAQNT GVVEVEEGEVNGQELCIASHSIARISFAKEPHVEQITRKFRLNSEGKLEQTVSMATTTQPMTQH LHVTYKKVTPGGLVPRGSHHHHHH Human Scn construct for downstream multimer fusions: IgK-sFLAG-H6-GGS-humanScn-GGS-ENLYFQ-GG-heptamer SEQ ID NO: 81- METDTLLLWVLLLWVPGSTGDYKDEHHHHHHGGSQDSTSDLIPAPPLSKVPLQQNFQDNQF QGKWYVVGLAGNAILREDKDPQKMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGSQP GEFTLGNIKSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTSELKENFI RFSKSLGLPENHIVFPVPIDQCIDGGGSENLYFQGGGRSAGAHAGWETPEGCEQVLTGKRLM QCLPNPEDVKMALEVYKLSLEIEQLELQRDSARQSTLDKELVPRGS IgK-sFLAG-H6-GGS-humanScn-GGS-ENLYFQ-GG-CD80heptamer SEQ ID NO: 82- METDTLLLWVLLLWVPGSTGDYKDEHHHHHHGGSQDSTSDLIPAPPLSKVPLQQNFQDNQF QGKWYVVGLAGNAILREDKDPQKMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGSQP GEFTLGNIKSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTSELKENFI RFSKSLGLPENHIVFPVPIDQCIDGGGSENLYFQGGGIIQVNKTVKEVAVLSCDYNISTTELMKV RIYWQKDDEVVLAVTSGQTKVWSKYENRTFADFTNNLSIVIMALRLSDNGKYTCIVQKTEKRSY KVKHMTSVMLLVRADFPVPSITDLGNPSHDIKRIMCSTSGGFPKPHLSWWENEEELNAANTTV SQDPDTELYTISSELDFNITSNHSFVCLVKYGDLTVSQIFNWQKSVEPHPPNNSAWSHPQFEK GGSLVPRGSGSAGAHAGWETPEGCEQVLTGKRLMQCLPNPEDVKMALXVYKLSLEIEQLELQ RDSARQSTLDKELVPRGS IgK-sFLAG-H6-GGS-humanScn-GGS-ENLYFQ-GG-trimer SEQ ID NO: 83- METDTLLLWVLLLWVPGSTGDYKDEHHHHHHGGSQDSTSDLIPAPPLSKVPLQQNFQDNQF QGKWYVVGLAGNAILREDKDPQKMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGSQP GEFTLGNIKSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTSELKENFI RFSKSLGLPENHIVFPVPIDQCIDGGGSENLYFQGGGRNLVTAFSNMDDMLQKAHLVIEGTFIY LRDSTEFFIRVRDGWKKLQLGELIPIPA IgK-sFLAG-H6-GGS-humanScn-GGS-ENLYFQ-GG-CD80trimer SEQ ID NO: 84- METDTLLLWVLLLWVPGSTGDYKDEHHHHHHGGSQDSTSDLIPAPPLSKVPLQQNFQDNQF QGKWYVVGLAGNAILREDKDPQKMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGSQP GEFTLGNIKSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTSELKENFI RFSKSLGLPENHIVFPVPIDQCIDGGGSENLYFQGGGIIQVNKTVKEVAVLSCDYNISTTELMKV RIYWQKDDEVVLAVTSGQTKVWSKYENRTFADFTNNLSIVIMALRLSDNGKYTCIVQKTEKRSY KVKHMTSVMLLVRADFPVPSITDLGNPSHDIKRIMCSTSGGFPKPHLSWWENEEELNAANTTV SQDPDTELYTISSELDFNITSNHSFVCLVKYGDLTVSQIFNWQKSVEPHPPNNSAWSHPQFEK GGSLVPRGSGNLVTAFSNMDDMLQKAHLVIEGTFIYLRDSTEFFIRVRDGWKKLQLGELIPIPA IgK-sFLAG-H6-GGS-humanScn-GGS-ENLYFQ-GG-pentamer SEQ ID NO: 85- METDTLLLWVLLLWVPGSTGDYKDEHHHHHHGGSQDSTSDLIPAPPLSKVPLQQNFQDNQF

QGKWYVVGLAGNAILREDKDPQKMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGSQP GEFTLGNIKSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTSELKENFI RFSKSLGLPENHIVFPVPIDQCIDGGGSENLYFQGGGRSSNAKWDQWSSDWQTWNAKWDQ WSNDWNAWRSDWQAWKDDWARWNQRWDNWAT Human Scn construct for downstream subdomain fusions: IgK-sFLAG-H6-GGS-humanScn-GGS-ENLYFQ-GG-ROR1Kringle SEQ ID NO: 86- METDTLLLWVLLLWVPGSTGDYKDEHHHHHHGGSQDSTSDLIPAPPLSKVPLQQNFQDNQF QGKWYVVGLAGNAILREDKDPQKMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGSQP GEFTLGNIKSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTSELKENFI RFSKSLGLPENHIVFPVPIDQCIDGGGSENLYFQGGCYNSTGVDYRGTVSVTKSGRQCQPWN SQYPHTHTFTALRFPELNGGHSYCRNPGNQKEAPWCFTLDENFKSDLCDIPAC IgK-sFLAG-H6-GGS-humanScn-GGS-ENLYFQ-GG-CTLA4 SEQ ID NO: 87- METDTLLLWVLLLWVPGSTGDYKDEHHHHHHGGSQDSTSDLIPAPPLSKVPLQQNFQDNQF QGKWYVVGLAGNAILREDKDPQKMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGSQP GEFTLGNIKSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTSELKENFI RFSKSLGLPENHIVFPVPIDQCIDGGGSENLYFQGGMHVAQPAVVLASSRGVASFVCEYGSSG NAAEVRVTVLRQAGSQMTEVCAATYTVEDELAFLDDSTCTGTSSGNKVNLTIQGLRAMDTGLY ICKVELMYPPPYYVGMGNGTQIYVIDPEPC Human Scn construct for downstream knottin fusions: IgK-sFLAG-H6-GGS-humanScn-GGS-ENLYFQ-GG-Imperatoxin SEQ ID NO: 88- CTCGAGACCATGGAGACAGACACACTCCTGCTATGGGTACTGCTGCTCTGGGTTCCAGG TTCCACTGGTGACTACAAGGACGAGCATCACCATCATCACCATGGTGGAAGCCAGGACT CCACCTCAGACCTGATCCCAGCCCCACCTCTGAGCAAGGTCCCTCTGCAGCAGAACTTC CAGGACAACCAATTCCAGGGGAAGTGGTATGTGGTAGGCCTGGCAGGGAATGCAATTCT CAGAGAAGACAAAGACCCGCAAAAGATGTATGCCACCATCTATGAGCTGAAAGAAGAC AAGAGCTACAATGTCACCTCCGTCCTGTTTAGGAAAAAGAAGTGTGACTACTGGATCAG GACTTTTGTTCCAGGTTGCCAGCCCGGCGAGTTCACGCTGGGCAACATTAAGAGTTACC CTGGATTAACGAGTTACCTCGTCCGAGTGGTGAGCACCAACTACAACCAGCATGCTATG GTGTTCTTCAAGAAAGTTTCTCAAAACAGGGAGTACTTCAAGATCACCCTCTACGGGAGA ACCAAGGAGCTGACTTCGGAACTAAAGGAGAACTTCATCCGCTTCTCCAAATCTCTGGG CCTCCCTGAAAACCACATCGTCTTCCCTGTCCCAATCGACCAGTGTATCGACGGCGGAG GTAGCGAAAACCTGTATTTTCAGGGAGGCGACTGCCTGCCCCACCTGAGGAGGTGCAGG GCCGACAACGACTGCTGCGGCAGGAGGTGCAGGAGGAGGGGCACCAACGCCGAGAGGA GGTGCAGGTAAGCTAAGGATCC IgK SP: Murine IgK light chain signal peptide: SEQ ID NO: 89- METDTLLLWVLLLWVPGSTG SEQ ID NO: 90- ATGGAGACAGACACACTCCTGCTATGGGTACTGCTGCTCTGGGTTCCAGGTTCCACTGGT sFLAG: Shortened FLAG epitope: SEQ ID NO: 91- DYKDE SEQ ID NO: 92- GACTACAAGGACGAG HIS: 6xhistidine tag SEQ ID NO: 93- HHHHHH SEQ ID NO: 94- CATCATCATCATCATCAT TEV: Tobacco Etch Virus Protease recognition site: SEQ ID NO: 95- ENLYFQ SEQ ID NO: 96- GAGAATTTATATTTTCAG SEQ ID NO: 97- Furin - furin cleavage site with BamHI site (GGATCC): SEQ ID NO: 99- RARYKRGS SEQ ID NO: 100 CGGGCCCGGTATAAACGGGGATCC

Sequence CWU 1 SEQUENCE LISTING <160> NUMBER OF SEQ ID NOS: 176 <210> SEQ ID NO 1 <211> LENGTH: 721 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-SF-H6-GGS-lcn2C-GGS-ENLYFQ-GG-PARENTAL <400> SEQUENCE: 1 gactgagtcg cccgctcgag accatggaga cagacacact cctgctatgg gtactgctgc 60 tctgggttcc aggttccact ggtgactaca aggacgagca tcaccatcat caccatggtg 120 gaagccagga ctccacctca gacctgatcc cagccccacc tctgagcaag gtccctctgc 180 agcagaactt ccaggacaac caattccagg ggaagtggta tgtggtaggc ctggcaggga 240 atgcaattct cagagaagac aaagacccgc aaaagatgta tgccaccatc tatgagctga 300 aagaagacaa gagctacaat gtcacctccg tcctgtttag gaaaaagaag tgtgactact 360 ggatcaggac ttttgttcca ggttgccagc ccggcgagtt cacgctgggc aacattaaga 420 gttaccctgg attaacgagt tacctcgtcc gagtggtgag caccaactac aaccagcatg 480 ctatggtgtt cttcaagaaa gtttctcaaa acagggagta cttcaagatc accctctacg 540 ggagaaccaa ggagctgact tcggaactaa aggagaactt catccgcttc tccaaatctc 600 tgggcctccc tgaaaaccac atcgtcttcc ctgtcccaat cgaccagtgt atcgacggcg 660 gaggtagcga aaacctgtat tttcagggag gcggccgcta aggatcccgg accgcctctc 720 c 721 <210> SEQ ID NO 2 <211> LENGTH: 903 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-SF-H6-GGS-lcn2C-GGS-ENLYFQ-GG-BubbleProtein <400> SEQUENCE: 2 gactgagtcg cccgctcgag accatggaga cagacacact cctgctatgg gtactgctgc 60 tctgggttcc aggttccact ggtgactaca aggacgagca tcaccatcat caccatggtg 120 gaagccagga ctccacctca gacctgatcc cagccccacc tctgagcaag gtccctctgc 180 agcagaactt ccaggacaac caattccagg ggaagtggta tgtggtaggc ctggcaggga 240 atgcaattct cagagaagac aaagacccgc aaaagatgta tgccaccatc tatgagctga 300 aagaagacaa gagctacaat gtcacctccg tcctgtttag gaaaaagaag tgtgactact 360 ggatcaggac ttttgttcca ggttgccagc ccggcgagtt cacgctgggc aacattaaga 420 gttaccctgg attaacgagt tacctcgtcc gagtggtgag caccaactac aaccagcatg 480 ctatggtgtt cttcaagaaa gtttctcaaa acagggagta cttcaagatc accctctacg 540 ggagaaccaa ggagctgact tcggaactaa aggagaactt catccgcttc tccaaatctc 600 tgggcctccc tgaaaaccac atcgtcttcc ctgtcccaat cgaccagtgt atcgacggcg 660 gaggtagcga aaacctgtat tttcagggag gcgatacctg cggcagcggc tataatgtgg 720 atcagcgtcg taccaatagc ggctgcaaag cgggcaatgg cgatcgtcat ttttgcggct 780 gcgatcgtac cggcgtggtg gaatgcaaag gcggcaaatg gaccgaagtg caggattgcg 840 gcagcagcag ctgcaaaggc accagcaatg gcggcgcgac ctgctaatgc taaggatccc 900 gga 903 <210> SEQ ID NO 3 <211> LENGTH: 861 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-SF-H6-GGS-lcn2C-GGS-ENLYFQ-GG-BubbleProtein coding sequence <400> SEQUENCE: 3 atggagacag acacactcct gctatgggta ctgctgctct gggttccagg ttccactggt 60 gactacaagg acgagcatca ccatcatcac catggtggaa gccaggactc cacctcagac 120 ctgatcccag ccccacctct gagcaaggtc cctctgcagc agaacttcca ggacaaccaa 180 ttccagggga agtggtatgt ggtaggcctg gcagggaatg caattctcag agaagacaaa 240 gacccgcaaa agatgtatgc caccatctat gagctgaaag aagacaagag ctacaatgtc 300 acctccgtcc tgtttaggaa aaagaagtgt gactactgga tcaggacttt tgttccaggt 360 tgccagcccg gcgagttcac gctgggcaac attaagagtt accctggatt aacgagttac 420 ctcgtccgag tggtgagcac caactacaac cagcatgcta tggtgttctt caagaaagtt 480 tctcaaaaca gggagtactt caagatcacc ctctacggga gaaccaagga gctgacttcg 540 gaactaaagg agaacttcat ccgcttctcc aaatctctgg gcctccctga aaaccacatc 600 gtcttccctg tcccaatcga ccagtgtatc gacggcggag gtagcgaaaa cctgtatttt 660 cagggaggcg atacctgcgg cagcggctat aatgtggatc agcgtcgtac caatagcggc 720 tgcaaagcgg gcaatggcga tcgtcatttt tgcggctgcg atcgtaccgg cgtggtggaa 780 tgcaaaggcg gcaaatggac cgaagtgcag gattgcggca gcagcagctg caaaggcacc 840 agcaatggcg gcgcgacctg c 861 <210> SEQ ID NO 4 <211> LENGTH: 885 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-SF-H6-GGS-lcn2C-GGS-ENLYFQ-GG-Attractin <400> SEQUENCE: 4 gactgagtcg cccgctcgag accatggaga cagacacact cctgctatgg gtactgctgc 60 tctgggttcc aggttccact ggtgactaca aggacgagca tcaccatcat caccatggtg 120 gaagccagga ctccacctca gacctgatcc cagccccacc tctgagcaag gtccctctgc 180 agcagaactt ccaggacaac caattccagg ggaagtggta tgtggtaggc ctggcaggga 240 atgcaattct cagagaagac aaagacccgc aaaagatgta tgccaccatc tatgagctga 300 aagaagacaa gagctacaat gtcacctccg tcctgtttag gaaaaagaag tgtgactact 360 ggatcaggac ttttgttcca ggttgccagc ccggcgagtt cacgctgggc aacattaaga 420 gttaccctgg attaacgagt tacctcgtcc gagtggtgag caccaactac aaccagcatg 480 ctatggtgtt cttcaagaaa gtttctcaaa acagggagta cttcaagatc accctctacg 540 ggagaaccaa ggagctgact tcggaactaa aggagaactt catccgcttc tccaaatctc 600 tgggcctccc tgaaaaccac atcgtcttcc ctgtcccaat cgaccagtgt atcgacggcg 660 gaggtagcga aaacctgtat tttcagggag gcgatcagaa ttgcgatatt ggcaatatta 720 ccagccagtg ccagatgcag cataaaaatt gcgaagatgc gaatggctgc gataccatta 780 ttgaagaatg caaaaccagc atggtggaac gttgccagaa tcaggaattt gaaagcgcgg 840 cgggcagcac caccctgggc ccgcagtaat gctaaggatc ccgga 885 <210> SEQ ID NO 5 <211> LENGTH: 843 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-SF-H6-GGS-lcn2C-GGS-ENLYFQ-GG-Attractin coding sequence <400> SEQUENCE: 5 atggagacag acacactcct gctatgggta ctgctgctct gggttccagg ttccactggt 60 gactacaagg acgagcatca ccatcatcac catggtggaa gccaggactc cacctcagac 120 ctgatcccag ccccacctct gagcaaggtc cctctgcagc agaacttcca ggacaaccaa 180 ttccagggga agtggtatgt ggtaggcctg gcagggaatg caattctcag agaagacaaa 240 gacccgcaaa agatgtatgc caccatctat gagctgaaag aagacaagag ctacaatgtc 300 acctccgtcc tgtttaggaa aaagaagtgt gactactgga tcaggacttt tgttccaggt 360 tgccagcccg gcgagttcac gctgggcaac attaagagtt accctggatt aacgagttac 420 ctcgtccgag tggtgagcac caactacaac cagcatgcta tggtgttctt caagaaagtt 480 tctcaaaaca gggagtactt caagatcacc ctctacggga gaaccaagga gctgacttcg 540 gaactaaagg agaacttcat ccgcttctcc aaatctctgg gcctccctga aaaccacatc 600 gtcttccctg tcccaatcga ccagtgtatc gacggcggag gtagcgaaaa cctgtatttt 660 cagggaggcg atcagaattg cgatattggc aatattacca gccagtgcca gatgcagcat 720 aaaaattgcg aagatgcgaa tggctgcgat accattattg aagaatgcaa aaccagcatg 780 gtggaacgtt gccagaatca ggaatttgaa agcgcggcgg gcagcaccac cctgggcccg 840 cag 843 <210> SEQ ID NO 6 <211> LENGTH: 782 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-SF-H6-GGS-lcn2C-GGS-ENLYFQ-GG-Hefutoxin <400> SEQUENCE: 6 gactgagtcg cccgctcgag accatggaga cagacacact cctgctatgg gtactgctgc 60 tctgggttcc aggttccact ggtgactaca aggacgagca tcaccatcat caccatggtg 120 gaagccagga ctccacctca gacctgatcc cagccccacc tctgagcaag gtccctctgc 180 agcagaactt ccaggacaac caattccagg ggaagtggta tgtggtaggc ctggcaggga 240 atgcaattct cagagaagac aaagacccgc aaaagatgta tgccaccatc tatgagctga 300 aagaagacaa gagctacaat gtcacctccg tcctgtttag gaaaaagaag tgtgactact 360 ggatcaggac ttttgttcca ggttgccagc ccggcgagtt cacgctgggc aacattaaga 420 gttaccctgg attaacgagt tacctcgtcc gagtggtgag caccaactac aaccagcatg 480 ctatggtgtt cttcaagaaa gtttctcaaa acagggagta cttcaagatc accctctacg 540 ggagaaccaa ggagctgact tcggaactaa aggagaactt catccgcttc tccaaatctc 600 tgggcctccc tgaaaaccac atcgtcttcc ctgtcccaat cgaccagtgt atcgacggcg 660 gaggtagcga aaacctgtat tttcagggag gcggccatgc gtgctatcgt aattgctggc 720 gtgaaggcaa tgatgaagaa acctgcaaag aacgttgcta atgctaagga tcccggaccg 780 cc 782 <210> SEQ ID NO 7 <211> LENGTH: 735 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-SF-H6-GGS-lcn2C-GGS-ENLYFQ-GG-Hefutoxin coding sequence <400> SEQUENCE: 7 atggagacag acacactcct gctatgggta ctgctgctct gggttccagg ttccactggt 60 gactacaagg acgagcatca ccatcatcac catggtggaa gccaggactc cacctcagac 120 ctgatcccag ccccacctct gagcaaggtc cctctgcagc agaacttcca ggacaaccaa 180 ttccagggga agtggtatgt ggtaggcctg gcagggaatg caattctcag agaagacaaa 240 gacccgcaaa agatgtatgc caccatctat gagctgaaag aagacaagag ctacaatgtc 300 acctccgtcc tgtttaggaa aaagaagtgt gactactgga tcaggacttt tgttccaggt 360 tgccagcccg gcgagttcac gctgggcaac attaagagtt accctggatt aacgagttac 420 ctcgtccgag tggtgagcac caactacaac cagcatgcta tggtgttctt caagaaagtt 480 tctcaaaaca gggagtactt caagatcacc ctctacggga gaaccaagga gctgacttcg 540 gaactaaagg agaacttcat ccgcttctcc aaatctctgg gcctccctga aaaccacatc 600 gtcttccctg tcccaatcga ccagtgtatc gacggcggag gtagcgaaaa cctgtatttt 660 cagggaggcg gccatgcgtg ctatcgtaat tgctggcgtg aaggcaatga tgaagaaacc 720 tgcaaagaac gttgc 735 <210> SEQ ID NO 8 <211> LENGTH: 816 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-SF-H6-GGS-lcn2C-GGS-ENLYFQ-GG-Hanatoxin <400> SEQUENCE: 8 gactgagtcg cccgctcgag accatggaga cagacacact cctgctatgg gtactgctgc 60 tctgggttcc aggttccact ggtgactaca aggacgagca tcaccatcat caccatggtg 120 gaagccagga ctccacctca gacctgatcc cagccccacc tctgagcaag gtccctctgc 180 agcagaactt ccaggacaac caattccagg ggaagtggta tgtggtaggc ctggcaggga 240 atgcaattct cagagaagac aaagacccgc aaaagatgta tgccaccatc tatgagctga 300 aagaagacaa gagctacaat gtcacctccg tcctgtttag gaaaaagaag tgtgactact 360 ggatcaggac ttttgttcca ggttgccagc ccggcgagtt cacgctgggc aacattaaga 420 gttaccctgg attaacgagt tacctcgtcc gagtggtgag caccaactac aaccagcatg 480 ctatggtgtt cttcaagaaa gtttctcaaa acagggagta cttcaagatc accctctacg 540 ggagaaccaa ggagctgact tcggaactaa aggagaactt catccgcttc tccaaatctc 600 tgggcctccc tgaaaaccac atcgtcttcc ctgtcccaat cgaccagtgt atcgacggcg 660 gaggtagcga aaacctgtat tttcagggag gcgaatgccg ttatctgttt ggcggctgca 720 aaaccaccag cgattgctgc aaacatctgg gctgcaaatt tcgtgataaa tattgcgcgt 780 gggattttac ctttagctaa tgctaaggat cccgga 816 <210> SEQ ID NO 9 <211> LENGTH: 774 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-SF-H6-GGS-lcn2C-GGS-ENLYFQ-GG-Hanatoxin coding sequence <400> SEQUENCE: 9 atggagacag acacactcct gctatgggta ctgctgctct gggttccagg ttccactggt 60 gactacaagg acgagcatca ccatcatcac catggtggaa gccaggactc cacctcagac 120 ctgatcccag ccccacctct gagcaaggtc cctctgcagc agaacttcca ggacaaccaa 180 ttccagggga agtggtatgt ggtaggcctg gcagggaatg caattctcag agaagacaaa 240 gacccgcaaa agatgtatgc caccatctat gagctgaaag aagacaagag ctacaatgtc 300 acctccgtcc tgtttaggaa aaagaagtgt gactactgga tcaggacttt tgttccaggt 360 tgccagcccg gcgagttcac gctgggcaac attaagagtt accctggatt aacgagttac 420 ctcgtccgag tggtgagcac caactacaac cagcatgcta tggtgttctt caagaaagtt 480 tctcaaaaca gggagtactt caagatcacc ctctacggga gaaccaagga gctgacttcg 540 gaactaaagg agaacttcat ccgcttctcc aaatctctgg gcctccctga aaaccacatc 600 gtcttccctg tcccaatcga ccagtgtatc gacggcggag gtagcgaaaa cctgtatttt 660 cagggaggcg aatgccgtta tctgtttggc ggctgcaaaa ccaccagcga ttgctgcaaa 720 catctgggct gcaaatttcg tgataaatat tgcgcgtggg attttacctt tagc 774 <210> SEQ ID NO 10 <211> LENGTH: 819 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-SF-H6-GGS-lcn2C-GGS-ENLYFQ-GG-Chymotrypsin Inhibitor <400> SEQUENCE: 10 gactgagtcg cccgctcgag accatggaga cagacacact cctgctatgg gtactgctgc 60 tctgggttcc aggttccact ggtgactaca aggacgagca tcaccatcat caccatggtg 120 gaagccagga ctccacctca gacctgatcc cagccccacc tctgagcaag gtccctctgc 180 agcagaactt ccaggacaac caattccagg ggaagtggta tgtggtaggc ctggcaggga 240 atgcaattct cagagaagac aaagacccgc aaaagatgta tgccaccatc tatgagctga 300 aagaagacaa gagctacaat gtcacctccg tcctgtttag gaaaaagaag tgtgactact 360 ggatcaggac ttttgttcca ggttgccagc ccggcgagtt cacgctgggc aacattaaga 420 gttaccctgg attaacgagt tacctcgtcc gagtggtgag caccaactac aaccagcatg 480 ctatggtgtt cttcaagaaa gtttctcaaa acagggagta cttcaagatc accctctacg 540 ggagaaccaa ggagctgact tcggaactaa aggagaactt catccgcttc tccaaatctc 600 tgggcctccc tgaaaaccac atcgtcttcc ctgtcccaat cgaccagtgt atcgacggcg 660 gaggtagcga aaacctgtat tttcagggag gcgaaattag ctgcgaaccg ggcaaaacct 720 ttaaagataa atgcaatacc tgccgttgcg gcgcggatgg caaaagcgcg gcgtgcaccc 780 tgaaagcgtg cccgaatcag taatgctaag gatcccgga 819 <210> SEQ ID NO 11 <211> LENGTH: 777 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-SF-H6-GGS-lcn2C-GGS-ENLYFQ-GG-Chymotrypsin Inhibitor coding sequence <400> SEQUENCE: 11 atggagacag acacactcct gctatgggta ctgctgctct gggttccagg ttccactggt 60 gactacaagg acgagcatca ccatcatcac catggtggaa gccaggactc cacctcagac 120 ctgatcccag ccccacctct gagcaaggtc cctctgcagc agaacttcca ggacaaccaa 180 ttccagggga agtggtatgt ggtaggcctg gcagggaatg caattctcag agaagacaaa 240 gacccgcaaa agatgtatgc caccatctat gagctgaaag aagacaagag ctacaatgtc 300 acctccgtcc tgtttaggaa aaagaagtgt gactactgga tcaggacttt tgttccaggt 360 tgccagcccg gcgagttcac gctgggcaac attaagagtt accctggatt aacgagttac 420 ctcgtccgag tggtgagcac caactacaac cagcatgcta tggtgttctt caagaaagtt 480 tctcaaaaca gggagtactt caagatcacc ctctacggga gaaccaagga gctgacttcg 540 gaactaaagg agaacttcat ccgcttctcc aaatctctgg gcctccctga aaaccacatc 600 gtcttccctg tcccaatcga ccagtgtatc gacggcggag gtagcgaaaa cctgtatttt 660 cagggaggcg aaattagctg cgaaccgggc aaaaccttta aagataaatg caatacctgc 720 cgttgcggcg cggatggcaa aagcgcggcg tgcaccctga aagcgtgccc gaatcag 777 <210> SEQ ID NO 12 <211> LENGTH: 822 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-SF-H6-GGS-lcn2C-GGS-ENLYFQ-GG-ToxinK <400> SEQUENCE: 12 gactgagtcg cccgctcgag accatggaga cagacacact cctgctatgg gtactgctgc 60 tctgggttcc aggttccact ggtgactaca aggacgagca tcaccatcat caccatggtg 120 gaagccagga ctccacctca gacctgatcc cagccccacc tctgagcaag gtccctctgc 180 agcagaactt ccaggacaac caattccagg ggaagtggta tgtggtaggc ctggcaggga 240 atgcaattct cagagaagac aaagacccgc aaaagatgta tgccaccatc tatgagctga 300 aagaagacaa gagctacaat gtcacctccg tcctgtttag gaaaaagaag tgtgactact 360 ggatcaggac ttttgttcca ggttgccagc ccggcgagtt cacgctgggc aacattaaga 420 gttaccctgg attaacgagt tacctcgtcc gagtggtgag caccaactac aaccagcatg 480 ctatggtgtt cttcaagaaa gtttctcaaa acagggagta cttcaagatc accctctacg 540 ggagaaccaa ggagctgact tcggaactaa aggagaactt catccgcttc tccaaatctc 600 tgggcctccc tgaaaaccac atcgtcttcc ctgtcccaat cgaccagtgt atcgacggcg 660 gaggtagcga aaacctgtat tttcagggag gcgtgtgccg tgattggttt aaagaaaccg 720 cgtgccgtca tgcgaaaagc ctgggcaatt gccgtaccag ccagaaatat cgtgcgaatt 780 gcgcgaaaac ctgcgaactg tgctaatgct aaggatcccg ga 822 <210> SEQ ID NO 13 <211> LENGTH: 780 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-SF-H6-GGS-lcn2C-GGS-ENLYFQ-GG-ToxinK coding sequence <400> SEQUENCE: 13 atggagacag acacactcct gctatgggta ctgctgctct gggttccagg ttccactggt 60 gactacaagg acgagcatca ccatcatcac catggtggaa gccaggactc cacctcagac 120 ctgatcccag ccccacctct gagcaaggtc cctctgcagc agaacttcca ggacaaccaa 180 ttccagggga agtggtatgt ggtaggcctg gcagggaatg caattctcag agaagacaaa 240 gacccgcaaa agatgtatgc caccatctat gagctgaaag aagacaagag ctacaatgtc 300 acctccgtcc tgtttaggaa aaagaagtgt gactactgga tcaggacttt tgttccaggt 360 tgccagcccg gcgagttcac gctgggcaac attaagagtt accctggatt aacgagttac 420 ctcgtccgag tggtgagcac caactacaac cagcatgcta tggtgttctt caagaaagtt 480 tctcaaaaca gggagtactt caagatcacc ctctacggga gaaccaagga gctgacttcg 540 gaactaaagg agaacttcat ccgcttctcc aaatctctgg gcctccctga aaaccacatc 600 gtcttccctg tcccaatcga ccagtgtatc gacggcggag gtagcgaaaa cctgtatttt 660 cagggaggcg tgtgccgtga ttggtttaaa gaaaccgcgt gccgtcatgc gaaaagcctg 720 ggcaattgcc gtaccagcca gaaatatcgt gcgaattgcg cgaaaacctg cgaactgtgc 780 <210> SEQ ID NO 14 <211> LENGTH: 849 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-SF-H6-GGS-lcn2C-GGS-ENLYFQ-GG-EGFepiregulin Core <400> SEQUENCE: 14 gactgagtcg cccgctcgag accatggaga cagacacact cctgctatgg gtactgctgc 60 tctgggttcc aggttccact ggtgactaca aggacgagca tcaccatcat caccatggtg 120 gaagccagga ctccacctca gacctgatcc cagccccacc tctgagcaag gtccctctgc 180 agcagaactt ccaggacaac caattccagg ggaagtggta tgtggtaggc ctggcaggga 240 atgcaattct cagagaagac aaagacccgc aaaagatgta tgccaccatc tatgagctga 300 aagaagacaa gagctacaat gtcacctccg tcctgtttag gaaaaagaag tgtgactact 360 ggatcaggac ttttgttcca ggttgccagc ccggcgagtt cacgctgggc aacattaaga 420 gttaccctgg attaacgagt tacctcgtcc gagtggtgag caccaactac aaccagcatg 480 ctatggtgtt cttcaagaaa gtttctcaaa acagggagta cttcaagatc accctctacg 540 ggagaaccaa ggagctgact tcggaactaa aggagaactt catccgcttc tccaaatctc 600 tgggcctccc tgaaaaccac atcgtcttcc ctgtcccaat cgaccagtgt atcgacggcg 660 gaggtagcga aaacctgtat tttcagggag gcgtgagcat taccaaatgc agcagcgata 720 tgaatggcta ttgcctgcat ggccagtgca tttatctggt ggatatgagc cagaattatt 780 gccgttgcga agtgggctat accggcgtgc gttgcgaaca tttttttctg taatgctaag 840 gatcccgga 849 <210> SEQ ID NO 15 <211> LENGTH: 807 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-SF-H6-GGS-lcn2C-GGS-ENLYFQ-GG-EGFepiregulin Core coding sequence <400> SEQUENCE: 15 atggagacag acacactcct gctatgggta ctgctgctct gggttccagg ttccactggt 60 gactacaagg acgagcatca ccatcatcac catggtggaa gccaggactc cacctcagac 120 ctgatcccag ccccacctct gagcaaggtc cctctgcagc agaacttcca ggacaaccaa 180 ttccagggga agtggtatgt ggtaggcctg gcagggaatg caattctcag agaagacaaa 240 gacccgcaaa agatgtatgc caccatctat gagctgaaag aagacaagag ctacaatgtc 300 acctccgtcc tgtttaggaa aaagaagtgt gactactgga tcaggacttt tgttccaggt 360 tgccagcccg gcgagttcac gctgggcaac attaagagtt accctggatt aacgagttac 420 ctcgtccgag tggtgagcac caactacaac cagcatgcta tggtgttctt caagaaagtt 480 tctcaaaaca gggagtactt caagatcacc ctctacggga gaaccaagga gctgacttcg 540 gaactaaagg agaacttcat ccgcttctcc aaatctctgg gcctccctga aaaccacatc 600 gtcttccctg tcccaatcga ccagtgtatc gacggcggag gtagcgaaaa cctgtatttt 660 cagggaggcg tgagcattac caaatgcagc agcgatatga atggctattg cctgcatggc 720 cagtgcattt atctggtgga tatgagccag aattattgcc gttgcgaagt gggctatacc 780 ggcgtgcgtt gcgaacattt ttttctg 807 <210> SEQ ID NO 16 <211> LENGTH: 801 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-SF-H6-GGS-lcn2C-GGS-ENLYFQ-GG-Circulin <400> SEQUENCE: 16 gactgagtcg cccgctcgag accatggaga cagacacact cctgctatgg gtactgctgc 60 tctgggttcc aggttccact ggtgactaca aggacgagca tcaccatcat caccatggtg 120 gaagccagga ctccacctca gacctgatcc cagccccacc tctgagcaag gtccctctgc 180 agcagaactt ccaggacaac caattccagg ggaagtggta tgtggtaggc ctggcaggga 240 atgcaattct cagagaagac aaagacccgc aaaagatgta tgccaccatc tatgagctga 300 aagaagacaa gagctacaat gtcacctccg tcctgtttag gaaaaagaag tgtgactact 360 ggatcaggac ttttgttcca ggttgccagc ccggcgagtt cacgctgggc aacattaaga 420 gttaccctgg attaacgagt tacctcgtcc gagtggtgag caccaactac aaccagcatg 480 ctatggtgtt cttcaagaaa gtttctcaaa acagggagta cttcaagatc accctctacg 540 ggagaaccaa ggagctgact tcggaactaa aggagaactt catccgcttc tccaaatctc 600 tgggcctccc tgaaaaccac atcgtcttcc ctgtcccaat cgaccagtgt atcgacggcg 660 gaggtagcga aaacctgtat tttcagggag gcggcattcc gtgcggcgaa agctgcgtgt 720 ggattccgtg cattagcgcg gcgctgggct gcagctgcaa aaataaagtg tgctatcgta 780 attaatgcta aggatcccgg a 801 <210> SEQ ID NO 17 <211> LENGTH: 759 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-SF-H6-GGS-lcn2C-GGS-ENLYFQ-GG-Circulin coding sequence <400> SEQUENCE: 17 atggagacag acacactcct gctatgggta ctgctgctct gggttccagg ttccactggt 60 gactacaagg acgagcatca ccatcatcac catggtggaa gccaggactc cacctcagac 120 ctgatcccag ccccacctct gagcaaggtc cctctgcagc agaacttcca ggacaaccaa 180 ttccagggga agtggtatgt ggtaggcctg gcagggaatg caattctcag agaagacaaa 240 gacccgcaaa agatgtatgc caccatctat gagctgaaag aagacaagag ctacaatgtc 300 acctccgtcc tgtttaggaa aaagaagtgt gactactgga tcaggacttt tgttccaggt 360 tgccagcccg gcgagttcac gctgggcaac attaagagtt accctggatt aacgagttac 420 ctcgtccgag tggtgagcac caactacaac cagcatgcta tggtgttctt caagaaagtt 480 tctcaaaaca gggagtactt caagatcacc ctctacggga gaaccaagga gctgacttcg 540 gaactaaagg agaacttcat ccgcttctcc aaatctctgg gcctccctga aaaccacatc 600 gtcttccctg tcccaatcga ccagtgtatc gacggcggag gtagcgaaaa cctgtatttt 660 cagggaggcg gcattccgtg cggcgaaagc tgcgtgtgga ttccgtgcat tagcgcggcg 720 ctgggctgca gctgcaaaaa taaagtgtgc tatcgtaat 759 <210> SEQ ID NO 18 <211> LENGTH: 873 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-SF-H6-GGS-lcn2C-GGS-ENLYFQ-GG-Brazzein <400> SEQUENCE: 18 gactgagtcg cccgctcgag accatggaga cagacacact cctgctatgg gtactgctgc 60 tctgggttcc aggttccact ggtgactaca aggacgagca tcaccatcat caccatggtg 120 gaagccagga ctccacctca gacctgatcc cagccccacc tctgagcaag gtccctctgc 180 agcagaactt ccaggacaac caattccagg ggaagtggta tgtggtaggc ctggcaggga 240 atgcaattct cagagaagac aaagacccgc aaaagatgta tgccaccatc tatgagctga 300 aagaagacaa gagctacaat gtcacctccg tcctgtttag gaaaaagaag tgtgactact 360 ggatcaggac ttttgttcca ggttgccagc ccggcgagtt cacgctgggc aacattaaga 420 gttaccctgg attaacgagt tacctcgtcc gagtggtgag caccaactac aaccagcatg 480 ctatggtgtt cttcaagaaa gtttctcaaa acagggagta cttcaagatc accctctacg 540 ggagaaccaa ggagctgact tcggaactaa aggagaactt catccgcttc tccaaatctc 600 tgggcctccc tgaaaaccac atcgtcttcc ctgtcccaat cgaccagtgt atcgacggcg 660 gaggtagcga aaacctgtat tttcagggag gccaggataa atgcaaaaaa gtgtatgaaa 720 attatccggt gagcaaatgc cagctggcga atcagtgcaa ttatgattgc aaactggata 780 aacatgcgcg tagcggcgaa tgcttttatg atgaaaaacg taatctgcag tgcatttgcg 840 attattgcga atattaatgc taaggatccc gga 873 <210> SEQ ID NO 19 <211> LENGTH: 831 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-SF-H6-GGS-lcn2C-GGS-ENLYFQ-GG-Brazzein coding sequence <400> SEQUENCE: 19 atggagacag acacactcct gctatgggta ctgctgctct gggttccagg ttccactggt 60 gactacaagg acgagcatca ccatcatcac catggtggaa gccaggactc cacctcagac 120 ctgatcccag ccccacctct gagcaaggtc cctctgcagc agaacttcca ggacaaccaa 180 ttccagggga agtggtatgt ggtaggcctg gcagggaatg caattctcag agaagacaaa 240 gacccgcaaa agatgtatgc caccatctat gagctgaaag aagacaagag ctacaatgtc 300 acctccgtcc tgtttaggaa aaagaagtgt gactactgga tcaggacttt tgttccaggt 360 tgccagcccg gcgagttcac gctgggcaac attaagagtt accctggatt aacgagttac 420 ctcgtccgag tggtgagcac caactacaac cagcatgcta tggtgttctt caagaaagtt 480 tctcaaaaca gggagtactt caagatcacc ctctacggga gaaccaagga gctgacttcg 540 gaactaaagg agaacttcat ccgcttctcc aaatctctgg gcctccctga aaaccacatc 600 gtcttccctg tcccaatcga ccagtgtatc gacggcggag gtagcgaaaa cctgtatttt 660 cagggaggcc aggataaatg caaaaaagtg tatgaaaatt atccggtgag caaatgccag 720 ctggcgaatc agtgcaatta tgattgcaaa ctggataaac atgcgcgtag cggcgaatgc 780 ttttatgatg aaaaacgtaa tctgcagtgc atttgcgatt attgcgaata t 831 <210> SEQ ID NO 20 <211> LENGTH: 777 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-SF-H6-GGS-lcn2C-GGS-ENLYFQ-GG-chlorotoxin coding sequence <400> SEQUENCE: 20 atggagacag acacactcct gctatgggta ctgctgctct gggttccagg ttccactggt 60 gactacaagg acgagcatca ccatcatcac catggtggaa gccaggactc cacctcagac 120 ctgatcccag ccccacctct gagcaaggtc cctctgcagc agaacttcca ggacaaccaa 180 ttccagggga agtggtatgt ggtaggcctg gcagggaatg caattctcag agaagacaaa 240 gacccgcaaa agatgtatgc caccatctat gagctgaaag aagacaagag ctacaatgtc 300 acctccgtcc tgtttaggaa aaagaagtgt gactactgga tcaggacttt tgttccaggt 360 tgccagcccg gcgagttcac gctgggcaac attaagagtt accctggatt aacgagttac 420 ctcgtccgag tggtgagcac caactacaac cagcatgcta tggtgttctt caagaaagtt 480 tctcaaaaca gggagtactt caagatcacc ctctacggga gaaccaagga gctgacttcg 540 gaactaaagg agaacttcat ccgcttctcc aaatctctgg gcctccctga aaaccacatc 600 gtcttccctg tcccaatcga ccagtgtatc gacggcggag gtagcgaaaa cctgtatttt 660 cagggaggca tgtgcatgcc gtgctttacc accgatcatc agatggcgcg taaatgcgat 720 gattgctgcg gcggcaaagg ccgtggcaaa tgctatggcc cgcagtgcct gtgccgt 777 <210> SEQ ID NO 21 <211> LENGTH: 734 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-SF-H6-GGS-lcn2C-GGS-ENLYFQ-GS-PARENTAL <400> SEQUENCE: 21 gactgagtcg cccgctcgag accatggaga cagacacact cctgctatgg gtactgctgc 60 tctgggttcc aggttccact ggtgactaca aggacgagca tcaccatcat caccatggtg 120 gaagccagga ctccacctca gacctgatcc cagccccacc tctgagcaag gtccctctgc 180 agcagaactt ccaggacaac caattccagg ggaagtggta tgtggtaggc ctggcaggga 240 atgcaattct cagagaagac aaagacccgc aaaagatgta tgccaccatc tatgagctga 300 aagaagacaa gagctacaat gtcacctccg tcctgtttag gaaaaagaag tgtgactact 360 ggatcaggac ttttgttcca ggttgccagc ccggcgagtt cacgctgggc aacattaaga 420 gttaccctgg attaacgagt tacctcgtcc gagtggtgag caccaactac aaccagcatg 480 ctatggtgtt cttcaagaaa gtttctcaaa acagggagta cttcaagatc accctctacg 540 ggagaaccaa ggagctgact tcggaactaa aggagaactt catccgcttc tccaaatctc 600 tgggcctccc tgaaaaccac atcgtcttcc ctgtcccaat cgaccagtgt atcgacggcg 660 gaggtagcga aaacctgtat tttcagggat cctaatgttg gccatgatgt taggcggccg 720 ctaaggatcc cgga 734 <210> SEQ ID NO 22 <211> LENGTH: 734 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-SF-H6-GGS-lcn2C-GGS-furin-GS-PARENTAL <400> SEQUENCE: 22 gactgagtcg cccgctcgag accatggaga cagacacact cctgctatgg gtactgctgc 60 tctgggttcc aggttccact ggtgactaca aggacgagca tcaccatcat caccatggtg 120 gaagccagga ctccacctca gacctgatcc cagccccacc tctgagcaag gtccctctgc 180 agcagaactt ccaggacaac caattccagg ggaagtggta tgtggtaggc ctggcaggga 240 atgcaattct cagagaagac aaagacccgc aaaagatgta tgccaccatc tatgagctga 300 aagaagacaa gagctacaat gtcacctccg tcctgtttag gaaaaagaag tgtgactact 360 ggatcaggac ttttgttcca ggttgccagc ccggcgagtt cacgctgggc aacattaaga 420 gttaccctgg attaacgagt tacctcgtcc gagtggtgag caccaactac aaccagcatg 480 ctatggtgtt cttcaagaaa gtttctcaaa acagggagta cttcaagatc accctctacg 540 ggagaaccaa ggagctgact tcggaactaa aggagaactt catccgcttc tccaaatctc 600 tgggcctccc tgaaaaccac atcgtcttcc ctgtcccaat cgaccagtgt atcgacggcg 660 gaggtagccg cgcgcgctat aaacgcggat cctaatgttg gccatgatgt taggcggccg 720 ctaaggatcc cgga 734 <210> SEQ ID NO 23 <211> LENGTH: 848 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-SF-H6-GGS-lcn2C-GGS-ENLYFQ-GS-MIDKINE <400> SEQUENCE: 23 gactgagtcg cccgctcgag accatggaga cagacacact cctgctatgg gtactgctgc 60 tctgggttcc aggttccact ggtgactaca aggacgagca tcaccatcat caccatggtg 120 gaagccagga ctccacctca gacctgatcc cagccccacc tctgagcaag gtccctctgc 180 agcagaactt ccaggacaac caattccagg ggaagtggta tgtggtaggc ctggcaggga 240 atgcaattct cagagaagac aaagacccgc aaaagatgta tgccaccatc tatgagctga 300 aagaagacaa gagctacaat gtcacctccg tcctgtttag gaaaaagaag tgtgactact 360 ggatcaggac ttttgttcca ggttgccagc ccggcgagtt cacgctgggc aacattaaga 420 gttaccctgg attaacgagt tacctcgtcc gagtggtgag caccaactac aaccagcatg 480 ctatggtgtt cttcaagaaa gtttctcaaa acagggagta cttcaagatc accctctacg 540 ggagaaccaa ggagctgact tcggaactaa aggagaactt catccgcttc tccaaatctc 600 tgggcctccc tgaaaaccac atcgtcttcc ctgtcccaat cgaccagtgt atcgacggcg 660 gaggtagcga aaacctgtat tttcagagcg attgcaaata taaatttgaa aactggggcg 720 cgtgcgatgg cggcaccggc accaaagtgc gccagggcac cctgaaaaaa gcgcgctata 780 acgcgcagtg ccaggaaacc attcgcgtga ccaaaccgtg ctaatgctgg atcccggacc 840 gcctctcc 848 <210> SEQ ID NO 24 <211> LENGTH: 798 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-SF-H6-GGS-lcn2C-GGS-ENLYFQ-GS-MIDKINE coding sequence <400> SEQUENCE: 24 atggagacag acacactcct gctatgggta ctgctgctct gggttccagg ttccactggt 60 gactacaagg acgagcatca ccatcatcac catggtggaa gccaggactc cacctcagac 120 ctgatcccag ccccacctct gagcaaggtc cctctgcagc agaacttcca ggacaaccaa 180 ttccagggga agtggtatgt ggtaggcctg gcagggaatg caattctcag agaagacaaa 240 gacccgcaaa agatgtatgc caccatctat gagctgaaag aagacaagag ctacaatgtc 300 acctccgtcc tgtttaggaa aaagaagtgt gactactgga tcaggacttt tgttccaggt 360 tgccagcccg gcgagttcac gctgggcaac attaagagtt accctggatt aacgagttac 420 ctcgtccgag tggtgagcac caactacaac cagcatgcta tggtgttctt caagaaagtt 480 tctcaaaaca gggagtactt caagatcacc ctctacggga gaaccaagga gctgacttcg 540 gaactaaagg agaacttcat ccgcttctcc aaatctctgg gcctccctga aaaccacatc 600 gtcttccctg tcccaatcga ccagtgtatc gacggcggag gtagcgaaaa cctgtatttt 660 cagagcgatt gcaaatataa atttgaaaac tggggcgcgt gcgatggcgg caccggcacc 720 aaagtgcgcc agggcaccct gaaaaaagcg cgctataacg cgcagtgcca ggaaaccatt 780 cgcgtgacca aaccgtgc 798 <210> SEQ ID NO 25 <211> LENGTH: 796 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-SF-H6-GGS-lcn2C-GGS-ENLYFQ-GG-Violacin A <400> SEQUENCE: 25 gactgagtcg cccgctcgag accatggaga cagacacact cctgctatgg gtactgctgc 60 tctgggttcc aggttccact ggtgactaca aggacgagca tcaccatcat caccatggtg 120 gaagccagga ctccacctca gacctgatcc cagccccacc tctgagcaag gtccctctgc 180 agcagaactt ccaggacaac caattccagg ggaagtggta tgtggtaggc ctggcaggga 240 atgcaattct cagagaagac aaagacccgc aaaagatgta tgccaccatc tatgagctga 300 aagaagacaa gagctacaat gtcacctccg tcctgtttag gaaaaagaag tgtgactact 360 ggatcaggac ttttgttcca ggttgccagc ccggcgagtt cacgctgggc aacattaaga 420 gttaccctgg attaacgagt tacctcgtcc gagtggtgag caccaactac aaccagcatg 480 ctatggtgtt cttcaagaaa gtttctcaaa acagggagta cttcaagatc accctctacg 540 ggagaaccaa ggagctgact tcggaactaa aggagaactt catccgcttc tccaaatctc 600 tgggcctccc tgaaaaccac atcgtcttcc ctgtcccaat cgaccagtgt atcgacggcg 660 gaggtagcga aaacctgtat tttcagggag gcagcgccat cagctgcggc gagacctgct 720 tcaagttcaa gtgctacacc cccagatgca gctgcagcta ccccgtgtgc aagtaagcta 780 aggatcccgg accgcc 796 <210> SEQ ID NO 26 <211> LENGTH: 750 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-SF-H6-GGS-lcn2C-GGS-ENLYFQ-GG-Violacin A coding sequence <400> SEQUENCE: 26 atggagacag acacactcct gctatgggta ctgctgctct gggttccagg ttccactggt 60 gactacaagg acgagcatca ccatcatcac catggtggaa gccaggactc cacctcagac 120 ctgatcccag ccccacctct gagcaaggtc cctctgcagc agaacttcca ggacaaccaa 180 ttccagggga agtggtatgt ggtaggcctg gcagggaatg caattctcag agaagacaaa 240 gacccgcaaa agatgtatgc caccatctat gagctgaaag aagacaagag ctacaatgtc 300 acctccgtcc tgtttaggaa aaagaagtgt gactactgga tcaggacttt tgttccaggt 360 tgccagcccg gcgagttcac gctgggcaac attaagagtt accctggatt aacgagttac 420 ctcgtccgag tggtgagcac caactacaac cagcatgcta tggtgttctt caagaaagtt 480 tctcaaaaca gggagtactt caagatcacc ctctacggga gaaccaagga gctgacttcg 540 gaactaaagg agaacttcat ccgcttctcc aaatctctgg gcctccctga aaaccacatc 600 gtcttccctg tcccaatcga ccagtgtatc gacggcggag gtagcgaaaa cctgtatttt 660 cagggaggca gcgccatcag ctgcggcgag acctgcttca agttcaagtg ctacaccccc 720 agatgcagct gcagctaccc cgtgtgcaag 750 <210> SEQ ID NO 27 <211> LENGTH: 745 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-SF-H6-GGS-lcn2C-GGS-ENLYFQ-GG-Lambda Toxin <400> SEQUENCE: 27 gactgagtcg cccgctcgag accatggaga cagacacact cctgctatgg gtactgctgc 60 tctgggttcc aggttccact ggtgactaca aggacgagca tcaccatcat caccatggtg 120 gaagccagga ctccacctca gacctgatcc cagccccacc tctgagcaag gtccctctgc 180 agcagaactt ccaggacaac caattccagg ggaagtggta tgtggtaggc ctggcaggga 240 atgcaattct cagagaagac aaagacccgc aaaagatgta tgccaccatc tatgagctga 300 aagaagacaa gagctacaat gtcacctccg tcctgtttag gaaaaagaag tgtgactact 360 ggatcaggac ttttgttcca ggttgccagc ccggcgagtt cacgctgggc aacattaaga 420 gttaccctgg attaacgagt tacctcgtcc gagtggtgag caccaactac aaccagcatg 480 ctatggtgtt cttcaagaaa gtttctcaaa acagggagta cttcaagatc accctctacg 540 ggagaaccaa ggagctgact tcggaactaa aggagaactt catccgcttc tccaaatctc 600 tgggcctccc tgaaaaccac atcgtcttcc ctgtcccaat cgaccagtgt atcgacggcg 660 gaggtagcga aaacctgtat tttcagggag gcgtgtgctg cggctacaag ctgtgccacc 720 cctgctaagc taaggatccc ggacc 745 <210> SEQ ID NO 28 <211> LENGTH: 702 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-SF-H6-GGS-lcn2C-GGS-ENLYFQ-GG-Lambda Toxin coding sequence <400> SEQUENCE: 28 atggagacag acacactcct gctatgggta ctgctgctct gggttccagg ttccactggt 60 gactacaagg acgagcatca ccatcatcac catggtggaa gccaggactc cacctcagac 120 ctgatcccag ccccacctct gagcaaggtc cctctgcagc agaacttcca ggacaaccaa 180 ttccagggga agtggtatgt ggtaggcctg gcagggaatg caattctcag agaagacaaa 240 gacccgcaaa agatgtatgc caccatctat gagctgaaag aagacaagag ctacaatgtc 300 acctccgtcc tgtttaggaa aaagaagtgt gactactgga tcaggacttt tgttccaggt 360 tgccagcccg gcgagttcac gctgggcaac attaagagtt accctggatt aacgagttac 420 ctcgtccgag tggtgagcac caactacaac cagcatgcta tggtgttctt caagaaagtt 480 tctcaaaaca gggagtactt caagatcacc ctctacggga gaaccaagga gctgacttcg 540 gaactaaagg agaacttcat ccgcttctcc aaatctctgg gcctccctga aaaccacatc 600 gtcttccctg tcccaatcga ccagtgtatc gacggcggag gtagcgaaaa cctgtatttt 660 cagggaggcg tgtgctgcgg ctacaagctg tgccacccct gc 702 <210> SEQ ID NO 29 <211> LENGTH: 751 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-SF-H6-GGS-lcn2C-GGS-ENLYFQ-GG-Lambda Toxin NG <400> SEQUENCE: 29 gactgagtcg cccgctcgag accatggaga cagacacact cctgctatgg gtactgctgc 60 tctgggttcc aggttccact ggtgactaca aggacgagca tcaccatcat caccatggtg 120 gaagccagga ctccacctca gacctgatcc cagccccacc tctgagcaag gtccctctgc 180 agcagaactt ccaggacaac caattccagg ggaagtggta tgtggtaggc ctggcaggga 240 atgcaattct cagagaagac aaagacccgc aaaagatgta tgccaccatc tatgagctga 300 aagaagacaa gagctacaat gtcacctccg tcctgtttag gaaaaagaag tgtgactact 360 ggatcaggac ttttgttcca ggttgccagc ccggcgagtt cacgctgggc aacattaaga 420 gttaccctgg attaacgagt tacctcgtcc gagtggtgag caccaactac aaccagcatg 480 ctatggtgtt cttcaagaaa gtttctcaaa acagggagta cttcaagatc accctctacg 540 ggagaaccaa ggagctgact tcggaactaa aggagaactt catccgcttc tccaaatctc 600 tgggcctccc tgaaaaccac atcgtcttcc ctgtcccaat cgaccagtgt atcgacggcg 660 gaggtagcga aaacctgtat tttcagggag gcaacggcgt gtgctgcggc tacaagctgt 720 gccacccctg ctaagctaag gatcccggac c 751 <210> SEQ ID NO 30 <211> LENGTH: 708 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-SF-H6-GGS-lcn2C-GGS-ENLYFQ-GG-Lambda Toxin NG coding sequence <400> SEQUENCE: 30 atggagacag acacactcct gctatgggta ctgctgctct gggttccagg ttccactggt 60 gactacaagg acgagcatca ccatcatcac catggtggaa gccaggactc cacctcagac 120 ctgatcccag ccccacctct gagcaaggtc cctctgcagc agaacttcca ggacaaccaa 180 ttccagggga agtggtatgt ggtaggcctg gcagggaatg caattctcag agaagacaaa 240 gacccgcaaa agatgtatgc caccatctat gagctgaaag aagacaagag ctacaatgtc 300 acctccgtcc tgtttaggaa aaagaagtgt gactactgga tcaggacttt tgttccaggt 360 tgccagcccg gcgagttcac gctgggcaac attaagagtt accctggatt aacgagttac 420 ctcgtccgag tggtgagcac caactacaac cagcatgcta tggtgttctt caagaaagtt 480 tctcaaaaca gggagtactt caagatcacc ctctacggga gaaccaagga gctgacttcg 540 gaactaaagg agaacttcat ccgcttctcc aaatctctgg gcctccctga aaaccacatc 600 gtcttccctg tcccaatcga ccagtgtatc gacggcggag gtagcgaaaa cctgtatttt 660 cagggaggca acggcgtgtg ctgcggctac aagctgtgcc acccctgc 708 <210> SEQ ID NO 31 <211> LENGTH: 831 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-SF-H6-GGS-lcn2C-GGS-ENLYFQ-GG-Potato Carboxypeptidase Inhibitor <400> SEQUENCE: 31 gactgagtcg cccgctcgag accatggaga cagacacact cctgctatgg gtactgctgc 60 tctgggttcc aggttccact ggtgactaca aggacgagca tcaccatcat caccatggtg 120 gaagccagga ctccacctca gacctgatcc cagccccacc tctgagcaag gtccctctgc 180 agcagaactt ccaggacaac caattccagg ggaagtggta tgtggtaggc ctggcaggga 240 atgcaattct cagagaagac aaagacccgc aaaagatgta tgccaccatc tatgagctga 300 aagaagacaa gagctacaat gtcacctccg tcctgtttag gaaaaagaag tgtgactact 360 ggatcaggac ttttgttcca ggttgccagc ccggcgagtt cacgctgggc aacattaaga 420 gttaccctgg attaacgagt tacctcgtcc gagtggtgag caccaactac aaccagcatg 480 ctatggtgtt cttcaagaaa gtttctcaaa acagggagta cttcaagatc accctctacg 540 ggagaaccaa ggagctgact tcggaactaa aggagaactt catccgcttc tccaaatctc 600 tgggcctccc tgaaaaccac atcgtcttcc ctgtcccaat cgaccagtgt atcgacggcg 660 gaggtagcga aaacctgtat tttcagggag gccagcagca tgcggatccg atttgcaaca 720 aaccgtgcaa aacccatgat gattgcagcg gcgcgtggtt ttgccaggcg tgctggaaca 780 gcgcgcgcac ctgcggcccg tatgtgggct aatgctaagg atcccggacc g 831 <210> SEQ ID NO 32 <211> LENGTH: 789 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-SF-H6-GGS-lcn2C-GGS-ENLYFQ-GG-Potato Carboxypeptidase Inhibitor coding sequence <400> SEQUENCE: 32 atggagacag acacactcct gctatgggta ctgctgctct gggttccagg ttccactggt 60 gactacaagg acgagcatca ccatcatcac catggtggaa gccaggactc cacctcagac 120 ctgatcccag ccccacctct gagcaaggtc cctctgcagc agaacttcca ggacaaccaa 180 ttccagggga agtggtatgt ggtaggcctg gcagggaatg caattctcag agaagacaaa 240 gacccgcaaa agatgtatgc caccatctat gagctgaaag aagacaagag ctacaatgtc 300 acctccgtcc tgtttaggaa aaagaagtgt gactactgga tcaggacttt tgttccaggt 360 tgccagcccg gcgagttcac gctgggcaac attaagagtt accctggatt aacgagttac 420 ctcgtccgag tggtgagcac caactacaac cagcatgcta tggtgttctt caagaaagtt 480 tctcaaaaca gggagtactt caagatcacc ctctacggga gaaccaagga gctgacttcg 540 gaactaaagg agaacttcat ccgcttctcc aaatctctgg gcctccctga aaaccacatc 600 gtcttccctg tcccaatcga ccagtgtatc gacggcggag gtagcgaaaa cctgtatttt 660 cagggaggcc agcagcatgc ggatccgatt tgcaacaaac cgtgcaaaac ccatgatgat 720 tgcagcggcg cgtggttttg ccaggcgtgc tggaacagcg cgcgcacctg cggcccgtat 780 gtgggctaa 789 <210> SEQ ID NO 33 <211> LENGTH: 269 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: The anti-CD3 is an OKT3 variant from the C-terminus of patent 7635462 <400> SEQUENCE: 33 Gly Ser Asp Ile Lys Leu Gln Gln Ser Gly Ala Glu Leu Ala Arg Pro 1 5 10 15 Gly Ala Ser Val Lys Met Ser Cys Lys Thr Ser Gly Tyr Thr Phe Thr 20 25 30 Arg Tyr Thr Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu 35 40 45 Trp Ile Gly Tyr Ile Asn Pro Ser Arg Gly Tyr Thr Asn Tyr Asn Gln 50 55 60 Lys Phe Lys Asp Lys Ala Thr Leu Thr Thr Asp Lys Ser Ser Ser Thr 65 70 75 80 Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr 85 90 95 Tyr Cys Ala Arg Tyr Tyr Asp Asp His Tyr Cys Leu Asp Tyr Trp Gly 100 105 110 Gln Gly Thr Thr Leu Thr Val Ser Ser Val Glu Gly Gly Ser Gly Gly 115 120 125 Ser Gly Gly Ser Gly Gly Ser Gly Gly Val Asp Asp Ile Gln Leu Thr 130 135 140 Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly Glu Lys Val Thr Met 145 150 155 160 Thr Cys Arg Ala Ser Ser Ser Val Ser Tyr Met Asn Trp Tyr Gln Gln 165 170 175 Lys Ser Gly Thr Ser Pro Lys Arg Trp Ile Tyr Asp Thr Ser Lys Val 180 185 190 Ala Ser Gly Val Pro Tyr Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser 195 200 205 Tyr Ser Leu Thr Ile Ser Ser Met Glu Ala Glu Asp Ala Ala Thr Tyr 210 215 220 Tyr Cys Gln Gln Trp Ser Ser Asn Pro Leu Thr Phe Gly Ala Gly Thr 225 230 235 240 Lys Leu Glu Leu Lys Gly Gly Gly Gly Ser Asn Ser Ser Asn Tyr Cys 245 250 255 Cys Glu Leu Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr 260 265 <210> SEQ ID NO 34 <211> LENGTH: 848 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: anti-CD3 is an OKT3 variant from the C-terminus of patent 7635462 dropped into the Bam/Not cut library vector as a TEV-cleavable siderocalin fusion <400> SEQUENCE: 34 acctgtattt tcagggatcc gatattaaac tgcagcagag cggcgcggaa ctggcgcgcc 60 cgggcgcgag cgtgaaaatg agctgcaaaa ccagcggcta tacctttacc cgctatacca 120 tgcattgggt gaaacagcgc ccgggccagg gcctggaatg gattggctat attaacccga 180 gccgcggcta taccaactat aaccagaaat ttaaagataa agcgaccctg accaccgata 240 aaagcagcag caccgcgtat atgcagctga gcagcctgac cagcgaagat agcgcggtgt 300 attattgcgc gcgctattat gatgatcatt attgcctgga ttattggggc cagggcacca 360 ccctgaccgt gagcagcgtg gaaggcggca gcggcggcag cggcggcagc ggcggcagcg 420 gcggcgtgga tgatattcag ctgacccaga gcccggcgat tatgagcgcg agcccgggcg 480 aaaaagtgac catgacctgc cgcgcgagca gcagcgtgag ctatatgaac tggtatcagc 540 agaaaagcgg caccagcccg aaacgctgga tttatgatac cagcaaagtg gcgagcggcg 600 tgccgtatcg ctttagcggc agcggcagcg gcaccagcta tagcctgacc attagcagca 660 tggaagcgga agatgcggcg acctattatt gccagcagtg gagcagcaac ccgctgacct 720 ttggcgcggg caccaaactg gaactgaaag gcggcggcgg cagcaacagc agcaactatt 780 gctgcgaact gtgctgcaac ccggcgtgca ccggctgcta ttaatgcggc cgctcatcac 840 cattaatc 848 <210> SEQ ID NO 35 <211> LENGTH: 684 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: Parental cloning construct 1: IgK-sFLAG-H6-GGS-humanScn-GGS-ENLYFQ-GG-NotI <400> SEQUENCE: 35 ctcgagacca tggagacaga cacactcctg ctatgggtac tgctgctctg ggttccaggt 60 tccactggtg actacaagga cgagcatcac catcatcacc atggtggaag ccaggactcc 120 acctcagacc tgatcccagc cccacctctg agcaaggtcc ctctgcagca gaacttccag 180 gacaaccaat tccaggggaa gtggtatgtg gtaggcctgg cagggaatgc aattctcaga 240 gaagacaaag acccgcaaaa gatgtatgcc accatctatg agctgaaaga agacaagagc 300 tacaatgtca cctccgtcct gtttaggaaa aagaagtgtg actactggat caggactttt 360 gttccaggtt gccagcccgg cgagttcacg ctgggcaaca ttaagagtta ccctggatta 420 acgagttacc tcgtccgagt ggtgagcacc aactacaacc agcatgctat ggtgttcttc 480 aagaaagttt ctcaaaacag ggagtacttc aagatcaccc tctacgggag aaccaaggag 540 ctgacttcgg aactaaagga gaacttcatc cgcttctcca aatctctggg cctccctgaa 600 aaccacatcg tcttccctgt cccaatcgac cagtgtatcg acggcggagg tagcgaaaac 660 ctgtattttc agggaggcgg ccgc 684 <210> SEQ ID NO 36 <211> LENGTH: 1402 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: Parental cloning construct 2: IgK-sFLAG-H6-GGS-humanScnC87S-GGS-ENLYFQ-GS-STUFFER <400> SEQUENCE: 36 ctcgagacca tggagacaga cacactcctg ctatgggtac tgctgctctg ggttccaggt 60 tccactggtg actacaagga cgagcatcac catcatcacc atggtggaag ccaggactcc 120 acctcagacc tgatcccagc cccacctctg agcaaggtcc ctctgcagca gaacttccag 180 gacaaccaat tccaggggaa gtggtatgtg gtaggcctgg cagggaatgc aattctcaga 240 gaagacaaag acccgcaaaa gatgtatgcc accatctatg agctgaaaga agacaagagc 300 tacaatgtca cctccgtcct gtttaggaaa aagaagtgtg actactggat caggactttt 360 gttccaggtt cccagcccgg cgagttcacg ctgggcaaca ttaagagtta ccctggatta 420 acgagttacc tcgtccgagt ggtgagcacc aactacaacc agcatgctat ggtgttcttc 480 aagaaagttt ctcaaaacag ggagtacttc aagatcaccc tctacgggag aaccaaggag 540 ctgacttcgg aactaaagga gaacttcatc cgcttctcca aatctctggg cctccctgaa 600 aaccacatcg tcttccctgt cccaatcgac cagtgtatcg acggcggagg tagcgaaaac 660 ctgtattttc agggatccat gtacggtctt aagggacccg acatttacaa aggagtttac 720 caatttaagt cagtggagtt tgatatgtca catctgaacc tgaccatgcc caacgcatgt 780 tcagccaaca actcccacca ttacatcagt atggggactt ctggactaga attgaccttc 840 accaatgatt ccatcatcag tcacaacttt tgcaatctga cctctgcctt caacaaaaag 900 acctttgacc acacactcat gagtatagtt tcgagcctac acctcagtat cagagggaac 960 tccaactata aggcagtatc ctgcgacttc aacaatggca taaccatcca atacaacttg 1020 acattctcag atcgacaaag tgctcagagc cagtgtagaa ccttcagagg tagagtccta 1080 gatatgttta gaactgcctt cggggggaaa tacatgagga gtggctgggg ctggacaggc 1140 tcagatggca agaccacctg gtgtagccag acgagttacc aatacctgat tatacaaaat 1200 agaacctggg aaaaccactg cacatatgca ggtccttttg ggatgtccag gattctcctt 1260 tcccaagaga agactaagtt cttcactagg agactggtgc ccaggggcag cggcctgaac 1320 gacatcttcg aggcccagaa gatcgagtgg cacgagtaat gcggccgctc atcaccatta 1380 atcatcacca ttaatcggac cg 1402 <210> SEQ ID NO 37 <211> LENGTH: 1299 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: Parental cloning construct 3: LightChain-GRGGSGGS-humanScnC87S <400> SEQUENCE: 37 ctcgagacca tggatttcca ggtgcagatt tttagctttc tgctgatttc cgcttccgtg 60 attatgagcc gaggcgacat tgtgatgacc caggcagctc ctagcgtgcc agtcacccca 120 ggagagtcag tgagcatctc ctgcagaagt actaagtcac tgctgcacag caacggcaat 180 acctacctgt attggttcct gcagagacct gggcagtccc cacagaggct gatctactat 240 atgagtaacc tggcatcagg agtgcctgac aggttcagcg gacgaggcag cggcactgat 300 tttaccctgc ggatttctag agtggaggca gaagacgccg gcgtctacta ttgcatgcag 360 agtctggagt acccttatac tttcggcggg ggaaccaaac tggaaatcaa gagggccgat 420 gccgctccaa ccgtgtccat ttttccccct agctccgagc agctgacatc tggcggggct 480 agtgtggtct gtttcctgaa caatttttac ccaaaggaca tcaacgtgaa atggaagatt 540 gatggaagtg aaaggcagaa cggcgtcctg aattcatgga cagaccagga tagcaaagac 600 tccacttatt ctatgtctag taccctgaca ctgactaagg atgagtacga acgccacaat 660 tcttatacat gcgaggcaac tcataaaacc tctacaagtc ccatcgtgaa gagctttaac 720 cgaaatgaat gcggccgcgg aggctccgga ggctcccagg actcaacaag cgatctgatt 780 ccagccccac ccctgagcaa agtgcccctg cagcagaact tccaggacaa tcagtttcag 840 ggcaagtggt acgtggtcgg gctggctgga aacgcaatcc tgcgggagga caaagatccc 900 cagaagatgt acgccactat ctacgagctg aaagaagaca agtcatacaa tgtgaccagc 960 gtcctgttcc gcaagaaaaa gtgtgattat tggatcagaa cattcgtgcc cggctcccag 1020 cctggggagt ttactctggg gaatattaag tcctaccctg gactgacctc ttatctggtg 1080 cgagtggtct ctacaaacta caatcagcat gctatggtgt tctttaaaaa ggtcagccag 1140 aaccgggagt actttaaaat caccctgtat ggcagaacca aagaactgac aagcgagctg 1200 aaggaaaatt tcattcgctt ttccaagtct ctggggctgc cagagaatca tattgtgttc 1260 ccagtcccca ttgaccagtg tattgacggg tgaggatcc 1299 <210> SEQ ID NO 38 <211> LENGTH: 606 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: Super stable ScnC87S (humanScn-I8C-N39C-C87S) <400> SEQUENCE: 38 ctcgagatgc ccctgggcct gctgtggctg ggcctggccc tgctgggcgc cctgcacgcc 60 caggcccagg actccacctc agacctgtgt ccagccccac ctctgagcaa ggtccctctg 120 cagcagaact tccaggacaa ccaattccag gggaagtggt atgtggtagg cctggcaggg 180 tgtgcaattc tcagagaaga caaagacccg caaaagatgt atgccaccat ctatgagctg 240 aaagaagaca agagctacaa tgtcacctcc gtcctgttta ggaaaaagaa gtgtgactac 300 tggatcagga cttttgttcc aggttcccag ccgggcgagt tcacgctggg caacattaag 360 agttaccctg gattaacgag ttacctcgtc cgagtggtga gcaccaacta caaccagcat 420 gctatggtgt tcttcaagaa agtttctcaa aacagggagt acttcaagat caccctctac 480 gggagaacca aggagctgac ttcggaacta aaggagaact tcatccgctt ctccaaatct 540 ctgggcctcc ctgaaaacca catcgtcttc cctgtcccaa tcgaccagtg tatcgacggc 600 ggatcc 606 <210> SEQ ID NO 39 <211> LENGTH: 178 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 39 Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser Lys Val 1 5 10 15 Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe Gln Gly Lys Trp Tyr 20 25 30 Val Val Gly Leu Ala Gly Asn Ala Ile Leu Arg Glu Asp Lys Asp Pro 35 40 45 Gln Lys Met Tyr Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys Ser Tyr 50 55 60 Asn Val Thr Ser Val Leu Phe Arg Lys Lys Lys Cys Asp Tyr Trp Ile 65 70 75 80 Arg Thr Phe Val Pro Gly Cys Gln Pro Gly Glu Phe Thr Leu Gly Asn 85 90 95 Ile Lys Ser Tyr Pro Gly Leu Thr Ser Tyr Leu Val Arg Val Val Ser 100 105 110 Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys Lys Val Ser Gln 115 120 125 Asn Arg Glu Tyr Phe Lys Ile Thr Leu Tyr Gly Arg Thr Lys Glu Leu 130 135 140 Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser Leu Gly 145 150 155 160 Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile Asp Gln Cys Ile 165 170 175 Asp Gly <210> SEQ ID NO 40 <211> LENGTH: 178 <212> TYPE: PRT <213> ORGANISM: Pan troglodytes <400> SEQUENCE: 40 Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser Lys Val 1 5 10 15 Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe Gln Gly Lys Trp Tyr 20 25 30 Val Val Gly Leu Ala Gly Asn Ala Ile Leu Arg Glu Asp Lys Asp Pro 35 40 45 Gln Lys Met Tyr Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys Ser Tyr 50 55 60 Asn Val Thr Ser Val Leu Phe Arg Lys Lys Lys Cys Asp Tyr Trp Ile 65 70 75 80 Arg Thr Phe Val Pro Gly Arg Gln Pro Gly Glu Phe Thr Leu Gly Asn 85 90 95 Ile Lys Ser Tyr Pro Gly Leu Thr Ser Tyr Leu Val Arg Val Val Ser 100 105 110 Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys Lys Val Ser Gln 115 120 125 Asn Arg Glu Tyr Phe Lys Ile Thr Leu Tyr Gly Arg Thr Lys Glu Leu 130 135 140 Thr Ser Glu Leu Gln Glu Asn Phe Ile Arg Phe Ser Lys Ser Leu Gly 145 150 155 160 Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile Asp Gln Cys Ile 165 170 175 Asp Gly <210> SEQ ID NO 41 <211> LENGTH: 178 <212> TYPE: PRT <213> ORGANISM: Canis familiaris <400> SEQUENCE: 41 Gln Asp Ser Thr Pro Ser Leu Ile Pro Ala Pro Pro Pro Leu Lys Val 1 5 10 15 Pro Leu Gln Pro Asp Phe Gln His Asp Gln Phe Gln Gly Lys Trp Tyr 20 25 30 Val Ile Gly Ile Ala Gly Asn Ile Leu Lys Lys Glu Gly His Gly Gln 35 40 45 Leu Lys Met Tyr Thr Thr Thr Tyr Glu Leu Lys Asp Asp Gln Ser Tyr 50 55 60 Asn Val Thr Ser Thr Leu Leu Arg Asn Glu Arg Cys Asp Tyr Trp Asn 65 70 75 80 Arg Asp Phe Val Pro Ser Phe Gln Pro Gly Gln Phe Ser Leu Gly Asp 85 90 95 Ile Gln Leu Tyr Pro Gly Val Gln Ser Tyr Leu Val Gln Val Val Ala 100 105 110 Thr Asn Tyr Asn Gln Tyr Ala Leu Val Tyr Phe Arg Lys Val Tyr Lys 115 120 125 Ser Gln Glu Tyr Phe Lys Ile Thr Leu Tyr Gly Arg Thr Lys Glu Leu 130 135 140 Pro Leu Glu Leu Lys Lys Glu Phe Ile Arg Phe Ala Lys Ser Ile Gly 145 150 155 160 Leu Thr Glu Asp His Ile Ile Phe Pro Val Pro Ile Asp Gln Cys Ile 165 170 175 Asp Glu <210> SEQ ID NO 42 <211> LENGTH: 179 <212> TYPE: PRT <213> ORGANISM: Bos taurus <400> SEQUENCE: 42 Arg Ser Ser Ser Ser Arg Leu Leu Arg Ala Pro Pro Leu Ser Arg Ile 1 5 10 15 Pro Leu Gln Pro Asn Phe Gln Ala Asp Gln Phe Gln Gly Lys Trp Tyr 20 25 30 Thr Val Gly Val Ala Gly Asn Ala Ile Lys Lys Glu Glu Gln Asp Pro 35 40 45 Leu Lys Met Tyr Ser Ser Asn Tyr Glu Leu Lys Glu Asp Gly Ser Tyr 50 55 60 Asn Val Thr Ser Ile Leu Leu Lys Asp Asp Leu Cys Asp Tyr Trp Ile 65 70 75 80 Arg Thr Phe Val Pro Ser Ser Gln Pro Gly Gln Phe Thr Leu Gly Asn 85 90 95 Ile Lys Ser Tyr Arg Gly Ile Arg Ser Tyr Thr Val Arg Val Val Asn 100 105 110 Thr Asp Tyr Asn Gln Phe Ala Ile Val Tyr Phe Lys Lys Val Gln Arg 115 120 125 Lys Lys Thr Tyr Phe Lys Ile Thr Leu Tyr Gly Arg Thr Lys Glu Leu 130 135 140 Thr Pro Glu Val Arg Glu Asn Phe Ile Asn Phe Ala Lys Ser Leu Gly 145 150 155 160 Leu Thr Asp Asp His Ile Val Phe Thr Val Pro Ile Asp Arg Cys Ile 165 170 175 Asp Asp Gln <210> SEQ ID NO 43 <211> LENGTH: 180 <212> TYPE: PRT <213> ORGANISM: Mus musculus <400> SEQUENCE: 43 Gln Asp Ser Thr Gln Asn Leu Ile Pro Ala Pro Ser Leu Leu Thr Val 1 5 10 15 Pro Leu Gln Pro Asp Phe Arg Ser Asp Gln Phe Arg Gly Arg Trp Tyr 20 25 30 Val Val Gly Leu Ala Gly Asn Ala Val Gln Lys Lys Thr Glu Gly Ser 35 40 45 Phe Thr Met Tyr Ser Thr Ile Tyr Glu Leu Gln Glu Asn Asn Ser Tyr 50 55 60 Asn Val Thr Ser Ile Leu Val Arg Asp Gln Asp Gln Gly Cys Arg Tyr 65 70 75 80 Trp Ile Arg Thr Phe Val Pro Ser Ser Arg Ala Gly Gln Phe Thr Leu 85 90 95 Gly Asn Met His Arg Tyr Pro Gln Val Gln Ser Tyr Asn Val Gln Val 100 105 110 Ala Thr Thr Asp Tyr Asn Gln Phe Ala Met Val Phe Phe Arg Lys Thr 115 120 125 Ser Glu Asn Lys Gln Tyr Phe Lys Ile Thr Leu Tyr Gly Arg Thr Lys 130 135 140 Glu Leu Ser Pro Glu Leu Lys Glu Arg Phe Thr Arg Phe Ala Lys Ser 145 150 155 160 Leu Gly Leu Lys Asp Asp Asn Ile Ile Phe Ser Val Pro Thr Asp Gln 165 170 175 Cys Ile Asp Asn 180 <210> SEQ ID NO 44 <211> LENGTH: 178 <212> TYPE: PRT <213> ORGANISM: Rattus norvegicus <400> SEQUENCE: 44 Gln Asp Ser Thr Gln Asn Leu Ile Pro Ala Pro Pro Leu Ile Ser Val 1 5 10 15 Pro Leu Gln Pro Gly Phe Trp Thr Glu Arg Phe Gln Gly Arg Trp Phe 20 25 30 Val Val Gly Leu Ala Ala Asn Ala Val Gln Lys Glu Arg Gln Ser Arg 35 40 45 Phe Thr Met Tyr Ser Thr Ile Tyr Glu Leu Gln Glu Asp Asn Ser Tyr 50 55 60 Asn Val Thr Ser Ile Leu Val Arg Gly Gln Gly Cys Arg Tyr Trp Ile 65 70 75 80 Arg Thr Phe Val Pro Ser Ser Arg Pro Gly Gln Phe Thr Leu Gly Asn 85 90 95 Ile His Ser Tyr Pro Gln Ile Gln Ser Tyr Asp Val Gln Val Ala Asp 100 105 110 Thr Asp Tyr Asp Gln Phe Ala Met Val Phe Phe Gln Lys Thr Ser Glu 115 120 125 Asn Lys Gln Tyr Phe Lys Val Thr Leu Tyr Gly Arg Thr Lys Gly Leu 130 135 140 Ser Asp Glu Leu Lys Glu Arg Phe Val Ser Phe Ala Lys Ser Leu Gly 145 150 155 160 Leu Lys Asp Asn Asn Ile Val Phe Ser Val Pro Thr Asp Gln Cys Ile 165 170 175 Asp Asn <210> SEQ ID NO 45 <211> LENGTH: 178 <212> TYPE: PRT <213> ORGANISM: Macaca mulatta <400> SEQUENCE: 45 Gln Asp Ser Ser Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser Lys Val 1 5 10 15 Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe Gln Gly Lys Trp Tyr 20 25 30 Val Val Gly Leu Ser Gly Asn Ala Val Gly Arg Lys Asp Glu Ala Pro 35 40 45 Leu Lys Met Tyr Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys Ser Tyr 50 55 60 Asn Val Thr Ser Ile Leu Phe Arg Lys Glu Lys Cys Asp Tyr Trp Ile 65 70 75 80 Arg Thr Phe Val Pro Gly Ser Gln Pro Gly Glu Phe Thr Leu Gly Asn 85 90 95 Ile Gln Asn His Pro Gly Leu Thr Ser Tyr Val Val Arg Val Val Ser 100 105 110 Thr Asn Tyr Lys Gln Tyr Ala Met Val Phe Phe Lys Lys Val Ser Gln 115 120 125 Asn Lys Glu Tyr Phe Lys Ile Thr Leu Tyr Gly Arg Thr Lys Glu Leu 130 135 140 Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser Leu Gly 145 150 155 160 Leu Pro Glu Asn His Ile Val Phe Ser Val Pro Ile Asp Gln Cys Ile 165 170 175 Asn Gly <210> SEQ ID NO 46 <211> LENGTH: 181 <212> TYPE: PRT <213> ORGANISM: Tursiops truncatus <400> SEQUENCE: 46 Gln Asp Ser Thr Pro Asn Leu Ile Pro Ala Pro Pro Leu Phe Arg Val 1 5 10 15 Pro Leu Gln Pro Asn Phe Gln Pro Asp Gln Phe Gln Gly Lys Trp Tyr 20 25 30 Ile Val Gly Leu Ala Gly Asn Ala Phe Lys Lys Glu Lys Gln Gly Gln 35 40 45 Phe Lys Met Tyr Ala Thr Thr Tyr Glu Leu Lys Glu Asp Arg Ser Tyr 50 55 60 Asn Val Thr Ser Ala Leu Leu Arg Gly Lys Thr Gln Arg Cys Asp His 65 70 75 80 Trp Ile Arg Thr Phe Val Pro Ser Ser Arg Pro Gly Gln Phe Thr Leu 85 90 95 Gly Asn Ile Lys Gly Phe Pro Gly Val Gln Ser Tyr Thr Val Arg Val 100 105 110 Ala Thr Thr Asn Tyr Asn Gln Phe Ala Ile Val Tyr Phe Lys Lys Val 115 120 125 Tyr Lys Asn Gln Glu Tyr Phe Lys Thr Thr Leu Tyr Gly Arg Thr Lys 130 135 140 Glu Leu Thr Pro Gln Leu Lys Glu Asn Phe Ile His Phe Ala Lys Ser 145 150 155 160 Leu Gly Leu Thr Asp Glu Tyr Ile Leu Phe Pro Val Pro Ile Asp Lys 165 170 175 Cys Ile Asp Asp Gln 180 <210> SEQ ID NO 47 <211> LENGTH: 180 <212> TYPE: PRT <213> ORGANISM: Gorilla gorilla <400> SEQUENCE: 47 Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser Lys Val 1 5 10 15 Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe Gln Gly Lys Trp Tyr 20 25 30 Val Val Gly Leu Ala Gly Asn Ala Ile Leu Arg Glu Asp Lys Asp Pro 35 40 45 Gln Lys Met Tyr Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys Ser Tyr 50 55 60 Asn Val Thr Ser Val Leu Phe Arg Glu Lys Ala Gln Lys Cys Asp Tyr 65 70 75 80 Trp Ile Arg Thr Phe Val Pro Gly Ser Gln Pro Gly Glu Phe Thr Leu 85 90 95 Gly Asn Ile Lys Ser Tyr Pro Gly Leu Thr Ser Tyr Leu Val Arg Val 100 105 110 Val Ser Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys Lys Val 115 120 125 Ser Gln Asn Arg Glu Tyr Phe Lys Ile Thr Leu Tyr Gly Arg Thr Lys 130 135 140 Glu Leu Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser 145 150 155 160 Leu Gly Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile Asp Gln 165 170 175 Cys Ile Asp Gly 180 <210> SEQ ID NO 48 <211> LENGTH: 179 <212> TYPE: PRT <213> ORGANISM: Procavia capensis <400> SEQUENCE: 48 Gln Glu Pro Thr Pro Thr Leu Ile Pro Ala Pro Pro Leu Ser Ser Ile 1 5 10 15 Pro Leu Lys Pro Asn Phe His Asn Asp Lys Phe Gln Gly Lys Trp Tyr 20 25 30 Val Val Gly Val Ala Gly Asn Ala Ile Thr Lys Glu Lys Asp Pro Ser 35 40 45 Leu Met Tyr Thr Thr Thr Tyr Glu Leu Arg Asp Asp Gly Ser Tyr Asn 50 55 60 Val Thr Ser Thr Gln Phe Arg Glu Lys Ile Asn Cys Thr His Trp Thr 65 70 75 80 Arg Thr Phe Val Pro Thr Ser Gln Pro Gly Gln Phe Ser Leu Gly Asn 85 90 95 Ile Asp Lys Tyr Pro His Leu Ser Ser Tyr Thr Val Arg Val Thr Ala 100 105 110 Thr Asn Tyr Asn Tyr Phe Ala Ile Val Tyr Phe Lys Lys Val Ser Lys 115 120 125 Asn Gln Glu Tyr Phe Lys Thr Thr Leu Tyr Lys Arg Ile Lys Lys Leu 130 135 140 Thr His Gly Leu Lys Lys His Phe Ile Gln Phe Ala Lys Ser Leu Gly 145 150 155 160 Leu Pro Asp Asn His Ile Thr Phe Leu Val Pro Thr Asp Arg Cys Ile 165 170 175 Asp Asp Ala <210> SEQ ID NO 49 <211> LENGTH: 179 <212> TYPE: PRT <213> ORGANISM: Callithrix jacchus <400> SEQUENCE: 49 Gln Asp Ser Pro Ser Pro Leu Ile Pro Ala Pro Pro Leu Ser Lys Val 1 5 10 15 Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe Gln Gly Lys Trp Tyr 20 25 30 Val Val Gly Leu Ala Gly Asn Ala Ile Arg Arg Glu Asp Gln Asp Ser 35 40 45 Leu Lys Met Tyr Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys Ser Tyr 50 55 60 Asn Val Thr Ser Val Leu Phe Arg Lys Ala Gln Lys Cys Asp Tyr Trp 65 70 75 80 Ile Arg Thr Phe Val Pro Ser Ser Arg Pro Gly Glu Phe Lys Leu Gly 85 90 95 Asn Ile Glu Ser His Pro Gly Leu Thr Ser Tyr Ile Val Arg Val Val 100 105 110 Asn Thr Asp Tyr Lys Gln His Ala Met Val Phe Phe Met Lys Ala Ser 115 120 125 His Asn Arg Lys Tyr Phe Lys Val Thr Leu Tyr Gly Arg Thr Lys Glu 130 135 140 Leu Thr Ser Asp Leu Lys Glu Asn Phe Thr Ser Phe Ser Lys Ser Leu 145 150 155 160 Gly Leu Thr Glu Asn His Ile Ile Phe Pro Val Pro Ile Asp Gln Cys 165 170 175 Ile Asp Gly <210> SEQ ID NO 50 <211> LENGTH: 178 <212> TYPE: PRT <213> ORGANISM: Microcebus murinus <400> SEQUENCE: 50 Gln Asp Ser Lys Glu Lys Leu Ile Pro Ala Pro Pro Leu Leu Arg Val 1 5 10 15 Pro Leu Gln Pro Asp Phe Gln Asp Asp Gln Phe Arg Glu Thr Ser Trp 20 25 30 Pro Arg Gly Ser Lys Met Lys Glu Thr Pro Ala Gly Ser Arg Asp Ala 35 40 45 Gly Thr Gly Trp Ala Thr Thr Tyr Glu Leu Lys Asp His Ser Tyr Asn 50 55 60 Val Thr Ser Thr Leu Leu Arg Gln Asn Gly Lys Cys Asp Tyr Trp Ile 65 70 75 80 Arg Thr Phe Val Leu Thr Ser Gln Pro Gly Gln Phe Ala Leu Gly Asn 85 90 95 Ile Asn Arg Tyr Pro Gly Ile Gln Ser Tyr Thr Val Arg Val Val Thr 100 105 110 Thr Asn Tyr Asn Gln Phe Ala Ile Val Phe Phe Lys Lys Val Ser Glu 115 120 125 Asn Lys Glu Tyr Phe Lys Thr Thr Leu Tyr Gly Arg Thr Lys Glu Leu 130 135 140 Pro Pro Glu Leu Lys Glu Asn Phe Ile Arg Phe Ala Lys Ser Leu Gly 145 150 155 160 Leu Thr Glu Asp His Ile Ile Tyr Pro Val Pro Ile Asp Gln Cys Ile 165 170 175 Asp Asp <210> SEQ ID NO 51 <211> LENGTH: 178 <212> TYPE: PRT <213> ORGANISM: Pongo abelii <400> SEQUENCE: 51 Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser Lys Val 1 5 10 15 Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe Gln Gly Lys Trp Tyr 20 25 30 Val Val Gly Leu Ala Gly Asn Ala Ile Arg Arg Glu Asp Lys Asp Ser 35 40 45 Gln Lys Met Tyr Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys Ser Tyr 50 55 60 Asn Val Thr Ser Val Leu Phe Arg Lys Lys Lys Cys Asp Tyr Trp Ile 65 70 75 80 Arg Thr Phe Val Pro Gly Ser Gln Pro Gly Glu Phe Thr Leu Gly Asn 85 90 95 Thr Lys Gly Tyr Pro Gly Leu Thr Ser Tyr Leu Val Arg Val Val Ser 100 105 110 Thr Asn Tyr Asn Gln Tyr Ala Met Val Phe Phe Lys Lys Val Ser Gln 115 120 125 Asn Arg Glu Tyr Phe Lys Ile Thr Leu Tyr Gly Arg Thr Lys Glu Leu 130 135 140 Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser Leu Gly 145 150 155 160 Leu Pro Glu Asn His Ile Val Phe Pro Ala Pro Ile Asp Gln Cys Ile 165 170 175 Asp Gly <210> SEQ ID NO 52 <211> LENGTH: 181 <212> TYPE: PRT <213> ORGANISM: Ochotona princeps <400> SEQUENCE: 52 Gln Glu Leu Thr Thr Asp Leu Ile Pro Val Pro Ser Leu Arg Lys Ile 1 5 10 15 His Val Gln Lys Asn Phe Gln Ser Asp Gln Phe Gln Gly Lys Trp Tyr 20 25 30 Val Val Gly Leu Ala Gly Asn Asn Ile His Asn Ser Asp Gln Glu His 35 40 45 Gln Gln Met Tyr Ser Thr Thr Tyr Glu Leu Lys Glu Asp Gly Ser Tyr 50 55 60 Asn Val Thr Ser Thr Leu Leu Arg Gln Arg Asn Gln Gln Cys Asp His 65 70 75 80 Trp Ile Arg Thr Phe Val Pro Gly Ser Lys Leu Gly His Phe Asn Leu 85 90 95 Gly Asn Ile Lys Ser Tyr Pro Thr Leu Lys Ser Tyr Leu Ile Arg Val 100 105 110 Val Thr Thr Asp Tyr Asn Gln Phe Ala Ile Val Phe Phe Arg Lys Val 115 120 125 Tyr Lys Asn Asn Lys Lys Phe Phe Lys Ile Val Leu Tyr Gly Arg Thr 130 135 140 Lys Glu Leu Ser Pro Glu Leu Arg Gly Arg Phe Thr Ser Phe Ala Lys 145 150 155 160 Thr Leu Gly Leu Thr Asp Asn His Ile Val Phe Pro Ala Pro Ile Gly 165 170 175 Gln Cys Ile Asp Asp 180 <210> SEQ ID NO 53 <211> LENGTH: 178 <212> TYPE: PRT <213> ORGANISM: Loxodonta africana <400> SEQUENCE: 53 Gln Thr His Ser Pro Thr Leu Ile Pro Ala Pro Pro Leu Leu Arg Val 1 5 10 15 Pro Leu Gln Pro Asp Phe Gln Asp Asp Lys Phe Gln Gly Lys Trp Tyr 20 25 30 Val Ile Gly Leu Ala Gly Asn Ala Val Glu Lys Lys Glu Gln Gly Gln 35 40 45 Phe Lys Met Tyr Thr Thr Thr Tyr Glu Leu Lys Glu Asp Gly Ser Tyr 50 55 60 Asn Val Thr Ser Thr Leu Leu Gln Glu Asp Gly Lys Cys Ser Tyr Trp 65 70 75 80 Ile Arg Thr Phe Val Pro Ser Phe Gln Pro Gly Gln Phe Asn Leu Gly 85 90 95 Asn Ile Lys Asn Phe Pro Gly Leu Gln Ser Tyr Thr Val Arg Val Thr 100 105 110 Ala Thr Asn Tyr Asn Gln Phe Ala Ile Val Phe Phe Lys Lys Val Ser 115 120 125 Lys Asn Gly Glu Tyr Phe Lys Thr Thr Leu Tyr Gly Arg Thr Lys Glu 130 135 140 Leu Thr Pro Glu Leu Lys Glu Arg Phe Ile Arg Phe Ala Lys Ser Leu 145 150 155 160 Gly Leu Ser Asp His Ile Ile Phe Pro Val Pro Ile Asp Arg Cys Ile 165 170 175 Asp Asp <210> SEQ ID NO 54 <211> LENGTH: 178 <212> TYPE: PRT <213> ORGANISM: Oryctolagus cuniculus <400> SEQUENCE: 54 Gln Asp Pro Thr Pro Lys Leu Ile Pro Ala Pro Ser Leu Arg Arg Val 1 5 10 15 Pro Leu Gln Arg Asn Phe Gln Asp Glu Gln Phe Gln Gly Lys Trp Tyr 20 25 30 Val Val Gly Leu Ala Gly Asn Ala Val Gln Lys Arg Glu Glu Gly Gln 35 40 45 Glu Pro Met Tyr Ser Thr Thr Tyr Glu Leu Asn Glu Asp Arg Ser Phe 50 55 60 Asn Val Thr Ser Thr Leu Leu Arg Asp Gln Arg Cys Asp His Trp Ile 65 70 75 80 Arg Thr Phe Val Pro Thr Ser Arg Pro Gly Gln Tyr Asn Leu Gly Asn 85 90 95 Ile Lys Ser Tyr Pro Gly Val Lys Asn Tyr Ile Val Arg Val Val Ala 100 105 110 Thr Asp Tyr Ser Gln Tyr Ala Met Met Phe Phe Arg Lys Gly Ser Arg 115 120 125 Asn Lys Gln Phe Phe Lys Thr Thr Leu Tyr Gly Arg Thr Lys Glu Leu 130 135 140 Ser Pro Glu Leu Arg Glu Arg Phe Thr Arg Phe Ala Lys Ser Leu Gly 145 150 155 160 Leu Pro Asp Asp Arg Ile Val Phe Pro Thr Pro Ile Asp Gln Cys Ile 165 170 175 Asp Asp <210> SEQ ID NO 55 <211> LENGTH: 997 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: Murine Scn construct for downstream viral fusions: IgK-H6-murineScn-StrepII-GGGGS-E7.16 <400> SEQUENCE: 55 ctcgagacca tggagaccga cacgctcttg ttgtgggttc tcttgttgtg ggtgcctggg 60 tctacaggcg accaccacca tcatcaccac ctcgttccta gaggcagcca ggatagtacc 120 cagaatctta tcccagcacc atctttgctc acagtaccat tgcaacccga ctttcggtct 180 gatcaatttc ggggacgctg gtacgtggtt ggactggccg gcaatgctgt acagaaaaaa 240 acagagggca gtttcaccat gtactcaaca atctatgagc tccaagagaa taatagttac 300 aacgttacct ccatcttggt gagggaccag gatcagggat gtcgctactg gattcggaca 360 ttcgtaccaa gttctcgggc cggtcagttt actctgggca acatgcacag gtatccccaa 420 gttcaatctt acaacgtgca ggtggcgact accgactaca accaattcgc tatggtgttc 480 ttccgcaaaa caagcgagaa caagcagtat tttaaaatca ctctgtacgg tagaactaag 540 gagctgagcc ctgaacttaa ggagcggttc accagattcg ctaagtccct gggactgaag 600 gatgataata taatcttttc cgtccccacc gatcagtgta tcgataattc agcttggtca 660 catccccagt tcgagaaagg aggcggtgga tccatgcatg gcgacactcc gaccctgcac 720 gaatacatgc tggacctgca gcccgaaacc actgacctgt attgttacga gcaactcaac 780 gattctagcg aggaggagga cgagatcgat ggaccggcag gccaggccga accagaccgc 840 gcacattata acattgttac cttctgttgc aaatgtgatt caactcttag actttgtgtc 900 cagagtacac acgtggacat ccgcaccctg gaagatctgc tgatgggaac tctgggtatc 960 gtgtgtccta tatgtagcca gaaaccctga cggaccg 997 <210> SEQ ID NO 56 <211> LENGTH: 326 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-H6-murineScn-StrepII-GGGGS-E7.16 <400> SEQUENCE: 56 Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Asp His His His His His His Leu Val Pro Arg Gly 20 25 30 Ser Gln Asp Ser Thr Gln Asn Leu Ile Pro Ala Pro Ser Leu Leu Thr 35 40 45 Val Pro Leu Gln Pro Asp Phe Arg Ser Asp Gln Phe Arg Gly Arg Trp 50 55 60 Tyr Val Val Gly Leu Ala Gly Asn Ala Val Gln Lys Lys Thr Glu Gly 65 70 75 80 Ser Phe Thr Met Tyr Ser Thr Ile Tyr Glu Leu Gln Glu Asn Asn Ser 85 90 95 Tyr Asn Val Thr Ser Ile Leu Val Arg Asp Gln Asp Gln Gly Cys Arg 100 105 110 Tyr Trp Ile Arg Thr Phe Val Pro Ser Ser Arg Ala Gly Gln Phe Thr 115 120 125 Leu Gly Asn Met His Arg Tyr Pro Gln Val Gln Ser Tyr Asn Val Gln 130 135 140 Val Ala Thr Thr Asp Tyr Asn Gln Phe Ala Met Val Phe Phe Arg Lys 145 150 155 160 Thr Ser Glu Asn Lys Gln Tyr Phe Lys Ile Thr Leu Tyr Gly Arg Thr 165 170 175 Lys Glu Leu Ser Pro Glu Leu Lys Glu Arg Phe Thr Arg Phe Ala Lys 180 185 190 Ser Leu Gly Leu Lys Asp Asp Asn Ile Ile Phe Ser Val Pro Thr Asp 195 200 205 Gln Cys Ile Asp Asn Ser Ala Trp Ser His Pro Gln Phe Glu Lys Gly 210 215 220 Gly Gly Gly Ser Met His Gly Asp Thr Pro Thr Leu His Glu Tyr Met 225 230 235 240 Leu Asp Leu Gln Pro Glu Thr Thr Asp Leu Tyr Cys Tyr Glu Gln Leu 245 250 255 Asn Asp Ser Ser Glu Glu Glu Asp Glu Ile Asp Gly Pro Ala Gly Gln 260 265 270 Ala Glu Pro Asp Arg Ala His Tyr Asn Ile Val Thr Phe Cys Cys Lys 275 280 285 Cys Asp Ser Thr Leu Arg Leu Cys Val Gln Ser Thr His Val Asp Ile 290 295 300 Arg Thr Leu Glu Asp Leu Leu Met Gly Thr Leu Gly Ile Val Cys Pro 305 310 315 320 Ile Cys Ser Gln Lys Pro 325 <210> SEQ ID NO 57 <211> LENGTH: 1189 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-H6-murineScn-StrepII-GGGGS-E6.16 <400> SEQUENCE: 57 ctcgagacca tggagaccga cacgctcttg ttgtgggttc tcttgttgtg ggtgcctggg 60 tctacaggcg accaccacca tcatcaccac ctcgttccta gaggcagcca ggatagtacc 120 cagaatctta tcccagcacc atctttgctc acagtaccat tgcaacccga ctttcggtct 180 gatcaatttc ggggacgctg gtacgtggtt ggactggccg gcaatgctgt acagaaaaaa 240 acagagggca gtttcaccat gtactcaaca atctatgagc tccaagagaa taatagttac 300 aacgttacct ccatcttggt gagggaccag gatcagggat gtcgctactg gattcggaca 360 ttcgtaccaa gttctcgggc cggtcagttt actctgggca acatgcacag gtatccccaa 420 gttcaatctt acaacgtgca ggtggcgact accgactaca accaattcgc tatggtgttc 480 ttccgcaaaa caagcgagaa caagcagtat tttaaaatca ctctgtacgg tagaactaag 540 gagctgagcc ctgaacttaa ggagcggttc accagattcg ctaagtccct gggactgaag 600 gatgataata taatcttttc cgtccccacc gatcagtgta tcgataattc agcttggtca 660 catccccagt tcgagaaagg aggcggtgga tccatgcacc agaagagaac cgccatgttc 720 caggacccac aagagcggcc ccggaaactg ccccaactgt gcactgaatt gcagaccacc 780 atccacgaca tcattttgga atgtgtctac tgtaagcagc agctcctcag gcgagaggtg 840 tatgacttcg ccttccggga tttgtgtatt gtctacaggg atggtaatcc ctatgccgtt 900 tgtgataagt gcctgaaatt ttatagcaag atcagcgagt accgacatta ctgttacagc 960 gtttatggaa caacattgga gcagcagtac aacaaacctc tttgcgacct cctgattcgc 1020 tgcatcaact gccagaagcc cctgtgcccc gaagagaaac aaaggcattt ggataagaag 1080 cagaggttcc acaacatccg cggtcgctgg acggggcgct gcatgagttg ctgcaggagt 1140 tcccgcactc ggcgcgagac ccaactctga cggaccgcct ctccctccc 1189 <210> SEQ ID NO 58 <211> LENGTH: 1189 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-H6-murineScn-StrepII-GGGGS-E6.18 <400> SEQUENCE: 58 ctcgagacca tggagaccga cacgctcttg ttgtgggttc tcttgttgtg ggtgcctggg 60 tctacaggcg accaccacca tcatcaccac ctcgttccta gaggcagcca ggatagtacc 120 cagaatctta tcccagcacc atctttgctc acagtaccat tgcaacccga ctttcggtct 180 gatcaatttc ggggacgctg gtacgtggtt ggactggccg gcaatgctgt acagaaaaaa 240 acagagggca gtttcaccat gtactcaaca atctatgagc tccaagagaa taatagttac 300 aacgttacct ccatcttggt gagggaccag gatcagggat gtcgctactg gattcggaca 360 ttcgtaccaa gttctcgggc cggtcagttt actctgggca acatgcacag gtatccccaa 420 gttcaatctt acaacgtgca ggtggcgact accgactaca accaattcgc tatggtgttc 480 ttccgcaaaa caagcgagaa caagcagtat tttaaaatca ctctgtacgg tagaactaag 540 gagctgagcc ctgaacttaa ggagcggttc accagattcg ctaagtccct gggactgaag 600 gatgataata taatcttttc cgtccccacc gatcagtgta tcgataattc agcttggtca 660 catccccagt tcgagaaagg aggcggtgga tccatggcca gatttgaaga ccccacaagg 720 cgcccctata aactgccgga tctttgcacc gaactgaata ctagcctgca agatattgag 780 attacctgcg tgtactgtaa aacggtgctc gaattgaccg aggtttttga gttcgcattc 840 aaggacctgt ttgttgtata tcgcgattcc atcccgcacg cagcttgcca taaatgcatt 900 gacttttact cccggatacg cgagctgcga cactatagtg atagcgtgta cggcgataca 960 cttgagaagc ttaccaacac cggtctgtac aatcttctga ttcggtgttt gaggtgccag 1020 aagccgctca acccagctga gaaactgcgg catctgaacg aaaaaagaag attccacaac 1080 attgctggcc actacagggg ccagtgccat tcttgttgta atagagcaag gcaggagcgg 1140 ctgcaacggc ggcgcgagac ccaggtatga cggaccgcct ctccctccc 1189 <210> SEQ ID NO 59 <211> LENGTH: 1030 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-H6-murineScn-StrepII-GGGGS-E7.18 <400> SEQUENCE: 59 ctcgagacca tggagaccga cacgctcttg ttgtgggttc tcttgttgtg ggtgcctggg 60 tctacaggcg accaccacca tcatcaccac ctcgttccta gaggcagcca ggatagtacc 120 cagaatctta tcccagcacc atctttgctc acagtaccat tgcaacccga ctttcggtct 180 gatcaatttc ggggacgctg gtacgtggtt ggactggccg gcaatgctgt acagaaaaaa 240 acagagggca gtttcaccat gtactcaaca atctatgagc tccaagagaa taatagttac 300 aacgttacct ccatcttggt gagggaccag gatcagggat gtcgctactg gattcggaca 360 ttcgtaccaa gttctcgggc cggtcagttt actctgggca acatgcacag gtatccccaa 420 gttcaatctt acaacgtgca ggtggcgact accgactaca accaattcgc tatggtgttc 480 ttccgcaaaa caagcgagaa caagcagtat tttaaaatca ctctgtacgg tagaactaag 540 gagctgagcc ctgaacttaa ggagcggttc accagattcg ctaagtccct gggactgaag 600 gatgataata taatcttttc cgtccccacc gatcagtgta tcgataattc agcttggtca 660 catccccagt tcgagaaagg aggcggtgga tccatgcacg gacctaaagc aacactccag 720 gacatcgtcc tgcatttgga accacaaaac gaaatacccg tggacctttt gtgtcacgaa 780 cagctttcag attctgagga agagaatgat gaaatcgacg gtgtcaacca ccagcatctc 840 cccgctaggc gggcagaacc ccagcgccac acaatgctgt gcatgtgttg caaatgcgaa 900 gctcgaattg aactcgtggt tgagtcctcc gcggacgact tgagggcatt ccagcaactg 960 ttcctcaaca cactgagctt tgtctgtcct tggtgcgcta gtcagcagtg acggaccgcc 1020 tctccctccc 1030 <210> SEQ ID NO 60 <211> LENGTH: 1162 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-H6-murineScn-StrepII-GGGGS-E6.33 <400> SEQUENCE: 60 ctcgagacca tggagaccga cacgctcttg ttgtgggttc tcttgttgtg ggtgcctggg 60 tctacaggcg accaccacca tcatcaccac ctcgttccta gaggcagcca ggatagtacc 120 cagaatctta tcccagcacc atctttgctc acagtaccat tgcaacccga ctttcggtct 180 gatcaatttc ggggacgctg gtacgtggtt ggactggccg gcaatgctgt acagaaaaaa 240 acagagggca gtttcaccat gtactcaaca atctatgagc tccaagagaa taatagttac 300 aacgttacct ccatcttggt gagggaccag gatcagggat gtcgctactg gattcggaca 360 ttcgtaccaa gttctcgggc cggtcagttt actctgggca acatgcacag gtatccccaa 420 gttcaatctt acaacgtgca ggtggcgact accgactaca accaattcgc tatggtgttc 480 ttccgcaaaa caagcgagaa caagcagtat tttaaaatca ctctgtacgg tagaactaag 540 gagctgagcc ctgaacttaa ggagcggttc accagattcg ctaagtccct gggactgaag 600 gatgataata taatcttttc cgtccccacc gatcagtgta tcgataattc agcttggtca 660 catccccagt tcgagaaagg aggcggtgga tccatgttcc aagacactga ggagaagcca 720 cgcacgctgc acgatctgtg ccaggccctt gagactacca tccataacat cgagctccag 780 tgtgtcgaat gcaggaatcc tcttcagcgg agcgaggtgt acgattttgc cttcgcggac 840 ctgacggtgg tctaccggga aggtaaccca ttcgggattt gcaagctgtg tctcagattt 900 cttagtaaga taagtgaata ccggcactac aactattcag tttacggtca cactctggaa 960 cagaccgtga acaaacccct gaacgagatc ctcattcgat gtatcatctg tcagagacct 1020 ctctgtccgc gcgaaaagaa gaggcacgtc gacctgaata agcgatttca taatatctct 1080 ggacggtggg cggggcgctg tgcagcctgt tggagatccc ggagacggga aacagctctt 1140 tgacggaccg cctctccctc cc 1162 <210> SEQ ID NO 61 <211> LENGTH: 1007 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-H6-murineScn-StrepII-GGGGS-E7.33 <400> SEQUENCE: 61 ctcgagacca tggagaccga cacgctcttg ttgtgggttc tcttgttgtg ggtgcctggg 60 tctacaggcg accaccacca tcatcaccac ctcgttccta gaggcagcca ggatagtacc 120 cagaatctta tcccagcacc atctttgctc acagtaccat tgcaacccga ctttcggtct 180 gatcaatttc ggggacgctg gtacgtggtt ggactggccg gcaatgctgt acagaaaaaa 240 acagagggca gtttcaccat gtactcaaca atctatgagc tccaagagaa taatagttac 300 aacgttacct ccatcttggt gagggaccag gatcagggat gtcgctactg gattcggaca 360 ttcgtaccaa gttctcgggc cggtcagttt actctgggca acatgcacag gtatccccaa 420 gttcaatctt acaacgtgca ggtggcgact accgactaca accaattcgc tatggtgttc 480 ttccgcaaaa caagcgagaa caagcagtat tttaaaatca ctctgtacgg tagaactaag 540 gagctgagcc ctgaacttaa ggagcggttc accagattcg ctaagtccct gggactgaag 600 gatgataata taatcttttc cgtccccacc gatcagtgta tcgataattc agcttggtca 660 catccccagt tcgagaaagg aggcggtgga tccatgcggg gacatgaacc tactctgaag 720 gagtacgtcc tggaccttta cccggagccg acagatcttt actgttacga gcaattgtct 780 gactccagcg acgaggatga gggccttgac agacctgatg gccaggctca gccagctact 840 gccgattatt atatcgttac gtgttgtcac acctgcaaca caaccgtaag gttgtgtgtg 900 aactccaccg ccagtgactt gagaacgata caacaactcc tcatgggcac tgtcaatatc 960 gtctgtccta catgtgctca gctgctgacg gaccgcctct ccctccc 1007 <210> SEQ ID NO 62 <211> LENGTH: 1189 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-H6-murineScn-StrepII-GGGGS-E6.45 <400> SEQUENCE: 62 ctcgagacca tggagaccga cacgctcttg ttgtgggttc tcttgttgtg ggtgcctggg 60 tctacaggcg accaccacca tcatcaccac ctcgttccta gaggcagcca ggatagtacc 120 cagaatctta tcccagcacc atctttgctc acagtaccat tgcaacccga ctttcggtct 180 gatcaatttc ggggacgctg gtacgtggtt ggactggccg gcaatgctgt acagaaaaaa 240 acagagggca gtttcaccat gtactcaaca atctatgagc tccaagagaa taatagttac 300 aacgttacct ccatcttggt gagggaccag gatcagggat gtcgctactg gattcggaca 360 ttcgtaccaa gttctcgggc cggtcagttt actctgggca acatgcacag gtatccccaa 420 gttcaatctt acaacgtgca ggtggcgact accgactaca accaattcgc tatggtgttc 480 ttccgcaaaa caagcgagaa caagcagtat tttaaaatca ctctgtacgg tagaactaag 540 gagctgagcc ctgaacttaa ggagcggttc accagattcg ctaagtccct gggactgaag 600 gatgataata taatcttttc cgtccccacc gatcagtgta tcgataattc agcttggtca 660 catccccagt tcgagaaagg aggcggtgga tccatggcca ggttcgatga tcccacccag 720 cgaccctata agttgcccga tctctgcaca gaacttaaca ctagcttgca ggacgtaagc 780 attgcatgtg tttactgtaa agctacgctg gagcgaaccg aggtgtacca attcgccttc 840 aaagacttgt tcatcgtgta tagagactgt atcgcttatg ccgcctgcca caaatgcata 900 gacttttaca gcaggatcag ggaattgagg tactattcca actcagtcta tggagaaacg 960 ctggagaaga taactaacac tgagctttat aacctcctga ttcgctgcct ccggtgtcag 1020 aagccactga atcctgccga aaagagacgc catctgaagg acaagcggcg ctttcatagc 1080 attgcaggac agtacagagg ccaatgtaat acttgctgtg accaagcacg ccaagaaagg 1140 ctcaggagaa ggagagagac acaggtgtga cggaccgcct ctccctccc 1189 <210> SEQ ID NO 63 <211> LENGTH: 1033 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-H6-murineScn-StrepII-GGGGS-E7.45 <400> SEQUENCE: 63 ctcgagacca tggagaccga cacgctcttg ttgtgggttc tcttgttgtg ggtgcctggg 60 tctacaggcg accaccacca tcatcaccac ctcgttccta gaggcagcca ggatagtacc 120 cagaatctta tcccagcacc atctttgctc acagtaccat tgcaacccga ctttcggtct 180 gatcaatttc ggggacgctg gtacgtggtt ggactggccg gcaatgctgt acagaaaaaa 240 acagagggca gtttcaccat gtactcaaca atctatgagc tccaagagaa taatagttac 300 aacgttacct ccatcttggt gagggaccag gatcagggat gtcgctactg gattcggaca 360 ttcgtaccaa gttctcgggc cggtcagttt actctgggca acatgcacag gtatccccaa 420 gttcaatctt acaacgtgca ggtggcgact accgactaca accaattcgc tatggtgttc 480 ttccgcaaaa caagcgagaa caagcagtat tttaaaatca ctctgtacgg tagaactaag 540 gagctgagcc ctgaacttaa ggagcggttc accagattcg ctaagtccct gggactgaag 600 gatgataata taatcttttc cgtccccacc gatcagtgta tcgataattc agcttggtca 660 catccccagt tcgagaaagg aggcggtgga tccatgcacg gcccacaggc aaccctgcaa 720 gagatcgtgc tgcatctcga accacagaat gaattggacc ctgtggatct gctgtgttac 780 gagcagctct ctgaaagcga agaggagaat gacgaggccg acggcgtgtc tcatgcacag 840 ctgcctgctc gccgggccga acctcagcga cacaaaattc tgtgcgtgtg ctgcaaatgc 900 gacggccgca tagagctgac ggtagaatca tcagccgacg atctgcgaac tcttcaacaa 960 ctcttcctga gcacgctcag cttcgtgtgt ccttggtgtg ctacaaatca gtgacggacc 1020 gcctctccct ccc 1033 <210> SEQ ID NO 64 <211> LENGTH: 1162 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-H6-murineScn-StrepII-GGGGS-E6.31 <400> SEQUENCE: 64 Cys Thr Cys Gly Ala Gly Ala Cys Cys Ala Thr Gly Gly Ala Gly Ala 1 5 10 15 Cys Cys Gly Ala Cys Ala Cys Gly Cys Thr Cys Thr Thr Gly Thr Thr 20 25 30 Gly Thr Gly Gly Gly Thr Thr Cys Thr Cys Thr Thr Gly Thr Thr Gly 35 40 45 Thr Gly Gly Gly Thr Gly Cys Cys Thr Gly Gly Gly Thr Cys Thr Ala 50 55 60 Cys Ala Gly Gly Cys Gly Ala Cys Cys Ala Cys Cys Ala Cys Cys Ala 65 70 75 80 Thr Cys Ala Thr Cys Ala Cys Cys Ala Cys Cys Thr Cys Gly Thr Thr 85 90 95 Cys Cys Thr Ala Gly Ala Gly Gly Cys Ala Gly Cys Cys Ala Gly Gly 100 105 110 Ala Thr Ala Gly Thr Ala Cys Cys Cys Ala Gly Ala Ala Thr Cys Thr 115 120 125 Thr Ala Thr Cys Cys Cys Ala Gly Cys Ala Cys Cys Ala Thr Cys Thr 130 135 140 Thr Thr Gly Cys Thr Cys Ala Cys Ala Gly Thr Ala Cys Cys Ala Thr 145 150 155 160 Thr Gly Cys Ala Ala Cys Cys Cys Gly Ala Cys Thr Thr Thr Cys Gly 165 170 175 Gly Thr Cys Thr Gly Ala Thr Cys Ala Ala Thr Thr Thr Cys Gly Gly 180 185 190 Gly Gly Ala Cys Gly Cys Thr Gly Gly Thr Ala Cys Gly Thr Gly Gly 195 200 205 Thr Thr Gly Gly Ala Cys Thr Gly Gly Cys Cys Gly Gly Cys Ala Ala 210 215 220 Thr Gly Cys Thr Gly Thr Ala Cys Ala Gly Ala Ala Ala Ala Ala Ala 225 230 235 240 Ala Cys Ala Gly Ala Gly Gly Gly Cys Ala Gly Thr Thr Thr Cys Ala 245 250 255 Cys Cys Ala Thr Gly Thr Ala Cys Thr Cys Ala Ala Cys Ala Ala Thr 260 265 270 Cys Thr Ala Thr Gly Ala Gly Cys Thr Cys Cys Ala Ala Gly Ala Gly 275 280 285 Ala Ala Thr Ala Ala Thr Ala Gly Thr Thr Ala Cys Ala Ala Cys Gly 290 295 300 Thr Thr Ala Cys Cys Thr Cys Cys Ala Thr Cys Thr Thr Gly Gly Thr 305 310 315 320 Gly Ala Gly Gly Gly Ala Cys Cys Ala Gly Gly Ala Thr Cys Ala Gly 325 330 335 Gly Gly Ala Thr Gly Thr Cys Gly Cys Thr Ala Cys Thr Gly Gly Ala 340 345 350 Thr Thr Cys Gly Gly Ala Cys Ala Thr Thr Cys Gly Thr Ala Cys Cys 355 360 365 Ala Ala Gly Thr Thr Cys Thr Cys Gly Gly Gly Cys Cys Gly Gly Thr 370 375 380 Cys Ala Gly Thr Thr Thr Ala Cys Thr Cys Thr Gly Gly Gly Cys Ala 385 390 395 400 Ala Cys Ala Thr Gly Cys Ala Cys Ala Gly Gly Thr Ala Thr Cys Cys 405 410 415 Cys Cys Ala Ala Gly Thr Thr Cys Ala Ala Thr Cys Thr Thr Ala Cys 420 425 430 Ala Ala Cys Gly Thr Gly Cys Ala Gly Gly Thr Gly Gly Cys Gly Ala 435 440 445 Cys Thr Ala Cys Cys Gly Ala Cys Thr Ala Cys Ala Ala Cys Cys Ala 450 455 460 Ala Thr Thr Cys Gly Cys Thr Ala Thr Gly Gly Thr Gly Thr Thr Cys 465 470 475 480 Thr Thr Cys Cys Gly Cys Ala Ala Ala Ala Cys Ala Ala Gly Cys Gly 485 490 495 Ala Gly Ala Ala Cys Ala Ala Gly Cys Ala Gly Thr Ala Thr Thr Thr 500 505 510 Thr Ala Ala Ala Ala Thr Cys Ala Cys Thr Cys Thr Gly Thr Ala Cys 515 520 525 Gly Gly Thr Ala Gly Ala Ala Cys Thr Ala Ala Gly Gly Ala Gly Cys 530 535 540 Thr Gly Ala Gly Cys Cys Cys Thr Gly Ala Ala Cys Thr Thr Ala Ala 545 550 555 560 Gly Gly Ala Gly Cys Gly Gly Thr Thr Cys Ala Cys Cys Ala Gly Ala 565 570 575 Thr Thr Cys Gly Cys Thr Ala Ala Gly Thr Cys Cys Cys Thr Gly Gly 580 585 590 Gly Ala Cys Thr Gly Ala Ala Gly Gly Ala Thr Gly Ala Thr Ala Ala 595 600 605 Thr Ala Thr Ala Ala Thr Cys Thr Thr Thr Thr Cys Cys Gly Thr Cys 610 615 620 Cys Cys Cys Ala Cys Cys Gly Ala Thr Cys Ala Gly Thr Gly Thr Ala 625 630 635 640 Thr Cys Gly Ala Thr Ala Ala Thr Thr Cys Ala Gly Cys Thr Thr Gly 645 650 655 Gly Thr Cys Ala Cys Ala Thr Cys Cys Cys Cys Ala Gly Thr Thr Cys 660 665 670 Gly Ala Gly Ala Ala Ala Gly Gly Ala Gly Gly Cys Gly Gly Thr Gly 675 680 685 Gly Ala Thr Cys Cys Ala Thr Gly Thr Thr Cys Ala Ala Ala Ala Ala 690 695 700 Cys Cys Cys Gly Gly Cys Thr Gly Ala Gly Ala Gly Ala Cys Cys Gly 705 710 715 720 Cys Gly Gly Ala Ala Gly Thr Thr Gly Cys Ala Cys Gly Ala Gly Cys 725 730 735 Thr Cys Thr Cys Ala Thr Cys Cys Gly Cys Gly Cys Thr Gly Gly Ala 740 745 750 Ala Ala Thr Ala Cys Cys Thr Thr Ala Thr Gly Ala Thr Gly Ala Gly 755 760 765 Cys Thr Thr Cys Gly Cys Thr Thr Gly Ala Ala Thr Thr Gly Thr Gly 770 775 780 Thr Gly Thr Ala Cys Thr Gly Cys Ala Ala Ala Gly Gly Cys Cys Ala 785 790 795 800 Gly Cys Thr Cys Ala Cys Thr Gly Ala Gly Ala Cys Cys Gly Ala Ala 805 810 815 Gly Thr Ala Cys Thr Thr Gly Ala Thr Thr Thr Thr Gly Cys Cys Thr 820 825 830 Thr Thr Ala Cys Thr Gly Ala Cys Cys Thr Gly Ala Cys Ala Ala Thr 835 840 845 Cys Gly Thr Cys Thr Ala Thr Ala Gly Ala Gly Ala Cys Gly Ala Cys 850 855 860 Ala Cys Thr Cys Cys Ala Cys Ala Cys Gly Gly Gly Gly Thr Cys Thr 865 870 875 880 Gly Thr Ala Cys Ala Ala Ala Ala Thr Gly Thr Cys Thr Gly Cys Gly 885 890 895 Gly Thr Thr Thr Thr Ala Thr Ala Gly Thr Ala Ala Ala Gly Thr Gly 900 905 910 Ala Gly Cys Gly Ala Ala Thr Thr Cys Cys Gly Gly Thr Gly Gly Thr 915 920 925 Ala Thr Cys Gly Cys Thr Ala Thr Thr Cys Ala Gly Thr Gly Thr Ala 930 935 940 Thr Gly Gly Ala Ala Cys Cys Ala Cys Ala Thr Thr Gly Gly Ala Gly 945 950 955 960 Ala Ala Ala Cys Thr Cys Ala Cys Thr Ala Ala Cys Ala Ala Ala Gly 965 970 975 Gly Thr Ala Thr Cys Thr Gly Thr Gly Ala Cys Cys Thr Gly Cys Thr 980 985 990 Gly Ala Thr Cys Ala Gly Gly Thr Gly Cys Ala Thr Ala Ala Cys Thr 995 1000 1005 Thr Gly Thr Cys Ala Gly Ala Gly Gly Cys Cys Gly Cys Thr Cys 1010 1015 1020 Thr Gly Cys Cys Cys Cys Gly Ala Gly Gly Ala Gly Ala Ala Gly 1025 1030 1035 Cys Ala Gly Cys Gly Cys Cys Ala Cys Cys Thr Gly Gly Ala Thr 1040 1045 1050 Ala Ala Gly Ala Ala Gly Ala Ala Gly Ala Gly Ala Thr Thr Cys 1055 1060 1065 Cys Ala Cys Ala Ala Cys Ala Thr Thr Gly Gly Ala Gly Gly Cys 1070 1075 1080 Ala Gly Ala Thr Gly Gly Ala Cys Ala Gly Gly Cys Cys Gly Gly 1085 1090 1095 Thr Gly Cys Ala Thr Thr Gly Cys Thr Thr Gly Thr Thr Gly Gly 1100 1105 1110 Cys Gly Cys Ala Gly Gly Cys Cys Ala Ala Gly Ala Ala Cys Cys 1115 1120 1125 Gly Ala Gly Ala Cys Cys Cys Ala Ala Gly Thr Thr Thr Gly Ala 1130 1135 1140 Cys Gly Gly Ala Cys Cys Gly Cys Cys Thr Cys Thr Cys Cys Cys 1145 1150 1155 Thr Cys Cys Cys 1160 <210> SEQ ID NO 65 <211> LENGTH: 1009 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-H6-murineScn-StrepII-GGGGS-E7.31 <400> SEQUENCE: 65 ctcgagacca tggagaccga cacgctcttg ttgtgggttc tcttgttgtg ggtgcctggg 60 tctacaggcg accaccacca tcatcaccac ctcgttccta gaggcagcca ggatagtacc 120 cagaatctta tcccagcacc atctttgctc acagtaccat tgcaacccga ctttcggtct 180 gatcaatttc ggggacgctg gtacgtggtt ggactggccg gcaatgctgt acagaaaaaa 240 acagagggca gtttcaccat gtactcaaca atctatgagc tccaagagaa taatagttac 300 aacgttacct ccatcttggt gagggaccag gatcagggat gtcgctactg gattcggaca 360 ttcgtaccaa gttctcgggc cggtcagttt actctgggca acatgcacag gtatccccaa 420 gttcaatctt acaacgtgca ggtggcgact accgactaca accaattcgc tatggtgttc 480 ttccgcaaaa caagcgagaa caagcagtat tttaaaatca ctctgtacgg tagaactaag 540 gagctgagcc ctgaacttaa ggagcggttc accagattcg ctaagtccct gggactgaag 600 gatgataata taatcttttc cgtccccacc gatcagtgta tcgataattc agcttggtca 660 catccccagt tcgagaaagg aggcggtgga tccatgcggg gtgagacacc aactcttcag 720 gattatgttc tggatctgca gccagaggcc acagatctgc actgttacga gcaattgcct 780 gattccagcg acgaggagga tgtcatcgat agccctgctg ggcaggccaa gccagacact 840 tcaaattaca acattgtaac gttttgttgt cagtgcgaat ccaccctcag gctttgcgtc 900 cagagcactc aggttgacat tcgaatactc caggagctgt tgatggggag ctttggaatc 960 gtgtgcccaa attgtagtac acgactgtga cggaccgcct ctccctccc 1009 <210> SEQ ID NO 66 <211> LENGTH: 1162 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-H6-murineScn-StrepII-GGGGS-E6.58 <400> SEQUENCE: 66 ctcgagacca tggagaccga cacgctcttg ttgtgggttc tcttgttgtg ggtgcctggg 60 tctacaggcg accaccacca tcatcaccac ctcgttccta gaggcagcca ggatagtacc 120 cagaatctta tcccagcacc atctttgctc acagtaccat tgcaacccga ctttcggtct 180 gatcaatttc ggggacgctg gtacgtggtt ggactggccg gcaatgctgt acagaaaaaa 240 acagagggca gtttcaccat gtactcaaca atctatgagc tccaagagaa taatagttac 300 aacgttacct ccatcttggt gagggaccag gatcagggat gtcgctactg gattcggaca 360 ttcgtaccaa gttctcgggc cggtcagttt actctgggca acatgcacag gtatccccaa 420 gttcaatctt acaacgtgca ggtggcgact accgactaca accaattcgc tatggtgttc 480 ttccgcaaaa caagcgagaa caagcagtat tttaaaatca ctctgtacgg tagaactaag 540 gagctgagcc ctgaacttaa ggagcggttc accagattcg ctaagtccct gggactgaag 600 gatgataata taatcttttc cgtccccacc gatcagtgta tcgataattc agcttggtca 660 catccccagt tcgagaaagg aggcggtgga tccatgtttc aggacgctga ggagaagccc 720 agaactctgc acgatctgtg tcaggccttg gagacgtctg tgcataaaat tgagcttaaa 780 tgtgtcgaat gtaagaagac actccagcgc agcgaagttt atgacttcgt gttcgcggat 840 ctgagaatcg tgtatcggga cggcaaccct tttgctgttt gcaaggtttg ccttaggctc 900 ctgtccaaaa ttagcgagta ccgccactat aactactctc tctacggtga tactctcgag 960 caaacactga agaagtgctt gaacgagatc ctgattagat gcatcatttg tcaaaggcca 1020 ctttgtccac aggagaagaa gaggcacgtg gacctgaata agcgctttca taacatctct 1080 ggcagatgga caggccgatg cgctgtatgt tggcgcccac ggagaaggca aacccaggtg 1140 tgacggaccg cctctccctc cc 1162 <210> SEQ ID NO 67 <211> LENGTH: 1009 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-H6-murineScn-StrepII-GGGGS-E7.58 <400> SEQUENCE: 67 ctcgagacca tggagaccga cacgctcttg ttgtgggttc tcttgttgtg ggtgcctggg 60 tctacaggcg accaccacca tcatcaccac ctcgttccta gaggcagcca ggatagtacc 120 cagaatctta tcccagcacc atctttgctc acagtaccat tgcaacccga ctttcggtct 180 gatcaatttc ggggacgctg gtacgtggtt ggactggccg gcaatgctgt acagaaaaaa 240 acagagggca gtttcaccat gtactcaaca atctatgagc tccaagagaa taatagttac 300 aacgttacct ccatcttggt gagggaccag gatcagggat gtcgctactg gattcggaca 360 ttcgtaccaa gttctcgggc cggtcagttt actctgggca acatgcacag gtatccccaa 420 gttcaatctt acaacgtgca ggtggcgact accgactaca accaattcgc tatggtgttc 480 ttccgcaaaa caagcgagaa caagcagtat tttaaaatca ctctgtacgg tagaactaag 540 gagctgagcc ctgaacttaa ggagcggttc accagattcg ctaagtccct gggactgaag 600 gatgataata taatcttttc cgtccccacc gatcagtgta tcgataattc agcttggtca 660 catccccagt tcgagaaagg aggcggtgga tccatgcggg ggaataaccc caccctgcgc 720 gagtacattc ttgacctgca cccagagcct acggatctgt tttgttacga acaactgtgc 780 gactcctccg acgaggatga gatcgggctg gatggcccag acgggcaggc acagcctgct 840 acagctaact actatattgt gacatgttgc tacacatgcg gaacgacggt cagactgtgc 900 attaatagca ctgccacaga cgtgcggacc ctgcagcaac tgctcatggg gacctgcact 960 attgtgtgtc cttcatgtgc gcagcaatga cggaccgcct ctccctccc 1009 <210> SEQ ID NO 68 <211> LENGTH: 319 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-sFLAG-H6-GGS-humanScn-GGS-ENLYFQ-GG-Adv2E3/19K <400> SEQUENCE: 68 Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Asp Tyr Lys Asp Glu His His His His His His Gly 20 25 30 Gly Ser Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser 35 40 45 Lys Val Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe Gln Gly Lys 50 55 60 Trp Tyr Val Val Gly Leu Ala Gly Asn Ala Ile Leu Arg Glu Asp Lys 65 70 75 80 Asp Pro Gln Lys Met Tyr Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys 85 90 95 Ser Tyr Asn Val Thr Ser Val Leu Phe Arg Lys Lys Lys Cys Asp Tyr 100 105 110 Trp Ile Arg Thr Phe Val Pro Gly Ser Gln Pro Gly Glu Phe Thr Leu 115 120 125 Gly Asn Ile Lys Ser Tyr Pro Gly Leu Thr Ser Tyr Leu Val Arg Val 130 135 140 Val Ser Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys Lys Val 145 150 155 160 Ser Gln Asn Arg Glu Tyr Phe Lys Ile Thr Leu Tyr Gly Arg Thr Lys 165 170 175 Glu Leu Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser 180 185 190 Leu Gly Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile Asp Gln 195 200 205 Cys Ile Asp Gly Gly Gly Ser Glu Asn Leu Tyr Phe Gln Gly Gly Ala 210 215 220 Lys Lys Val Glu Phe Lys Glu Pro Ala Cys Asn Val Thr Phe Lys Ser 225 230 235 240 Glu Ala Asn Glu Cys Thr Thr Leu Ile Lys Cys Thr Thr Glu His Glu 245 250 255 Lys Leu Ile Ile Arg His Lys Asp Lys Ile Gly Lys Tyr Ala Val Tyr 260 265 270 Ala Ile Trp Gln Pro Gly Asp Thr Asn Asp Tyr Asn Val Thr Val Phe 275 280 285 Gln Gly Glu Asn Arg Lys Thr Phe Met Tyr Lys Phe Pro Phe Tyr Glu 290 295 300 Met Cys Asp Ile Thr Met Tyr Met Ser Lys Gln Tyr Lys Leu Trp 305 310 315 <210> SEQ ID NO 69 <211> LENGTH: 704 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-sFLAG-H6-GGS-humanScn-GGS-ENLYFQ-GG-SF162gp120 <400> SEQUENCE: 69 Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Asp Tyr Lys Asp Glu His His His His His His Gly 20 25 30 Gly Ser Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser 35 40 45 Lys Val Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe Gln Gly Lys 50 55 60 Trp Tyr Val Val Gly Leu Ala Gly Asn Ala Ile Leu Arg Glu Asp Lys 65 70 75 80 Asp Pro Gln Lys Met Tyr Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys 85 90 95 Ser Tyr Asn Val Thr Ser Val Leu Phe Arg Lys Lys Lys Cys Asp Tyr 100 105 110 Trp Ile Arg Thr Phe Val Pro Gly Ser Gln Pro Gly Glu Phe Thr Leu 115 120 125 Gly Asn Ile Lys Ser Tyr Pro Gly Leu Thr Ser Tyr Leu Val Arg Val 130 135 140 Val Ser Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys Lys Val 145 150 155 160 Ser Gln Asn Arg Glu Tyr Phe Lys Ile Thr Leu Tyr Gly Arg Thr Lys 165 170 175 Glu Leu Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser 180 185 190 Leu Gly Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile Asp Gln 195 200 205 Cys Ile Asp Gly Gly Gly Ser Glu Asn Leu Tyr Phe Gln Gly Gly Trp 210 215 220 Val Thr Val Tyr Tyr Gly Val Pro Val Trp Lys Glu Ala Thr Thr Thr 225 230 235 240 Leu Phe Cys Ala Ser Asp Ala Lys Ala Tyr Asp Thr Glu Val His Asn 245 250 255 Val Trp Ala Thr His Ala Cys Val Pro Thr Asp Pro Asn Pro Gln Glu 260 265 270 Ile Val Leu Glu Asn Val Thr Glu Asn Phe Asn Met Trp Lys Asn Asn 275 280 285 Met Val Glu Gln Met His Glu Asp Ile Ile Ser Leu Trp Asp Gln Ser 290 295 300 Leu Lys Pro Cys Val Lys Leu Thr Pro Leu Cys Val Thr Leu His Cys 305 310 315 320 Thr Asn Leu Lys Asn Ala Thr Asn Thr Lys Ser Ser Asn Trp Lys Glu 325 330 335 Met Asp Arg Gly Glu Ile Lys Asn Cys Ser Phe Lys Val Thr Thr Ser 340 345 350 Ile Arg Asn Lys Met Gln Lys Glu Tyr Ala Leu Phe Tyr Lys Leu Asp 355 360 365 Val Val Pro Ile Asp Asn Asp Asn Thr Ser Tyr Lys Leu Ile Asn Cys 370 375 380 Asn Thr Ser Val Ile Thr Gln Ala Cys Pro Lys Val Ser Phe Glu Pro 385 390 395 400 Ile Pro Ile His Tyr Cys Ala Pro Ala Gly Phe Ala Ile Leu Lys Cys 405 410 415 Asn Asp Lys Lys Phe Asn Gly Ser Gly Pro Cys Thr Asn Val Ser Thr 420 425 430 Val Gln Cys Thr His Gly Ile Arg Pro Val Val Ser Thr Gln Leu Leu 435 440 445 Leu Asn Gly Ser Leu Ala Glu Glu Gly Val Val Ile Arg Ser Glu Asn 450 455 460 Phe Thr Asp Asn Ala Lys Thr Ile Ile Val Gln Leu Lys Glu Ser Val 465 470 475 480 Glu Ile Asn Cys Thr Arg Pro Asn Asn Asn Thr Arg Lys Ser Ile Thr 485 490 495 Ile Gly Pro Gly Arg Ala Phe Tyr Ala Thr Gly Asp Ile Ile Gly Asp 500 505 510 Ile Arg Gln Ala His Cys Asn Ile Ser Gly Glu Lys Trp Asn Asn Thr 515 520 525 Leu Lys Gln Ile Val Thr Lys Leu Gln Ala Gln Phe Gly Asn Lys Thr 530 535 540 Ile Val Phe Lys Gln Ser Ser Gly Gly Asp Pro Glu Ile Val Met His 545 550 555 560 Ser Phe Asn Cys Gly Gly Glu Phe Phe Tyr Cys Asn Ser Thr Gln Leu 565 570 575 Phe Asn Ser Thr Trp Asn Asn Thr Ile Gly Pro Asn Asn Thr Asn Gly 580 585 590 Thr Ile Thr Leu Pro Cys Arg Ile Lys Gln Ile Ile Asn Arg Trp Gln 595 600 605 Glu Val Gly Lys Ala Met Tyr Ala Pro Pro Ile Arg Gly Gln Ile Arg 610 615 620 Cys Ser Ser Asn Ile Thr Gly Leu Leu Leu Thr Arg Asp Gly Gly Lys 625 630 635 640 Glu Ile Ser Asn Thr Thr Glu Ile Phe Arg Pro Gly Gly Gly Asp Met 645 650 655 Arg Asp Asn Trp Arg Ser Glu Leu Tyr Lys Tyr Lys Val Val Lys Ile 660 665 670 Glu Pro Leu Gly Val Ala Pro Thr Lys Ala Lys Arg Arg Val Val Gln 675 680 685 Gln Gly Leu Asn Asp Ile Phe Glu Ala Gln Lys Ile Glu Trp His Glu 690 695 700 <210> SEQ ID NO 70 <211> LENGTH: 723 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-sFLAG-H6-GGS-humanScn-GGS-ENLYFQ-GG-QH0692gp120 <400> SEQUENCE: 70 Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Asp Tyr Lys Asp Glu His His His His His His Gly 20 25 30 Gly Ser Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser 35 40 45 Lys Val Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe Gln Gly Lys 50 55 60 Trp Tyr Val Val Gly Leu Ala Gly Asn Ala Ile Leu Arg Glu Asp Lys 65 70 75 80 Asp Pro Gln Lys Met Tyr Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys 85 90 95 Ser Tyr Asn Val Thr Ser Val Leu Phe Arg Lys Lys Lys Cys Asp Tyr 100 105 110 Trp Ile Arg Thr Phe Val Pro Gly Ser Gln Pro Gly Glu Phe Thr Leu 115 120 125 Gly Asn Ile Lys Ser Tyr Pro Gly Leu Thr Ser Tyr Leu Val Arg Val 130 135 140 Val Ser Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys Lys Val 145 150 155 160 Ser Gln Asn Arg Glu Tyr Phe Lys Ile Thr Leu Tyr Gly Arg Thr Lys 165 170 175 Glu Leu Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser 180 185 190 Leu Gly Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile Asp Gln 195 200 205 Cys Ile Asp Gly Gly Gly Ser Glu Asn Leu Tyr Phe Gln Gly Gly Trp 210 215 220 Val Thr Val Tyr Tyr Gly Val Pro Val Trp Lys Glu Ala Thr Thr Thr 225 230 235 240 Leu Phe Cys Ala Ser Asp Ala Lys Ala Tyr Glu Thr Glu Lys His Asn 245 250 255 Val Trp Ala Thr His Ala Cys Val Pro Thr Asp Pro Asn Pro Gln Glu 260 265 270 Val Val Leu Gly Asn Val Thr Glu Asn Phe Asn Met Trp Lys Asn Asn 275 280 285 Met Val Glu Gln Met His Glu Asp Ile Ile Ser Leu Trp Asp Glu Ser 290 295 300 Leu Lys Pro Cys Val Lys Leu Thr Pro Leu Cys Val Thr Leu Asn Cys 305 310 315 320 Thr Asp Glu Val Lys Thr Ser Tyr Ala Asn Lys Thr Ser Asn Glu Thr 325 330 335 Tyr Lys Thr Ser Asn Glu Thr Phe Gly Glu Ile Lys Asn Cys Ser Phe 340 345 350 Ser Val Pro Thr Gly Ile Lys Asp Lys Val Gln Asn Val Tyr Ala Leu 355 360 365 Phe Tyr Lys Leu Asp Val Ile Pro Ile Asp Asp Asn Asn Asn Ser Ser 370 375 380 Lys Asn Asn Asn Gly Ser Tyr Ser Ser Tyr Arg Leu Ile Asn Cys Asn 385 390 395 400 Thr Ser Val Ile Thr Gln Ala Cys Pro Lys Val Ser Phe Glu Pro Ile 405 410 415 Pro Ile His Tyr Cys Ala Pro Ala Gly Phe Ala Ile Leu Lys Cys Asn 420 425 430 Asn Lys Thr Phe Asn Gly Thr Gly Pro Cys Thr Asn Val Ser Thr Val 435 440 445 Gln Cys Thr His Gly Ile Arg Pro Val Val Ser Thr Gln Leu Leu Leu 450 455 460 Asn Gly Ser Leu Ala Glu Glu Glu Val Val Ile Arg Ser Glu Asn Phe 465 470 475 480 Thr Asn Asn Ala Lys Thr Ile Ile Val His Leu Lys Lys Ser Val Glu 485 490 495 Ile Asn Cys Thr Arg Pro Gly Asn Asn Thr Arg Lys Ser Ile His Ile 500 505 510 Gly Pro Gly Arg Ala Phe Tyr Ala Thr Gly Asp Ile Ile Gly Asp Ile 515 520 525 Arg Gln Ala His Cys Asn Leu Ser Ser Val Gln Trp Asn Asp Thr Leu 530 535 540 Lys Gln Ile Val Ile Lys Leu Gly Glu Gln Phe Gly Thr Asn Lys Thr 545 550 555 560 Ile Ala Phe Asn Gln Ser Ser Gly Gly Asp Pro Glu Ile Val Met His 565 570 575 Ser Phe Asn Cys Gly Gly Glu Phe Phe Tyr Cys Asn Thr Thr Gln Leu 580 585 590 Phe Asn Ser Thr Trp Glu Phe His Gly Asn Trp Thr Arg Ser Asn Phe 595 600 605 Thr Glu Ser Asn Ser Thr Thr Ile Thr Leu Pro Cys Arg Ile Lys Gln 610 615 620 Ile Val Asn Met Trp Gln Glu Val Gly Lys Ala Met Tyr Ala Pro Pro 625 630 635 640 Ile Arg Gly Gln Ile Arg Cys Ser Ser Asn Ile Thr Gly Leu Leu Leu 645 650 655 Thr Arg Asp Gly Gly Val Asn Gly Thr Arg Glu Thr Phe Arg Pro Gly 660 665 670 Gly Gly Asp Met Arg Asp Asn Trp Arg Ser Glu Leu Tyr Lys Tyr Lys 675 680 685 Val Val Lys Ile Glu Pro Leu Gly Val Ala Pro Thr Lys Ala Lys Arg 690 695 700 Arg Val Val Gln Gly Leu Asn Asp Ile Phe Glu Ala Gln Lys Ile Glu 705 710 715 720 Trp His Glu <210> SEQ ID NO 71 <211> LENGTH: 259 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-sFLAG-H6-GGS-humanScn-GGS-ENLYFQ-GG-ITPR-1 <400> SEQUENCE: 71 Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Asp Tyr Lys Asp Glu His His His His His His Gly 20 25 30 Gly Ser Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser 35 40 45 Lys Val Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe Gln Gly Lys 50 55 60 Trp Tyr Val Val Gly Leu Ala Gly Asn Ala Ile Leu Arg Glu Asp Lys 65 70 75 80 Asp Pro Gln Lys Met Tyr Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys 85 90 95 Ser Tyr Asn Val Thr Ser Val Leu Phe Arg Lys Lys Lys Cys Asp Tyr 100 105 110 Trp Ile Arg Thr Phe Val Pro Gly Ser Gln Pro Gly Glu Phe Thr Leu 115 120 125 Gly Asn Ile Lys Ser Tyr Pro Gly Leu Thr Ser Tyr Leu Val Arg Val 130 135 140 Val Ser Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys Lys Val 145 150 155 160 Ser Gln Asn Arg Glu Tyr Phe Lys Ile Thr Leu Tyr Gly Arg Thr Lys 165 170 175 Glu Leu Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser 180 185 190 Leu Gly Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile Asp Gln 195 200 205 Cys Ile Asp Gly Gly Gly Ser Glu Asn Leu Tyr Phe Gln Gly Gly Ser 210 215 220 Lys Cys Arg Val Phe Asn Thr Thr Glu Arg Asp Glu Gln Gly Ser Lys 225 230 235 240 Val Asn Asp Phe Phe Gln Gln Thr Glu Asp Leu Tyr Asn Glu Met Lys 245 250 255 Trp Gln Lys <210> SEQ ID NO 72 <211> LENGTH: 259 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-sFLAG-H6-GGS-humanScn-GGS-ENLYFQ-GG-ITPR-2 <400> SEQUENCE: 72 Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Asp Tyr Lys Asp Glu His His His His His His Gly 20 25 30 Gly Ser Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser 35 40 45 Lys Val Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe Gln Gly Lys 50 55 60 Trp Tyr Val Val Gly Leu Ala Gly Asn Ala Ile Leu Arg Glu Asp Lys 65 70 75 80 Asp Pro Gln Lys Met Tyr Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys 85 90 95 Ser Tyr Asn Val Thr Ser Val Leu Phe Arg Lys Lys Lys Cys Asp Tyr 100 105 110 Trp Ile Arg Thr Phe Val Pro Gly Ser Gln Pro Gly Glu Phe Thr Leu 115 120 125 Gly Asn Ile Lys Ser Tyr Pro Gly Leu Thr Ser Tyr Leu Val Arg Val 130 135 140 Val Ser Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys Lys Val 145 150 155 160 Ser Gln Asn Arg Glu Tyr Phe Lys Ile Thr Leu Tyr Gly Arg Thr Lys 165 170 175 Glu Leu Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser 180 185 190 Leu Gly Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile Asp Gln 195 200 205 Cys Ile Asp Gly Gly Gly Ser Glu Asn Leu Tyr Phe Gln Gly Gly Pro 210 215 220 Pro His Glu Leu Thr Glu Glu Glu Lys Gln Gln Ile Leu His Ser Glu 225 230 235 240 Glu Phe Leu Ser Phe Phe Asp His Ser Thr Arg Ile Val Glu Arg Ala 245 250 255 Leu Ser Glu <210> SEQ ID NO 73 <211> LENGTH: 259 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-sFLAG-H6-GGS-humanScn-GGS-ENLYFQ-GG-ITPR-3 <400> SEQUENCE: 73 Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Asp Tyr Lys Asp Glu His His His His His His Gly 20 25 30 Gly Ser Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser 35 40 45 Lys Val Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe Gln Gly Lys 50 55 60 Trp Tyr Val Val Gly Leu Ala Gly Asn Ala Ile Leu Arg Glu Asp Lys 65 70 75 80 Asp Pro Gln Lys Met Tyr Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys 85 90 95 Ser Tyr Asn Val Thr Ser Val Leu Phe Arg Lys Lys Lys Cys Asp Tyr 100 105 110 Trp Ile Arg Thr Phe Val Pro Gly Ser Gln Pro Gly Glu Phe Thr Leu 115 120 125 Gly Asn Ile Lys Ser Tyr Pro Gly Leu Thr Ser Tyr Leu Val Arg Val 130 135 140 Val Ser Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys Lys Val 145 150 155 160 Ser Gln Asn Arg Glu Tyr Phe Lys Ile Thr Leu Tyr Gly Arg Thr Lys 165 170 175 Glu Leu Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser 180 185 190 Leu Gly Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile Asp Gln 195 200 205 Cys Ile Asp Gly Gly Gly Ser Glu Asn Leu Tyr Phe Gln Gly Gly Pro 210 215 220 Pro Pro Arg Cys Ile Ser Thr Asn Lys Cys Thr Ala Pro Glu Val Glu 225 230 235 240 Asn Ala Ile Arg Val Pro Gly Asn Arg Ser Phe Phe Ser Leu Thr Glu 245 250 255 Ile Val Arg <210> SEQ ID NO 74 <211> LENGTH: 259 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-sFLAG-H6-GGS-humanScn-GGS-ENLYFQ-GG-ITPR-4 <400> SEQUENCE: 74 Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Asp Tyr Lys Asp Glu His His His His His His Gly 20 25 30 Gly Ser Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser 35 40 45 Lys Val Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe Gln Gly Lys 50 55 60 Trp Tyr Val Val Gly Leu Ala Gly Asn Ala Ile Leu Arg Glu Asp Lys 65 70 75 80 Asp Pro Gln Lys Met Tyr Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys 85 90 95 Ser Tyr Asn Val Thr Ser Val Leu Phe Arg Lys Lys Lys Cys Asp Tyr 100 105 110 Trp Ile Arg Thr Phe Val Pro Gly Ser Gln Pro Gly Glu Phe Thr Leu 115 120 125 Gly Asn Ile Lys Ser Tyr Pro Gly Leu Thr Ser Tyr Leu Val Arg Val 130 135 140 Val Ser Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys Lys Val 145 150 155 160 Ser Gln Asn Arg Glu Tyr Phe Lys Ile Thr Leu Tyr Gly Arg Thr Lys 165 170 175 Glu Leu Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser 180 185 190 Leu Gly Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile Asp Gln 195 200 205 Cys Ile Asp Gly Gly Gly Ser Glu Asn Leu Tyr Phe Gln Gly Gly Thr 210 215 220 Glu Arg Asp Glu Gln Gly Ser Lys Ile Asn Asp Phe Phe Leu Arg Ser 225 230 235 240 Glu Asp Leu Phe Asn Glu Met Asn Trp Gln Lys Lys Leu Arg Ala Gln 245 250 255 Pro Val Leu <210> SEQ ID NO 75 <211> LENGTH: 259 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-sFLAG-H6-GGS-humanScn-GGS-ENLYFQ-GG-ITPR-5 <400> SEQUENCE: 75 Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Asp Tyr Lys Asp Glu His His His His His His Gly 20 25 30 Gly Ser Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser 35 40 45 Lys Val Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe Gln Gly Lys 50 55 60 Trp Tyr Val Val Gly Leu Ala Gly Asn Ala Ile Leu Arg Glu Asp Lys 65 70 75 80 Asp Pro Gln Lys Met Tyr Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys 85 90 95 Ser Tyr Asn Val Thr Ser Val Leu Phe Arg Lys Lys Lys Cys Asp Tyr 100 105 110 Trp Ile Arg Thr Phe Val Pro Gly Ser Gln Pro Gly Glu Phe Thr Leu 115 120 125 Gly Asn Ile Lys Ser Tyr Pro Gly Leu Thr Ser Tyr Leu Val Arg Val 130 135 140 Val Ser Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys Lys Val 145 150 155 160 Ser Gln Asn Arg Glu Tyr Phe Lys Ile Thr Leu Tyr Gly Arg Thr Lys 165 170 175 Glu Leu Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser 180 185 190 Leu Gly Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile Asp Gln 195 200 205 Cys Ile Asp Gly Gly Gly Ser Glu Asn Leu Tyr Phe Gln Gly Gly Leu 210 215 220 Thr Glu Glu Thr Lys His Arg Leu Phe Thr Thr Thr Glu Gln Asp Glu 225 230 235 240 Gln Gly Ser Lys Val Ser Asp Phe Phe Asp Gln Ser Ser Phe Leu His 245 250 255 Asn Glu Met <210> SEQ ID NO 76 <211> LENGTH: 259 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-sFLAG-H6-GGS-humanScn-GGS-ENLYFQ-GG-ITPR-8 <400> SEQUENCE: 76 Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Asp Tyr Lys Asp Glu His His His His His His Gly 20 25 30 Gly Ser Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser 35 40 45 Lys Val Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe Gln Gly Lys 50 55 60 Trp Tyr Val Val Gly Leu Ala Gly Asn Ala Ile Leu Arg Glu Asp Lys 65 70 75 80 Asp Pro Gln Lys Met Tyr Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys 85 90 95 Ser Tyr Asn Val Thr Ser Val Leu Phe Arg Lys Lys Lys Cys Asp Tyr 100 105 110 Trp Ile Arg Thr Phe Val Pro Gly Ser Gln Pro Gly Glu Phe Thr Leu 115 120 125 Gly Asn Ile Lys Ser Tyr Pro Gly Leu Thr Ser Tyr Leu Val Arg Val 130 135 140 Val Ser Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys Lys Val 145 150 155 160 Ser Gln Asn Arg Glu Tyr Phe Lys Ile Thr Leu Tyr Gly Arg Thr Lys 165 170 175 Glu Leu Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser 180 185 190 Leu Gly Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile Asp Gln 195 200 205 Cys Ile Asp Gly Gly Gly Ser Glu Asn Leu Tyr Phe Gln Gly Gly Gly 210 215 220 Ala Gln Pro Pro Phe Asp Ala Gln Ser Pro Leu Asp Ser Gln Pro Gln 225 230 235 240 Pro Ser Gly Gln Pro Trp Asn Phe His Ala Ser Thr Ser Trp Tyr Trp 245 250 255 Arg Gln Ser <210> SEQ ID NO 77 <211> LENGTH: 488 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-sFLAG-H6-GGS-humanScn-GGS-ENLYFQ-GG-human HMOX1 <400> SEQUENCE: 77 Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Asp Tyr Lys Asp Glu His His His His His His Gly 20 25 30 Gly Ser Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser 35 40 45 Lys Val Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe Gln Gly Lys 50 55 60 Trp Tyr Val Val Gly Leu Ala Gly Asn Ala Ile Leu Arg Glu Asp Lys 65 70 75 80 Asp Pro Gln Lys Met Tyr Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys 85 90 95 Ser Tyr Asn Val Thr Ser Val Leu Phe Arg Lys Lys Lys Cys Asp Tyr 100 105 110 Trp Ile Arg Thr Phe Val Pro Gly Ser Gln Pro Gly Glu Phe Thr Leu 115 120 125 Gly Asn Ile Lys Ser Tyr Pro Gly Leu Thr Ser Tyr Leu Val Arg Val 130 135 140 Val Ser Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys Lys Val 145 150 155 160 Ser Gln Asn Arg Glu Tyr Phe Lys Ile Thr Leu Tyr Gly Arg Thr Lys 165 170 175 Glu Leu Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser 180 185 190 Leu Gly Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile Asp Gln 195 200 205 Cys Ile Asp Gly Gly Gly Ser Glu Asn Leu Tyr Phe Gln Gly Gly Met 210 215 220 Glu Arg Pro Gln Pro Asp Ser Met Pro Gln Asp Leu Ser Glu Ala Leu 225 230 235 240 Lys Glu Ala Thr Lys Glu Val His Thr Gln Ala Glu Asn Ala Glu Phe 245 250 255 Met Arg Asn Phe Gln Lys Gly Gln Val Thr Arg Asp Gly Phe Lys Leu 260 265 270 Val Met Ala Ser Leu Tyr His Ile Tyr Val Ala Leu Glu Glu Glu Ile 275 280 285 Glu Arg Asn Lys Glu Ser Pro Val Phe Ala Pro Val Tyr Phe Pro Glu 290 295 300 Glu Leu His Arg Lys Ala Ala Leu Glu Gln Asp Leu Ala Phe Trp Tyr 305 310 315 320 Gly Pro Arg Trp Gln Glu Val Ile Pro Tyr Thr Pro Ala Met Gln Arg 325 330 335 Tyr Val Lys Arg Leu His Glu Val Gly Arg Thr Glu Pro Glu Leu Leu 340 345 350 Val Ala His Ala Tyr Thr Arg Tyr Leu Gly Asp Leu Ser Gly Gly Gln 355 360 365 Val Leu Lys Lys Ile Ala Gln Lys Ala Leu Asp Leu Pro Ser Ser Gly 370 375 380 Glu Gly Leu Ala Phe Phe Thr Phe Pro Asn Ile Ala Ser Ala Thr Lys 385 390 395 400 Phe Lys Gln Leu Tyr Arg Ser Arg Met Asn Ser Leu Glu Met Thr Pro 405 410 415 Ala Val Arg Gln Arg Val Ile Glu Glu Ala Lys Thr Ala Phe Leu Leu 420 425 430 Asn Ile Gln Leu Phe Glu Glu Leu Gln Glu Leu Leu Thr His Asp Thr 435 440 445 Lys Asp Gln Ser Pro Ser Arg Ala Pro Gly Leu Arg Gln Arg Ala Ser 450 455 460 Asn Lys Val Gln Asp Ser Ala Pro Val Glu Thr Pro Arg Gly Lys Pro 465 470 475 480 Pro Leu Asn Thr Arg Ser Gln Ala 485 <210> SEQ ID NO 78 <211> LENGTH: 488 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-sFLAG-H6-GGS-humanScn-GGS-ENLYFQ-GG-murineHMOX1 <400> SEQUENCE: 78 Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Asp Tyr Lys Asp Glu His His His His His His Gly 20 25 30 Gly Ser Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser 35 40 45 Lys Val Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe Gln Gly Lys 50 55 60 Trp Tyr Val Val Gly Leu Ala Gly Asn Ala Ile Leu Arg Glu Asp Lys 65 70 75 80 Asp Pro Gln Lys Met Tyr Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys 85 90 95 Ser Tyr Asn Val Thr Ser Val Leu Phe Arg Lys Lys Lys Cys Asp Tyr 100 105 110 Trp Ile Arg Thr Phe Val Pro Gly Ser Gln Pro Gly Glu Phe Thr Leu 115 120 125 Gly Asn Ile Lys Ser Tyr Pro Gly Leu Thr Ser Tyr Leu Val Arg Val 130 135 140 Val Ser Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys Lys Val 145 150 155 160 Ser Gln Asn Arg Glu Tyr Phe Lys Ile Thr Leu Tyr Gly Arg Thr Lys 165 170 175 Glu Leu Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser 180 185 190 Leu Gly Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile Asp Gln 195 200 205 Cys Ile Asp Gly Gly Gly Ser Glu Asn Leu Tyr Phe Gln Gly Gly Met 210 215 220 Glu Arg Pro Gln Pro Asp Ser Met Pro Gln Asp Leu Ser Glu Ala Leu 225 230 235 240 Lys Glu Ala Thr Lys Glu Val His Ile Gln Ala Glu Asn Ala Glu Phe 245 250 255 Met Lys Asn Phe Gln Lys Gly Gln Val Ser Arg Glu Gly Phe Lys Leu 260 265 270 Val Met Ala Ser Leu Tyr His Ile Tyr Thr Ala Leu Glu Glu Glu Ile 275 280 285 Glu Arg Asn Lys Gln Asn Pro Val Tyr Ala Pro Leu Tyr Phe Pro Glu 290 295 300 Glu Leu His Arg Arg Ala Ala Leu Glu Gln Asp Met Ala Phe Trp Tyr 305 310 315 320 Gly Pro His Trp Gln Glu Ile Ile Pro Cys Thr Pro Ala Thr Gln His 325 330 335 Tyr Val Lys Arg Leu His Glu Val Gly Arg Thr His Pro Glu Leu Leu 340 345 350 Val Ala His Ala Tyr Thr Arg Tyr Leu Gly Asp Leu Ser Gly Gly Gln 355 360 365 Val Leu Lys Lys Ile Ala Gln Lys Ala Met Ala Leu Pro Ser Ser Gly 370 375 380 Glu Gly Leu Ala Phe Phe Thr Phe Pro Asn Ile Asp Ser Pro Thr Lys 385 390 395 400 Phe Lys Gln Leu Tyr Arg Ala Arg Met Asn Thr Leu Glu Met Thr Pro 405 410 415 Glu Val Lys His Arg Val Thr Glu Glu Ala Lys Thr Ala Phe Leu Leu 420 425 430 Asn Ile Glu Leu Phe Glu Glu Leu Gln Val Met Leu Thr Glu Glu His 435 440 445 Lys Asp Gln Ser Pro Ser Gln Met Ala Ser Leu Arg Gln Arg Pro Ala 450 455 460 Ser Leu Val Gln Asp Thr Ala Pro Ala Glu Thr Pro Arg Gly Lys Pro 465 470 475 480 Gln Ile Ser Thr Ser Ser Ser Gln 485 <210> SEQ ID NO 79 <211> LENGTH: 489 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: humanScn-humanHMOX1 <400> SEQUENCE: 79 Met Pro Leu Gly Leu Leu Trp Leu Gly Leu Ala Leu Leu Gly Ala Leu 1 5 10 15 His Ala Gln Ala Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro 20 25 30 Leu Ser Lys Val Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe Gln 35 40 45 Gly Lys Trp Tyr Val Val Gly Leu Ala Gly Asn Ala Ile Leu Arg Glu 50 55 60 Asp Lys Asp Pro Gln Lys Met Tyr Ala Thr Ile Tyr Glu Leu Lys Glu 65 70 75 80 Asp Lys Ser Tyr Asn Val Thr Ser Val Leu Phe Arg Lys Lys Lys Cys 85 90 95 Asp Tyr Trp Ile Arg Thr Phe Val Pro Gly Ser Gln Pro Gly Glu Phe 100 105 110 Thr Leu Gly Asn Ile Lys Ser Tyr Pro Gly Leu Thr Ser Tyr Leu Val 115 120 125 Arg Val Val Ser Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys 130 135 140 Lys Val Ser Gln Asn Arg Glu Tyr Phe Lys Ile Thr Leu Tyr Gly Arg 145 150 155 160 Thr Lys Glu Leu Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser 165 170 175 Lys Ser Leu Gly Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile 180 185 190 Asp Gln Cys Ile Asp Gly Gly Gly Ser Glu Asn Leu Tyr Phe Gln Gly 195 200 205 Gly Gly Met Glu Arg Pro Gln Pro Asp Ser Met Pro Gln Asp Leu Ser 210 215 220 Glu Ala Leu Lys Glu Ala Thr Lys Glu Val His Thr Gln Ala Glu Asn 225 230 235 240 Ala Glu Phe Met Arg Asn Phe Gln Lys Gly Gln Val Thr Arg Asp Gly 245 250 255 Phe Lys Leu Val Met Ala Ser Leu Tyr His Ile Tyr Val Ala Leu Glu 260 265 270 Glu Glu Ile Glu Arg Asn Lys Glu Ser Pro Val Phe Ala Pro Val Tyr 275 280 285 Phe Pro Glu Glu Leu His Arg Lys Ala Ala Leu Glu Gln Asp Leu Ala 290 295 300 Phe Trp Tyr Gly Pro Arg Trp Gln Glu Val Ile Pro Tyr Thr Pro Ala 305 310 315 320 Met Gln Arg Tyr Val Lys Arg Leu His Glu Val Gly Arg Thr Glu Pro 325 330 335 Glu Leu Leu Val Ala His Ala Tyr Thr Arg Tyr Leu Gly Asp Leu Ser 340 345 350 Gly Gly Gln Val Leu Lys Lys Ile Ala Gln Lys Ala Leu Asp Leu Pro 355 360 365 Ser Ser Gly Glu Gly Leu Ala Phe Phe Thr Phe Pro Asn Ile Ala Ser 370 375 380 Ala Thr Lys Phe Lys Gln Leu Tyr Arg Ser Arg Met Asn Ser Leu Glu 385 390 395 400 Met Thr Pro Ala Val Arg Gln Arg Val Ile Glu Glu Ala Lys Thr Ala 405 410 415 Phe Leu Leu Asn Ile Gln Leu Phe Glu Glu Leu Gln Glu Leu Leu Thr 420 425 430 His Asp Thr Lys Asp Gln Ser Pro Ser Arg Ala Pro Gly Leu Arg Gln 435 440 445 Arg Ala Ser Asn Lys Val Gln Asp Ser Ala Pro Val Glu Thr Pro Arg 450 455 460 Gly Lys Pro Pro Leu Asn Thr Arg Ser Gln Ala Gly Gly Leu Val Pro 465 470 475 480 Arg Gly Ser His His His His His His 485 <210> SEQ ID NO 80 <211> LENGTH: 387 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: humanScn-cTHAP4 <400> SEQUENCE: 80 Met Pro Leu Gly Leu Leu Trp Leu Gly Leu Ala Leu Leu Gly Ala Leu 1 5 10 15 His Ala Gln Ala Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro 20 25 30 Leu Ser Lys Val Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe Gln 35 40 45 Gly Lys Trp Tyr Val Val Gly Leu Ala Gly Asn Ala Ile Leu Arg Glu 50 55 60 Asp Lys Asp Pro Gln Lys Met Tyr Ala Thr Ile Tyr Glu Leu Lys Glu 65 70 75 80 Asp Lys Ser Tyr Asn Val Thr Ser Val Leu Phe Arg Lys Lys Lys Cys 85 90 95 Asp Tyr Trp Ile Arg Thr Phe Val Pro Gly Ser Gln Pro Gly Glu Phe 100 105 110 Thr Leu Gly Asn Ile Lys Ser Tyr Pro Gly Leu Thr Ser Tyr Leu Val 115 120 125 Arg Val Val Ser Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys 130 135 140 Lys Val Ser Gln Asn Arg Glu Tyr Phe Lys Ile Thr Leu Tyr Gly Arg 145 150 155 160 Thr Lys Glu Leu Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser 165 170 175 Lys Ser Leu Gly Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile 180 185 190 Asp Gln Cys Ile Asp Gly Gly Gly Ser Glu Asn Leu Tyr Phe Gln Gly 195 200 205 Gly Gly Pro Pro Lys Met Asn Pro Val Val Glu Pro Leu Ser Trp Met 210 215 220 Leu Gly Thr Trp Leu Ser Asp Pro Pro Gly Ala Gly Thr Tyr Pro Thr 225 230 235 240 Leu Gln Pro Phe Gln Tyr Leu Glu Glu Val His Ile Ser His Val Gly 245 250 255 Gln Pro Met Leu Asn Phe Ser Phe Asn Ser Phe His Pro Asp Thr Arg 260 265 270 Lys Pro Met His Arg Glu Cys Gly Phe Ile Arg Leu Lys Pro Asp Thr 275 280 285 Asn Lys Val Ala Phe Val Ser Ala Gln Asn Thr Gly Val Val Glu Val 290 295 300 Glu Glu Gly Glu Val Asn Gly Gln Glu Leu Cys Ile Ala Ser His Ser 305 310 315 320 Ile Ala Arg Ile Ser Phe Ala Lys Glu Pro His Val Glu Gln Ile Thr 325 330 335 Arg Lys Phe Arg Leu Asn Ser Glu Gly Lys Leu Glu Gln Thr Val Ser 340 345 350 Met Ala Thr Thr Thr Gln Pro Met Thr Gln His Leu His Val Thr Tyr 355 360 365 Lys Lys Val Thr Pro Gly Gly Leu Val Pro Arg Gly Ser His His His 370 375 380 His His His 385 <210> SEQ ID NO 81 <211> LENGTH: 295 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-sFLAG-H6-GGS-humanScn-GGS-ENLYFQ-GG-heptamer <400> SEQUENCE: 81 Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Asp Tyr Lys Asp Glu His His His His His His Gly 20 25 30 Gly Ser Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser 35 40 45 Lys Val Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe Gln Gly Lys 50 55 60 Trp Tyr Val Val Gly Leu Ala Gly Asn Ala Ile Leu Arg Glu Asp Lys 65 70 75 80 Asp Pro Gln Lys Met Tyr Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys 85 90 95 Ser Tyr Asn Val Thr Ser Val Leu Phe Arg Lys Lys Lys Cys Asp Tyr 100 105 110 Trp Ile Arg Thr Phe Val Pro Gly Ser Gln Pro Gly Glu Phe Thr Leu 115 120 125 Gly Asn Ile Lys Ser Tyr Pro Gly Leu Thr Ser Tyr Leu Val Arg Val 130 135 140 Val Ser Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys Lys Val 145 150 155 160 Ser Gln Asn Arg Glu Tyr Phe Lys Ile Thr Leu Tyr Gly Arg Thr Lys 165 170 175 Glu Leu Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser 180 185 190 Leu Gly Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile Asp Gln 195 200 205 Cys Ile Asp Gly Gly Gly Ser Glu Asn Leu Tyr Phe Gln Gly Gly Gly 210 215 220 Arg Ser Ala Gly Ala His Ala Gly Trp Glu Thr Pro Glu Gly Cys Glu 225 230 235 240 Gln Val Leu Thr Gly Lys Arg Leu Met Gln Cys Leu Pro Asn Pro Glu 245 250 255 Asp Val Lys Met Ala Leu Glu Val Tyr Lys Leu Ser Leu Glu Ile Glu 260 265 270 Gln Leu Glu Leu Gln Arg Asp Ser Ala Arg Gln Ser Thr Leu Asp Lys 275 280 285 Glu Leu Val Pro Arg Gly Ser 290 295 <210> SEQ ID NO 82 <211> LENGTH: 522 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-sFLAG-H6-GGS-humanScn-GGS-ENLYFQ-GG-CD80heptamer <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: (490)..(490) <223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid <400> SEQUENCE: 82 Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Asp Tyr Lys Asp Glu His His His His His His Gly 20 25 30 Gly Ser Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser 35 40 45 Lys Val Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe Gln Gly Lys 50 55 60 Trp Tyr Val Val Gly Leu Ala Gly Asn Ala Ile Leu Arg Glu Asp Lys 65 70 75 80 Asp Pro Gln Lys Met Tyr Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys 85 90 95 Ser Tyr Asn Val Thr Ser Val Leu Phe Arg Lys Lys Lys Cys Asp Tyr 100 105 110 Trp Ile Arg Thr Phe Val Pro Gly Ser Gln Pro Gly Glu Phe Thr Leu 115 120 125 Gly Asn Ile Lys Ser Tyr Pro Gly Leu Thr Ser Tyr Leu Val Arg Val 130 135 140 Val Ser Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys Lys Val 145 150 155 160 Ser Gln Asn Arg Glu Tyr Phe Lys Ile Thr Leu Tyr Gly Arg Thr Lys 165 170 175 Glu Leu Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser 180 185 190 Leu Gly Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile Asp Gln 195 200 205 Cys Ile Asp Gly Gly Gly Ser Glu Asn Leu Tyr Phe Gln Gly Gly Gly 210 215 220 Ile Ile Gln Val Asn Lys Thr Val Lys Glu Val Ala Val Leu Ser Cys 225 230 235 240 Asp Tyr Asn Ile Ser Thr Thr Glu Leu Met Lys Val Arg Ile Tyr Trp 245 250 255 Gln Lys Asp Asp Glu Val Val Leu Ala Val Thr Ser Gly Gln Thr Lys 260 265 270 Val Trp Ser Lys Tyr Glu Asn Arg Thr Phe Ala Asp Phe Thr Asn Asn 275 280 285 Leu Ser Ile Val Ile Met Ala Leu Arg Leu Ser Asp Asn Gly Lys Tyr 290 295 300 Thr Cys Ile Val Gln Lys Thr Glu Lys Arg Ser Tyr Lys Val Lys His 305 310 315 320 Met Thr Ser Val Met Leu Leu Val Arg Ala Asp Phe Pro Val Pro Ser 325 330 335 Ile Thr Asp Leu Gly Asn Pro Ser His Asp Ile Lys Arg Ile Met Cys 340 345 350 Ser Thr Ser Gly Gly Phe Pro Lys Pro His Leu Ser Trp Trp Glu Asn 355 360 365 Glu Glu Glu Leu Asn Ala Ala Asn Thr Thr Val Ser Gln Asp Pro Asp 370 375 380 Thr Glu Leu Tyr Thr Ile Ser Ser Glu Leu Asp Phe Asn Ile Thr Ser 385 390 395 400 Asn His Ser Phe Val Cys Leu Val Lys Tyr Gly Asp Leu Thr Val Ser 405 410 415 Gln Ile Phe Asn Trp Gln Lys Ser Val Glu Pro His Pro Pro Asn Asn 420 425 430 Ser Ala Trp Ser His Pro Gln Phe Glu Lys Gly Gly Ser Leu Val Pro 435 440 445 Arg Gly Ser Gly Ser Ala Gly Ala His Ala Gly Trp Glu Thr Pro Glu 450 455 460 Gly Cys Glu Gln Val Leu Thr Gly Lys Arg Leu Met Gln Cys Leu Pro 465 470 475 480 Asn Pro Glu Asp Val Lys Met Ala Leu Xaa Val Tyr Lys Leu Ser Leu 485 490 495 Glu Ile Glu Gln Leu Glu Leu Gln Arg Asp Ser Ala Arg Gln Ser Thr 500 505 510 Leu Asp Lys Glu Leu Val Pro Arg Gly Ser 515 520 <210> SEQ ID NO 83 <211> LENGTH: 279 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-sFLAG-H6-GGS-humanScn-GGS-ENLYFQ-GG-trimer <400> SEQUENCE: 83 Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Asp Tyr Lys Asp Glu His His His His His His Gly 20 25 30 Gly Ser Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser 35 40 45 Lys Val Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe Gln Gly Lys 50 55 60 Trp Tyr Val Val Gly Leu Ala Gly Asn Ala Ile Leu Arg Glu Asp Lys 65 70 75 80 Asp Pro Gln Lys Met Tyr Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys 85 90 95 Ser Tyr Asn Val Thr Ser Val Leu Phe Arg Lys Lys Lys Cys Asp Tyr 100 105 110 Trp Ile Arg Thr Phe Val Pro Gly Ser Gln Pro Gly Glu Phe Thr Leu 115 120 125 Gly Asn Ile Lys Ser Tyr Pro Gly Leu Thr Ser Tyr Leu Val Arg Val 130 135 140 Val Ser Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys Lys Val 145 150 155 160 Ser Gln Asn Arg Glu Tyr Phe Lys Ile Thr Leu Tyr Gly Arg Thr Lys 165 170 175 Glu Leu Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser 180 185 190 Leu Gly Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile Asp Gln 195 200 205 Cys Ile Asp Gly Gly Gly Ser Glu Asn Leu Tyr Phe Gln Gly Gly Gly 210 215 220 Arg Asn Leu Val Thr Ala Phe Ser Asn Met Asp Asp Met Leu Gln Lys 225 230 235 240 Ala His Leu Val Ile Glu Gly Thr Phe Ile Tyr Leu Arg Asp Ser Thr 245 250 255 Glu Phe Phe Ile Arg Val Arg Asp Gly Trp Lys Lys Leu Gln Leu Gly 260 265 270 Glu Leu Ile Pro Ile Pro Ala 275 <210> SEQ ID NO 84 <211> LENGTH: 506 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-sFLAG-H6-GGS-humanScn-GGS-ENLYFQ-GG-CD80trimer <400> SEQUENCE: 84 Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Asp Tyr Lys Asp Glu His His His His His His Gly 20 25 30 Gly Ser Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser 35 40 45 Lys Val Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe Gln Gly Lys 50 55 60 Trp Tyr Val Val Gly Leu Ala Gly Asn Ala Ile Leu Arg Glu Asp Lys 65 70 75 80 Asp Pro Gln Lys Met Tyr Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys 85 90 95 Ser Tyr Asn Val Thr Ser Val Leu Phe Arg Lys Lys Lys Cys Asp Tyr 100 105 110 Trp Ile Arg Thr Phe Val Pro Gly Ser Gln Pro Gly Glu Phe Thr Leu 115 120 125 Gly Asn Ile Lys Ser Tyr Pro Gly Leu Thr Ser Tyr Leu Val Arg Val 130 135 140 Val Ser Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys Lys Val 145 150 155 160 Ser Gln Asn Arg Glu Tyr Phe Lys Ile Thr Leu Tyr Gly Arg Thr Lys 165 170 175 Glu Leu Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser 180 185 190 Leu Gly Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile Asp Gln 195 200 205 Cys Ile Asp Gly Gly Gly Ser Glu Asn Leu Tyr Phe Gln Gly Gly Gly 210 215 220 Ile Ile Gln Val Asn Lys Thr Val Lys Glu Val Ala Val Leu Ser Cys 225 230 235 240 Asp Tyr Asn Ile Ser Thr Thr Glu Leu Met Lys Val Arg Ile Tyr Trp 245 250 255 Gln Lys Asp Asp Glu Val Val Leu Ala Val Thr Ser Gly Gln Thr Lys 260 265 270 Val Trp Ser Lys Tyr Glu Asn Arg Thr Phe Ala Asp Phe Thr Asn Asn 275 280 285 Leu Ser Ile Val Ile Met Ala Leu Arg Leu Ser Asp Asn Gly Lys Tyr 290 295 300 Thr Cys Ile Val Gln Lys Thr Glu Lys Arg Ser Tyr Lys Val Lys His 305 310 315 320 Met Thr Ser Val Met Leu Leu Val Arg Ala Asp Phe Pro Val Pro Ser 325 330 335 Ile Thr Asp Leu Gly Asn Pro Ser His Asp Ile Lys Arg Ile Met Cys 340 345 350 Ser Thr Ser Gly Gly Phe Pro Lys Pro His Leu Ser Trp Trp Glu Asn 355 360 365 Glu Glu Glu Leu Asn Ala Ala Asn Thr Thr Val Ser Gln Asp Pro Asp 370 375 380 Thr Glu Leu Tyr Thr Ile Ser Ser Glu Leu Asp Phe Asn Ile Thr Ser 385 390 395 400 Asn His Ser Phe Val Cys Leu Val Lys Tyr Gly Asp Leu Thr Val Ser 405 410 415 Gln Ile Phe Asn Trp Gln Lys Ser Val Glu Pro His Pro Pro Asn Asn 420 425 430 Ser Ala Trp Ser His Pro Gln Phe Glu Lys Gly Gly Ser Leu Val Pro 435 440 445 Arg Gly Ser Gly Asn Leu Val Thr Ala Phe Ser Asn Met Asp Asp Met 450 455 460 Leu Gln Lys Ala His Leu Val Ile Glu Gly Thr Phe Ile Tyr Leu Arg 465 470 475 480 Asp Ser Thr Glu Phe Phe Ile Arg Val Arg Asp Gly Trp Lys Lys Leu 485 490 495 Gln Leu Gly Glu Leu Ile Pro Ile Pro Ala 500 505 <210> SEQ ID NO 85 <211> LENGTH: 278 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-sFLAG-H6-GGS-humanScn-GGS-ENLYFQ-GG-pentamer <400> SEQUENCE: 85 Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Asp Tyr Lys Asp Glu His His His His His His Gly 20 25 30 Gly Ser Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser 35 40 45 Lys Val Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe Gln Gly Lys 50 55 60 Trp Tyr Val Val Gly Leu Ala Gly Asn Ala Ile Leu Arg Glu Asp Lys 65 70 75 80 Asp Pro Gln Lys Met Tyr Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys 85 90 95 Ser Tyr Asn Val Thr Ser Val Leu Phe Arg Lys Lys Lys Cys Asp Tyr 100 105 110 Trp Ile Arg Thr Phe Val Pro Gly Ser Gln Pro Gly Glu Phe Thr Leu 115 120 125 Gly Asn Ile Lys Ser Tyr Pro Gly Leu Thr Ser Tyr Leu Val Arg Val 130 135 140 Val Ser Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys Lys Val 145 150 155 160 Ser Gln Asn Arg Glu Tyr Phe Lys Ile Thr Leu Tyr Gly Arg Thr Lys 165 170 175 Glu Leu Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser 180 185 190 Leu Gly Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile Asp Gln 195 200 205 Cys Ile Asp Gly Gly Gly Ser Glu Asn Leu Tyr Phe Gln Gly Gly Gly 210 215 220 Arg Ser Ser Asn Ala Lys Trp Asp Gln Trp Ser Ser Asp Trp Gln Thr 225 230 235 240 Trp Asn Ala Lys Trp Asp Gln Trp Ser Asn Asp Trp Asn Ala Trp Arg 245 250 255 Ser Asp Trp Gln Ala Trp Lys Asp Asp Trp Ala Arg Trp Asn Gln Arg 260 265 270 Trp Asp Asn Trp Ala Thr 275 <210> SEQ ID NO 86 <211> LENGTH: 302 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-sFLAG-H6-GGS-humanScn-GGS-ENLYFQ-GG-ROR1Kringle <400> SEQUENCE: 86 Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Asp Tyr Lys Asp Glu His His His His His His Gly 20 25 30 Gly Ser Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser 35 40 45 Lys Val Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe Gln Gly Lys 50 55 60 Trp Tyr Val Val Gly Leu Ala Gly Asn Ala Ile Leu Arg Glu Asp Lys 65 70 75 80 Asp Pro Gln Lys Met Tyr Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys 85 90 95 Ser Tyr Asn Val Thr Ser Val Leu Phe Arg Lys Lys Lys Cys Asp Tyr 100 105 110 Trp Ile Arg Thr Phe Val Pro Gly Ser Gln Pro Gly Glu Phe Thr Leu 115 120 125 Gly Asn Ile Lys Ser Tyr Pro Gly Leu Thr Ser Tyr Leu Val Arg Val 130 135 140 Val Ser Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys Lys Val 145 150 155 160 Ser Gln Asn Arg Glu Tyr Phe Lys Ile Thr Leu Tyr Gly Arg Thr Lys 165 170 175 Glu Leu Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser 180 185 190 Leu Gly Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile Asp Gln 195 200 205 Cys Ile Asp Gly Gly Gly Ser Glu Asn Leu Tyr Phe Gln Gly Gly Cys 210 215 220 Tyr Asn Ser Thr Gly Val Asp Tyr Arg Gly Thr Val Ser Val Thr Lys 225 230 235 240 Ser Gly Arg Gln Cys Gln Pro Trp Asn Ser Gln Tyr Pro His Thr His 245 250 255 Thr Phe Thr Ala Leu Arg Phe Pro Glu Leu Asn Gly Gly His Ser Tyr 260 265 270 Cys Arg Asn Pro Gly Asn Gln Lys Glu Ala Pro Trp Cys Phe Thr Leu 275 280 285 Asp Glu Asn Phe Lys Ser Asp Leu Cys Asp Ile Pro Ala Cys 290 295 300 <210> SEQ ID NO 87 <211> LENGTH: 343 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-sFLAG-H6-GGS-humanScn-GGS-ENLYFQ-GG-CTLA4 <400> SEQUENCE: 87 Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Asp Tyr Lys Asp Glu His His His His His His Gly 20 25 30 Gly Ser Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser 35 40 45 Lys Val Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe Gln Gly Lys 50 55 60 Trp Tyr Val Val Gly Leu Ala Gly Asn Ala Ile Leu Arg Glu Asp Lys 65 70 75 80 Asp Pro Gln Lys Met Tyr Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys 85 90 95 Ser Tyr Asn Val Thr Ser Val Leu Phe Arg Lys Lys Lys Cys Asp Tyr 100 105 110 Trp Ile Arg Thr Phe Val Pro Gly Ser Gln Pro Gly Glu Phe Thr Leu 115 120 125 Gly Asn Ile Lys Ser Tyr Pro Gly Leu Thr Ser Tyr Leu Val Arg Val 130 135 140 Val Ser Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys Lys Val 145 150 155 160 Ser Gln Asn Arg Glu Tyr Phe Lys Ile Thr Leu Tyr Gly Arg Thr Lys 165 170 175 Glu Leu Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser 180 185 190 Leu Gly Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile Asp Gln 195 200 205 Cys Ile Asp Gly Gly Gly Ser Glu Asn Leu Tyr Phe Gln Gly Gly Met 210 215 220 His Val Ala Gln Pro Ala Val Val Leu Ala Ser Ser Arg Gly Val Ala 225 230 235 240 Ser Phe Val Cys Glu Tyr Gly Ser Ser Gly Asn Ala Ala Glu Val Arg 245 250 255 Val Thr Val Leu Arg Gln Ala Gly Ser Gln Met Thr Glu Val Cys Ala 260 265 270 Ala Thr Tyr Thr Val Glu Asp Glu Leu Ala Phe Leu Asp Asp Ser Thr 275 280 285 Cys Thr Gly Thr Ser Ser Gly Asn Lys Val Asn Leu Thr Ile Gln Gly 290 295 300 Leu Arg Ala Met Asp Thr Gly Leu Tyr Ile Cys Lys Val Glu Leu Met 305 310 315 320 Tyr Pro Pro Pro Tyr Tyr Val Gly Met Gly Asn Gly Thr Gln Ile Tyr 325 330 335 Val Ile Asp Pro Glu Pro Cys 340 <210> SEQ ID NO 88 <211> LENGTH: 788 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-sFLAG-H6-GGS-humanScn-GGS-ENLYFQ-GG-Imperatoxin <400> SEQUENCE: 88 ctcgagacca tggagacaga cacactcctg ctatgggtac tgctgctctg ggttccaggt 60 tccactggtg actacaagga cgagcatcac catcatcacc atggtggaag ccaggactcc 120 acctcagacc tgatcccagc cccacctctg agcaaggtcc ctctgcagca gaacttccag 180 gacaaccaat tccaggggaa gtggtatgtg gtaggcctgg cagggaatgc aattctcaga 240 gaagacaaag acccgcaaaa gatgtatgcc accatctatg agctgaaaga agacaagagc 300 tacaatgtca cctccgtcct gtttaggaaa aagaagtgtg actactggat caggactttt 360 gttccaggtt gccagcccgg cgagttcacg ctgggcaaca ttaagagtta ccctggatta 420 acgagttacc tcgtccgagt ggtgagcacc aactacaacc agcatgctat ggtgttcttc 480 aagaaagttt ctcaaaacag ggagtacttc aagatcaccc tctacgggag aaccaaggag 540 ctgacttcgg aactaaagga gaacttcatc cgcttctcca aatctctggg cctccctgaa 600 aaccacatcg tcttccctgt cccaatcgac cagtgtatcg acggcggagg tagcgaaaac 660 ctgtattttc agggaggcga ctgcctgccc cacctgagga ggtgcagggc cgacaacgac 720 tgctgcggca ggaggtgcag gaggaggggc accaacgccg agaggaggtg caggtaagct 780 aaggatcc 788 <210> SEQ ID NO 89 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: synthesized murine IgK light chain signal peptide <400> SEQUENCE: 89 Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly 20 <210> SEQ ID NO 90 <211> LENGTH: 60 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: coding sequence for synthesized murine IgK light chain signal peptide <400> SEQUENCE: 90 atggagacag acacactcct gctatgggta ctgctgctct gggttccagg ttccactggt 60 <210> SEQ ID NO 91 <211> LENGTH: 5 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: Shortened FLAG epitope <400> SEQUENCE: 91 Asp Tyr Lys Asp Glu 1 5 <210> SEQ ID NO 92 <211> LENGTH: 15 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: Shortened FLAG epitope coding <400> SEQUENCE: 92 gactacaagg acgag 15 <210> SEQ ID NO 93 <211> LENGTH: 6 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: 6xhistidine tag <400> SEQUENCE: 93 His His His His His His 1 5 <210> SEQ ID NO 94 <211> LENGTH: 18 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: 6xhistidine tag coding <400> SEQUENCE: 94 catcatcatc atcatcat 18 <210> SEQ ID NO 95 <211> LENGTH: 6 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: Tobacco Etch Virus Protease recognition site <400> SEQUENCE: 95 Glu Asn Leu Tyr Phe Gln 1 5 <210> SEQ ID NO 96 <211> LENGTH: 18 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: Coding sequencee for Tobacco Etch Virus Protease recognition site <400> SEQUENCE: 96 gagaatttat attttcag 18 <210> SEQ ID NO 97 <400> SEQUENCE: 97 000 <210> SEQ ID NO 98 <400> SEQUENCE: 98 000 <210> SEQ ID NO 99 <211> LENGTH: 8 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: furin cleavage site used for a BamHI site <400> SEQUENCE: 99 Arg Ala Arg Tyr Lys Arg Gly Ser 1 5 <210> SEQ ID NO 100 <211> LENGTH: 24 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: coding sequence for furin cleavage site used for a BamHI site <400> SEQUENCE: 100 cgggcccggt ataaacgggg atcc 24 <210> SEQ ID NO 101 <211> LENGTH: 6 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: furin cleavage site <400> SEQUENCE: 101 Arg Ala Arg Tyr Lys Arg 1 5 <210> SEQ ID NO 102 <211> LENGTH: 4 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: 4 amino acid residues of a siderocalin right before a cleavage site in a siderocalin fusion construct <400> SEQUENCE: 102 Cys Ile Asp Gly 1 <210> SEQ ID NO 103 <211> LENGTH: 198 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: a lipocalin fusion protein <400> SEQUENCE: 103 Met Pro Leu Gly Leu Leu Trp Leu Gly Leu Ala Leu Leu Gly Ala Leu 1 5 10 15 His Ala Gln Ala Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro 20 25 30 Leu Ser Lys Val Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe Gln 35 40 45 Gly Lys Trp Tyr Val Val Gly Leu Ala Gly Asn Ala Ile Leu Arg Glu 50 55 60 Asp Lys Asp Pro Gln Lys Met Tyr Ala Thr Ile Tyr Glu Leu Lys Glu 65 70 75 80 Asp Lys Ser Tyr Asn Val Thr Ser Val Leu Phe Arg Lys Lys Lys Cys 85 90 95 Asp Tyr Trp Ile Arg Thr Phe Val Pro Gly Cys Gln Pro Gly Glu Phe 100 105 110 Thr Leu Gly Asn Ile Lys Ser Tyr Pro Gly Leu Thr Ser Tyr Leu Val 115 120 125 Arg Val Val Ser Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys 130 135 140 Lys Val Ser Gln Asn Arg Glu Tyr Phe Lys Ile Thr Leu Tyr Gly Arg 145 150 155 160 Thr Lys Glu Leu Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser 165 170 175 Lys Ser Leu Gly Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile 180 185 190 Asp Gln Cys Ile Asp Gly 195 <210> SEQ ID NO 104 <211> LENGTH: 8 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: amino acid sequence in a light chain-siderocalin fusion <400> SEQUENCE: 104 Gly Arg Gly Gly Ser Gly Gly Ser 1 5 <210> SEQ ID NO 105 <211> LENGTH: 5 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: amino acid sequence in a siderocalin construct for downstream viral fusions <400> SEQUENCE: 105 Gly Gly Gly Gly Ser 1 5 <210> SEQ ID NO 106 <211> LENGTH: 287 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-SF-H6-GGS-lcn2C-GGS-ENLYFQ-GG-BubbleProtein amino acid sequence <400> SEQUENCE: 106 Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Asp Tyr Lys Asp Glu His His His His His His Gly 20 25 30 Gly Ser Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser 35 40 45 Lys Val Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe Gln Gly Lys 50 55 60 Trp Tyr Val Val Gly Leu Ala Gly Asn Ala Ile Leu Arg Glu Asp Lys 65 70 75 80 Asp Pro Gln Lys Met Tyr Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys 85 90 95 Ser Tyr Asn Val Thr Ser Val Leu Phe Arg Lys Lys Lys Cys Asp Tyr 100 105 110 Trp Ile Arg Thr Phe Val Pro Gly Cys Gln Pro Gly Glu Phe Thr Leu 115 120 125 Gly Asn Ile Lys Ser Tyr Pro Gly Leu Thr Ser Tyr Leu Val Arg Val 130 135 140 Val Ser Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys Lys Val 145 150 155 160 Ser Gln Asn Arg Glu Tyr Phe Lys Ile Thr Leu Tyr Gly Arg Thr Lys 165 170 175 Glu Leu Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser 180 185 190 Leu Gly Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile Asp Gln 195 200 205 Cys Ile Asp Gly Gly Gly Ser Glu Asn Leu Tyr Phe Gln Gly Gly Asp 210 215 220 Thr Cys Gly Ser Gly Tyr Asn Val Asp Gln Arg Arg Thr Asn Ser Gly 225 230 235 240 Cys Lys Ala Gly Asn Gly Asp Arg His Phe Cys Gly Cys Asp Arg Thr 245 250 255 Gly Val Val Glu Cys Lys Gly Gly Lys Trp Thr Glu Val Gln Asp Cys 260 265 270 Gly Ser Ser Ser Cys Lys Gly Thr Ser Asn Gly Gly Ala Thr Cys 275 280 285 <210> SEQ ID NO 107 <211> LENGTH: 281 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-SF-H6-GGS-lcn2C-GGS-ENLYFQ-GG-Attractin amino acid sequence <400> SEQUENCE: 107 Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Asp Tyr Lys Asp Glu His His His His His His Gly 20 25 30 Gly Ser Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser 35 40 45 Lys Val Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe Gln Gly Lys 50 55 60 Trp Tyr Val Val Gly Leu Ala Gly Asn Ala Ile Leu Arg Glu Asp Lys 65 70 75 80 Asp Pro Gln Lys Met Tyr Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys 85 90 95 Ser Tyr Asn Val Thr Ser Val Leu Phe Arg Lys Lys Lys Cys Asp Tyr 100 105 110 Trp Ile Arg Thr Phe Val Pro Gly Cys Gln Pro Gly Glu Phe Thr Leu 115 120 125 Gly Asn Ile Lys Ser Tyr Pro Gly Leu Thr Ser Tyr Leu Val Arg Val 130 135 140 Val Ser Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys Lys Val 145 150 155 160 Ser Gln Asn Arg Glu Tyr Phe Lys Ile Thr Leu Tyr Gly Arg Thr Lys 165 170 175 Glu Leu Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser 180 185 190 Leu Gly Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile Asp Gln 195 200 205 Cys Ile Asp Gly Gly Gly Ser Glu Asn Leu Tyr Phe Gln Gly Gly Asp 210 215 220 Gln Asn Cys Asp Ile Gly Asn Ile Thr Ser Gln Cys Gln Met Gln His 225 230 235 240 Lys Asn Cys Glu Asp Ala Asn Gly Cys Asp Thr Ile Ile Glu Glu Cys 245 250 255 Lys Thr Ser Met Val Glu Arg Cys Gln Asn Gln Glu Phe Glu Ser Ala 260 265 270 Ala Gly Ser Thr Thr Leu Gly Pro Gln 275 280 <210> SEQ ID NO 108 <211> LENGTH: 245 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-SF-H6-GGS-lcn2C-GGS-ENLYFQ-GG-Hefutoxin amino acid sequence <400> SEQUENCE: 108 Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Asp Tyr Lys Asp Glu His His His His His His Gly 20 25 30 Gly Ser Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser 35 40 45 Lys Val Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe Gln Gly Lys 50 55 60 Trp Tyr Val Val Gly Leu Ala Gly Asn Ala Ile Leu Arg Glu Asp Lys 65 70 75 80 Asp Pro Gln Lys Met Tyr Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys 85 90 95 Ser Tyr Asn Val Thr Ser Val Leu Phe Arg Lys Lys Lys Cys Asp Tyr 100 105 110 Trp Ile Arg Thr Phe Val Pro Gly Cys Gln Pro Gly Glu Phe Thr Leu 115 120 125 Gly Asn Ile Lys Ser Tyr Pro Gly Leu Thr Ser Tyr Leu Val Arg Val 130 135 140 Val Ser Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys Lys Val 145 150 155 160 Ser Gln Asn Arg Glu Tyr Phe Lys Ile Thr Leu Tyr Gly Arg Thr Lys 165 170 175 Glu Leu Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser 180 185 190 Leu Gly Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile Asp Gln 195 200 205 Cys Ile Asp Gly Gly Gly Ser Glu Asn Leu Tyr Phe Gln Gly Gly Gly 210 215 220 His Ala Cys Tyr Arg Asn Cys Trp Arg Glu Gly Asn Asp Glu Glu Thr 225 230 235 240 Cys Lys Glu Arg Cys 245 <210> SEQ ID NO 109 <211> LENGTH: 258 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-SF-H6-GGS-lcn2C-GGS-ENLYFQ-GG-Hanatoxin amino acid sequence <400> SEQUENCE: 109 Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Asp Tyr Lys Asp Glu His His His His His His Gly 20 25 30 Gly Ser Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser 35 40 45 Lys Val Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe Gln Gly Lys 50 55 60 Trp Tyr Val Val Gly Leu Ala Gly Asn Ala Ile Leu Arg Glu Asp Lys 65 70 75 80 Asp Pro Gln Lys Met Tyr Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys 85 90 95 Ser Tyr Asn Val Thr Ser Val Leu Phe Arg Lys Lys Lys Cys Asp Tyr 100 105 110 Trp Ile Arg Thr Phe Val Pro Gly Cys Gln Pro Gly Glu Phe Thr Leu 115 120 125 Gly Asn Ile Lys Ser Tyr Pro Gly Leu Thr Ser Tyr Leu Val Arg Val 130 135 140 Val Ser Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys Lys Val 145 150 155 160 Ser Gln Asn Arg Glu Tyr Phe Lys Ile Thr Leu Tyr Gly Arg Thr Lys 165 170 175 Glu Leu Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser 180 185 190 Leu Gly Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile Asp Gln 195 200 205 Cys Ile Asp Gly Gly Gly Ser Glu Asn Leu Tyr Phe Gln Gly Gly Glu 210 215 220 Cys Arg Tyr Leu Phe Gly Gly Cys Lys Thr Thr Ser Asp Cys Cys Lys 225 230 235 240 His Leu Gly Cys Lys Phe Arg Asp Lys Tyr Cys Ala Trp Asp Phe Thr 245 250 255 Phe Ser <210> SEQ ID NO 110 <211> LENGTH: 259 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-SF-H6-GGS-lcn2C-GGS-ENLYFQ-GG-Chymotrypsin Inhibitor amino acid sequence <400> SEQUENCE: 110 Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Asp Tyr Lys Asp Glu His His His His His His Gly 20 25 30 Gly Ser Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser 35 40 45 Lys Val Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe Gln Gly Lys 50 55 60 Trp Tyr Val Val Gly Leu Ala Gly Asn Ala Ile Leu Arg Glu Asp Lys 65 70 75 80 Asp Pro Gln Lys Met Tyr Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys 85 90 95 Ser Tyr Asn Val Thr Ser Val Leu Phe Arg Lys Lys Lys Cys Asp Tyr 100 105 110 Trp Ile Arg Thr Phe Val Pro Gly Cys Gln Pro Gly Glu Phe Thr Leu 115 120 125 Gly Asn Ile Lys Ser Tyr Pro Gly Leu Thr Ser Tyr Leu Val Arg Val 130 135 140 Val Ser Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys Lys Val 145 150 155 160 Ser Gln Asn Arg Glu Tyr Phe Lys Ile Thr Leu Tyr Gly Arg Thr Lys 165 170 175 Glu Leu Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser 180 185 190 Leu Gly Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile Asp Gln 195 200 205 Cys Ile Asp Gly Gly Gly Ser Glu Asn Leu Tyr Phe Gln Gly Gly Glu 210 215 220 Ile Ser Cys Glu Pro Gly Lys Thr Phe Lys Asp Lys Cys Asn Thr Cys 225 230 235 240 Arg Cys Gly Ala Asp Gly Lys Ser Ala Ala Cys Thr Leu Lys Ala Cys 245 250 255 Pro Asn Gln <210> SEQ ID NO 111 <211> LENGTH: 260 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-SF-H6-GGS-lcn2C-GGS-ENLYFQ-GG-ToxinK amino acid sequence <400> SEQUENCE: 111 Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Asp Tyr Lys Asp Glu His His His His His His Gly 20 25 30 Gly Ser Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser 35 40 45 Lys Val Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe Gln Gly Lys 50 55 60 Trp Tyr Val Val Gly Leu Ala Gly Asn Ala Ile Leu Arg Glu Asp Lys 65 70 75 80 Asp Pro Gln Lys Met Tyr Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys 85 90 95 Ser Tyr Asn Val Thr Ser Val Leu Phe Arg Lys Lys Lys Cys Asp Tyr 100 105 110 Trp Ile Arg Thr Phe Val Pro Gly Cys Gln Pro Gly Glu Phe Thr Leu 115 120 125 Gly Asn Ile Lys Ser Tyr Pro Gly Leu Thr Ser Tyr Leu Val Arg Val 130 135 140 Val Ser Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys Lys Val 145 150 155 160 Ser Gln Asn Arg Glu Tyr Phe Lys Ile Thr Leu Tyr Gly Arg Thr Lys 165 170 175 Glu Leu Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser 180 185 190 Leu Gly Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile Asp Gln 195 200 205 Cys Ile Asp Gly Gly Gly Ser Glu Asn Leu Tyr Phe Gln Gly Gly Val 210 215 220 Cys Arg Asp Trp Phe Lys Glu Thr Ala Cys Arg His Ala Lys Ser Leu 225 230 235 240 Gly Asn Cys Arg Thr Ser Gln Lys Tyr Arg Ala Asn Cys Ala Lys Thr 245 250 255 Cys Glu Leu Cys 260 <210> SEQ ID NO 112 <211> LENGTH: 269 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-SF-H6-GGS-lcn2C-GGS-ENLYFQ-GG-EGFepiregulin Core amino acid sequence <400> SEQUENCE: 112 Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Asp Tyr Lys Asp Glu His His His His His His Gly 20 25 30 Gly Ser Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser 35 40 45 Lys Val Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe Gln Gly Lys 50 55 60 Trp Tyr Val Val Gly Leu Ala Gly Asn Ala Ile Leu Arg Glu Asp Lys 65 70 75 80 Asp Pro Gln Lys Met Tyr Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys 85 90 95 Ser Tyr Asn Val Thr Ser Val Leu Phe Arg Lys Lys Lys Cys Asp Tyr 100 105 110 Trp Ile Arg Thr Phe Val Pro Gly Cys Gln Pro Gly Glu Phe Thr Leu 115 120 125 Gly Asn Ile Lys Ser Tyr Pro Gly Leu Thr Ser Tyr Leu Val Arg Val 130 135 140 Val Ser Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys Lys Val 145 150 155 160 Ser Gln Asn Arg Glu Tyr Phe Lys Ile Thr Leu Tyr Gly Arg Thr Lys 165 170 175 Glu Leu Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser 180 185 190 Leu Gly Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile Asp Gln 195 200 205 Cys Ile Asp Gly Gly Gly Ser Glu Asn Leu Tyr Phe Gln Gly Gly Val 210 215 220 Ser Ile Thr Lys Cys Ser Ser Asp Met Asn Gly Tyr Cys Leu His Gly 225 230 235 240 Gln Cys Ile Tyr Leu Val Asp Met Ser Gln Asn Tyr Cys Arg Cys Glu 245 250 255 Val Gly Tyr Thr Gly Val Arg Cys Glu His Phe Phe Leu 260 265 <210> SEQ ID NO 113 <211> LENGTH: 253 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-SF-H6-GGS-lcn2C-GGS-ENLYFQ-GG-Circulin amino acid sequence <400> SEQUENCE: 113 Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Asp Tyr Lys Asp Glu His His His His His His Gly 20 25 30 Gly Ser Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser 35 40 45 Lys Val Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe Gln Gly Lys 50 55 60 Trp Tyr Val Val Gly Leu Ala Gly Asn Ala Ile Leu Arg Glu Asp Lys 65 70 75 80 Asp Pro Gln Lys Met Tyr Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys 85 90 95 Ser Tyr Asn Val Thr Ser Val Leu Phe Arg Lys Lys Lys Cys Asp Tyr 100 105 110 Trp Ile Arg Thr Phe Val Pro Gly Cys Gln Pro Gly Glu Phe Thr Leu 115 120 125 Gly Asn Ile Lys Ser Tyr Pro Gly Leu Thr Ser Tyr Leu Val Arg Val 130 135 140 Val Ser Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys Lys Val 145 150 155 160 Ser Gln Asn Arg Glu Tyr Phe Lys Ile Thr Leu Tyr Gly Arg Thr Lys 165 170 175 Glu Leu Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser 180 185 190 Leu Gly Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile Asp Gln 195 200 205 Cys Ile Asp Gly Gly Gly Ser Glu Asn Leu Tyr Phe Gln Gly Gly Gly 210 215 220 Ile Pro Cys Gly Glu Ser Cys Val Trp Ile Pro Cys Ile Ser Ala Ala 225 230 235 240 Leu Gly Cys Ser Cys Lys Asn Lys Val Cys Tyr Arg Asn 245 250 <210> SEQ ID NO 114 <211> LENGTH: 277 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-SF-H6-GGS-lcn2C-GGS-ENLYFQ-GG-Brazzein amino acid sequence <400> SEQUENCE: 114 Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Asp Tyr Lys Asp Glu His His His His His His Gly 20 25 30 Gly Ser Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser 35 40 45 Lys Val Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe Gln Gly Lys 50 55 60 Trp Tyr Val Val Gly Leu Ala Gly Asn Ala Ile Leu Arg Glu Asp Lys 65 70 75 80 Asp Pro Gln Lys Met Tyr Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys 85 90 95 Ser Tyr Asn Val Thr Ser Val Leu Phe Arg Lys Lys Lys Cys Asp Tyr 100 105 110 Trp Ile Arg Thr Phe Val Pro Gly Cys Gln Pro Gly Glu Phe Thr Leu 115 120 125 Gly Asn Ile Lys Ser Tyr Pro Gly Leu Thr Ser Tyr Leu Val Arg Val 130 135 140 Val Ser Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys Lys Val 145 150 155 160 Ser Gln Asn Arg Glu Tyr Phe Lys Ile Thr Leu Tyr Gly Arg Thr Lys 165 170 175 Glu Leu Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser 180 185 190 Leu Gly Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile Asp Gln 195 200 205 Cys Ile Asp Gly Gly Gly Ser Glu Asn Leu Tyr Phe Gln Gly Gly Gln 210 215 220 Asp Lys Cys Lys Lys Val Tyr Glu Asn Tyr Pro Val Ser Lys Cys Gln 225 230 235 240 Leu Ala Asn Gln Cys Asn Tyr Asp Cys Lys Leu Asp Lys His Ala Arg 245 250 255 Ser Gly Glu Cys Phe Tyr Asp Glu Lys Arg Asn Leu Gln Cys Ile Cys 260 265 270 Asp Tyr Cys Glu Tyr 275 <210> SEQ ID NO 115 <211> LENGTH: 259 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: amino acid sequence for IgK-SF-H6-GGS-lcn2C-GGS-ENLYFQ-GG-fusion construct <400> SEQUENCE: 115 Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Asp Tyr Lys Asp Glu His His His His His His Gly 20 25 30 Gly Ser Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser 35 40 45 Lys Val Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe Gln Gly Lys 50 55 60 Trp Tyr Val Val Gly Leu Ala Gly Asn Ala Ile Leu Arg Glu Asp Lys 65 70 75 80 Asp Pro Gln Lys Met Tyr Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys 85 90 95 Ser Tyr Asn Val Thr Ser Val Leu Phe Arg Lys Lys Lys Cys Asp Tyr 100 105 110 Trp Ile Arg Thr Phe Val Pro Gly Cys Gln Pro Gly Glu Phe Thr Leu 115 120 125 Gly Asn Ile Lys Ser Tyr Pro Gly Leu Thr Ser Tyr Leu Val Arg Val 130 135 140 Val Ser Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys Lys Val 145 150 155 160 Ser Gln Asn Arg Glu Tyr Phe Lys Ile Thr Leu Tyr Gly Arg Thr Lys 165 170 175 Glu Leu Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser 180 185 190 Leu Gly Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile Asp Gln 195 200 205 Cys Ile Asp Gly Gly Gly Ser Glu Asn Leu Tyr Phe Gln Gly Gly Met 210 215 220 Cys Met Pro Cys Phe Thr Thr Asp His Gln Met Ala Arg Lys Cys Asp 225 230 235 240 Asp Cys Cys Gly Gly Lys Gly Arg Gly Lys Cys Tyr Gly Pro Gln Cys 245 250 255 Leu Cys Arg <210> SEQ ID NO 116 <211> LENGTH: 7 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: idealized furin cut site <400> SEQUENCE: 116 Arg Ala Arg Tyr Lys Arg Ser 1 5 <210> SEQ ID NO 117 <211> LENGTH: 266 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-SF-H6-GGS-lcn2C-GGS-ENLYFQ-GS-MIDKINE amino acid sequence <400> SEQUENCE: 117 Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Asp Tyr Lys Asp Glu His His His His His His Gly 20 25 30 Gly Ser Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser 35 40 45 Lys Val Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe Gln Gly Lys 50 55 60 Trp Tyr Val Val Gly Leu Ala Gly Asn Ala Ile Leu Arg Glu Asp Lys 65 70 75 80 Asp Pro Gln Lys Met Tyr Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys 85 90 95 Ser Tyr Asn Val Thr Ser Val Leu Phe Arg Lys Lys Lys Cys Asp Tyr 100 105 110 Trp Ile Arg Thr Phe Val Pro Gly Cys Gln Pro Gly Glu Phe Thr Leu 115 120 125 Gly Asn Ile Lys Ser Tyr Pro Gly Leu Thr Ser Tyr Leu Val Arg Val 130 135 140 Val Ser Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys Lys Val 145 150 155 160 Ser Gln Asn Arg Glu Tyr Phe Lys Ile Thr Leu Tyr Gly Arg Thr Lys 165 170 175 Glu Leu Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser 180 185 190 Leu Gly Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile Asp Gln 195 200 205 Cys Ile Asp Gly Gly Gly Ser Glu Asn Leu Tyr Phe Gln Ser Asp Cys 210 215 220 Lys Tyr Lys Phe Glu Asn Trp Gly Ala Cys Asp Gly Gly Thr Gly Thr 225 230 235 240 Lys Val Arg Gln Gly Thr Leu Lys Lys Ala Arg Tyr Asn Ala Gln Cys 245 250 255 Gln Glu Thr Ile Arg Val Thr Lys Pro Cys 260 265 <210> SEQ ID NO 118 <211> LENGTH: 250 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-SF-H6-GGS-lcn2C-GGS-ENLYFQ-GG-Violacin A amino acid sequence <400> SEQUENCE: 118 Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Asp Tyr Lys Asp Glu His His His His His His Gly 20 25 30 Gly Ser Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser 35 40 45 Lys Val Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe Gln Gly Lys 50 55 60 Trp Tyr Val Val Gly Leu Ala Gly Asn Ala Ile Leu Arg Glu Asp Lys 65 70 75 80 Asp Pro Gln Lys Met Tyr Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys 85 90 95 Ser Tyr Asn Val Thr Ser Val Leu Phe Arg Lys Lys Lys Cys Asp Tyr 100 105 110 Trp Ile Arg Thr Phe Val Pro Gly Cys Gln Pro Gly Glu Phe Thr Leu 115 120 125 Gly Asn Ile Lys Ser Tyr Pro Gly Leu Thr Ser Tyr Leu Val Arg Val 130 135 140 Val Ser Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys Lys Val 145 150 155 160 Ser Gln Asn Arg Glu Tyr Phe Lys Ile Thr Leu Tyr Gly Arg Thr Lys 165 170 175 Glu Leu Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser 180 185 190 Leu Gly Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile Asp Gln 195 200 205 Cys Ile Asp Gly Gly Gly Ser Glu Asn Leu Tyr Phe Gln Gly Gly Ser 210 215 220 Ala Ile Ser Cys Gly Glu Thr Cys Phe Lys Phe Lys Cys Tyr Thr Pro 225 230 235 240 Arg Cys Ser Cys Ser Tyr Pro Val Cys Lys 245 250 <210> SEQ ID NO 119 <211> LENGTH: 234 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-SF-H6-GGS-lcn2C-GGS-ENLYFQ-GG-Lambda Toxin amino acid sequence <400> SEQUENCE: 119 Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Asp Tyr Lys Asp Glu His His His His His His Gly 20 25 30 Gly Ser Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser 35 40 45 Lys Val Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe Gln Gly Lys 50 55 60 Trp Tyr Val Val Gly Leu Ala Gly Asn Ala Ile Leu Arg Glu Asp Lys 65 70 75 80 Asp Pro Gln Lys Met Tyr Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys 85 90 95 Ser Tyr Asn Val Thr Ser Val Leu Phe Arg Lys Lys Lys Cys Asp Tyr 100 105 110 Trp Ile Arg Thr Phe Val Pro Gly Cys Gln Pro Gly Glu Phe Thr Leu 115 120 125 Gly Asn Ile Lys Ser Tyr Pro Gly Leu Thr Ser Tyr Leu Val Arg Val 130 135 140 Val Ser Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys Lys Val 145 150 155 160 Ser Gln Asn Arg Glu Tyr Phe Lys Ile Thr Leu Tyr Gly Arg Thr Lys 165 170 175 Glu Leu Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser 180 185 190 Leu Gly Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile Asp Gln 195 200 205 Cys Ile Asp Gly Gly Gly Ser Glu Asn Leu Tyr Phe Gln Gly Gly Val 210 215 220 Cys Cys Gly Tyr Lys Leu Cys His Pro Cys 225 230 <210> SEQ ID NO 120 <211> LENGTH: 236 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-SF-H6-GGS-lcn2C-GGS-ENLYFQ-GG-Lambda Toxin NG amino acid sequence <400> SEQUENCE: 120 Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Asp Tyr Lys Asp Glu His His His His His His Gly 20 25 30 Gly Ser Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser 35 40 45 Lys Val Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe Gln Gly Lys 50 55 60 Trp Tyr Val Val Gly Leu Ala Gly Asn Ala Ile Leu Arg Glu Asp Lys 65 70 75 80 Asp Pro Gln Lys Met Tyr Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys 85 90 95 Ser Tyr Asn Val Thr Ser Val Leu Phe Arg Lys Lys Lys Cys Asp Tyr 100 105 110 Trp Ile Arg Thr Phe Val Pro Gly Cys Gln Pro Gly Glu Phe Thr Leu 115 120 125 Gly Asn Ile Lys Ser Tyr Pro Gly Leu Thr Ser Tyr Leu Val Arg Val 130 135 140 Val Ser Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys Lys Val 145 150 155 160 Ser Gln Asn Arg Glu Tyr Phe Lys Ile Thr Leu Tyr Gly Arg Thr Lys 165 170 175 Glu Leu Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser 180 185 190 Leu Gly Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile Asp Gln 195 200 205 Cys Ile Asp Gly Gly Gly Ser Glu Asn Leu Tyr Phe Gln Gly Gly Asn 210 215 220 Gly Val Cys Cys Gly Tyr Lys Leu Cys His Pro Cys 225 230 235 <210> SEQ ID NO 121 <211> LENGTH: 262 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-SF-H6-GGS-lcn2C-GGS-ENLYFQ-GG-Potato Carboxypeptidase Inhibitor amino acid sequence <400> SEQUENCE: 121 Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Asp Tyr Lys Asp Glu His His His His His His Gly 20 25 30 Gly Ser Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser 35 40 45 Lys Val Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe Gln Gly Lys 50 55 60 Trp Tyr Val Val Gly Leu Ala Gly Asn Ala Ile Leu Arg Glu Asp Lys 65 70 75 80 Asp Pro Gln Lys Met Tyr Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys 85 90 95 Ser Tyr Asn Val Thr Ser Val Leu Phe Arg Lys Lys Lys Cys Asp Tyr 100 105 110 Trp Ile Arg Thr Phe Val Pro Gly Cys Gln Pro Gly Glu Phe Thr Leu 115 120 125 Gly Asn Ile Lys Ser Tyr Pro Gly Leu Thr Ser Tyr Leu Val Arg Val 130 135 140 Val Ser Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys Lys Val 145 150 155 160 Ser Gln Asn Arg Glu Tyr Phe Lys Ile Thr Leu Tyr Gly Arg Thr Lys 165 170 175 Glu Leu Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser 180 185 190 Leu Gly Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile Asp Gln 195 200 205 Cys Ile Asp Gly Gly Gly Ser Glu Asn Leu Tyr Phe Gln Gly Gly Gln 210 215 220 Gln His Ala Asp Pro Ile Cys Asn Lys Pro Cys Lys Thr His Asp Asp 225 230 235 240 Cys Ser Gly Ala Trp Phe Cys Gln Ala Cys Trp Asn Ser Ala Arg Thr 245 250 255 Cys Gly Pro Tyr Val Gly 260 <210> SEQ ID NO 122 <211> LENGTH: 191 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: sequence of an oligonucleotide coding for a knottin variant in a libary vector <400> SEQUENCE: 122 ctgtaacctg atcctgctag cgggtctcaa ggtggatcca tgtgcatgcc gtgcttcacc 60 accgataacg aaatggcggc gaactgcgat cgctgctgcg gtggccgtgg ccgtggccgc 120 tgctatggcc cgcagtgcct gtgccgctaa tgcggccgct agtgagaccg cttgcatggc 180 tagtacctac g 191 <210> SEQ ID NO 123 <211> LENGTH: 191 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: sequence of an oligonucleotide coding for a knottin variant in a libary vector <400> SEQUENCE: 123 ctgtaacctg atcctgctag cgggtctcaa ggtggatcca tgtgcatgcc gtgcttcacc 60 accgataacg atatggcgga tgaatgcgat cgctgctgcg gtggccgtgg ccgtggccgc 120 tgctatggcc cgcagtgcct gtgccgctaa tgcggccgct agtgagaccg cttgcatggc 180 tagtacctac g 191 <210> SEQ ID NO 124 <211> LENGTH: 36 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: unique tryptic peptide of a knottin <220> FEATURE: <221> NAME/KEY: MISC_FEATURE <222> LOCATION: (21)..(27) <223> OTHER INFORMATION: Xaa can be any amino acid <220> FEATURE: <221> NAME/KEY: MISC_FEATURE <222> LOCATION: (29)..(32) <223> OTHER INFORMATION: Xaa can be any amino acid <220> FEATURE: <221> NAME/KEY: MISC_FEATURE <222> LOCATION: (34)..(34) <223> OTHER INFORMATION: Xaa can be any amino acid <220> FEATURE: <221> NAME/KEY: MISC_FEATURE <222> LOCATION: (36)..(36) <223> OTHER INFORMATION: Xaa can be any amino acid <400> SEQUENCE: 124 Met Cys Met Pro Cys Phe Thr Thr Asp Asn Glu Met Ala Ala Asn Cys 1 5 10 15 Asp Arg Cys Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa 20 25 30 Cys Xaa Cys Xaa 35 <210> SEQ ID NO 125 <211> LENGTH: 36 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: unique tryptic peptide of a knottin <220> FEATURE: <221> NAME/KEY: MISC_FEATURE <222> LOCATION: (21)..(27) <223> OTHER INFORMATION: Xaa can be any amino acid <220> FEATURE: <221> NAME/KEY: MISC_FEATURE <222> LOCATION: (29)..(32) <223> OTHER INFORMATION: Xaa can be any amino acid <220> FEATURE: <221> NAME/KEY: MISC_FEATURE <222> LOCATION: (34)..(34) <223> OTHER INFORMATION: Xaa can be any amino acid <220> FEATURE: <221> NAME/KEY: MISC_FEATURE <222> LOCATION: (36)..(36) <223> OTHER INFORMATION: Xaa can be any amino acid <400> SEQUENCE: 125 Met Cys Met Pro Cys Phe Thr Thr Asp Asn Asp Met Ala Asp Glu Cys 1 5 10 15 Asp Arg Cys Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa 20 25 30 Cys Xaa Cys Xaa 35 <210> SEQ ID NO 126 <211> LENGTH: 112 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: sequence of an oligonucleotide coding for a knottin variant in a libary vector <400> SEQUENCE: 126 atgtgcatgc cgtgcttcac caccgataac gaaatggcgg cgaactgcga tcgctgctgc 60 ggtggccgtg gccgtggccg ctgctatggc ccgcagtgcc tgtgccgcta at 112 <210> SEQ ID NO 127 <211> LENGTH: 36 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: unique tryptic peptide of a knottin <220> FEATURE: <221> NAME/KEY: MISC_FEATURE <222> LOCATION: (21)..(27) <223> OTHER INFORMATION: Xaa can be any amino acid <220> FEATURE: <221> NAME/KEY: MISC_FEATURE <222> LOCATION: (29)..(32) <223> OTHER INFORMATION: Xaa can be any amino acid <220> FEATURE: <221> NAME/KEY: MISC_FEATURE <222> LOCATION: (34)..(34) <223> OTHER INFORMATION: Xaa can be any amino acid <400> SEQUENCE: 127 Met Cys Met Pro Cys Phe Thr Thr Asp Asn Glu Met Ala Ala Asn Cys 1 5 10 15 Asp Arg Cys Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa 20 25 30 Cys Xaa Cys Arg 35 <210> SEQ ID NO 128 <211> LENGTH: 38 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: representative sequence from a cloned knottin library <400> SEQUENCE: 128 Gly Ser Glu Ile Ser Cys Glu Pro Gly Arg Thr Phe Arg Asp Arg Cys 1 5 10 15 Asn Gln Cys Phe Cys Gly Phe Asp Gly Arg Arg Ala Ala Cys Thr Ile 20 25 30 Arg Ala Cys Pro Asn Gln 35 <210> SEQ ID NO 129 <211> LENGTH: 38 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: representative sequence from a cloned knottin library <400> SEQUENCE: 129 Gly Ser Glu Ile His Cys Gln Pro Gly Arg Thr Phe Arg Asp Arg Cys 1 5 10 15 Asn Thr Cys Tyr Cys Gly Trp Tyr Gly Arg Ser Ala Ala Cys Thr Leu 20 25 30 Arg Ala Cys Pro Asn Gln 35 <210> SEQ ID NO 130 <211> LENGTH: 38 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: representative sequence from a cloned knottin library <400> SEQUENCE: 130 Gly Ser Glu Ile Ser Cys Glu Pro Gly Gly Thr Phe Glu Asp Arg Cys 1 5 10 15 Asn Val Cys Arg Cys Gly Ala Asp Gly Arg Ser Ala Gly Cys Thr Leu 20 25 30 Arg Ala Cys Pro Asn Gln 35 <210> SEQ ID NO 131 <211> LENGTH: 38 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: representative sequence from a cloned knottin library <400> SEQUENCE: 131 Gly Ser Arg Ile Asp Cys Arg Pro Gly Arg Thr Phe Arg Asp Arg Cys 1 5 10 15 Asn Thr Cys Met Cys Gly Trp Thr Gly His Ser Ala Ala Cys Thr Leu 20 25 30 Arg Ala Cys Pro Asn Gln 35 <210> SEQ ID NO 132 <211> LENGTH: 38 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: representative sequence from a cloned knottin library <400> SEQUENCE: 132 Gly Ser Glu Ile Ser Cys Glu Pro Gly Arg Thr Phe Arg Asp Arg Cys 1 5 10 15 Asn Thr Cys His Cys Trp Ala Asp Gly Arg Gly Ala Ala Cys Thr Glu 20 25 30 Arg Ala Cys Pro Asn Gln 35 <210> SEQ ID NO 133 <211> LENGTH: 38 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: representative sequence from a cloned knottin library <400> SEQUENCE: 133 Gly Ser Glu Ser Ser Cys Glu Pro Gly Ala Thr Trp Arg Asp Arg Cys 1 5 10 15 Asn Thr Cys Arg Cys Arg Ala Asp Gly Arg Ser Ala Ala Cys Thr Val 20 25 30 Arg Gln Cys Pro Asn Gln 35 <210> SEQ ID NO 134 <211> LENGTH: 38 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: representative sequence from a cloned knottin library <400> SEQUENCE: 134 Gly Ser Glu Ile Phe Cys Ile Pro Gly Arg Thr Phe Arg Asp Arg Cys 1 5 10 15 Asn Thr Cys Arg Cys Gly Arg Arg Gly Ile Ser Ala Ala Cys Thr Leu 20 25 30 Arg Ala Cys Pro Asn Gln 35 <210> SEQ ID NO 135 <211> LENGTH: 38 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: representative sequence from a cloned knottin library <400> SEQUENCE: 135 Gly Ser Glu Ile Ser Cys Glu Pro Gly Arg Thr Phe Arg Asp Arg Cys 1 5 10 15 Asn Thr Cys Arg Cys Gly Ala Asp Gly Arg Ser Ala Ala Cys Thr Leu 20 25 30 Phe Asp Cys Ser Leu Gln 35 <210> SEQ ID NO 136 <211> LENGTH: 38 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: representative sequence from a cloned knottin library <400> SEQUENCE: 136 Gly Ser Glu Ile Ser Cys Glu Pro Gly Arg Thr Ser Arg Asp Arg Cys 1 5 10 15 Asn Thr Cys Arg Cys Gly Ala Asp Gly Arg Ser Ala Ala Cys Thr Leu 20 25 30 Ile Asp Cys Pro Gly Gln 35 <210> SEQ ID NO 137 <211> LENGTH: 38 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: representative sequence from a cloned knottin library <400> SEQUENCE: 137 Gly Ser Glu Ile Ser Cys Glu Pro Gly Arg Thr Phe Arg Asp Arg Cys 1 5 10 15 Asn Thr Cys Arg Cys Gly Ala Asp Gly Arg Asp Ala Ala Cys Thr Leu 20 25 30 Gly His Cys Phe Phe Tyr 35 <210> SEQ ID NO 138 <211> LENGTH: 38 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: representative sequence from a cloned knottin library <400> SEQUENCE: 138 Gly Ser Glu Ile Ser Cys Glu Pro Gly Phe Thr Glu Gln Asp Arg Cys 1 5 10 15 Asn Thr Cys Arg Cys Gly Ala Ile Gly Arg Ser Ala Ala Cys Thr Leu 20 25 30 Arg Ala Cys Pro Asn Gln 35 <210> SEQ ID NO 139 <211> LENGTH: 38 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: representative sequence from a cloned knottin library <400> SEQUENCE: 139 Gly Ser Glu Ile Ser Cys Glu Pro Tyr Ser Thr Phe Arg Asp Arg Cys 1 5 10 15 Asn Thr Cys Ser Cys Gly Ala Asp Gly Arg Gly Ala Ala Cys Thr Met 20 25 30 Arg Ala Cys Pro Asn Gln 35 <210> SEQ ID NO 140 <211> LENGTH: 38 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: representative sequence from a cloned knottin library <400> SEQUENCE: 140 Gly Ser Glu Ile Ser Cys Glu Pro Gly Arg Thr Phe Arg Asp Arg Cys 1 5 10 15 Asn Thr Cys Arg Cys Gly Ala Asp Gly Arg Ser Ala Ala Cys Thr Leu 20 25 30 Val Ala Cys Leu Ile Thr 35 <210> SEQ ID NO 141 <211> LENGTH: 38 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: representative sequence from a cloned knottin library <400> SEQUENCE: 141 Gly Ser Glu Ile Phe Cys Ile Pro Gly Val Thr Phe Arg Phe Arg Cys 1 5 10 15 Asn Thr Cys Arg Cys Gly Met Asp Gly Arg Ser Ala Ala Cys Thr Leu 20 25 30 Arg Ala Cys Pro Asn Gln 35 <210> SEQ ID NO 142 <211> LENGTH: 38 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: representative sequence from a cloned knottin library <400> SEQUENCE: 142 Gly Ser Glu Asn Asp Cys His Pro Gly Thr Thr Phe Arg Asp Arg Cys 1 5 10 15 Asn Thr Cys Arg Cys Gly Gly Glu Gly Arg Ser Ala Ala Cys Thr Leu 20 25 30 Arg Ala Cys Pro Asn Gln 35 <210> SEQ ID NO 143 <211> LENGTH: 38 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: representative sequence from a cloned knottin library <400> SEQUENCE: 143 Gly Ser Gln Arg Ser Cys Glu Pro Gly Arg Thr Phe Arg Asp Arg Cys 1 5 10 15 Asn Thr Cys Arg Cys Gly Ala Asp Gly Arg Ser Ala Ala Cys Thr Leu 20 25 30 Phe Ile Cys Pro Phe Gln 35 <210> SEQ ID NO 144 <211> LENGTH: 38 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: representative sequence from a cloned knottin library <400> SEQUENCE: 144 Gly Ser Glu Ile Ser Cys Glu Pro Gly Arg Thr Phe Arg Asp Arg Cys 1 5 10 15 Asn Thr Cys Arg Cys Gly Ala Asp Gly Arg Ser Ala Ala Cys Thr Leu 20 25 30 Phe Leu Cys Gly Phe Ile 35 <210> SEQ ID NO 145 <211> LENGTH: 38 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: representative sequence from a cloned knottin library <400> SEQUENCE: 145 Gly Ser Glu Ile Ser Cys Glu Pro Asp Ser Thr Thr Arg Asp Arg Cys 1 5 10 15 Asn Ser Cys Arg Cys Gly Asn Asp Gly Arg Ser Ala Ala Cys Thr Leu 20 25 30 Arg Ala Cys Pro Asn Gln 35 <210> SEQ ID NO 146 <211> LENGTH: 38 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: representative sequence from a cloned knottin library <400> SEQUENCE: 146 Gly Ser Glu Ile Ser Cys Glu Pro Gly Arg Thr Phe Arg Asp Arg Cys 1 5 10 15 Asn Thr Cys Arg Cys Gly Ala Asp Gly Arg Ser Glu Ala Cys Thr Leu 20 25 30 His Asn Cys Arg Glu Gln 35 <210> SEQ ID NO 147 <211> LENGTH: 38 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: representative sequence from a cloned knottin library <400> SEQUENCE: 147 Gly Ser Asp Ile Ser Cys Glu Pro Gly Ser Thr His Arg Asp Arg Cys 1 5 10 15 Asn Thr Cys Arg Cys Ser Ala Asp Gly Arg Ser Arg Ala Cys Thr Leu 20 25 30 Arg Ala Cys Pro Asn Gln 35 <210> SEQ ID NO 148 <211> LENGTH: 38 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: representative sequence from a cloned knottin library <400> SEQUENCE: 148 Gly Ser Glu Asp Ser Cys Glu Pro Gly Trp Thr Gln Arg Met Arg Cys 1 5 10 15 Asn Thr Cys Arg Cys Thr Ala Asp Gly Arg Ser Ala Ala Cys Thr Leu 20 25 30 Arg Ala Cys Pro Asn Gln 35 <210> SEQ ID NO 149 <211> LENGTH: 38 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: representative sequence from a cloned knottin library <400> SEQUENCE: 149 Gly Ser Glu Ile Ser Cys Glu Pro Gly Arg Thr Phe Arg Asp Arg Cys 1 5 10 15 Asn Thr Cys Arg Cys Gly Ala Asp Gly Arg Ser Ala Ala Cys Thr Leu 20 25 30 His His Cys Ile Tyr Trp 35 <210> SEQ ID NO 150 <211> LENGTH: 38 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: representative sequence from a cloned knottin library <400> SEQUENCE: 150 Gly Ser Glu Val Ser Cys Glu Pro Gly Arg Thr Phe Arg Ser Arg Cys 1 5 10 15 Asn Asp Cys Val Cys Gly Ala Asp Gly Arg His Ala Ala Cys Thr Ile 20 25 30 Arg Ala Cys Pro Asn Gln 35 <210> SEQ ID NO 151 <211> LENGTH: 38 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: representative sequence from a cloned knottin library <400> SEQUENCE: 151 Gly Ser Glu Ile Ser Cys Glu Pro Gly Arg Thr Phe Arg Asp Arg Cys 1 5 10 15 Asn Thr Cys Arg Cys Gly Ala Asp Gly Arg Ser Ala Ala Cys Thr Leu 20 25 30 Val Phe Cys His Glu Asp 35 <210> SEQ ID NO 152 <211> LENGTH: 38 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: representative sequence from a cloned knottin library <400> SEQUENCE: 152 Gly Ser Glu Ile Ser Cys Glu Pro Trp Arg Thr Phe Arg Asp Arg Cys 1 5 10 15 Asn Thr Cys Arg Cys Gly Ala Asp Gly Arg Gly Ala Ala Cys Thr Leu 20 25 30 Val Ile Cys Gly Met Gln 35 <210> SEQ ID NO 153 <211> LENGTH: 38 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: representative sequence from a cloned knottin library <400> SEQUENCE: 153 Gly Ser Glu Ile Ser Cys Glu Pro Gly Arg Thr Phe Arg Asp Arg Cys 1 5 10 15 Asn Met Cys Gly Cys Gly Ala Asp Gly Arg Trp Ala Arg Cys Thr Arg 20 25 30 Arg Ala Cys Pro Asn Gln 35 <210> SEQ ID NO 154 <211> LENGTH: 38 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: representative sequence from a cloned knottin library <400> SEQUENCE: 154 Gly Ser Glu Ile Ser Cys Glu Pro Gly Arg Thr Phe Arg Asp Arg Cys 1 5 10 15 Asn Thr Cys Arg Cys Gly Ala Asp Gly Arg Ser Ala Ala Cys Thr Leu 20 25 30 Phe Thr Cys Thr Tyr Phe 35 <210> SEQ ID NO 155 <211> LENGTH: 38 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: representative sequence from a cloned knottin library <400> SEQUENCE: 155 Gly Ser Glu Ile Ser Cys Glu Pro Gly Arg Thr Trp Arg Asp Arg Cys 1 5 10 15 Asn Thr Cys Arg Cys Gly Ala Asp Gly Arg Ser Ala Ala Cys Thr Leu 20 25 30 Asn Gly Cys Leu Leu Gln 35 <210> SEQ ID NO 156 <211> LENGTH: 38 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: representative sequence from a cloned knottin library <400> SEQUENCE: 156 Gly Ser Glu Ile Ser Cys Glu Pro Gly Arg Thr Phe Arg Asp Arg Cys 1 5 10 15 Asn Thr Cys Arg Cys Gly Ala Asp Gly Arg Ser Ala Ala Cys Thr Leu 20 25 30 Ala Asn Cys Phe Phe Ala 35 <210> SEQ ID NO 157 <211> LENGTH: 178 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 157 Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser Lys Val 1 5 10 15 Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe Gln Gly Lys Trp Tyr 20 25 30 Val Val Gly Leu Ala Gly Asn Ala Ile Leu Arg Glu Asp Lys Asp Pro 35 40 45 Gln Lys Met Tyr Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys Ser Tyr 50 55 60 Asn Val Thr Ser Val Leu Phe Arg Lys Lys Lys Cys Asp Tyr Trp Ile 65 70 75 80 Arg Thr Phe Val Pro Gly Cys Gln Pro Gly Glu Phe Thr Leu Gly Asn 85 90 95 Ile Lys Ser Tyr Pro Gly Leu Thr Ser Tyr Leu Val Arg Val Val Ser 100 105 110 Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys Lys Val Ser Gln 115 120 125 Asn Arg Glu Tyr Phe Lys Ile Thr Leu Tyr Gly Arg Thr Lys Glu Leu 130 135 140 Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser Leu Gly 145 150 155 160 Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile Asp Gln Cys Ile 165 170 175 Asp Gly <210> SEQ ID NO 158 <211> LENGTH: 178 <212> TYPE: PRT <213> ORGANISM: Pan troglodytes <400> SEQUENCE: 158 Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser Lys Val 1 5 10 15 Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe Gln Gly Lys Trp Tyr 20 25 30 Val Val Gly Leu Ala Gly Asn Ala Ile Leu Arg Glu Asp Lys Asp Pro 35 40 45 Gln Lys Met Tyr Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys Ser Tyr 50 55 60 Asn Val Thr Ser Val Leu Phe Arg Lys Lys Lys Cys Asp Tyr Trp Ile 65 70 75 80 Arg Thr Phe Val Pro Gly Arg Gln Pro Gly Glu Phe Thr Leu Gly Asn 85 90 95 Ile Lys Ser Tyr Pro Gly Leu Thr Ser Tyr Leu Val Arg Val Val Ser 100 105 110 Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys Lys Val Ser Gln 115 120 125 Asn Arg Glu Tyr Phe Lys Ile Thr Leu Tyr Gly Arg Thr Lys Glu Leu 130 135 140 Thr Ser Glu Leu Gln Glu Asn Phe Ile Arg Phe Ser Lys Ser Leu Gly 145 150 155 160 Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile Asp Gln Cys Ile 165 170 175 Asp Gly <210> SEQ ID NO 159 <211> LENGTH: 180 <212> TYPE: PRT <213> ORGANISM: Gorilla gorilla <400> SEQUENCE: 159 Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser Lys Val 1 5 10 15 Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe Gln Gly Lys Trp Tyr 20 25 30 Val Val Gly Leu Ala Gly Asn Ala Ile Leu Arg Glu Asp Lys Asp Pro 35 40 45 Gln Lys Met Tyr Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys Ser Tyr 50 55 60 Asn Val Thr Ser Val Leu Phe Arg Glu Lys Ala Gln Lys Cys Asp Tyr 65 70 75 80 Trp Ile Arg Thr Phe Val Pro Gly Ser Gln Pro Gly Glu Phe Thr Leu 85 90 95 Gly Asn Ile Lys Ser Tyr Pro Gly Leu Thr Ser Tyr Leu Val Arg Val 100 105 110 Val Ser Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys Lys Val 115 120 125 Ser Gln Asn Arg Glu Tyr Phe Lys Ile Thr Leu Tyr Gly Arg Thr Lys 130 135 140 Glu Leu Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser 145 150 155 160 Leu Gly Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile Asp Gln 165 170 175 Cys Ile Asp Gly 180 <210> SEQ ID NO 160 <211> LENGTH: 178 <212> TYPE: PRT <213> ORGANISM: Pongo pygmaeus <400> SEQUENCE: 160 Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser Lys Val 1 5 10 15 Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe Gln Gly Lys Trp Tyr 20 25 30 Val Val Gly Leu Ala Gly Asn Ala Ile Arg Arg Glu Asp Lys Asp Ser 35 40 45 Gln Lys Met Tyr Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys Ser Tyr 50 55 60 Asn Val Thr Ser Val Leu Phe Arg Lys Lys Lys Cys Asp Tyr Trp Ile 65 70 75 80 Arg Thr Phe Val Pro Gly Ser Gln Pro Gly Glu Phe Thr Leu Gly Asn 85 90 95 Thr Lys Gly Tyr Pro Gly Leu Thr Ser Tyr Leu Val Arg Val Val Ser 100 105 110 Thr Asn Tyr Asn Gln Tyr Ala Met Val Phe Phe Lys Lys Val Ser Gln 115 120 125 Asn Arg Glu Tyr Phe Lys Ile Thr Leu Tyr Gly Arg Thr Lys Glu Leu 130 135 140 Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser Leu Gly 145 150 155 160 Leu Pro Glu Asn His Ile Val Phe Pro Ala Pro Ile Asp Gln Cys Ile 165 170 175 Asp Gly <210> SEQ ID NO 161 <211> LENGTH: 178 <212> TYPE: PRT <213> ORGANISM: Macaca mulatta <400> SEQUENCE: 161 Gln Asp Ser Ser Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser Lys Val 1 5 10 15 Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe Gln Gly Lys Trp Tyr 20 25 30 Val Val Gly Leu Ser Gly Asn Ala Val Gly Arg Lys Asp Glu Ala Pro 35 40 45 Leu Lys Met Tyr Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys Ser Tyr 50 55 60 Asn Val Thr Ser Ile Leu Phe Arg Lys Glu Lys Cys Asp Tyr Trp Ile 65 70 75 80 Arg Thr Phe Val Pro Gly Ser Gln Pro Gly Glu Phe Thr Leu Gly Asn 85 90 95 Ile Gln Asn His Pro Gly Leu Thr Ser Tyr Val Val Arg Val Val Ser 100 105 110 Thr Asn Tyr Lys Gln Tyr Ala Met Val Phe Phe Lys Lys Val Ser Gln 115 120 125 Asn Lys Glu Tyr Phe Lys Ile Thr Leu Tyr Gly Arg Thr Lys Glu Leu 130 135 140 Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser Leu Gly 145 150 155 160 Leu Pro Glu Asn His Ile Val Phe Ser Val Pro Ile Asp Gln Cys Ile 165 170 175 Asn Gly <210> SEQ ID NO 162 <211> LENGTH: 179 <212> TYPE: PRT <213> ORGANISM: Callithrix jacchus <400> SEQUENCE: 162 Gln Asp Ser Pro Ser Pro Leu Ile Pro Ala Pro Pro Leu Ser Lys Val 1 5 10 15 Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe Gln Gly Lys Trp Tyr 20 25 30 Val Val Gly Leu Ala Gly Asn Ala Ile Arg Arg Glu Asp Gln Asp Ser 35 40 45 Leu Lys Met Tyr Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys Ser Tyr 50 55 60 Asn Val Thr Ser Val Leu Phe Arg Lys Ala Gln Lys Cys Asp Tyr Trp 65 70 75 80 Ile Arg Thr Phe Val Pro Ser Ser Arg Pro Gly Glu Phe Lys Leu Gly 85 90 95 Asn Ile Glu Ser His Pro Gly Leu Thr Ser Tyr Ile Val Arg Val Val 100 105 110 Asn Thr Asp Tyr Lys Gln His Ala Met Val Phe Phe Met Lys Ala Ser 115 120 125 His Asn Arg Lys Tyr Phe Lys Val Thr Leu Tyr Gly Arg Thr Lys Glu 130 135 140 Leu Thr Ser Asp Leu Lys Glu Asn Phe Thr Ser Phe Ser Lys Ser Leu 145 150 155 160 Gly Leu Thr Glu Asn His Ile Ile Phe Pro Val Pro Ile Asp Gln Cys 165 170 175 Ile Asp Gly <210> SEQ ID NO 163 <211> LENGTH: 180 <212> TYPE: PRT <213> ORGANISM: Mus musculus <400> SEQUENCE: 163 Gln Asp Ser Thr Gln Asn Leu Ile Pro Ala Pro Ser Leu Leu Thr Val 1 5 10 15 Pro Leu Gln Pro Asp Phe Arg Ser Asp Gln Phe Arg Gly Arg Trp Tyr 20 25 30 Val Val Gly Leu Ala Gly Asn Ala Val Gln Lys Lys Thr Glu Gly Ser 35 40 45 Phe Thr Met Tyr Ser Thr Ile Tyr Glu Leu Gln Glu Asn Asn Ser Tyr 50 55 60 Asn Val Thr Ser Ile Leu Val Arg Asp Gln Asp Gln Gly Cys Arg Tyr 65 70 75 80 Trp Ile Arg Thr Phe Val Pro Ser Ser Arg Ala Gly Gln Phe Thr Leu 85 90 95 Gly Asn Met His Arg Tyr Pro Gln Val Gln Ser Tyr Asn Val Gln Val 100 105 110 Ala Thr Thr Asp Tyr Asn Gln Phe Ala Met Val Phe Phe Arg Lys Thr 115 120 125 Ser Glu Asn Lys Gln Tyr Phe Lys Ile Thr Leu Tyr Gly Arg Thr Lys 130 135 140 Glu Leu Ser Pro Glu Leu Lys Glu Arg Phe Thr Arg Phe Ala Lys Ser 145 150 155 160 Leu Gly Leu Lys Asp Asp Asn Ile Ile Phe Ser Val Pro Thr Asp Gln 165 170 175 Cys Ile Asp Asn 180 <210> SEQ ID NO 164 <211> LENGTH: 178 <212> TYPE: PRT <213> ORGANISM: Rattus norvegicus <400> SEQUENCE: 164 Gln Asp Ser Thr Gln Asn Leu Ile Pro Ala Pro Pro Leu Ile Ser Val 1 5 10 15 Pro Leu Gln Pro Gly Phe Trp Thr Glu Arg Phe Gln Gly Arg Trp Phe 20 25 30 Val Val Gly Leu Ala Ala Asn Ala Val Gln Lys Glu Arg Gln Ser Arg 35 40 45 Phe Thr Met Tyr Ser Thr Ile Tyr Glu Leu Gln Glu Asp Asn Ser Tyr 50 55 60 Asn Val Thr Ser Ile Leu Val Arg Gly Gln Gly Cys Arg Tyr Trp Ile 65 70 75 80 Arg Thr Phe Val Pro Ser Ser Arg Pro Gly Gln Phe Thr Leu Gly Asn 85 90 95 Ile His Ser Tyr Pro Gln Ile Gln Ser Tyr Asp Val Gln Val Ala Asp 100 105 110 Thr Asp Tyr Asp Gln Phe Ala Met Val Phe Phe Gln Lys Thr Ser Glu 115 120 125 Asn Lys Gln Tyr Phe Lys Val Thr Leu Tyr Gly Arg Thr Lys Gly Leu 130 135 140 Ser Asp Glu Leu Lys Glu Arg Phe Val Ser Phe Ala Lys Ser Leu Gly 145 150 155 160 Leu Lys Asp Asn Asn Ile Val Phe Ser Val Pro Thr Asp Gln Cys Ile 165 170 175 Asp Asn <210> SEQ ID NO 165 <211> LENGTH: 181 <212> TYPE: PRT <213> ORGANISM: Ochotona princeps <400> SEQUENCE: 165 Gln Glu Leu Thr Thr Asp Leu Ile Pro Val Pro Ser Leu Arg Lys Ile 1 5 10 15 His Val Gln Lys Asn Phe Gln Ser Asp Gln Phe Gln Gly Lys Trp Tyr 20 25 30 Val Val Gly Leu Ala Gly Asn Asn Ile His Asn Ser Asp Gln Glu His 35 40 45 Gln Gln Met Tyr Ser Thr Thr Tyr Glu Leu Lys Glu Asp Gly Ser Tyr 50 55 60 Asn Val Thr Ser Thr Leu Leu Arg Gln Arg Asn Gln Gln Cys Asp His 65 70 75 80 Trp Ile Arg Thr Phe Val Pro Gly Ser Lys Leu Gly His Phe Asn Leu 85 90 95 Gly Asn Ile Lys Ser Tyr Pro Thr Leu Lys Ser Tyr Leu Ile Arg Val 100 105 110 Val Thr Thr Asp Tyr Asn Gln Phe Ala Ile Val Phe Phe Arg Lys Val 115 120 125 Tyr Lys Asn Asn Lys Lys Phe Phe Lys Ile Val Leu Tyr Gly Arg Thr 130 135 140 Lys Glu Leu Ser Pro Glu Leu Arg Gly Arg Phe Thr Ser Phe Ala Lys 145 150 155 160 Thr Leu Gly Leu Thr Asp Asn His Ile Val Phe Pro Ala Pro Ile Gly 165 170 175 Gln Cys Ile Asp Asp 180 <210> SEQ ID NO 166 <211> LENGTH: 178 <212> TYPE: PRT <213> ORGANISM: Oryctolagus cuniculus <400> SEQUENCE: 166 Gln Asp Pro Thr Pro Lys Leu Ile Pro Ala Pro Ser Leu Arg Arg Val 1 5 10 15 Pro Leu Gln Arg Asn Phe Gln Asp Glu Gln Phe Gln Gly Lys Trp Tyr 20 25 30 Val Val Gly Leu Ala Gly Asn Ala Val Gln Lys Arg Glu Glu Gly Gln 35 40 45 Glu Pro Met Tyr Ser Thr Thr Tyr Glu Leu Asn Glu Asp Arg Ser Phe 50 55 60 Asn Val Thr Ser Thr Leu Leu Arg Asp Gln Arg Cys Asp His Trp Ile 65 70 75 80 Arg Thr Phe Val Pro Thr Ser Arg Pro Gly Gln Tyr Asn Leu Gly Asn 85 90 95 Ile Lys Ser Tyr Pro Gly Val Lys Asn Tyr Ile Val Arg Val Val Ala 100 105 110 Thr Asp Tyr Ser Gln Tyr Ala Met Met Phe Phe Arg Lys Gly Ser Arg 115 120 125 Asn Lys Gln Phe Phe Lys Thr Thr Leu Tyr Gly Arg Thr Lys Glu Leu 130 135 140 Ser Pro Glu Leu Arg Glu Arg Phe Thr Arg Phe Ala Lys Ser Leu Gly 145 150 155 160 Leu Pro Asp Asp Arg Ile Val Phe Pro Thr Pro Ile Asp Gln Cys Ile 165 170 175 Asp Asp <210> SEQ ID NO 167 <211> LENGTH: 179 <212> TYPE: PRT <213> ORGANISM: Bos taurus <400> SEQUENCE: 167 Arg Ser Ser Ser Ser Arg Leu Leu Arg Ala Pro Pro Leu Ser Arg Ile 1 5 10 15 Pro Leu Gln Pro Asn Phe Gln Ala Asp Gln Phe Gln Gly Lys Trp Tyr 20 25 30 Thr Val Gly Val Ala Gly Asn Ala Ile Lys Lys Glu Glu Gln Asp Pro 35 40 45 Leu Lys Met Tyr Ser Ser Asn Tyr Glu Leu Lys Glu Asp Gly Ser Tyr 50 55 60 Asn Val Thr Ser Ile Leu Leu Lys Asp Asp Leu Cys Asp Tyr Trp Ile 65 70 75 80 Arg Thr Phe Val Pro Ser Ser Gln Pro Gly Gln Phe Thr Leu Gly Asn 85 90 95 Ile Lys Ser Tyr Arg Gly Ile Arg Ser Tyr Thr Val Arg Val Val Asn 100 105 110 Thr Asp Tyr Asn Gln Phe Ala Ile Val Tyr Phe Lys Lys Val Gln Arg 115 120 125 Lys Lys Thr Tyr Phe Lys Ile Thr Leu Tyr Gly Arg Thr Lys Glu Leu 130 135 140 Thr Pro Glu Val Arg Glu Asn Phe Ile Asn Phe Ala Lys Ser Leu Gly 145 150 155 160 Leu Thr Asp Asp His Ile Val Phe Thr Val Pro Ile Asp Arg Cys Ile 165 170 175 Asp Asp Gln <210> SEQ ID NO 168 <211> LENGTH: 179 <212> TYPE: PRT <213> ORGANISM: Sus scrofa <400> SEQUENCE: 168 Gln Gly Thr Ile Pro Asn Trp Ile Pro Ala Pro Pro Leu Ser Lys Val 1 5 10 15 Pro Leu Gln Pro Asn Phe Gln Ala Asp Gln Phe Gln Gly Lys Trp Tyr 20 25 30 Val Val Gly Leu Ala Gly Asn Ala Val Lys Lys Glu Glu Gln Gly Arg 35 40 45 Phe Lys Met Tyr Thr Thr Thr Tyr Glu Leu Lys Glu Asp Gly Ser Tyr 50 55 60 Asn Val Ile Ser Thr Leu Leu Arg Gly Gln Leu Cys Asp Asn Trp Ile 65 70 75 80 Arg Thr Phe Val Pro Ser Leu Gln Pro Gly Gln Phe Lys Leu Gly Asp 85 90 95 Ile Lys Lys Tyr Ser Gly Leu Gln Ser Tyr Val Val Arg Val Val Ser 100 105 110 Thr Asn Tyr Ser Gln Phe Ala Ile Val Phe Phe Lys Lys Val Ser Asn 115 120 125 Asn Gln Glu Tyr Phe Lys Thr Thr Leu Tyr Gly Arg Thr Lys Val Leu 130 135 140 Ser Pro Glu Leu Lys Glu Asn Phe Val Arg Phe Ala Lys Ser Leu Gly 145 150 155 160 Leu Ser Asp Asp Asn Ile Ile Phe Pro Val Ala Ile Asp Gln Cys Ile 165 170 175 Asp Gly Gln <210> SEQ ID NO 169 <211> LENGTH: 181 <212> TYPE: PRT <213> ORGANISM: Tursiops truncatus <400> SEQUENCE: 169 Gln Asp Ser Thr Pro Asn Leu Ile Pro Ala Pro Pro Leu Phe Arg Val 1 5 10 15 Pro Leu Gln Pro Asn Phe Gln Pro Asp Gln Phe Gln Gly Lys Trp Tyr 20 25 30 Ile Val Gly Leu Ala Gly Asn Ala Phe Lys Lys Glu Lys Gln Gly Gln 35 40 45 Phe Lys Met Tyr Ala Thr Thr Tyr Glu Leu Lys Glu Asp Arg Ser Tyr 50 55 60 Asn Val Thr Ser Ala Leu Leu Arg Gly Lys Thr Gln Arg Cys Asp His 65 70 75 80 Trp Ile Arg Thr Phe Val Pro Ser Ser Arg Pro Gly Gln Phe Thr Leu 85 90 95 Gly Asn Ile Lys Gly Phe Pro Gly Val Gln Ser Tyr Thr Val Arg Val 100 105 110 Ala Thr Thr Asn Tyr Asn Gln Phe Ala Ile Val Tyr Phe Lys Lys Val 115 120 125 Tyr Lys Asn Gln Glu Tyr Phe Lys Thr Thr Leu Tyr Gly Arg Thr Lys 130 135 140 Glu Leu Thr Pro Gln Leu Lys Glu Asn Phe Ile His Phe Ala Lys Ser 145 150 155 160 Leu Gly Leu Thr Asp Glu Tyr Ile Leu Phe Pro Val Pro Ile Asp Lys 165 170 175 Cys Ile Asp Asp Gln 180 <210> SEQ ID NO 170 <211> LENGTH: 179 <212> TYPE: PRT <213> ORGANISM: Equus caballus <400> SEQUENCE: 170 Arg Asp Pro Ala Pro Lys Leu Ile Pro Ala Pro Pro Leu Asp Arg Val 1 5 10 15 Pro Leu Gln Pro Asp Phe Lys Asp Asp Gln Phe Gln Gly Lys Trp Tyr 20 25 30 Val Val Gly Val Ala Gly Asn Ala Phe Lys Lys Glu Glu Gln Gly Gln 35 40 45 Phe Thr Met Tyr Thr Thr Thr Tyr Glu Leu Lys Glu Asp His Ser Tyr 50 55 60 Asn Val Thr Ser Ile Leu Leu Arg Asp Gln Asn Cys Asp His Trp Ile 65 70 75 80 Arg Thr Phe Ile Pro Ser Ser Gln Pro Gly Gln Phe Asn Leu Gly Asp 85 90 95 Ile Lys Arg Tyr Phe Gly Val Gln Ser Tyr Ile Val Arg Val Ala Asp 100 105 110 Thr Asp Tyr Asn Gln Phe Ala Ile Val Phe Phe Arg Lys Val Tyr Lys 115 120 125 Asn Gln Glu Tyr Phe Lys Thr Thr Leu Tyr Arg Arg Thr Lys Glu Leu 130 135 140 Thr Pro Glu Leu Arg Glu Lys Phe Ile Ser Phe Ala Lys Ser Leu Gly 145 150 155 160 Leu Thr Asp Asp His Ile Ile Phe Pro Val Pro Ile Asp Gln Cys Ile 165 170 175 Asp Glu Glu <210> SEQ ID NO 171 <211> LENGTH: 178 <212> TYPE: PRT <213> ORGANISM: Microcebus murinus <400> SEQUENCE: 171 Gln Asp Ser Lys Glu Lys Leu Ile Pro Ala Pro Pro Leu Leu Arg Val 1 5 10 15 Pro Leu Gln Pro Asp Phe Gln Asp Asp Gln Phe Arg Glu Thr Ser Trp 20 25 30 Pro Arg Gly Ser Lys Met Lys Glu Thr Pro Ala Gly Ser Arg Asp Ala 35 40 45 Gly Thr Gly Trp Ala Thr Thr Tyr Glu Leu Lys Asp His Ser Tyr Asn 50 55 60 Val Thr Ser Thr Leu Leu Arg Gln Asn Gly Lys Cys Asp Tyr Trp Ile 65 70 75 80 Arg Thr Phe Val Leu Thr Ser Gln Pro Gly Gln Phe Ala Leu Gly Asn 85 90 95 Ile Asn Arg Tyr Pro Gly Ile Gln Ser Tyr Thr Val Arg Val Val Thr 100 105 110 Thr Asn Tyr Asn Gln Phe Ala Ile Val Phe Phe Lys Lys Val Ser Glu 115 120 125 Asn Lys Glu Tyr Phe Lys Thr Thr Leu Tyr Gly Arg Thr Lys Glu Leu 130 135 140 Pro Pro Glu Leu Lys Glu Asn Phe Ile Arg Phe Ala Lys Ser Leu Gly 145 150 155 160 Leu Thr Glu Asp His Ile Ile Tyr Pro Val Pro Ile Asp Gln Cys Ile 165 170 175 Asp Asp <210> SEQ ID NO 172 <211> LENGTH: 178 <212> TYPE: PRT <213> ORGANISM: Loxodonta africana <400> SEQUENCE: 172 Gln Thr His Ser Pro Thr Leu Ile Pro Ala Pro Pro Leu Leu Arg Val 1 5 10 15 Pro Leu Gln Pro Asp Phe Gln Asp Asp Lys Phe Gln Gly Lys Trp Tyr 20 25 30 Val Ile Gly Leu Ala Gly Asn Ala Val Glu Lys Lys Glu Gln Gly Gln 35 40 45 Phe Lys Met Tyr Thr Thr Thr Tyr Glu Leu Lys Glu Asp Gly Ser Tyr 50 55 60 Asn Val Thr Ser Thr Leu Leu Gln Glu Asp Gly Lys Cys Ser Tyr Trp 65 70 75 80 Ile Arg Thr Phe Val Pro Ser Phe Gln Pro Gly Gln Phe Asn Leu Gly 85 90 95 Asn Ile Lys Asn Phe Pro Gly Leu Gln Ser Tyr Thr Val Arg Val Thr 100 105 110 Ala Thr Asn Tyr Asn Gln Phe Ala Ile Val Phe Phe Lys Lys Val Ser 115 120 125 Lys Asn Gly Glu Tyr Phe Lys Thr Thr Leu Tyr Gly Arg Thr Lys Glu 130 135 140 Leu Thr Pro Glu Leu Lys Glu Arg Phe Ile Arg Phe Ala Lys Ser Leu 145 150 155 160 Gly Leu Ser Asp His Ile Ile Phe Pro Val Pro Ile Asp Arg Cys Ile 165 170 175 Asp Asp <210> SEQ ID NO 173 <211> LENGTH: 179 <212> TYPE: PRT <213> ORGANISM: Procavia capensis <400> SEQUENCE: 173 Gln Glu Pro Thr Pro Thr Leu Ile Pro Ala Pro Pro Leu Ser Ser Ile 1 5 10 15 Pro Leu Lys Pro Asn Phe His Asn Asp Lys Phe Gln Gly Lys Trp Tyr 20 25 30 Val Val Gly Val Ala Gly Asn Ala Ile Thr Lys Glu Lys Asp Pro Ser 35 40 45 Leu Met Tyr Thr Thr Thr Tyr Glu Leu Arg Asp Asp Gly Ser Tyr Asn 50 55 60 Val Thr Ser Thr Gln Phe Arg Glu Lys Ile Asn Cys Thr His Trp Thr 65 70 75 80 Arg Thr Phe Val Pro Thr Ser Gln Pro Gly Gln Phe Ser Leu Gly Asn 85 90 95 Ile Asp Lys Tyr Pro His Leu Ser Ser Tyr Thr Val Arg Val Thr Ala 100 105 110 Thr Asn Tyr Asn Tyr Phe Ala Ile Val Tyr Phe Lys Lys Val Ser Lys 115 120 125 Asn Gln Glu Tyr Phe Lys Thr Thr Leu Tyr Lys Arg Ile Lys Lys Leu 130 135 140 Thr His Gly Leu Lys Lys His Phe Ile Gln Phe Ala Lys Ser Leu Gly 145 150 155 160 Leu Pro Asp Asn His Ile Thr Phe Leu Val Pro Thr Asp Arg Cys Ile 165 170 175 Asp Asp Ala <210> SEQ ID NO 174 <211> LENGTH: 178 <212> TYPE: PRT <213> ORGANISM: Canis familiaris <400> SEQUENCE: 174 Gln Asp Ser Thr Pro Ser Leu Ile Pro Ala Pro Pro Pro Leu Lys Val 1 5 10 15 Pro Leu Gln Pro Asp Phe Gln His Asp Gln Phe Gln Gly Lys Trp Tyr 20 25 30 Val Ile Gly Ile Ala Gly Asn Ile Leu Lys Lys Glu Gly His Gly Gln 35 40 45 Leu Lys Met Tyr Thr Thr Thr Tyr Glu Leu Lys Asp Asp Gln Ser Tyr 50 55 60 Asn Val Thr Ser Thr Leu Leu Arg Asn Glu Arg Cys Asp Tyr Trp Asn 65 70 75 80 Arg Asp Phe Val Pro Ser Phe Gln Pro Gly Gln Phe Ser Leu Gly Asp 85 90 95 Ile Gln Leu Tyr Pro Gly Val Gln Ser Tyr Leu Val Gln Val Val Ala 100 105 110 Thr Asn Tyr Asn Gln Tyr Ala Leu Val Tyr Phe Arg Lys Val Tyr Lys 115 120 125 Ser Gln Glu Tyr Phe Lys Ile Thr Leu Tyr Gly Arg Thr Lys Glu Leu 130 135 140 Pro Leu Glu Leu Lys Lys Glu Phe Ile Arg Phe Ala Lys Ser Ile Gly 145 150 155 160 Leu Thr Glu Asp His Ile Ile Phe Pro Val Pro Ile Asp Gln Cys Ile 165 170 175 Asp Glu <210> SEQ ID NO 175 <211> LENGTH: 427 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: amino acid sequence of a light chain antibody fusion with Scn <400> SEQUENCE: 175 Met Asp Phe Gln Val Gln Ile Phe Ser Phe Leu Leu Ile Ser Ala Ser 1 5 10 15 Val Ile Met Ser Arg Gly Asp Ile Val Met Thr Gln Ala Ala Pro Ser 20 25 30 Val Pro Val Thr Pro Gly Glu Ser Val Ser Ile Ser Cys Arg Ser Thr 35 40 45 Lys Ser Leu Leu His Ser Asn Gly Asn Thr Tyr Leu Tyr Trp Phe Leu 50 55 60 Gln Arg Pro Gly Gln Ser Pro Gln Arg Leu Ile Tyr Tyr Met Ser Asn 65 70 75 80 Leu Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Arg Gly Ser Gly Thr 85 90 95 Asp Phe Thr Leu Arg Ile Ser Arg Val Glu Ala Glu Asp Ala Gly Val 100 105 110 Tyr Tyr Cys Met Gln Ser Leu Glu Tyr Pro Tyr Thr Phe Gly Gly Gly 115 120 125 Thr Lys Leu Glu Ile Lys Arg Ala Asp Ala Ala Pro Thr Val Ser Ile 130 135 140 Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly Gly Ala Ser Val Val 145 150 155 160 Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile Asn Val Lys Trp Lys 165 170 175 Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu Asn Ser Trp Thr Asp 180 185 190 Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser Ser Thr Leu Thr Leu 195 200 205 Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr Thr Cys Glu Ala Thr 210 215 220 His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser Phe Asn Arg Asn Glu 225 230 235 240 Cys Gly Arg Gly Gly Ser Gly Gly Ser Gln Asp Ser Thr Ser Asp Leu 245 250 255 Ile Pro Ala Pro Pro Leu Ser Lys Val Pro Leu Gln Gln Asn Phe Gln 260 265 270 Asp Asn Gln Phe Gln Gly Lys Trp Tyr Val Val Gly Leu Ala Gly Asn 275 280 285 Ala Ile Leu Arg Glu Asp Lys Asp Pro Gln Lys Met Tyr Ala Thr Ile 290 295 300 Tyr Glu Leu Lys Glu Asp Lys Ser Tyr Asn Val Thr Ser Val Leu Phe 305 310 315 320 Arg Lys Lys Lys Cys Asp Tyr Trp Ile Arg Thr Phe Val Pro Gly Ser 325 330 335 Gln Pro Gly Glu Phe Thr Leu Gly Asn Ile Lys Ser Tyr Pro Gly Leu 340 345 350 Thr Ser Tyr Leu Val Arg Val Val Ser Thr Asn Tyr Asn Gln His Ala 355 360 365 Met Val Phe Phe Lys Lys Val Ser Gln Asn Arg Glu Tyr Phe Lys Ile 370 375 380 Thr Leu Tyr Gly Arg Thr Lys Glu Leu Thr Ser Glu Leu Lys Glu Asn 385 390 395 400 Phe Ile Arg Phe Ser Lys Ser Leu Gly Leu Pro Glu Asn His Ile Val 405 410 415 Phe Pro Val Pro Ile Asp Gln Cys Ile Asp Gly 420 425 <210> SEQ ID NO 176 <211> LENGTH: 46 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: sequence showing NotI cut for SEQ ID NO: 1 <400> SEQUENCE: 176 aacctgtatt ttcagggagg cgctaaggat cccggaccgc ctctcc 46

1 SEQUENCE LISTING <160> NUMBER OF SEQ ID NOS: 176 <210> SEQ ID NO 1 <211> LENGTH: 721 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-SF-H6-GGS-lcn2C-GGS-ENLYFQ-GG-PARENTAL <400> SEQUENCE: 1 gactgagtcg cccgctcgag accatggaga cagacacact cctgctatgg gtactgctgc 60 tctgggttcc aggttccact ggtgactaca aggacgagca tcaccatcat caccatggtg 120 gaagccagga ctccacctca gacctgatcc cagccccacc tctgagcaag gtccctctgc 180 agcagaactt ccaggacaac caattccagg ggaagtggta tgtggtaggc ctggcaggga 240 atgcaattct cagagaagac aaagacccgc aaaagatgta tgccaccatc tatgagctga 300 aagaagacaa gagctacaat gtcacctccg tcctgtttag gaaaaagaag tgtgactact 360 ggatcaggac ttttgttcca ggttgccagc ccggcgagtt cacgctgggc aacattaaga 420 gttaccctgg attaacgagt tacctcgtcc gagtggtgag caccaactac aaccagcatg 480 ctatggtgtt cttcaagaaa gtttctcaaa acagggagta cttcaagatc accctctacg 540 ggagaaccaa ggagctgact tcggaactaa aggagaactt catccgcttc tccaaatctc 600 tgggcctccc tgaaaaccac atcgtcttcc ctgtcccaat cgaccagtgt atcgacggcg 660 gaggtagcga aaacctgtat tttcagggag gcggccgcta aggatcccgg accgcctctc 720 c 721 <210> SEQ ID NO 2 <211> LENGTH: 903 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-SF-H6-GGS-lcn2C-GGS-ENLYFQ-GG-BubbleProtein <400> SEQUENCE: 2 gactgagtcg cccgctcgag accatggaga cagacacact cctgctatgg gtactgctgc 60 tctgggttcc aggttccact ggtgactaca aggacgagca tcaccatcat caccatggtg 120 gaagccagga ctccacctca gacctgatcc cagccccacc tctgagcaag gtccctctgc 180 agcagaactt ccaggacaac caattccagg ggaagtggta tgtggtaggc ctggcaggga 240 atgcaattct cagagaagac aaagacccgc aaaagatgta tgccaccatc tatgagctga 300 aagaagacaa gagctacaat gtcacctccg tcctgtttag gaaaaagaag tgtgactact 360 ggatcaggac ttttgttcca ggttgccagc ccggcgagtt cacgctgggc aacattaaga 420 gttaccctgg attaacgagt tacctcgtcc gagtggtgag caccaactac aaccagcatg 480 ctatggtgtt cttcaagaaa gtttctcaaa acagggagta cttcaagatc accctctacg 540 ggagaaccaa ggagctgact tcggaactaa aggagaactt catccgcttc tccaaatctc 600 tgggcctccc tgaaaaccac atcgtcttcc ctgtcccaat cgaccagtgt atcgacggcg 660 gaggtagcga aaacctgtat tttcagggag gcgatacctg cggcagcggc tataatgtgg 720 atcagcgtcg taccaatagc ggctgcaaag cgggcaatgg cgatcgtcat ttttgcggct 780 gcgatcgtac cggcgtggtg gaatgcaaag gcggcaaatg gaccgaagtg caggattgcg 840 gcagcagcag ctgcaaaggc accagcaatg gcggcgcgac ctgctaatgc taaggatccc 900 gga 903 <210> SEQ ID NO 3 <211> LENGTH: 861 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-SF-H6-GGS-lcn2C-GGS-ENLYFQ-GG-BubbleProtein coding sequence <400> SEQUENCE: 3 atggagacag acacactcct gctatgggta ctgctgctct gggttccagg ttccactggt 60 gactacaagg acgagcatca ccatcatcac catggtggaa gccaggactc cacctcagac 120 ctgatcccag ccccacctct gagcaaggtc cctctgcagc agaacttcca ggacaaccaa 180 ttccagggga agtggtatgt ggtaggcctg gcagggaatg caattctcag agaagacaaa 240 gacccgcaaa agatgtatgc caccatctat gagctgaaag aagacaagag ctacaatgtc 300 acctccgtcc tgtttaggaa aaagaagtgt gactactgga tcaggacttt tgttccaggt 360 tgccagcccg gcgagttcac gctgggcaac attaagagtt accctggatt aacgagttac 420 ctcgtccgag tggtgagcac caactacaac cagcatgcta tggtgttctt caagaaagtt 480 tctcaaaaca gggagtactt caagatcacc ctctacggga gaaccaagga gctgacttcg 540 gaactaaagg agaacttcat ccgcttctcc aaatctctgg gcctccctga aaaccacatc 600 gtcttccctg tcccaatcga ccagtgtatc gacggcggag gtagcgaaaa cctgtatttt 660 cagggaggcg atacctgcgg cagcggctat aatgtggatc agcgtcgtac caatagcggc 720 tgcaaagcgg gcaatggcga tcgtcatttt tgcggctgcg atcgtaccgg cgtggtggaa 780 tgcaaaggcg gcaaatggac cgaagtgcag gattgcggca gcagcagctg caaaggcacc 840 agcaatggcg gcgcgacctg c 861 <210> SEQ ID NO 4 <211> LENGTH: 885 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-SF-H6-GGS-lcn2C-GGS-ENLYFQ-GG-Attractin <400> SEQUENCE: 4 gactgagtcg cccgctcgag accatggaga cagacacact cctgctatgg gtactgctgc 60 tctgggttcc aggttccact ggtgactaca aggacgagca tcaccatcat caccatggtg 120 gaagccagga ctccacctca gacctgatcc cagccccacc tctgagcaag gtccctctgc 180 agcagaactt ccaggacaac caattccagg ggaagtggta tgtggtaggc ctggcaggga 240 atgcaattct cagagaagac aaagacccgc aaaagatgta tgccaccatc tatgagctga 300 aagaagacaa gagctacaat gtcacctccg tcctgtttag gaaaaagaag tgtgactact 360 ggatcaggac ttttgttcca ggttgccagc ccggcgagtt cacgctgggc aacattaaga 420 gttaccctgg attaacgagt tacctcgtcc gagtggtgag caccaactac aaccagcatg 480 ctatggtgtt cttcaagaaa gtttctcaaa acagggagta cttcaagatc accctctacg 540 ggagaaccaa ggagctgact tcggaactaa aggagaactt catccgcttc tccaaatctc 600 tgggcctccc tgaaaaccac atcgtcttcc ctgtcccaat cgaccagtgt atcgacggcg 660 gaggtagcga aaacctgtat tttcagggag gcgatcagaa ttgcgatatt ggcaatatta 720 ccagccagtg ccagatgcag cataaaaatt gcgaagatgc gaatggctgc gataccatta 780 ttgaagaatg caaaaccagc atggtggaac gttgccagaa tcaggaattt gaaagcgcgg 840 cgggcagcac caccctgggc ccgcagtaat gctaaggatc ccgga 885 <210> SEQ ID NO 5 <211> LENGTH: 843 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-SF-H6-GGS-lcn2C-GGS-ENLYFQ-GG-Attractin coding sequence <400> SEQUENCE: 5 atggagacag acacactcct gctatgggta ctgctgctct gggttccagg ttccactggt 60 gactacaagg acgagcatca ccatcatcac catggtggaa gccaggactc cacctcagac 120 ctgatcccag ccccacctct gagcaaggtc cctctgcagc agaacttcca ggacaaccaa 180 ttccagggga agtggtatgt ggtaggcctg gcagggaatg caattctcag agaagacaaa 240 gacccgcaaa agatgtatgc caccatctat gagctgaaag aagacaagag ctacaatgtc 300 acctccgtcc tgtttaggaa aaagaagtgt gactactgga tcaggacttt tgttccaggt 360 tgccagcccg gcgagttcac gctgggcaac attaagagtt accctggatt aacgagttac 420 ctcgtccgag tggtgagcac caactacaac cagcatgcta tggtgttctt caagaaagtt 480 tctcaaaaca gggagtactt caagatcacc ctctacggga gaaccaagga gctgacttcg 540 gaactaaagg agaacttcat ccgcttctcc aaatctctgg gcctccctga aaaccacatc 600 gtcttccctg tcccaatcga ccagtgtatc gacggcggag gtagcgaaaa cctgtatttt 660 cagggaggcg atcagaattg cgatattggc aatattacca gccagtgcca gatgcagcat 720 aaaaattgcg aagatgcgaa tggctgcgat accattattg aagaatgcaa aaccagcatg 780 gtggaacgtt gccagaatca ggaatttgaa agcgcggcgg gcagcaccac cctgggcccg 840 cag 843 <210> SEQ ID NO 6 <211> LENGTH: 782 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-SF-H6-GGS-lcn2C-GGS-ENLYFQ-GG-Hefutoxin <400> SEQUENCE: 6 gactgagtcg cccgctcgag accatggaga cagacacact cctgctatgg gtactgctgc 60 tctgggttcc aggttccact ggtgactaca aggacgagca tcaccatcat caccatggtg 120 gaagccagga ctccacctca gacctgatcc cagccccacc tctgagcaag gtccctctgc 180 agcagaactt ccaggacaac caattccagg ggaagtggta tgtggtaggc ctggcaggga 240 atgcaattct cagagaagac aaagacccgc aaaagatgta tgccaccatc tatgagctga 300 aagaagacaa gagctacaat gtcacctccg tcctgtttag gaaaaagaag tgtgactact 360 ggatcaggac ttttgttcca ggttgccagc ccggcgagtt cacgctgggc aacattaaga 420 gttaccctgg attaacgagt tacctcgtcc gagtggtgag caccaactac aaccagcatg 480 ctatggtgtt cttcaagaaa gtttctcaaa acagggagta cttcaagatc accctctacg 540 ggagaaccaa ggagctgact tcggaactaa aggagaactt catccgcttc tccaaatctc 600 tgggcctccc tgaaaaccac atcgtcttcc ctgtcccaat cgaccagtgt atcgacggcg 660 gaggtagcga aaacctgtat tttcagggag gcggccatgc gtgctatcgt aattgctggc 720 gtgaaggcaa tgatgaagaa acctgcaaag aacgttgcta atgctaagga tcccggaccg 780 cc 782 <210> SEQ ID NO 7 <211> LENGTH: 735 <212> TYPE: DNA

<213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-SF-H6-GGS-lcn2C-GGS-ENLYFQ-GG-Hefutoxin coding sequence <400> SEQUENCE: 7 atggagacag acacactcct gctatgggta ctgctgctct gggttccagg ttccactggt 60 gactacaagg acgagcatca ccatcatcac catggtggaa gccaggactc cacctcagac 120 ctgatcccag ccccacctct gagcaaggtc cctctgcagc agaacttcca ggacaaccaa 180 ttccagggga agtggtatgt ggtaggcctg gcagggaatg caattctcag agaagacaaa 240 gacccgcaaa agatgtatgc caccatctat gagctgaaag aagacaagag ctacaatgtc 300 acctccgtcc tgtttaggaa aaagaagtgt gactactgga tcaggacttt tgttccaggt 360 tgccagcccg gcgagttcac gctgggcaac attaagagtt accctggatt aacgagttac 420 ctcgtccgag tggtgagcac caactacaac cagcatgcta tggtgttctt caagaaagtt 480 tctcaaaaca gggagtactt caagatcacc ctctacggga gaaccaagga gctgacttcg 540 gaactaaagg agaacttcat ccgcttctcc aaatctctgg gcctccctga aaaccacatc 600 gtcttccctg tcccaatcga ccagtgtatc gacggcggag gtagcgaaaa cctgtatttt 660 cagggaggcg gccatgcgtg ctatcgtaat tgctggcgtg aaggcaatga tgaagaaacc 720 tgcaaagaac gttgc 735 <210> SEQ ID NO 8 <211> LENGTH: 816 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-SF-H6-GGS-lcn2C-GGS-ENLYFQ-GG-Hanatoxin <400> SEQUENCE: 8 gactgagtcg cccgctcgag accatggaga cagacacact cctgctatgg gtactgctgc 60 tctgggttcc aggttccact ggtgactaca aggacgagca tcaccatcat caccatggtg 120 gaagccagga ctccacctca gacctgatcc cagccccacc tctgagcaag gtccctctgc 180 agcagaactt ccaggacaac caattccagg ggaagtggta tgtggtaggc ctggcaggga 240 atgcaattct cagagaagac aaagacccgc aaaagatgta tgccaccatc tatgagctga 300 aagaagacaa gagctacaat gtcacctccg tcctgtttag gaaaaagaag tgtgactact 360 ggatcaggac ttttgttcca ggttgccagc ccggcgagtt cacgctgggc aacattaaga 420 gttaccctgg attaacgagt tacctcgtcc gagtggtgag caccaactac aaccagcatg 480 ctatggtgtt cttcaagaaa gtttctcaaa acagggagta cttcaagatc accctctacg 540 ggagaaccaa ggagctgact tcggaactaa aggagaactt catccgcttc tccaaatctc 600 tgggcctccc tgaaaaccac atcgtcttcc ctgtcccaat cgaccagtgt atcgacggcg 660 gaggtagcga aaacctgtat tttcagggag gcgaatgccg ttatctgttt ggcggctgca 720 aaaccaccag cgattgctgc aaacatctgg gctgcaaatt tcgtgataaa tattgcgcgt 780 gggattttac ctttagctaa tgctaaggat cccgga 816 <210> SEQ ID NO 9 <211> LENGTH: 774 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-SF-H6-GGS-lcn2C-GGS-ENLYFQ-GG-Hanatoxin coding sequence <400> SEQUENCE: 9 atggagacag acacactcct gctatgggta ctgctgctct gggttccagg ttccactggt 60 gactacaagg acgagcatca ccatcatcac catggtggaa gccaggactc cacctcagac 120 ctgatcccag ccccacctct gagcaaggtc cctctgcagc agaacttcca ggacaaccaa 180 ttccagggga agtggtatgt ggtaggcctg gcagggaatg caattctcag agaagacaaa 240 gacccgcaaa agatgtatgc caccatctat gagctgaaag aagacaagag ctacaatgtc 300 acctccgtcc tgtttaggaa aaagaagtgt gactactgga tcaggacttt tgttccaggt 360 tgccagcccg gcgagttcac gctgggcaac attaagagtt accctggatt aacgagttac 420 ctcgtccgag tggtgagcac caactacaac cagcatgcta tggtgttctt caagaaagtt 480 tctcaaaaca gggagtactt caagatcacc ctctacggga gaaccaagga gctgacttcg 540 gaactaaagg agaacttcat ccgcttctcc aaatctctgg gcctccctga aaaccacatc 600 gtcttccctg tcccaatcga ccagtgtatc gacggcggag gtagcgaaaa cctgtatttt 660 cagggaggcg aatgccgtta tctgtttggc ggctgcaaaa ccaccagcga ttgctgcaaa 720 catctgggct gcaaatttcg tgataaatat tgcgcgtggg attttacctt tagc 774 <210> SEQ ID NO 10 <211> LENGTH: 819 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-SF-H6-GGS-lcn2C-GGS-ENLYFQ-GG-Chymotrypsin Inhibitor <400> SEQUENCE: 10 gactgagtcg cccgctcgag accatggaga cagacacact cctgctatgg gtactgctgc 60 tctgggttcc aggttccact ggtgactaca aggacgagca tcaccatcat caccatggtg 120 gaagccagga ctccacctca gacctgatcc cagccccacc tctgagcaag gtccctctgc 180 agcagaactt ccaggacaac caattccagg ggaagtggta tgtggtaggc ctggcaggga 240 atgcaattct cagagaagac aaagacccgc aaaagatgta tgccaccatc tatgagctga 300 aagaagacaa gagctacaat gtcacctccg tcctgtttag gaaaaagaag tgtgactact 360 ggatcaggac ttttgttcca ggttgccagc ccggcgagtt cacgctgggc aacattaaga 420 gttaccctgg attaacgagt tacctcgtcc gagtggtgag caccaactac aaccagcatg 480 ctatggtgtt cttcaagaaa gtttctcaaa acagggagta cttcaagatc accctctacg 540 ggagaaccaa ggagctgact tcggaactaa aggagaactt catccgcttc tccaaatctc 600 tgggcctccc tgaaaaccac atcgtcttcc ctgtcccaat cgaccagtgt atcgacggcg 660 gaggtagcga aaacctgtat tttcagggag gcgaaattag ctgcgaaccg ggcaaaacct 720 ttaaagataa atgcaatacc tgccgttgcg gcgcggatgg caaaagcgcg gcgtgcaccc 780 tgaaagcgtg cccgaatcag taatgctaag gatcccgga 819 <210> SEQ ID NO 11 <211> LENGTH: 777 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-SF-H6-GGS-lcn2C-GGS-ENLYFQ-GG-Chymotrypsin Inhibitor coding sequence <400> SEQUENCE: 11 atggagacag acacactcct gctatgggta ctgctgctct gggttccagg ttccactggt 60 gactacaagg acgagcatca ccatcatcac catggtggaa gccaggactc cacctcagac 120 ctgatcccag ccccacctct gagcaaggtc cctctgcagc agaacttcca ggacaaccaa 180 ttccagggga agtggtatgt ggtaggcctg gcagggaatg caattctcag agaagacaaa 240 gacccgcaaa agatgtatgc caccatctat gagctgaaag aagacaagag ctacaatgtc 300 acctccgtcc tgtttaggaa aaagaagtgt gactactgga tcaggacttt tgttccaggt 360 tgccagcccg gcgagttcac gctgggcaac attaagagtt accctggatt aacgagttac 420 ctcgtccgag tggtgagcac caactacaac cagcatgcta tggtgttctt caagaaagtt 480 tctcaaaaca gggagtactt caagatcacc ctctacggga gaaccaagga gctgacttcg 540 gaactaaagg agaacttcat ccgcttctcc aaatctctgg gcctccctga aaaccacatc 600 gtcttccctg tcccaatcga ccagtgtatc gacggcggag gtagcgaaaa cctgtatttt 660 cagggaggcg aaattagctg cgaaccgggc aaaaccttta aagataaatg caatacctgc 720 cgttgcggcg cggatggcaa aagcgcggcg tgcaccctga aagcgtgccc gaatcag 777 <210> SEQ ID NO 12 <211> LENGTH: 822 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-SF-H6-GGS-lcn2C-GGS-ENLYFQ-GG-ToxinK <400> SEQUENCE: 12 gactgagtcg cccgctcgag accatggaga cagacacact cctgctatgg gtactgctgc 60 tctgggttcc aggttccact ggtgactaca aggacgagca tcaccatcat caccatggtg 120 gaagccagga ctccacctca gacctgatcc cagccccacc tctgagcaag gtccctctgc 180 agcagaactt ccaggacaac caattccagg ggaagtggta tgtggtaggc ctggcaggga 240 atgcaattct cagagaagac aaagacccgc aaaagatgta tgccaccatc tatgagctga 300 aagaagacaa gagctacaat gtcacctccg tcctgtttag gaaaaagaag tgtgactact 360 ggatcaggac ttttgttcca ggttgccagc ccggcgagtt cacgctgggc aacattaaga 420 gttaccctgg attaacgagt tacctcgtcc gagtggtgag caccaactac aaccagcatg 480 ctatggtgtt cttcaagaaa gtttctcaaa acagggagta cttcaagatc accctctacg 540 ggagaaccaa ggagctgact tcggaactaa aggagaactt catccgcttc tccaaatctc 600 tgggcctccc tgaaaaccac atcgtcttcc ctgtcccaat cgaccagtgt atcgacggcg 660 gaggtagcga aaacctgtat tttcagggag gcgtgtgccg tgattggttt aaagaaaccg 720 cgtgccgtca tgcgaaaagc ctgggcaatt gccgtaccag ccagaaatat cgtgcgaatt 780 gcgcgaaaac ctgcgaactg tgctaatgct aaggatcccg ga 822 <210> SEQ ID NO 13 <211> LENGTH: 780 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-SF-H6-GGS-lcn2C-GGS-ENLYFQ-GG-ToxinK coding sequence <400> SEQUENCE: 13 atggagacag acacactcct gctatgggta ctgctgctct gggttccagg ttccactggt 60 gactacaagg acgagcatca ccatcatcac catggtggaa gccaggactc cacctcagac 120 ctgatcccag ccccacctct gagcaaggtc cctctgcagc agaacttcca ggacaaccaa 180 ttccagggga agtggtatgt ggtaggcctg gcagggaatg caattctcag agaagacaaa 240 gacccgcaaa agatgtatgc caccatctat gagctgaaag aagacaagag ctacaatgtc 300 acctccgtcc tgtttaggaa aaagaagtgt gactactgga tcaggacttt tgttccaggt 360 tgccagcccg gcgagttcac gctgggcaac attaagagtt accctggatt aacgagttac 420 ctcgtccgag tggtgagcac caactacaac cagcatgcta tggtgttctt caagaaagtt 480

tctcaaaaca gggagtactt caagatcacc ctctacggga gaaccaagga gctgacttcg 540 gaactaaagg agaacttcat ccgcttctcc aaatctctgg gcctccctga aaaccacatc 600 gtcttccctg tcccaatcga ccagtgtatc gacggcggag gtagcgaaaa cctgtatttt 660 cagggaggcg tgtgccgtga ttggtttaaa gaaaccgcgt gccgtcatgc gaaaagcctg 720 ggcaattgcc gtaccagcca gaaatatcgt gcgaattgcg cgaaaacctg cgaactgtgc 780 <210> SEQ ID NO 14 <211> LENGTH: 849 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-SF-H6-GGS-lcn2C-GGS-ENLYFQ-GG-EGFepiregulin Core <400> SEQUENCE: 14 gactgagtcg cccgctcgag accatggaga cagacacact cctgctatgg gtactgctgc 60 tctgggttcc aggttccact ggtgactaca aggacgagca tcaccatcat caccatggtg 120 gaagccagga ctccacctca gacctgatcc cagccccacc tctgagcaag gtccctctgc 180 agcagaactt ccaggacaac caattccagg ggaagtggta tgtggtaggc ctggcaggga 240 atgcaattct cagagaagac aaagacccgc aaaagatgta tgccaccatc tatgagctga 300 aagaagacaa gagctacaat gtcacctccg tcctgtttag gaaaaagaag tgtgactact 360 ggatcaggac ttttgttcca ggttgccagc ccggcgagtt cacgctgggc aacattaaga 420 gttaccctgg attaacgagt tacctcgtcc gagtggtgag caccaactac aaccagcatg 480 ctatggtgtt cttcaagaaa gtttctcaaa acagggagta cttcaagatc accctctacg 540 ggagaaccaa ggagctgact tcggaactaa aggagaactt catccgcttc tccaaatctc 600 tgggcctccc tgaaaaccac atcgtcttcc ctgtcccaat cgaccagtgt atcgacggcg 660 gaggtagcga aaacctgtat tttcagggag gcgtgagcat taccaaatgc agcagcgata 720 tgaatggcta ttgcctgcat ggccagtgca tttatctggt ggatatgagc cagaattatt 780 gccgttgcga agtgggctat accggcgtgc gttgcgaaca tttttttctg taatgctaag 840 gatcccgga 849 <210> SEQ ID NO 15 <211> LENGTH: 807 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-SF-H6-GGS-lcn2C-GGS-ENLYFQ-GG-EGFepiregulin Core coding sequence <400> SEQUENCE: 15 atggagacag acacactcct gctatgggta ctgctgctct gggttccagg ttccactggt 60 gactacaagg acgagcatca ccatcatcac catggtggaa gccaggactc cacctcagac 120 ctgatcccag ccccacctct gagcaaggtc cctctgcagc agaacttcca ggacaaccaa 180 ttccagggga agtggtatgt ggtaggcctg gcagggaatg caattctcag agaagacaaa 240 gacccgcaaa agatgtatgc caccatctat gagctgaaag aagacaagag ctacaatgtc 300 acctccgtcc tgtttaggaa aaagaagtgt gactactgga tcaggacttt tgttccaggt 360 tgccagcccg gcgagttcac gctgggcaac attaagagtt accctggatt aacgagttac 420 ctcgtccgag tggtgagcac caactacaac cagcatgcta tggtgttctt caagaaagtt 480 tctcaaaaca gggagtactt caagatcacc ctctacggga gaaccaagga gctgacttcg 540 gaactaaagg agaacttcat ccgcttctcc aaatctctgg gcctccctga aaaccacatc 600 gtcttccctg tcccaatcga ccagtgtatc gacggcggag gtagcgaaaa cctgtatttt 660 cagggaggcg tgagcattac caaatgcagc agcgatatga atggctattg cctgcatggc 720 cagtgcattt atctggtgga tatgagccag aattattgcc gttgcgaagt gggctatacc 780 ggcgtgcgtt gcgaacattt ttttctg 807 <210> SEQ ID NO 16 <211> LENGTH: 801 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-SF-H6-GGS-lcn2C-GGS-ENLYFQ-GG-Circulin <400> SEQUENCE: 16 gactgagtcg cccgctcgag accatggaga cagacacact cctgctatgg gtactgctgc 60 tctgggttcc aggttccact ggtgactaca aggacgagca tcaccatcat caccatggtg 120 gaagccagga ctccacctca gacctgatcc cagccccacc tctgagcaag gtccctctgc 180 agcagaactt ccaggacaac caattccagg ggaagtggta tgtggtaggc ctggcaggga 240 atgcaattct cagagaagac aaagacccgc aaaagatgta tgccaccatc tatgagctga 300 aagaagacaa gagctacaat gtcacctccg tcctgtttag gaaaaagaag tgtgactact 360 ggatcaggac ttttgttcca ggttgccagc ccggcgagtt cacgctgggc aacattaaga 420 gttaccctgg attaacgagt tacctcgtcc gagtggtgag caccaactac aaccagcatg 480 ctatggtgtt cttcaagaaa gtttctcaaa acagggagta cttcaagatc accctctacg 540 ggagaaccaa ggagctgact tcggaactaa aggagaactt catccgcttc tccaaatctc 600 tgggcctccc tgaaaaccac atcgtcttcc ctgtcccaat cgaccagtgt atcgacggcg 660 gaggtagcga aaacctgtat tttcagggag gcggcattcc gtgcggcgaa agctgcgtgt 720 ggattccgtg cattagcgcg gcgctgggct gcagctgcaa aaataaagtg tgctatcgta 780 attaatgcta aggatcccgg a 801 <210> SEQ ID NO 17 <211> LENGTH: 759 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-SF-H6-GGS-lcn2C-GGS-ENLYFQ-GG-Circulin coding sequence <400> SEQUENCE: 17 atggagacag acacactcct gctatgggta ctgctgctct gggttccagg ttccactggt 60 gactacaagg acgagcatca ccatcatcac catggtggaa gccaggactc cacctcagac 120 ctgatcccag ccccacctct gagcaaggtc cctctgcagc agaacttcca ggacaaccaa 180 ttccagggga agtggtatgt ggtaggcctg gcagggaatg caattctcag agaagacaaa 240 gacccgcaaa agatgtatgc caccatctat gagctgaaag aagacaagag ctacaatgtc 300 acctccgtcc tgtttaggaa aaagaagtgt gactactgga tcaggacttt tgttccaggt 360 tgccagcccg gcgagttcac gctgggcaac attaagagtt accctggatt aacgagttac 420 ctcgtccgag tggtgagcac caactacaac cagcatgcta tggtgttctt caagaaagtt 480 tctcaaaaca gggagtactt caagatcacc ctctacggga gaaccaagga gctgacttcg 540 gaactaaagg agaacttcat ccgcttctcc aaatctctgg gcctccctga aaaccacatc 600 gtcttccctg tcccaatcga ccagtgtatc gacggcggag gtagcgaaaa cctgtatttt 660 cagggaggcg gcattccgtg cggcgaaagc tgcgtgtgga ttccgtgcat tagcgcggcg 720 ctgggctgca gctgcaaaaa taaagtgtgc tatcgtaat 759 <210> SEQ ID NO 18 <211> LENGTH: 873 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-SF-H6-GGS-lcn2C-GGS-ENLYFQ-GG-Brazzein <400> SEQUENCE: 18 gactgagtcg cccgctcgag accatggaga cagacacact cctgctatgg gtactgctgc 60 tctgggttcc aggttccact ggtgactaca aggacgagca tcaccatcat caccatggtg 120 gaagccagga ctccacctca gacctgatcc cagccccacc tctgagcaag gtccctctgc 180 agcagaactt ccaggacaac caattccagg ggaagtggta tgtggtaggc ctggcaggga 240 atgcaattct cagagaagac aaagacccgc aaaagatgta tgccaccatc tatgagctga 300 aagaagacaa gagctacaat gtcacctccg tcctgtttag gaaaaagaag tgtgactact 360 ggatcaggac ttttgttcca ggttgccagc ccggcgagtt cacgctgggc aacattaaga 420 gttaccctgg attaacgagt tacctcgtcc gagtggtgag caccaactac aaccagcatg 480 ctatggtgtt cttcaagaaa gtttctcaaa acagggagta cttcaagatc accctctacg 540 ggagaaccaa ggagctgact tcggaactaa aggagaactt catccgcttc tccaaatctc 600 tgggcctccc tgaaaaccac atcgtcttcc ctgtcccaat cgaccagtgt atcgacggcg 660 gaggtagcga aaacctgtat tttcagggag gccaggataa atgcaaaaaa gtgtatgaaa 720 attatccggt gagcaaatgc cagctggcga atcagtgcaa ttatgattgc aaactggata 780 aacatgcgcg tagcggcgaa tgcttttatg atgaaaaacg taatctgcag tgcatttgcg 840 attattgcga atattaatgc taaggatccc gga 873 <210> SEQ ID NO 19 <211> LENGTH: 831 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-SF-H6-GGS-lcn2C-GGS-ENLYFQ-GG-Brazzein coding sequence <400> SEQUENCE: 19 atggagacag acacactcct gctatgggta ctgctgctct gggttccagg ttccactggt 60 gactacaagg acgagcatca ccatcatcac catggtggaa gccaggactc cacctcagac 120 ctgatcccag ccccacctct gagcaaggtc cctctgcagc agaacttcca ggacaaccaa 180 ttccagggga agtggtatgt ggtaggcctg gcagggaatg caattctcag agaagacaaa 240 gacccgcaaa agatgtatgc caccatctat gagctgaaag aagacaagag ctacaatgtc 300 acctccgtcc tgtttaggaa aaagaagtgt gactactgga tcaggacttt tgttccaggt 360 tgccagcccg gcgagttcac gctgggcaac attaagagtt accctggatt aacgagttac 420 ctcgtccgag tggtgagcac caactacaac cagcatgcta tggtgttctt caagaaagtt 480 tctcaaaaca gggagtactt caagatcacc ctctacggga gaaccaagga gctgacttcg 540 gaactaaagg agaacttcat ccgcttctcc aaatctctgg gcctccctga aaaccacatc 600 gtcttccctg tcccaatcga ccagtgtatc gacggcggag gtagcgaaaa cctgtatttt 660 cagggaggcc aggataaatg caaaaaagtg tatgaaaatt atccggtgag caaatgccag 720 ctggcgaatc agtgcaatta tgattgcaaa ctggataaac atgcgcgtag cggcgaatgc 780 ttttatgatg aaaaacgtaa tctgcagtgc atttgcgatt attgcgaata t 831 <210> SEQ ID NO 20 <211> LENGTH: 777 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE:

<223> OTHER INFORMATION: IgK-SF-H6-GGS-lcn2C-GGS-ENLYFQ-GG-chlorotoxin coding sequence <400> SEQUENCE: 20 atggagacag acacactcct gctatgggta ctgctgctct gggttccagg ttccactggt 60 gactacaagg acgagcatca ccatcatcac catggtggaa gccaggactc cacctcagac 120 ctgatcccag ccccacctct gagcaaggtc cctctgcagc agaacttcca ggacaaccaa 180 ttccagggga agtggtatgt ggtaggcctg gcagggaatg caattctcag agaagacaaa 240 gacccgcaaa agatgtatgc caccatctat gagctgaaag aagacaagag ctacaatgtc 300 acctccgtcc tgtttaggaa aaagaagtgt gactactgga tcaggacttt tgttccaggt 360 tgccagcccg gcgagttcac gctgggcaac attaagagtt accctggatt aacgagttac 420 ctcgtccgag tggtgagcac caactacaac cagcatgcta tggtgttctt caagaaagtt 480 tctcaaaaca gggagtactt caagatcacc ctctacggga gaaccaagga gctgacttcg 540 gaactaaagg agaacttcat ccgcttctcc aaatctctgg gcctccctga aaaccacatc 600 gtcttccctg tcccaatcga ccagtgtatc gacggcggag gtagcgaaaa cctgtatttt 660 cagggaggca tgtgcatgcc gtgctttacc accgatcatc agatggcgcg taaatgcgat 720 gattgctgcg gcggcaaagg ccgtggcaaa tgctatggcc cgcagtgcct gtgccgt 777 <210> SEQ ID NO 21 <211> LENGTH: 734 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-SF-H6-GGS-lcn2C-GGS-ENLYFQ-GS-PARENTAL <400> SEQUENCE: 21 gactgagtcg cccgctcgag accatggaga cagacacact cctgctatgg gtactgctgc 60 tctgggttcc aggttccact ggtgactaca aggacgagca tcaccatcat caccatggtg 120 gaagccagga ctccacctca gacctgatcc cagccccacc tctgagcaag gtccctctgc 180 agcagaactt ccaggacaac caattccagg ggaagtggta tgtggtaggc ctggcaggga 240 atgcaattct cagagaagac aaagacccgc aaaagatgta tgccaccatc tatgagctga 300 aagaagacaa gagctacaat gtcacctccg tcctgtttag gaaaaagaag tgtgactact 360 ggatcaggac ttttgttcca ggttgccagc ccggcgagtt cacgctgggc aacattaaga 420 gttaccctgg attaacgagt tacctcgtcc gagtggtgag caccaactac aaccagcatg 480 ctatggtgtt cttcaagaaa gtttctcaaa acagggagta cttcaagatc accctctacg 540 ggagaaccaa ggagctgact tcggaactaa aggagaactt catccgcttc tccaaatctc 600 tgggcctccc tgaaaaccac atcgtcttcc ctgtcccaat cgaccagtgt atcgacggcg 660 gaggtagcga aaacctgtat tttcagggat cctaatgttg gccatgatgt taggcggccg 720 ctaaggatcc cgga 734 <210> SEQ ID NO 22 <211> LENGTH: 734 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-SF-H6-GGS-lcn2C-GGS-furin-GS-PARENTAL <400> SEQUENCE: 22 gactgagtcg cccgctcgag accatggaga cagacacact cctgctatgg gtactgctgc 60 tctgggttcc aggttccact ggtgactaca aggacgagca tcaccatcat caccatggtg 120 gaagccagga ctccacctca gacctgatcc cagccccacc tctgagcaag gtccctctgc 180 agcagaactt ccaggacaac caattccagg ggaagtggta tgtggtaggc ctggcaggga 240 atgcaattct cagagaagac aaagacccgc aaaagatgta tgccaccatc tatgagctga 300 aagaagacaa gagctacaat gtcacctccg tcctgtttag gaaaaagaag tgtgactact 360 ggatcaggac ttttgttcca ggttgccagc ccggcgagtt cacgctgggc aacattaaga 420 gttaccctgg attaacgagt tacctcgtcc gagtggtgag caccaactac aaccagcatg 480 ctatggtgtt cttcaagaaa gtttctcaaa acagggagta cttcaagatc accctctacg 540 ggagaaccaa ggagctgact tcggaactaa aggagaactt catccgcttc tccaaatctc 600 tgggcctccc tgaaaaccac atcgtcttcc ctgtcccaat cgaccagtgt atcgacggcg 660 gaggtagccg cgcgcgctat aaacgcggat cctaatgttg gccatgatgt taggcggccg 720 ctaaggatcc cgga 734 <210> SEQ ID NO 23 <211> LENGTH: 848 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-SF-H6-GGS-lcn2C-GGS-ENLYFQ-GS-MIDKINE <400> SEQUENCE: 23 gactgagtcg cccgctcgag accatggaga cagacacact cctgctatgg gtactgctgc 60 tctgggttcc aggttccact ggtgactaca aggacgagca tcaccatcat caccatggtg 120 gaagccagga ctccacctca gacctgatcc cagccccacc tctgagcaag gtccctctgc 180 agcagaactt ccaggacaac caattccagg ggaagtggta tgtggtaggc ctggcaggga 240 atgcaattct cagagaagac aaagacccgc aaaagatgta tgccaccatc tatgagctga 300 aagaagacaa gagctacaat gtcacctccg tcctgtttag gaaaaagaag tgtgactact 360 ggatcaggac ttttgttcca ggttgccagc ccggcgagtt cacgctgggc aacattaaga 420 gttaccctgg attaacgagt tacctcgtcc gagtggtgag caccaactac aaccagcatg 480 ctatggtgtt cttcaagaaa gtttctcaaa acagggagta cttcaagatc accctctacg 540 ggagaaccaa ggagctgact tcggaactaa aggagaactt catccgcttc tccaaatctc 600 tgggcctccc tgaaaaccac atcgtcttcc ctgtcccaat cgaccagtgt atcgacggcg 660 gaggtagcga aaacctgtat tttcagagcg attgcaaata taaatttgaa aactggggcg 720 cgtgcgatgg cggcaccggc accaaagtgc gccagggcac cctgaaaaaa gcgcgctata 780 acgcgcagtg ccaggaaacc attcgcgtga ccaaaccgtg ctaatgctgg atcccggacc 840 gcctctcc 848 <210> SEQ ID NO 24 <211> LENGTH: 798 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-SF-H6-GGS-lcn2C-GGS-ENLYFQ-GS-MIDKINE coding sequence <400> SEQUENCE: 24 atggagacag acacactcct gctatgggta ctgctgctct gggttccagg ttccactggt 60 gactacaagg acgagcatca ccatcatcac catggtggaa gccaggactc cacctcagac 120 ctgatcccag ccccacctct gagcaaggtc cctctgcagc agaacttcca ggacaaccaa 180 ttccagggga agtggtatgt ggtaggcctg gcagggaatg caattctcag agaagacaaa 240 gacccgcaaa agatgtatgc caccatctat gagctgaaag aagacaagag ctacaatgtc 300 acctccgtcc tgtttaggaa aaagaagtgt gactactgga tcaggacttt tgttccaggt 360 tgccagcccg gcgagttcac gctgggcaac attaagagtt accctggatt aacgagttac 420 ctcgtccgag tggtgagcac caactacaac cagcatgcta tggtgttctt caagaaagtt 480 tctcaaaaca gggagtactt caagatcacc ctctacggga gaaccaagga gctgacttcg 540 gaactaaagg agaacttcat ccgcttctcc aaatctctgg gcctccctga aaaccacatc 600 gtcttccctg tcccaatcga ccagtgtatc gacggcggag gtagcgaaaa cctgtatttt 660 cagagcgatt gcaaatataa atttgaaaac tggggcgcgt gcgatggcgg caccggcacc 720 aaagtgcgcc agggcaccct gaaaaaagcg cgctataacg cgcagtgcca ggaaaccatt 780 cgcgtgacca aaccgtgc 798 <210> SEQ ID NO 25 <211> LENGTH: 796 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-SF-H6-GGS-lcn2C-GGS-ENLYFQ-GG-Violacin A <400> SEQUENCE: 25 gactgagtcg cccgctcgag accatggaga cagacacact cctgctatgg gtactgctgc 60 tctgggttcc aggttccact ggtgactaca aggacgagca tcaccatcat caccatggtg 120 gaagccagga ctccacctca gacctgatcc cagccccacc tctgagcaag gtccctctgc 180 agcagaactt ccaggacaac caattccagg ggaagtggta tgtggtaggc ctggcaggga 240 atgcaattct cagagaagac aaagacccgc aaaagatgta tgccaccatc tatgagctga 300 aagaagacaa gagctacaat gtcacctccg tcctgtttag gaaaaagaag tgtgactact 360 ggatcaggac ttttgttcca ggttgccagc ccggcgagtt cacgctgggc aacattaaga 420 gttaccctgg attaacgagt tacctcgtcc gagtggtgag caccaactac aaccagcatg 480 ctatggtgtt cttcaagaaa gtttctcaaa acagggagta cttcaagatc accctctacg 540 ggagaaccaa ggagctgact tcggaactaa aggagaactt catccgcttc tccaaatctc 600 tgggcctccc tgaaaaccac atcgtcttcc ctgtcccaat cgaccagtgt atcgacggcg 660 gaggtagcga aaacctgtat tttcagggag gcagcgccat cagctgcggc gagacctgct 720 tcaagttcaa gtgctacacc cccagatgca gctgcagcta ccccgtgtgc aagtaagcta 780 aggatcccgg accgcc 796 <210> SEQ ID NO 26 <211> LENGTH: 750 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-SF-H6-GGS-lcn2C-GGS-ENLYFQ-GG-Violacin A coding sequence <400> SEQUENCE: 26 atggagacag acacactcct gctatgggta ctgctgctct gggttccagg ttccactggt 60 gactacaagg acgagcatca ccatcatcac catggtggaa gccaggactc cacctcagac 120 ctgatcccag ccccacctct gagcaaggtc cctctgcagc agaacttcca ggacaaccaa 180 ttccagggga agtggtatgt ggtaggcctg gcagggaatg caattctcag agaagacaaa 240 gacccgcaaa agatgtatgc caccatctat gagctgaaag aagacaagag ctacaatgtc 300 acctccgtcc tgtttaggaa aaagaagtgt gactactgga tcaggacttt tgttccaggt 360 tgccagcccg gcgagttcac gctgggcaac attaagagtt accctggatt aacgagttac 420 ctcgtccgag tggtgagcac caactacaac cagcatgcta tggtgttctt caagaaagtt 480 tctcaaaaca gggagtactt caagatcacc ctctacggga gaaccaagga gctgacttcg 540 gaactaaagg agaacttcat ccgcttctcc aaatctctgg gcctccctga aaaccacatc 600

gtcttccctg tcccaatcga ccagtgtatc gacggcggag gtagcgaaaa cctgtatttt 660 cagggaggca gcgccatcag ctgcggcgag acctgcttca agttcaagtg ctacaccccc 720 agatgcagct gcagctaccc cgtgtgcaag 750 <210> SEQ ID NO 27 <211> LENGTH: 745 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-SF-H6-GGS-lcn2C-GGS-ENLYFQ-GG-Lambda Toxin <400> SEQUENCE: 27 gactgagtcg cccgctcgag accatggaga cagacacact cctgctatgg gtactgctgc 60 tctgggttcc aggttccact ggtgactaca aggacgagca tcaccatcat caccatggtg 120 gaagccagga ctccacctca gacctgatcc cagccccacc tctgagcaag gtccctctgc 180 agcagaactt ccaggacaac caattccagg ggaagtggta tgtggtaggc ctggcaggga 240 atgcaattct cagagaagac aaagacccgc aaaagatgta tgccaccatc tatgagctga 300 aagaagacaa gagctacaat gtcacctccg tcctgtttag gaaaaagaag tgtgactact 360 ggatcaggac ttttgttcca ggttgccagc ccggcgagtt cacgctgggc aacattaaga 420 gttaccctgg attaacgagt tacctcgtcc gagtggtgag caccaactac aaccagcatg 480 ctatggtgtt cttcaagaaa gtttctcaaa acagggagta cttcaagatc accctctacg 540 ggagaaccaa ggagctgact tcggaactaa aggagaactt catccgcttc tccaaatctc 600 tgggcctccc tgaaaaccac atcgtcttcc ctgtcccaat cgaccagtgt atcgacggcg 660 gaggtagcga aaacctgtat tttcagggag gcgtgtgctg cggctacaag ctgtgccacc 720 cctgctaagc taaggatccc ggacc 745 <210> SEQ ID NO 28 <211> LENGTH: 702 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-SF-H6-GGS-lcn2C-GGS-ENLYFQ-GG-Lambda Toxin coding sequence <400> SEQUENCE: 28 atggagacag acacactcct gctatgggta ctgctgctct gggttccagg ttccactggt 60 gactacaagg acgagcatca ccatcatcac catggtggaa gccaggactc cacctcagac 120 ctgatcccag ccccacctct gagcaaggtc cctctgcagc agaacttcca ggacaaccaa 180 ttccagggga agtggtatgt ggtaggcctg gcagggaatg caattctcag agaagacaaa 240 gacccgcaaa agatgtatgc caccatctat gagctgaaag aagacaagag ctacaatgtc 300 acctccgtcc tgtttaggaa aaagaagtgt gactactgga tcaggacttt tgttccaggt 360 tgccagcccg gcgagttcac gctgggcaac attaagagtt accctggatt aacgagttac 420 ctcgtccgag tggtgagcac caactacaac cagcatgcta tggtgttctt caagaaagtt 480 tctcaaaaca gggagtactt caagatcacc ctctacggga gaaccaagga gctgacttcg 540 gaactaaagg agaacttcat ccgcttctcc aaatctctgg gcctccctga aaaccacatc 600 gtcttccctg tcccaatcga ccagtgtatc gacggcggag gtagcgaaaa cctgtatttt 660 cagggaggcg tgtgctgcgg ctacaagctg tgccacccct gc 702 <210> SEQ ID NO 29 <211> LENGTH: 751 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-SF-H6-GGS-lcn2C-GGS-ENLYFQ-GG-Lambda Toxin NG <400> SEQUENCE: 29 gactgagtcg cccgctcgag accatggaga cagacacact cctgctatgg gtactgctgc 60 tctgggttcc aggttccact ggtgactaca aggacgagca tcaccatcat caccatggtg 120 gaagccagga ctccacctca gacctgatcc cagccccacc tctgagcaag gtccctctgc 180 agcagaactt ccaggacaac caattccagg ggaagtggta tgtggtaggc ctggcaggga 240 atgcaattct cagagaagac aaagacccgc aaaagatgta tgccaccatc tatgagctga 300 aagaagacaa gagctacaat gtcacctccg tcctgtttag gaaaaagaag tgtgactact 360 ggatcaggac ttttgttcca ggttgccagc ccggcgagtt cacgctgggc aacattaaga 420 gttaccctgg attaacgagt tacctcgtcc gagtggtgag caccaactac aaccagcatg 480 ctatggtgtt cttcaagaaa gtttctcaaa acagggagta cttcaagatc accctctacg 540 ggagaaccaa ggagctgact tcggaactaa aggagaactt catccgcttc tccaaatctc 600 tgggcctccc tgaaaaccac atcgtcttcc ctgtcccaat cgaccagtgt atcgacggcg 660 gaggtagcga aaacctgtat tttcagggag gcaacggcgt gtgctgcggc tacaagctgt 720 gccacccctg ctaagctaag gatcccggac c 751 <210> SEQ ID NO 30 <211> LENGTH: 708 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-SF-H6-GGS-lcn2C-GGS-ENLYFQ-GG-Lambda Toxin NG coding sequence <400> SEQUENCE: 30 atggagacag acacactcct gctatgggta ctgctgctct gggttccagg ttccactggt 60 gactacaagg acgagcatca ccatcatcac catggtggaa gccaggactc cacctcagac 120 ctgatcccag ccccacctct gagcaaggtc cctctgcagc agaacttcca ggacaaccaa 180 ttccagggga agtggtatgt ggtaggcctg gcagggaatg caattctcag agaagacaaa 240 gacccgcaaa agatgtatgc caccatctat gagctgaaag aagacaagag ctacaatgtc 300 acctccgtcc tgtttaggaa aaagaagtgt gactactgga tcaggacttt tgttccaggt 360 tgccagcccg gcgagttcac gctgggcaac attaagagtt accctggatt aacgagttac 420 ctcgtccgag tggtgagcac caactacaac cagcatgcta tggtgttctt caagaaagtt 480 tctcaaaaca gggagtactt caagatcacc ctctacggga gaaccaagga gctgacttcg 540 gaactaaagg agaacttcat ccgcttctcc aaatctctgg gcctccctga aaaccacatc 600 gtcttccctg tcccaatcga ccagtgtatc gacggcggag gtagcgaaaa cctgtatttt 660 cagggaggca acggcgtgtg ctgcggctac aagctgtgcc acccctgc 708 <210> SEQ ID NO 31 <211> LENGTH: 831 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-SF-H6-GGS-lcn2C-GGS-ENLYFQ-GG-Potato Carboxypeptidase Inhibitor <400> SEQUENCE: 31 gactgagtcg cccgctcgag accatggaga cagacacact cctgctatgg gtactgctgc 60 tctgggttcc aggttccact ggtgactaca aggacgagca tcaccatcat caccatggtg 120 gaagccagga ctccacctca gacctgatcc cagccccacc tctgagcaag gtccctctgc 180 agcagaactt ccaggacaac caattccagg ggaagtggta tgtggtaggc ctggcaggga 240 atgcaattct cagagaagac aaagacccgc aaaagatgta tgccaccatc tatgagctga 300 aagaagacaa gagctacaat gtcacctccg tcctgtttag gaaaaagaag tgtgactact 360 ggatcaggac ttttgttcca ggttgccagc ccggcgagtt cacgctgggc aacattaaga 420 gttaccctgg attaacgagt tacctcgtcc gagtggtgag caccaactac aaccagcatg 480 ctatggtgtt cttcaagaaa gtttctcaaa acagggagta cttcaagatc accctctacg 540 ggagaaccaa ggagctgact tcggaactaa aggagaactt catccgcttc tccaaatctc 600 tgggcctccc tgaaaaccac atcgtcttcc ctgtcccaat cgaccagtgt atcgacggcg 660 gaggtagcga aaacctgtat tttcagggag gccagcagca tgcggatccg atttgcaaca 720 aaccgtgcaa aacccatgat gattgcagcg gcgcgtggtt ttgccaggcg tgctggaaca 780 gcgcgcgcac ctgcggcccg tatgtgggct aatgctaagg atcccggacc g 831 <210> SEQ ID NO 32 <211> LENGTH: 789 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-SF-H6-GGS-lcn2C-GGS-ENLYFQ-GG-Potato Carboxypeptidase Inhibitor coding sequence <400> SEQUENCE: 32 atggagacag acacactcct gctatgggta ctgctgctct gggttccagg ttccactggt 60 gactacaagg acgagcatca ccatcatcac catggtggaa gccaggactc cacctcagac 120 ctgatcccag ccccacctct gagcaaggtc cctctgcagc agaacttcca ggacaaccaa 180 ttccagggga agtggtatgt ggtaggcctg gcagggaatg caattctcag agaagacaaa 240 gacccgcaaa agatgtatgc caccatctat gagctgaaag aagacaagag ctacaatgtc 300 acctccgtcc tgtttaggaa aaagaagtgt gactactgga tcaggacttt tgttccaggt 360 tgccagcccg gcgagttcac gctgggcaac attaagagtt accctggatt aacgagttac 420 ctcgtccgag tggtgagcac caactacaac cagcatgcta tggtgttctt caagaaagtt 480 tctcaaaaca gggagtactt caagatcacc ctctacggga gaaccaagga gctgacttcg 540 gaactaaagg agaacttcat ccgcttctcc aaatctctgg gcctccctga aaaccacatc 600 gtcttccctg tcccaatcga ccagtgtatc gacggcggag gtagcgaaaa cctgtatttt 660 cagggaggcc agcagcatgc ggatccgatt tgcaacaaac cgtgcaaaac ccatgatgat 720 tgcagcggcg cgtggttttg ccaggcgtgc tggaacagcg cgcgcacctg cggcccgtat 780 gtgggctaa 789 <210> SEQ ID NO 33 <211> LENGTH: 269 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: The anti-CD3 is an OKT3 variant from the C-terminus of patent 7635462 <400> SEQUENCE: 33 Gly Ser Asp Ile Lys Leu Gln Gln Ser Gly Ala Glu Leu Ala Arg Pro 1 5 10 15 Gly Ala Ser Val Lys Met Ser Cys Lys Thr Ser Gly Tyr Thr Phe Thr 20 25 30 Arg Tyr Thr Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu 35 40 45 Trp Ile Gly Tyr Ile Asn Pro Ser Arg Gly Tyr Thr Asn Tyr Asn Gln 50 55 60

Lys Phe Lys Asp Lys Ala Thr Leu Thr Thr Asp Lys Ser Ser Ser Thr 65 70 75 80 Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr 85 90 95 Tyr Cys Ala Arg Tyr Tyr Asp Asp His Tyr Cys Leu Asp Tyr Trp Gly 100 105 110 Gln Gly Thr Thr Leu Thr Val Ser Ser Val Glu Gly Gly Ser Gly Gly 115 120 125 Ser Gly Gly Ser Gly Gly Ser Gly Gly Val Asp Asp Ile Gln Leu Thr 130 135 140 Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly Glu Lys Val Thr Met 145 150 155 160 Thr Cys Arg Ala Ser Ser Ser Val Ser Tyr Met Asn Trp Tyr Gln Gln 165 170 175 Lys Ser Gly Thr Ser Pro Lys Arg Trp Ile Tyr Asp Thr Ser Lys Val 180 185 190 Ala Ser Gly Val Pro Tyr Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser 195 200 205 Tyr Ser Leu Thr Ile Ser Ser Met Glu Ala Glu Asp Ala Ala Thr Tyr 210 215 220 Tyr Cys Gln Gln Trp Ser Ser Asn Pro Leu Thr Phe Gly Ala Gly Thr 225 230 235 240 Lys Leu Glu Leu Lys Gly Gly Gly Gly Ser Asn Ser Ser Asn Tyr Cys 245 250 255 Cys Glu Leu Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr 260 265 <210> SEQ ID NO 34 <211> LENGTH: 848 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: anti-CD3 is an OKT3 variant from the C-terminus of patent 7635462 dropped into the Bam/Not cut library vector as a TEV-cleavable siderocalin fusion <400> SEQUENCE: 34 acctgtattt tcagggatcc gatattaaac tgcagcagag cggcgcggaa ctggcgcgcc 60 cgggcgcgag cgtgaaaatg agctgcaaaa ccagcggcta tacctttacc cgctatacca 120 tgcattgggt gaaacagcgc ccgggccagg gcctggaatg gattggctat attaacccga 180 gccgcggcta taccaactat aaccagaaat ttaaagataa agcgaccctg accaccgata 240 aaagcagcag caccgcgtat atgcagctga gcagcctgac cagcgaagat agcgcggtgt 300 attattgcgc gcgctattat gatgatcatt attgcctgga ttattggggc cagggcacca 360 ccctgaccgt gagcagcgtg gaaggcggca gcggcggcag cggcggcagc ggcggcagcg 420 gcggcgtgga tgatattcag ctgacccaga gcccggcgat tatgagcgcg agcccgggcg 480 aaaaagtgac catgacctgc cgcgcgagca gcagcgtgag ctatatgaac tggtatcagc 540 agaaaagcgg caccagcccg aaacgctgga tttatgatac cagcaaagtg gcgagcggcg 600 tgccgtatcg ctttagcggc agcggcagcg gcaccagcta tagcctgacc attagcagca 660 tggaagcgga agatgcggcg acctattatt gccagcagtg gagcagcaac ccgctgacct 720 ttggcgcggg caccaaactg gaactgaaag gcggcggcgg cagcaacagc agcaactatt 780 gctgcgaact gtgctgcaac ccggcgtgca ccggctgcta ttaatgcggc cgctcatcac 840 cattaatc 848 <210> SEQ ID NO 35 <211> LENGTH: 684 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: Parental cloning construct 1: IgK-sFLAG-H6-GGS-humanScn-GGS-ENLYFQ-GG-NotI <400> SEQUENCE: 35 ctcgagacca tggagacaga cacactcctg ctatgggtac tgctgctctg ggttccaggt 60 tccactggtg actacaagga cgagcatcac catcatcacc atggtggaag ccaggactcc 120 acctcagacc tgatcccagc cccacctctg agcaaggtcc ctctgcagca gaacttccag 180 gacaaccaat tccaggggaa gtggtatgtg gtaggcctgg cagggaatgc aattctcaga 240 gaagacaaag acccgcaaaa gatgtatgcc accatctatg agctgaaaga agacaagagc 300 tacaatgtca cctccgtcct gtttaggaaa aagaagtgtg actactggat caggactttt 360 gttccaggtt gccagcccgg cgagttcacg ctgggcaaca ttaagagtta ccctggatta 420 acgagttacc tcgtccgagt ggtgagcacc aactacaacc agcatgctat ggtgttcttc 480 aagaaagttt ctcaaaacag ggagtacttc aagatcaccc tctacgggag aaccaaggag 540 ctgacttcgg aactaaagga gaacttcatc cgcttctcca aatctctggg cctccctgaa 600 aaccacatcg tcttccctgt cccaatcgac cagtgtatcg acggcggagg tagcgaaaac 660 ctgtattttc agggaggcgg ccgc 684 <210> SEQ ID NO 36 <211> LENGTH: 1402 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: Parental cloning construct 2: IgK-sFLAG-H6-GGS-humanScnC87S-GGS-ENLYFQ-GS-STUFFER <400> SEQUENCE: 36 ctcgagacca tggagacaga cacactcctg ctatgggtac tgctgctctg ggttccaggt 60 tccactggtg actacaagga cgagcatcac catcatcacc atggtggaag ccaggactcc 120 acctcagacc tgatcccagc cccacctctg agcaaggtcc ctctgcagca gaacttccag 180 gacaaccaat tccaggggaa gtggtatgtg gtaggcctgg cagggaatgc aattctcaga 240 gaagacaaag acccgcaaaa gatgtatgcc accatctatg agctgaaaga agacaagagc 300 tacaatgtca cctccgtcct gtttaggaaa aagaagtgtg actactggat caggactttt 360 gttccaggtt cccagcccgg cgagttcacg ctgggcaaca ttaagagtta ccctggatta 420 acgagttacc tcgtccgagt ggtgagcacc aactacaacc agcatgctat ggtgttcttc 480 aagaaagttt ctcaaaacag ggagtacttc aagatcaccc tctacgggag aaccaaggag 540 ctgacttcgg aactaaagga gaacttcatc cgcttctcca aatctctggg cctccctgaa 600 aaccacatcg tcttccctgt cccaatcgac cagtgtatcg acggcggagg tagcgaaaac 660 ctgtattttc agggatccat gtacggtctt aagggacccg acatttacaa aggagtttac 720 caatttaagt cagtggagtt tgatatgtca catctgaacc tgaccatgcc caacgcatgt 780 tcagccaaca actcccacca ttacatcagt atggggactt ctggactaga attgaccttc 840 accaatgatt ccatcatcag tcacaacttt tgcaatctga cctctgcctt caacaaaaag 900 acctttgacc acacactcat gagtatagtt tcgagcctac acctcagtat cagagggaac 960 tccaactata aggcagtatc ctgcgacttc aacaatggca taaccatcca atacaacttg 1020 acattctcag atcgacaaag tgctcagagc cagtgtagaa ccttcagagg tagagtccta 1080 gatatgttta gaactgcctt cggggggaaa tacatgagga gtggctgggg ctggacaggc 1140 tcagatggca agaccacctg gtgtagccag acgagttacc aatacctgat tatacaaaat 1200 agaacctggg aaaaccactg cacatatgca ggtccttttg ggatgtccag gattctcctt 1260 tcccaagaga agactaagtt cttcactagg agactggtgc ccaggggcag cggcctgaac 1320 gacatcttcg aggcccagaa gatcgagtgg cacgagtaat gcggccgctc atcaccatta 1380 atcatcacca ttaatcggac cg 1402 <210> SEQ ID NO 37 <211> LENGTH: 1299 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: Parental cloning construct 3: LightChain-GRGGSGGS-humanScnC87S <400> SEQUENCE: 37 ctcgagacca tggatttcca ggtgcagatt tttagctttc tgctgatttc cgcttccgtg 60 attatgagcc gaggcgacat tgtgatgacc caggcagctc ctagcgtgcc agtcacccca 120 ggagagtcag tgagcatctc ctgcagaagt actaagtcac tgctgcacag caacggcaat 180 acctacctgt attggttcct gcagagacct gggcagtccc cacagaggct gatctactat 240 atgagtaacc tggcatcagg agtgcctgac aggttcagcg gacgaggcag cggcactgat 300 tttaccctgc ggatttctag agtggaggca gaagacgccg gcgtctacta ttgcatgcag 360 agtctggagt acccttatac tttcggcggg ggaaccaaac tggaaatcaa gagggccgat 420 gccgctccaa ccgtgtccat ttttccccct agctccgagc agctgacatc tggcggggct 480 agtgtggtct gtttcctgaa caatttttac ccaaaggaca tcaacgtgaa atggaagatt 540 gatggaagtg aaaggcagaa cggcgtcctg aattcatgga cagaccagga tagcaaagac 600 tccacttatt ctatgtctag taccctgaca ctgactaagg atgagtacga acgccacaat 660 tcttatacat gcgaggcaac tcataaaacc tctacaagtc ccatcgtgaa gagctttaac 720 cgaaatgaat gcggccgcgg aggctccgga ggctcccagg actcaacaag cgatctgatt 780 ccagccccac ccctgagcaa agtgcccctg cagcagaact tccaggacaa tcagtttcag 840 ggcaagtggt acgtggtcgg gctggctgga aacgcaatcc tgcgggagga caaagatccc 900 cagaagatgt acgccactat ctacgagctg aaagaagaca agtcatacaa tgtgaccagc 960 gtcctgttcc gcaagaaaaa gtgtgattat tggatcagaa cattcgtgcc cggctcccag 1020 cctggggagt ttactctggg gaatattaag tcctaccctg gactgacctc ttatctggtg 1080 cgagtggtct ctacaaacta caatcagcat gctatggtgt tctttaaaaa ggtcagccag 1140 aaccgggagt actttaaaat caccctgtat ggcagaacca aagaactgac aagcgagctg 1200 aaggaaaatt tcattcgctt ttccaagtct ctggggctgc cagagaatca tattgtgttc 1260 ccagtcccca ttgaccagtg tattgacggg tgaggatcc 1299 <210> SEQ ID NO 38 <211> LENGTH: 606 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: Super stable ScnC87S (humanScn-I8C-N39C-C87S) <400> SEQUENCE: 38 ctcgagatgc ccctgggcct gctgtggctg ggcctggccc tgctgggcgc cctgcacgcc 60 caggcccagg actccacctc agacctgtgt ccagccccac ctctgagcaa ggtccctctg 120 cagcagaact tccaggacaa ccaattccag gggaagtggt atgtggtagg cctggcaggg 180 tgtgcaattc tcagagaaga caaagacccg caaaagatgt atgccaccat ctatgagctg 240 aaagaagaca agagctacaa tgtcacctcc gtcctgttta ggaaaaagaa gtgtgactac 300

tggatcagga cttttgttcc aggttcccag ccgggcgagt tcacgctggg caacattaag 360 agttaccctg gattaacgag ttacctcgtc cgagtggtga gcaccaacta caaccagcat 420 gctatggtgt tcttcaagaa agtttctcaa aacagggagt acttcaagat caccctctac 480 gggagaacca aggagctgac ttcggaacta aaggagaact tcatccgctt ctccaaatct 540 ctgggcctcc ctgaaaacca catcgtcttc cctgtcccaa tcgaccagtg tatcgacggc 600 ggatcc 606 <210> SEQ ID NO 39 <211> LENGTH: 178 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 39 Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser Lys Val 1 5 10 15 Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe Gln Gly Lys Trp Tyr 20 25 30 Val Val Gly Leu Ala Gly Asn Ala Ile Leu Arg Glu Asp Lys Asp Pro 35 40 45 Gln Lys Met Tyr Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys Ser Tyr 50 55 60 Asn Val Thr Ser Val Leu Phe Arg Lys Lys Lys Cys Asp Tyr Trp Ile 65 70 75 80 Arg Thr Phe Val Pro Gly Cys Gln Pro Gly Glu Phe Thr Leu Gly Asn 85 90 95 Ile Lys Ser Tyr Pro Gly Leu Thr Ser Tyr Leu Val Arg Val Val Ser 100 105 110 Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys Lys Val Ser Gln 115 120 125 Asn Arg Glu Tyr Phe Lys Ile Thr Leu Tyr Gly Arg Thr Lys Glu Leu 130 135 140 Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser Leu Gly 145 150 155 160 Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile Asp Gln Cys Ile 165 170 175 Asp Gly <210> SEQ ID NO 40 <211> LENGTH: 178 <212> TYPE: PRT <213> ORGANISM: Pan troglodytes <400> SEQUENCE: 40 Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser Lys Val 1 5 10 15 Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe Gln Gly Lys Trp Tyr 20 25 30 Val Val Gly Leu Ala Gly Asn Ala Ile Leu Arg Glu Asp Lys Asp Pro 35 40 45 Gln Lys Met Tyr Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys Ser Tyr 50 55 60 Asn Val Thr Ser Val Leu Phe Arg Lys Lys Lys Cys Asp Tyr Trp Ile 65 70 75 80 Arg Thr Phe Val Pro Gly Arg Gln Pro Gly Glu Phe Thr Leu Gly Asn 85 90 95 Ile Lys Ser Tyr Pro Gly Leu Thr Ser Tyr Leu Val Arg Val Val Ser 100 105 110 Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys Lys Val Ser Gln 115 120 125 Asn Arg Glu Tyr Phe Lys Ile Thr Leu Tyr Gly Arg Thr Lys Glu Leu 130 135 140 Thr Ser Glu Leu Gln Glu Asn Phe Ile Arg Phe Ser Lys Ser Leu Gly 145 150 155 160 Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile Asp Gln Cys Ile 165 170 175 Asp Gly <210> SEQ ID NO 41 <211> LENGTH: 178 <212> TYPE: PRT <213> ORGANISM: Canis familiaris <400> SEQUENCE: 41 Gln Asp Ser Thr Pro Ser Leu Ile Pro Ala Pro Pro Pro Leu Lys Val 1 5 10 15 Pro Leu Gln Pro Asp Phe Gln His Asp Gln Phe Gln Gly Lys Trp Tyr 20 25 30 Val Ile Gly Ile Ala Gly Asn Ile Leu Lys Lys Glu Gly His Gly Gln 35 40 45 Leu Lys Met Tyr Thr Thr Thr Tyr Glu Leu Lys Asp Asp Gln Ser Tyr 50 55 60 Asn Val Thr Ser Thr Leu Leu Arg Asn Glu Arg Cys Asp Tyr Trp Asn 65 70 75 80 Arg Asp Phe Val Pro Ser Phe Gln Pro Gly Gln Phe Ser Leu Gly Asp 85 90 95 Ile Gln Leu Tyr Pro Gly Val Gln Ser Tyr Leu Val Gln Val Val Ala 100 105 110 Thr Asn Tyr Asn Gln Tyr Ala Leu Val Tyr Phe Arg Lys Val Tyr Lys 115 120 125 Ser Gln Glu Tyr Phe Lys Ile Thr Leu Tyr Gly Arg Thr Lys Glu Leu 130 135 140 Pro Leu Glu Leu Lys Lys Glu Phe Ile Arg Phe Ala Lys Ser Ile Gly 145 150 155 160 Leu Thr Glu Asp His Ile Ile Phe Pro Val Pro Ile Asp Gln Cys Ile 165 170 175 Asp Glu <210> SEQ ID NO 42 <211> LENGTH: 179 <212> TYPE: PRT <213> ORGANISM: Bos taurus <400> SEQUENCE: 42 Arg Ser Ser Ser Ser Arg Leu Leu Arg Ala Pro Pro Leu Ser Arg Ile 1 5 10 15 Pro Leu Gln Pro Asn Phe Gln Ala Asp Gln Phe Gln Gly Lys Trp Tyr 20 25 30 Thr Val Gly Val Ala Gly Asn Ala Ile Lys Lys Glu Glu Gln Asp Pro 35 40 45 Leu Lys Met Tyr Ser Ser Asn Tyr Glu Leu Lys Glu Asp Gly Ser Tyr 50 55 60 Asn Val Thr Ser Ile Leu Leu Lys Asp Asp Leu Cys Asp Tyr Trp Ile 65 70 75 80 Arg Thr Phe Val Pro Ser Ser Gln Pro Gly Gln Phe Thr Leu Gly Asn 85 90 95 Ile Lys Ser Tyr Arg Gly Ile Arg Ser Tyr Thr Val Arg Val Val Asn 100 105 110 Thr Asp Tyr Asn Gln Phe Ala Ile Val Tyr Phe Lys Lys Val Gln Arg 115 120 125 Lys Lys Thr Tyr Phe Lys Ile Thr Leu Tyr Gly Arg Thr Lys Glu Leu 130 135 140 Thr Pro Glu Val Arg Glu Asn Phe Ile Asn Phe Ala Lys Ser Leu Gly 145 150 155 160 Leu Thr Asp Asp His Ile Val Phe Thr Val Pro Ile Asp Arg Cys Ile 165 170 175 Asp Asp Gln <210> SEQ ID NO 43 <211> LENGTH: 180 <212> TYPE: PRT <213> ORGANISM: Mus musculus <400> SEQUENCE: 43 Gln Asp Ser Thr Gln Asn Leu Ile Pro Ala Pro Ser Leu Leu Thr Val 1 5 10 15 Pro Leu Gln Pro Asp Phe Arg Ser Asp Gln Phe Arg Gly Arg Trp Tyr 20 25 30 Val Val Gly Leu Ala Gly Asn Ala Val Gln Lys Lys Thr Glu Gly Ser 35 40 45 Phe Thr Met Tyr Ser Thr Ile Tyr Glu Leu Gln Glu Asn Asn Ser Tyr 50 55 60 Asn Val Thr Ser Ile Leu Val Arg Asp Gln Asp Gln Gly Cys Arg Tyr 65 70 75 80 Trp Ile Arg Thr Phe Val Pro Ser Ser Arg Ala Gly Gln Phe Thr Leu 85 90 95 Gly Asn Met His Arg Tyr Pro Gln Val Gln Ser Tyr Asn Val Gln Val 100 105 110 Ala Thr Thr Asp Tyr Asn Gln Phe Ala Met Val Phe Phe Arg Lys Thr 115 120 125 Ser Glu Asn Lys Gln Tyr Phe Lys Ile Thr Leu Tyr Gly Arg Thr Lys 130 135 140 Glu Leu Ser Pro Glu Leu Lys Glu Arg Phe Thr Arg Phe Ala Lys Ser 145 150 155 160 Leu Gly Leu Lys Asp Asp Asn Ile Ile Phe Ser Val Pro Thr Asp Gln 165 170 175 Cys Ile Asp Asn 180 <210> SEQ ID NO 44 <211> LENGTH: 178 <212> TYPE: PRT <213> ORGANISM: Rattus norvegicus <400> SEQUENCE: 44 Gln Asp Ser Thr Gln Asn Leu Ile Pro Ala Pro Pro Leu Ile Ser Val 1 5 10 15 Pro Leu Gln Pro Gly Phe Trp Thr Glu Arg Phe Gln Gly Arg Trp Phe 20 25 30 Val Val Gly Leu Ala Ala Asn Ala Val Gln Lys Glu Arg Gln Ser Arg 35 40 45 Phe Thr Met Tyr Ser Thr Ile Tyr Glu Leu Gln Glu Asp Asn Ser Tyr 50 55 60 Asn Val Thr Ser Ile Leu Val Arg Gly Gln Gly Cys Arg Tyr Trp Ile 65 70 75 80

Arg Thr Phe Val Pro Ser Ser Arg Pro Gly Gln Phe Thr Leu Gly Asn 85 90 95 Ile His Ser Tyr Pro Gln Ile Gln Ser Tyr Asp Val Gln Val Ala Asp 100 105 110 Thr Asp Tyr Asp Gln Phe Ala Met Val Phe Phe Gln Lys Thr Ser Glu 115 120 125 Asn Lys Gln Tyr Phe Lys Val Thr Leu Tyr Gly Arg Thr Lys Gly Leu 130 135 140 Ser Asp Glu Leu Lys Glu Arg Phe Val Ser Phe Ala Lys Ser Leu Gly 145 150 155 160 Leu Lys Asp Asn Asn Ile Val Phe Ser Val Pro Thr Asp Gln Cys Ile 165 170 175 Asp Asn <210> SEQ ID NO 45 <211> LENGTH: 178 <212> TYPE: PRT <213> ORGANISM: Macaca mulatta <400> SEQUENCE: 45 Gln Asp Ser Ser Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser Lys Val 1 5 10 15 Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe Gln Gly Lys Trp Tyr 20 25 30 Val Val Gly Leu Ser Gly Asn Ala Val Gly Arg Lys Asp Glu Ala Pro 35 40 45 Leu Lys Met Tyr Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys Ser Tyr 50 55 60 Asn Val Thr Ser Ile Leu Phe Arg Lys Glu Lys Cys Asp Tyr Trp Ile 65 70 75 80 Arg Thr Phe Val Pro Gly Ser Gln Pro Gly Glu Phe Thr Leu Gly Asn 85 90 95 Ile Gln Asn His Pro Gly Leu Thr Ser Tyr Val Val Arg Val Val Ser 100 105 110 Thr Asn Tyr Lys Gln Tyr Ala Met Val Phe Phe Lys Lys Val Ser Gln 115 120 125 Asn Lys Glu Tyr Phe Lys Ile Thr Leu Tyr Gly Arg Thr Lys Glu Leu 130 135 140 Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser Leu Gly 145 150 155 160 Leu Pro Glu Asn His Ile Val Phe Ser Val Pro Ile Asp Gln Cys Ile 165 170 175 Asn Gly <210> SEQ ID NO 46 <211> LENGTH: 181 <212> TYPE: PRT <213> ORGANISM: Tursiops truncatus <400> SEQUENCE: 46 Gln Asp Ser Thr Pro Asn Leu Ile Pro Ala Pro Pro Leu Phe Arg Val 1 5 10 15 Pro Leu Gln Pro Asn Phe Gln Pro Asp Gln Phe Gln Gly Lys Trp Tyr 20 25 30 Ile Val Gly Leu Ala Gly Asn Ala Phe Lys Lys Glu Lys Gln Gly Gln 35 40 45 Phe Lys Met Tyr Ala Thr Thr Tyr Glu Leu Lys Glu Asp Arg Ser Tyr 50 55 60 Asn Val Thr Ser Ala Leu Leu Arg Gly Lys Thr Gln Arg Cys Asp His 65 70 75 80 Trp Ile Arg Thr Phe Val Pro Ser Ser Arg Pro Gly Gln Phe Thr Leu 85 90 95 Gly Asn Ile Lys Gly Phe Pro Gly Val Gln Ser Tyr Thr Val Arg Val 100 105 110 Ala Thr Thr Asn Tyr Asn Gln Phe Ala Ile Val Tyr Phe Lys Lys Val 115 120 125 Tyr Lys Asn Gln Glu Tyr Phe Lys Thr Thr Leu Tyr Gly Arg Thr Lys 130 135 140 Glu Leu Thr Pro Gln Leu Lys Glu Asn Phe Ile His Phe Ala Lys Ser 145 150 155 160 Leu Gly Leu Thr Asp Glu Tyr Ile Leu Phe Pro Val Pro Ile Asp Lys 165 170 175 Cys Ile Asp Asp Gln 180 <210> SEQ ID NO 47 <211> LENGTH: 180 <212> TYPE: PRT <213> ORGANISM: Gorilla gorilla <400> SEQUENCE: 47 Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser Lys Val 1 5 10 15 Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe Gln Gly Lys Trp Tyr 20 25 30 Val Val Gly Leu Ala Gly Asn Ala Ile Leu Arg Glu Asp Lys Asp Pro 35 40 45 Gln Lys Met Tyr Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys Ser Tyr 50 55 60 Asn Val Thr Ser Val Leu Phe Arg Glu Lys Ala Gln Lys Cys Asp Tyr 65 70 75 80 Trp Ile Arg Thr Phe Val Pro Gly Ser Gln Pro Gly Glu Phe Thr Leu 85 90 95 Gly Asn Ile Lys Ser Tyr Pro Gly Leu Thr Ser Tyr Leu Val Arg Val 100 105 110 Val Ser Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys Lys Val 115 120 125 Ser Gln Asn Arg Glu Tyr Phe Lys Ile Thr Leu Tyr Gly Arg Thr Lys 130 135 140 Glu Leu Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser 145 150 155 160 Leu Gly Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile Asp Gln 165 170 175 Cys Ile Asp Gly 180 <210> SEQ ID NO 48 <211> LENGTH: 179 <212> TYPE: PRT <213> ORGANISM: Procavia capensis <400> SEQUENCE: 48 Gln Glu Pro Thr Pro Thr Leu Ile Pro Ala Pro Pro Leu Ser Ser Ile 1 5 10 15 Pro Leu Lys Pro Asn Phe His Asn Asp Lys Phe Gln Gly Lys Trp Tyr 20 25 30 Val Val Gly Val Ala Gly Asn Ala Ile Thr Lys Glu Lys Asp Pro Ser 35 40 45 Leu Met Tyr Thr Thr Thr Tyr Glu Leu Arg Asp Asp Gly Ser Tyr Asn 50 55 60 Val Thr Ser Thr Gln Phe Arg Glu Lys Ile Asn Cys Thr His Trp Thr 65 70 75 80 Arg Thr Phe Val Pro Thr Ser Gln Pro Gly Gln Phe Ser Leu Gly Asn 85 90 95 Ile Asp Lys Tyr Pro His Leu Ser Ser Tyr Thr Val Arg Val Thr Ala 100 105 110 Thr Asn Tyr Asn Tyr Phe Ala Ile Val Tyr Phe Lys Lys Val Ser Lys 115 120 125 Asn Gln Glu Tyr Phe Lys Thr Thr Leu Tyr Lys Arg Ile Lys Lys Leu 130 135 140 Thr His Gly Leu Lys Lys His Phe Ile Gln Phe Ala Lys Ser Leu Gly 145 150 155 160 Leu Pro Asp Asn His Ile Thr Phe Leu Val Pro Thr Asp Arg Cys Ile 165 170 175 Asp Asp Ala <210> SEQ ID NO 49 <211> LENGTH: 179 <212> TYPE: PRT <213> ORGANISM: Callithrix jacchus <400> SEQUENCE: 49 Gln Asp Ser Pro Ser Pro Leu Ile Pro Ala Pro Pro Leu Ser Lys Val 1 5 10 15 Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe Gln Gly Lys Trp Tyr 20 25 30 Val Val Gly Leu Ala Gly Asn Ala Ile Arg Arg Glu Asp Gln Asp Ser 35 40 45 Leu Lys Met Tyr Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys Ser Tyr 50 55 60 Asn Val Thr Ser Val Leu Phe Arg Lys Ala Gln Lys Cys Asp Tyr Trp 65 70 75 80 Ile Arg Thr Phe Val Pro Ser Ser Arg Pro Gly Glu Phe Lys Leu Gly 85 90 95 Asn Ile Glu Ser His Pro Gly Leu Thr Ser Tyr Ile Val Arg Val Val 100 105 110 Asn Thr Asp Tyr Lys Gln His Ala Met Val Phe Phe Met Lys Ala Ser 115 120 125 His Asn Arg Lys Tyr Phe Lys Val Thr Leu Tyr Gly Arg Thr Lys Glu 130 135 140 Leu Thr Ser Asp Leu Lys Glu Asn Phe Thr Ser Phe Ser Lys Ser Leu 145 150 155 160 Gly Leu Thr Glu Asn His Ile Ile Phe Pro Val Pro Ile Asp Gln Cys 165 170 175 Ile Asp Gly <210> SEQ ID NO 50 <211> LENGTH: 178 <212> TYPE: PRT <213> ORGANISM: Microcebus murinus <400> SEQUENCE: 50 Gln Asp Ser Lys Glu Lys Leu Ile Pro Ala Pro Pro Leu Leu Arg Val 1 5 10 15 Pro Leu Gln Pro Asp Phe Gln Asp Asp Gln Phe Arg Glu Thr Ser Trp 20 25 30

Pro Arg Gly Ser Lys Met Lys Glu Thr Pro Ala Gly Ser Arg Asp Ala 35 40 45 Gly Thr Gly Trp Ala Thr Thr Tyr Glu Leu Lys Asp His Ser Tyr Asn 50 55 60 Val Thr Ser Thr Leu Leu Arg Gln Asn Gly Lys Cys Asp Tyr Trp Ile 65 70 75 80 Arg Thr Phe Val Leu Thr Ser Gln Pro Gly Gln Phe Ala Leu Gly Asn 85 90 95 Ile Asn Arg Tyr Pro Gly Ile Gln Ser Tyr Thr Val Arg Val Val Thr 100 105 110 Thr Asn Tyr Asn Gln Phe Ala Ile Val Phe Phe Lys Lys Val Ser Glu 115 120 125 Asn Lys Glu Tyr Phe Lys Thr Thr Leu Tyr Gly Arg Thr Lys Glu Leu 130 135 140 Pro Pro Glu Leu Lys Glu Asn Phe Ile Arg Phe Ala Lys Ser Leu Gly 145 150 155 160 Leu Thr Glu Asp His Ile Ile Tyr Pro Val Pro Ile Asp Gln Cys Ile 165 170 175 Asp Asp <210> SEQ ID NO 51 <211> LENGTH: 178 <212> TYPE: PRT <213> ORGANISM: Pongo abelii <400> SEQUENCE: 51 Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser Lys Val 1 5 10 15 Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe Gln Gly Lys Trp Tyr 20 25 30 Val Val Gly Leu Ala Gly Asn Ala Ile Arg Arg Glu Asp Lys Asp Ser 35 40 45 Gln Lys Met Tyr Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys Ser Tyr 50 55 60 Asn Val Thr Ser Val Leu Phe Arg Lys Lys Lys Cys Asp Tyr Trp Ile 65 70 75 80 Arg Thr Phe Val Pro Gly Ser Gln Pro Gly Glu Phe Thr Leu Gly Asn 85 90 95 Thr Lys Gly Tyr Pro Gly Leu Thr Ser Tyr Leu Val Arg Val Val Ser 100 105 110 Thr Asn Tyr Asn Gln Tyr Ala Met Val Phe Phe Lys Lys Val Ser Gln 115 120 125 Asn Arg Glu Tyr Phe Lys Ile Thr Leu Tyr Gly Arg Thr Lys Glu Leu 130 135 140 Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser Leu Gly 145 150 155 160 Leu Pro Glu Asn His Ile Val Phe Pro Ala Pro Ile Asp Gln Cys Ile 165 170 175 Asp Gly <210> SEQ ID NO 52 <211> LENGTH: 181 <212> TYPE: PRT <213> ORGANISM: Ochotona princeps <400> SEQUENCE: 52 Gln Glu Leu Thr Thr Asp Leu Ile Pro Val Pro Ser Leu Arg Lys Ile 1 5 10 15 His Val Gln Lys Asn Phe Gln Ser Asp Gln Phe Gln Gly Lys Trp Tyr 20 25 30 Val Val Gly Leu Ala Gly Asn Asn Ile His Asn Ser Asp Gln Glu His 35 40 45 Gln Gln Met Tyr Ser Thr Thr Tyr Glu Leu Lys Glu Asp Gly Ser Tyr 50 55 60 Asn Val Thr Ser Thr Leu Leu Arg Gln Arg Asn Gln Gln Cys Asp His 65 70 75 80 Trp Ile Arg Thr Phe Val Pro Gly Ser Lys Leu Gly His Phe Asn Leu 85 90 95 Gly Asn Ile Lys Ser Tyr Pro Thr Leu Lys Ser Tyr Leu Ile Arg Val 100 105 110 Val Thr Thr Asp Tyr Asn Gln Phe Ala Ile Val Phe Phe Arg Lys Val 115 120 125 Tyr Lys Asn Asn Lys Lys Phe Phe Lys Ile Val Leu Tyr Gly Arg Thr 130 135 140 Lys Glu Leu Ser Pro Glu Leu Arg Gly Arg Phe Thr Ser Phe Ala Lys 145 150 155 160 Thr Leu Gly Leu Thr Asp Asn His Ile Val Phe Pro Ala Pro Ile Gly 165 170 175 Gln Cys Ile Asp Asp 180 <210> SEQ ID NO 53 <211> LENGTH: 178 <212> TYPE: PRT <213> ORGANISM: Loxodonta africana <400> SEQUENCE: 53 Gln Thr His Ser Pro Thr Leu Ile Pro Ala Pro Pro Leu Leu Arg Val 1 5 10 15 Pro Leu Gln Pro Asp Phe Gln Asp Asp Lys Phe Gln Gly Lys Trp Tyr 20 25 30 Val Ile Gly Leu Ala Gly Asn Ala Val Glu Lys Lys Glu Gln Gly Gln 35 40 45 Phe Lys Met Tyr Thr Thr Thr Tyr Glu Leu Lys Glu Asp Gly Ser Tyr 50 55 60 Asn Val Thr Ser Thr Leu Leu Gln Glu Asp Gly Lys Cys Ser Tyr Trp 65 70 75 80 Ile Arg Thr Phe Val Pro Ser Phe Gln Pro Gly Gln Phe Asn Leu Gly 85 90 95 Asn Ile Lys Asn Phe Pro Gly Leu Gln Ser Tyr Thr Val Arg Val Thr 100 105 110 Ala Thr Asn Tyr Asn Gln Phe Ala Ile Val Phe Phe Lys Lys Val Ser 115 120 125 Lys Asn Gly Glu Tyr Phe Lys Thr Thr Leu Tyr Gly Arg Thr Lys Glu 130 135 140 Leu Thr Pro Glu Leu Lys Glu Arg Phe Ile Arg Phe Ala Lys Ser Leu 145 150 155 160 Gly Leu Ser Asp His Ile Ile Phe Pro Val Pro Ile Asp Arg Cys Ile 165 170 175 Asp Asp <210> SEQ ID NO 54 <211> LENGTH: 178 <212> TYPE: PRT <213> ORGANISM: Oryctolagus cuniculus <400> SEQUENCE: 54 Gln Asp Pro Thr Pro Lys Leu Ile Pro Ala Pro Ser Leu Arg Arg Val 1 5 10 15 Pro Leu Gln Arg Asn Phe Gln Asp Glu Gln Phe Gln Gly Lys Trp Tyr 20 25 30 Val Val Gly Leu Ala Gly Asn Ala Val Gln Lys Arg Glu Glu Gly Gln 35 40 45 Glu Pro Met Tyr Ser Thr Thr Tyr Glu Leu Asn Glu Asp Arg Ser Phe 50 55 60 Asn Val Thr Ser Thr Leu Leu Arg Asp Gln Arg Cys Asp His Trp Ile 65 70 75 80 Arg Thr Phe Val Pro Thr Ser Arg Pro Gly Gln Tyr Asn Leu Gly Asn 85 90 95 Ile Lys Ser Tyr Pro Gly Val Lys Asn Tyr Ile Val Arg Val Val Ala 100 105 110 Thr Asp Tyr Ser Gln Tyr Ala Met Met Phe Phe Arg Lys Gly Ser Arg 115 120 125 Asn Lys Gln Phe Phe Lys Thr Thr Leu Tyr Gly Arg Thr Lys Glu Leu 130 135 140 Ser Pro Glu Leu Arg Glu Arg Phe Thr Arg Phe Ala Lys Ser Leu Gly 145 150 155 160 Leu Pro Asp Asp Arg Ile Val Phe Pro Thr Pro Ile Asp Gln Cys Ile 165 170 175 Asp Asp <210> SEQ ID NO 55 <211> LENGTH: 997 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: Murine Scn construct for downstream viral fusions: IgK-H6-murineScn-StrepII-GGGGS-E7.16 <400> SEQUENCE: 55 ctcgagacca tggagaccga cacgctcttg ttgtgggttc tcttgttgtg ggtgcctggg 60 tctacaggcg accaccacca tcatcaccac ctcgttccta gaggcagcca ggatagtacc 120 cagaatctta tcccagcacc atctttgctc acagtaccat tgcaacccga ctttcggtct 180 gatcaatttc ggggacgctg gtacgtggtt ggactggccg gcaatgctgt acagaaaaaa 240 acagagggca gtttcaccat gtactcaaca atctatgagc tccaagagaa taatagttac 300 aacgttacct ccatcttggt gagggaccag gatcagggat gtcgctactg gattcggaca 360 ttcgtaccaa gttctcgggc cggtcagttt actctgggca acatgcacag gtatccccaa 420 gttcaatctt acaacgtgca ggtggcgact accgactaca accaattcgc tatggtgttc 480 ttccgcaaaa caagcgagaa caagcagtat tttaaaatca ctctgtacgg tagaactaag 540 gagctgagcc ctgaacttaa ggagcggttc accagattcg ctaagtccct gggactgaag 600 gatgataata taatcttttc cgtccccacc gatcagtgta tcgataattc agcttggtca 660 catccccagt tcgagaaagg aggcggtgga tccatgcatg gcgacactcc gaccctgcac 720 gaatacatgc tggacctgca gcccgaaacc actgacctgt attgttacga gcaactcaac 780 gattctagcg aggaggagga cgagatcgat ggaccggcag gccaggccga accagaccgc 840 gcacattata acattgttac cttctgttgc aaatgtgatt caactcttag actttgtgtc 900 cagagtacac acgtggacat ccgcaccctg gaagatctgc tgatgggaac tctgggtatc 960 gtgtgtccta tatgtagcca gaaaccctga cggaccg 997 <210> SEQ ID NO 56 <211> LENGTH: 326

<212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-H6-murineScn-StrepII-GGGGS-E7.16 <400> SEQUENCE: 56 Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Asp His His His His His His Leu Val Pro Arg Gly 20 25 30 Ser Gln Asp Ser Thr Gln Asn Leu Ile Pro Ala Pro Ser Leu Leu Thr 35 40 45 Val Pro Leu Gln Pro Asp Phe Arg Ser Asp Gln Phe Arg Gly Arg Trp 50 55 60 Tyr Val Val Gly Leu Ala Gly Asn Ala Val Gln Lys Lys Thr Glu Gly 65 70 75 80 Ser Phe Thr Met Tyr Ser Thr Ile Tyr Glu Leu Gln Glu Asn Asn Ser 85 90 95 Tyr Asn Val Thr Ser Ile Leu Val Arg Asp Gln Asp Gln Gly Cys Arg 100 105 110 Tyr Trp Ile Arg Thr Phe Val Pro Ser Ser Arg Ala Gly Gln Phe Thr 115 120 125 Leu Gly Asn Met His Arg Tyr Pro Gln Val Gln Ser Tyr Asn Val Gln 130 135 140 Val Ala Thr Thr Asp Tyr Asn Gln Phe Ala Met Val Phe Phe Arg Lys 145 150 155 160 Thr Ser Glu Asn Lys Gln Tyr Phe Lys Ile Thr Leu Tyr Gly Arg Thr 165 170 175 Lys Glu Leu Ser Pro Glu Leu Lys Glu Arg Phe Thr Arg Phe Ala Lys 180 185 190 Ser Leu Gly Leu Lys Asp Asp Asn Ile Ile Phe Ser Val Pro Thr Asp 195 200 205 Gln Cys Ile Asp Asn Ser Ala Trp Ser His Pro Gln Phe Glu Lys Gly 210 215 220 Gly Gly Gly Ser Met His Gly Asp Thr Pro Thr Leu His Glu Tyr Met 225 230 235 240 Leu Asp Leu Gln Pro Glu Thr Thr Asp Leu Tyr Cys Tyr Glu Gln Leu 245 250 255 Asn Asp Ser Ser Glu Glu Glu Asp Glu Ile Asp Gly Pro Ala Gly Gln 260 265 270 Ala Glu Pro Asp Arg Ala His Tyr Asn Ile Val Thr Phe Cys Cys Lys 275 280 285 Cys Asp Ser Thr Leu Arg Leu Cys Val Gln Ser Thr His Val Asp Ile 290 295 300 Arg Thr Leu Glu Asp Leu Leu Met Gly Thr Leu Gly Ile Val Cys Pro 305 310 315 320 Ile Cys Ser Gln Lys Pro 325 <210> SEQ ID NO 57 <211> LENGTH: 1189 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-H6-murineScn-StrepII-GGGGS-E6.16 <400> SEQUENCE: 57 ctcgagacca tggagaccga cacgctcttg ttgtgggttc tcttgttgtg ggtgcctggg 60 tctacaggcg accaccacca tcatcaccac ctcgttccta gaggcagcca ggatagtacc 120 cagaatctta tcccagcacc atctttgctc acagtaccat tgcaacccga ctttcggtct 180 gatcaatttc ggggacgctg gtacgtggtt ggactggccg gcaatgctgt acagaaaaaa 240 acagagggca gtttcaccat gtactcaaca atctatgagc tccaagagaa taatagttac 300 aacgttacct ccatcttggt gagggaccag gatcagggat gtcgctactg gattcggaca 360 ttcgtaccaa gttctcgggc cggtcagttt actctgggca acatgcacag gtatccccaa 420 gttcaatctt acaacgtgca ggtggcgact accgactaca accaattcgc tatggtgttc 480 ttccgcaaaa caagcgagaa caagcagtat tttaaaatca ctctgtacgg tagaactaag 540 gagctgagcc ctgaacttaa ggagcggttc accagattcg ctaagtccct gggactgaag 600 gatgataata taatcttttc cgtccccacc gatcagtgta tcgataattc agcttggtca 660 catccccagt tcgagaaagg aggcggtgga tccatgcacc agaagagaac cgccatgttc 720 caggacccac aagagcggcc ccggaaactg ccccaactgt gcactgaatt gcagaccacc 780 atccacgaca tcattttgga atgtgtctac tgtaagcagc agctcctcag gcgagaggtg 840 tatgacttcg ccttccggga tttgtgtatt gtctacaggg atggtaatcc ctatgccgtt 900 tgtgataagt gcctgaaatt ttatagcaag atcagcgagt accgacatta ctgttacagc 960 gtttatggaa caacattgga gcagcagtac aacaaacctc tttgcgacct cctgattcgc 1020 tgcatcaact gccagaagcc cctgtgcccc gaagagaaac aaaggcattt ggataagaag 1080 cagaggttcc acaacatccg cggtcgctgg acggggcgct gcatgagttg ctgcaggagt 1140 tcccgcactc ggcgcgagac ccaactctga cggaccgcct ctccctccc 1189 <210> SEQ ID NO 58 <211> LENGTH: 1189 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-H6-murineScn-StrepII-GGGGS-E6.18 <400> SEQUENCE: 58 ctcgagacca tggagaccga cacgctcttg ttgtgggttc tcttgttgtg ggtgcctggg 60 tctacaggcg accaccacca tcatcaccac ctcgttccta gaggcagcca ggatagtacc 120 cagaatctta tcccagcacc atctttgctc acagtaccat tgcaacccga ctttcggtct 180 gatcaatttc ggggacgctg gtacgtggtt ggactggccg gcaatgctgt acagaaaaaa 240 acagagggca gtttcaccat gtactcaaca atctatgagc tccaagagaa taatagttac 300 aacgttacct ccatcttggt gagggaccag gatcagggat gtcgctactg gattcggaca 360 ttcgtaccaa gttctcgggc cggtcagttt actctgggca acatgcacag gtatccccaa 420 gttcaatctt acaacgtgca ggtggcgact accgactaca accaattcgc tatggtgttc 480 ttccgcaaaa caagcgagaa caagcagtat tttaaaatca ctctgtacgg tagaactaag 540 gagctgagcc ctgaacttaa ggagcggttc accagattcg ctaagtccct gggactgaag 600 gatgataata taatcttttc cgtccccacc gatcagtgta tcgataattc agcttggtca 660 catccccagt tcgagaaagg aggcggtgga tccatggcca gatttgaaga ccccacaagg 720 cgcccctata aactgccgga tctttgcacc gaactgaata ctagcctgca agatattgag 780 attacctgcg tgtactgtaa aacggtgctc gaattgaccg aggtttttga gttcgcattc 840 aaggacctgt ttgttgtata tcgcgattcc atcccgcacg cagcttgcca taaatgcatt 900 gacttttact cccggatacg cgagctgcga cactatagtg atagcgtgta cggcgataca 960 cttgagaagc ttaccaacac cggtctgtac aatcttctga ttcggtgttt gaggtgccag 1020 aagccgctca acccagctga gaaactgcgg catctgaacg aaaaaagaag attccacaac 1080 attgctggcc actacagggg ccagtgccat tcttgttgta atagagcaag gcaggagcgg 1140 ctgcaacggc ggcgcgagac ccaggtatga cggaccgcct ctccctccc 1189 <210> SEQ ID NO 59 <211> LENGTH: 1030 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-H6-murineScn-StrepII-GGGGS-E7.18 <400> SEQUENCE: 59 ctcgagacca tggagaccga cacgctcttg ttgtgggttc tcttgttgtg ggtgcctggg 60 tctacaggcg accaccacca tcatcaccac ctcgttccta gaggcagcca ggatagtacc 120 cagaatctta tcccagcacc atctttgctc acagtaccat tgcaacccga ctttcggtct 180 gatcaatttc ggggacgctg gtacgtggtt ggactggccg gcaatgctgt acagaaaaaa 240 acagagggca gtttcaccat gtactcaaca atctatgagc tccaagagaa taatagttac 300 aacgttacct ccatcttggt gagggaccag gatcagggat gtcgctactg gattcggaca 360 ttcgtaccaa gttctcgggc cggtcagttt actctgggca acatgcacag gtatccccaa 420 gttcaatctt acaacgtgca ggtggcgact accgactaca accaattcgc tatggtgttc 480 ttccgcaaaa caagcgagaa caagcagtat tttaaaatca ctctgtacgg tagaactaag 540 gagctgagcc ctgaacttaa ggagcggttc accagattcg ctaagtccct gggactgaag 600 gatgataata taatcttttc cgtccccacc gatcagtgta tcgataattc agcttggtca 660 catccccagt tcgagaaagg aggcggtgga tccatgcacg gacctaaagc aacactccag 720 gacatcgtcc tgcatttgga accacaaaac gaaatacccg tggacctttt gtgtcacgaa 780 cagctttcag attctgagga agagaatgat gaaatcgacg gtgtcaacca ccagcatctc 840 cccgctaggc gggcagaacc ccagcgccac acaatgctgt gcatgtgttg caaatgcgaa 900 gctcgaattg aactcgtggt tgagtcctcc gcggacgact tgagggcatt ccagcaactg 960 ttcctcaaca cactgagctt tgtctgtcct tggtgcgcta gtcagcagtg acggaccgcc 1020 tctccctccc 1030 <210> SEQ ID NO 60 <211> LENGTH: 1162 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-H6-murineScn-StrepII-GGGGS-E6.33 <400> SEQUENCE: 60 ctcgagacca tggagaccga cacgctcttg ttgtgggttc tcttgttgtg ggtgcctggg 60 tctacaggcg accaccacca tcatcaccac ctcgttccta gaggcagcca ggatagtacc 120 cagaatctta tcccagcacc atctttgctc acagtaccat tgcaacccga ctttcggtct 180 gatcaatttc ggggacgctg gtacgtggtt ggactggccg gcaatgctgt acagaaaaaa 240 acagagggca gtttcaccat gtactcaaca atctatgagc tccaagagaa taatagttac 300 aacgttacct ccatcttggt gagggaccag gatcagggat gtcgctactg gattcggaca 360 ttcgtaccaa gttctcgggc cggtcagttt actctgggca acatgcacag gtatccccaa 420 gttcaatctt acaacgtgca ggtggcgact accgactaca accaattcgc tatggtgttc 480 ttccgcaaaa caagcgagaa caagcagtat tttaaaatca ctctgtacgg tagaactaag 540 gagctgagcc ctgaacttaa ggagcggttc accagattcg ctaagtccct gggactgaag 600 gatgataata taatcttttc cgtccccacc gatcagtgta tcgataattc agcttggtca 660 catccccagt tcgagaaagg aggcggtgga tccatgttcc aagacactga ggagaagcca 720 cgcacgctgc acgatctgtg ccaggccctt gagactacca tccataacat cgagctccag 780

tgtgtcgaat gcaggaatcc tcttcagcgg agcgaggtgt acgattttgc cttcgcggac 840 ctgacggtgg tctaccggga aggtaaccca ttcgggattt gcaagctgtg tctcagattt 900 cttagtaaga taagtgaata ccggcactac aactattcag tttacggtca cactctggaa 960 cagaccgtga acaaacccct gaacgagatc ctcattcgat gtatcatctg tcagagacct 1020 ctctgtccgc gcgaaaagaa gaggcacgtc gacctgaata agcgatttca taatatctct 1080 ggacggtggg cggggcgctg tgcagcctgt tggagatccc ggagacggga aacagctctt 1140 tgacggaccg cctctccctc cc 1162 <210> SEQ ID NO 61 <211> LENGTH: 1007 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-H6-murineScn-StrepII-GGGGS-E7.33 <400> SEQUENCE: 61 ctcgagacca tggagaccga cacgctcttg ttgtgggttc tcttgttgtg ggtgcctggg 60 tctacaggcg accaccacca tcatcaccac ctcgttccta gaggcagcca ggatagtacc 120 cagaatctta tcccagcacc atctttgctc acagtaccat tgcaacccga ctttcggtct 180 gatcaatttc ggggacgctg gtacgtggtt ggactggccg gcaatgctgt acagaaaaaa 240 acagagggca gtttcaccat gtactcaaca atctatgagc tccaagagaa taatagttac 300 aacgttacct ccatcttggt gagggaccag gatcagggat gtcgctactg gattcggaca 360 ttcgtaccaa gttctcgggc cggtcagttt actctgggca acatgcacag gtatccccaa 420 gttcaatctt acaacgtgca ggtggcgact accgactaca accaattcgc tatggtgttc 480 ttccgcaaaa caagcgagaa caagcagtat tttaaaatca ctctgtacgg tagaactaag 540 gagctgagcc ctgaacttaa ggagcggttc accagattcg ctaagtccct gggactgaag 600 gatgataata taatcttttc cgtccccacc gatcagtgta tcgataattc agcttggtca 660 catccccagt tcgagaaagg aggcggtgga tccatgcggg gacatgaacc tactctgaag 720 gagtacgtcc tggaccttta cccggagccg acagatcttt actgttacga gcaattgtct 780 gactccagcg acgaggatga gggccttgac agacctgatg gccaggctca gccagctact 840 gccgattatt atatcgttac gtgttgtcac acctgcaaca caaccgtaag gttgtgtgtg 900 aactccaccg ccagtgactt gagaacgata caacaactcc tcatgggcac tgtcaatatc 960 gtctgtccta catgtgctca gctgctgacg gaccgcctct ccctccc 1007 <210> SEQ ID NO 62 <211> LENGTH: 1189 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-H6-murineScn-StrepII-GGGGS-E6.45 <400> SEQUENCE: 62 ctcgagacca tggagaccga cacgctcttg ttgtgggttc tcttgttgtg ggtgcctggg 60 tctacaggcg accaccacca tcatcaccac ctcgttccta gaggcagcca ggatagtacc 120 cagaatctta tcccagcacc atctttgctc acagtaccat tgcaacccga ctttcggtct 180 gatcaatttc ggggacgctg gtacgtggtt ggactggccg gcaatgctgt acagaaaaaa 240 acagagggca gtttcaccat gtactcaaca atctatgagc tccaagagaa taatagttac 300 aacgttacct ccatcttggt gagggaccag gatcagggat gtcgctactg gattcggaca 360 ttcgtaccaa gttctcgggc cggtcagttt actctgggca acatgcacag gtatccccaa 420 gttcaatctt acaacgtgca ggtggcgact accgactaca accaattcgc tatggtgttc 480 ttccgcaaaa caagcgagaa caagcagtat tttaaaatca ctctgtacgg tagaactaag 540 gagctgagcc ctgaacttaa ggagcggttc accagattcg ctaagtccct gggactgaag 600 gatgataata taatcttttc cgtccccacc gatcagtgta tcgataattc agcttggtca 660 catccccagt tcgagaaagg aggcggtgga tccatggcca ggttcgatga tcccacccag 720 cgaccctata agttgcccga tctctgcaca gaacttaaca ctagcttgca ggacgtaagc 780 attgcatgtg tttactgtaa agctacgctg gagcgaaccg aggtgtacca attcgccttc 840 aaagacttgt tcatcgtgta tagagactgt atcgcttatg ccgcctgcca caaatgcata 900 gacttttaca gcaggatcag ggaattgagg tactattcca actcagtcta tggagaaacg 960 ctggagaaga taactaacac tgagctttat aacctcctga ttcgctgcct ccggtgtcag 1020 aagccactga atcctgccga aaagagacgc catctgaagg acaagcggcg ctttcatagc 1080 attgcaggac agtacagagg ccaatgtaat acttgctgtg accaagcacg ccaagaaagg 1140 ctcaggagaa ggagagagac acaggtgtga cggaccgcct ctccctccc 1189 <210> SEQ ID NO 63 <211> LENGTH: 1033 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-H6-murineScn-StrepII-GGGGS-E7.45 <400> SEQUENCE: 63 ctcgagacca tggagaccga cacgctcttg ttgtgggttc tcttgttgtg ggtgcctggg 60 tctacaggcg accaccacca tcatcaccac ctcgttccta gaggcagcca ggatagtacc 120 cagaatctta tcccagcacc atctttgctc acagtaccat tgcaacccga ctttcggtct 180 gatcaatttc ggggacgctg gtacgtggtt ggactggccg gcaatgctgt acagaaaaaa 240 acagagggca gtttcaccat gtactcaaca atctatgagc tccaagagaa taatagttac 300 aacgttacct ccatcttggt gagggaccag gatcagggat gtcgctactg gattcggaca 360 ttcgtaccaa gttctcgggc cggtcagttt actctgggca acatgcacag gtatccccaa 420 gttcaatctt acaacgtgca ggtggcgact accgactaca accaattcgc tatggtgttc 480 ttccgcaaaa caagcgagaa caagcagtat tttaaaatca ctctgtacgg tagaactaag 540 gagctgagcc ctgaacttaa ggagcggttc accagattcg ctaagtccct gggactgaag 600 gatgataata taatcttttc cgtccccacc gatcagtgta tcgataattc agcttggtca 660 catccccagt tcgagaaagg aggcggtgga tccatgcacg gcccacaggc aaccctgcaa 720 gagatcgtgc tgcatctcga accacagaat gaattggacc ctgtggatct gctgtgttac 780 gagcagctct ctgaaagcga agaggagaat gacgaggccg acggcgtgtc tcatgcacag 840 ctgcctgctc gccgggccga acctcagcga cacaaaattc tgtgcgtgtg ctgcaaatgc 900 gacggccgca tagagctgac ggtagaatca tcagccgacg atctgcgaac tcttcaacaa 960 ctcttcctga gcacgctcag cttcgtgtgt ccttggtgtg ctacaaatca gtgacggacc 1020 gcctctccct ccc 1033 <210> SEQ ID NO 64 <211> LENGTH: 1162 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-H6-murineScn-StrepII-GGGGS-E6.31 <400> SEQUENCE: 64 Cys Thr Cys Gly Ala Gly Ala Cys Cys Ala Thr Gly Gly Ala Gly Ala 1 5 10 15 Cys Cys Gly Ala Cys Ala Cys Gly Cys Thr Cys Thr Thr Gly Thr Thr 20 25 30 Gly Thr Gly Gly Gly Thr Thr Cys Thr Cys Thr Thr Gly Thr Thr Gly 35 40 45 Thr Gly Gly Gly Thr Gly Cys Cys Thr Gly Gly Gly Thr Cys Thr Ala 50 55 60 Cys Ala Gly Gly Cys Gly Ala Cys Cys Ala Cys Cys Ala Cys Cys Ala 65 70 75 80 Thr Cys Ala Thr Cys Ala Cys Cys Ala Cys Cys Thr Cys Gly Thr Thr 85 90 95 Cys Cys Thr Ala Gly Ala Gly Gly Cys Ala Gly Cys Cys Ala Gly Gly 100 105 110 Ala Thr Ala Gly Thr Ala Cys Cys Cys Ala Gly Ala Ala Thr Cys Thr 115 120 125 Thr Ala Thr Cys Cys Cys Ala Gly Cys Ala Cys Cys Ala Thr Cys Thr 130 135 140 Thr Thr Gly Cys Thr Cys Ala Cys Ala Gly Thr Ala Cys Cys Ala Thr 145 150 155 160 Thr Gly Cys Ala Ala Cys Cys Cys Gly Ala Cys Thr Thr Thr Cys Gly 165 170 175 Gly Thr Cys Thr Gly Ala Thr Cys Ala Ala Thr Thr Thr Cys Gly Gly 180 185 190 Gly Gly Ala Cys Gly Cys Thr Gly Gly Thr Ala Cys Gly Thr Gly Gly 195 200 205 Thr Thr Gly Gly Ala Cys Thr Gly Gly Cys Cys Gly Gly Cys Ala Ala 210 215 220 Thr Gly Cys Thr Gly Thr Ala Cys Ala Gly Ala Ala Ala Ala Ala Ala 225 230 235 240 Ala Cys Ala Gly Ala Gly Gly Gly Cys Ala Gly Thr Thr Thr Cys Ala 245 250 255 Cys Cys Ala Thr Gly Thr Ala Cys Thr Cys Ala Ala Cys Ala Ala Thr 260 265 270 Cys Thr Ala Thr Gly Ala Gly Cys Thr Cys Cys Ala Ala Gly Ala Gly 275 280 285 Ala Ala Thr Ala Ala Thr Ala Gly Thr Thr Ala Cys Ala Ala Cys Gly 290 295 300 Thr Thr Ala Cys Cys Thr Cys Cys Ala Thr Cys Thr Thr Gly Gly Thr 305 310 315 320 Gly Ala Gly Gly Gly Ala Cys Cys Ala Gly Gly Ala Thr Cys Ala Gly 325 330 335 Gly Gly Ala Thr Gly Thr Cys Gly Cys Thr Ala Cys Thr Gly Gly Ala 340 345 350 Thr Thr Cys Gly Gly Ala Cys Ala Thr Thr Cys Gly Thr Ala Cys Cys 355 360 365 Ala Ala Gly Thr Thr Cys Thr Cys Gly Gly Gly Cys Cys Gly Gly Thr 370 375 380 Cys Ala Gly Thr Thr Thr Ala Cys Thr Cys Thr Gly Gly Gly Cys Ala 385 390 395 400 Ala Cys Ala Thr Gly Cys Ala Cys Ala Gly Gly Thr Ala Thr Cys Cys 405 410 415 Cys Cys Ala Ala Gly Thr Thr Cys Ala Ala Thr Cys Thr Thr Ala Cys 420 425 430 Ala Ala Cys Gly Thr Gly Cys Ala Gly Gly Thr Gly Gly Cys Gly Ala 435 440 445 Cys Thr Ala Cys Cys Gly Ala Cys Thr Ala Cys Ala Ala Cys Cys Ala 450 455 460

Ala Thr Thr Cys Gly Cys Thr Ala Thr Gly Gly Thr Gly Thr Thr Cys 465 470 475 480 Thr Thr Cys Cys Gly Cys Ala Ala Ala Ala Cys Ala Ala Gly Cys Gly 485 490 495 Ala Gly Ala Ala Cys Ala Ala Gly Cys Ala Gly Thr Ala Thr Thr Thr 500 505 510 Thr Ala Ala Ala Ala Thr Cys Ala Cys Thr Cys Thr Gly Thr Ala Cys 515 520 525 Gly Gly Thr Ala Gly Ala Ala Cys Thr Ala Ala Gly Gly Ala Gly Cys 530 535 540 Thr Gly Ala Gly Cys Cys Cys Thr Gly Ala Ala Cys Thr Thr Ala Ala 545 550 555 560 Gly Gly Ala Gly Cys Gly Gly Thr Thr Cys Ala Cys Cys Ala Gly Ala 565 570 575 Thr Thr Cys Gly Cys Thr Ala Ala Gly Thr Cys Cys Cys Thr Gly Gly 580 585 590 Gly Ala Cys Thr Gly Ala Ala Gly Gly Ala Thr Gly Ala Thr Ala Ala 595 600 605 Thr Ala Thr Ala Ala Thr Cys Thr Thr Thr Thr Cys Cys Gly Thr Cys 610 615 620 Cys Cys Cys Ala Cys Cys Gly Ala Thr Cys Ala Gly Thr Gly Thr Ala 625 630 635 640 Thr Cys Gly Ala Thr Ala Ala Thr Thr Cys Ala Gly Cys Thr Thr Gly 645 650 655 Gly Thr Cys Ala Cys Ala Thr Cys Cys Cys Cys Ala Gly Thr Thr Cys 660 665 670 Gly Ala Gly Ala Ala Ala Gly Gly Ala Gly Gly Cys Gly Gly Thr Gly 675 680 685 Gly Ala Thr Cys Cys Ala Thr Gly Thr Thr Cys Ala Ala Ala Ala Ala 690 695 700 Cys Cys Cys Gly Gly Cys Thr Gly Ala Gly Ala Gly Ala Cys Cys Gly 705 710 715 720 Cys Gly Gly Ala Ala Gly Thr Thr Gly Cys Ala Cys Gly Ala Gly Cys 725 730 735 Thr Cys Thr Cys Ala Thr Cys Cys Gly Cys Gly Cys Thr Gly Gly Ala 740 745 750 Ala Ala Thr Ala Cys Cys Thr Thr Ala Thr Gly Ala Thr Gly Ala Gly 755 760 765 Cys Thr Thr Cys Gly Cys Thr Thr Gly Ala Ala Thr Thr Gly Thr Gly 770 775 780 Thr Gly Thr Ala Cys Thr Gly Cys Ala Ala Ala Gly Gly Cys Cys Ala 785 790 795 800 Gly Cys Thr Cys Ala Cys Thr Gly Ala Gly Ala Cys Cys Gly Ala Ala 805 810 815 Gly Thr Ala Cys Thr Thr Gly Ala Thr Thr Thr Thr Gly Cys Cys Thr 820 825 830 Thr Thr Ala Cys Thr Gly Ala Cys Cys Thr Gly Ala Cys Ala Ala Thr 835 840 845 Cys Gly Thr Cys Thr Ala Thr Ala Gly Ala Gly Ala Cys Gly Ala Cys 850 855 860 Ala Cys Thr Cys Cys Ala Cys Ala Cys Gly Gly Gly Gly Thr Cys Thr 865 870 875 880 Gly Thr Ala Cys Ala Ala Ala Ala Thr Gly Thr Cys Thr Gly Cys Gly 885 890 895 Gly Thr Thr Thr Thr Ala Thr Ala Gly Thr Ala Ala Ala Gly Thr Gly 900 905 910 Ala Gly Cys Gly Ala Ala Thr Thr Cys Cys Gly Gly Thr Gly Gly Thr 915 920 925 Ala Thr Cys Gly Cys Thr Ala Thr Thr Cys Ala Gly Thr Gly Thr Ala 930 935 940 Thr Gly Gly Ala Ala Cys Cys Ala Cys Ala Thr Thr Gly Gly Ala Gly 945 950 955 960 Ala Ala Ala Cys Thr Cys Ala Cys Thr Ala Ala Cys Ala Ala Ala Gly 965 970 975 Gly Thr Ala Thr Cys Thr Gly Thr Gly Ala Cys Cys Thr Gly Cys Thr 980 985 990 Gly Ala Thr Cys Ala Gly Gly Thr Gly Cys Ala Thr Ala Ala Cys Thr 995 1000 1005 Thr Gly Thr Cys Ala Gly Ala Gly Gly Cys Cys Gly Cys Thr Cys 1010 1015 1020 Thr Gly Cys Cys Cys Cys Gly Ala Gly Gly Ala Gly Ala Ala Gly 1025 1030 1035 Cys Ala Gly Cys Gly Cys Cys Ala Cys Cys Thr Gly Gly Ala Thr 1040 1045 1050 Ala Ala Gly Ala Ala Gly Ala Ala Gly Ala Gly Ala Thr Thr Cys 1055 1060 1065 Cys Ala Cys Ala Ala Cys Ala Thr Thr Gly Gly Ala Gly Gly Cys 1070 1075 1080 Ala Gly Ala Thr Gly Gly Ala Cys Ala Gly Gly Cys Cys Gly Gly 1085 1090 1095 Thr Gly Cys Ala Thr Thr Gly Cys Thr Thr Gly Thr Thr Gly Gly 1100 1105 1110 Cys Gly Cys Ala Gly Gly Cys Cys Ala Ala Gly Ala Ala Cys Cys 1115 1120 1125 Gly Ala Gly Ala Cys Cys Cys Ala Ala Gly Thr Thr Thr Gly Ala 1130 1135 1140 Cys Gly Gly Ala Cys Cys Gly Cys Cys Thr Cys Thr Cys Cys Cys 1145 1150 1155 Thr Cys Cys Cys 1160 <210> SEQ ID NO 65 <211> LENGTH: 1009 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-H6-murineScn-StrepII-GGGGS-E7.31 <400> SEQUENCE: 65 ctcgagacca tggagaccga cacgctcttg ttgtgggttc tcttgttgtg ggtgcctggg 60 tctacaggcg accaccacca tcatcaccac ctcgttccta gaggcagcca ggatagtacc 120 cagaatctta tcccagcacc atctttgctc acagtaccat tgcaacccga ctttcggtct 180 gatcaatttc ggggacgctg gtacgtggtt ggactggccg gcaatgctgt acagaaaaaa 240 acagagggca gtttcaccat gtactcaaca atctatgagc tccaagagaa taatagttac 300 aacgttacct ccatcttggt gagggaccag gatcagggat gtcgctactg gattcggaca 360 ttcgtaccaa gttctcgggc cggtcagttt actctgggca acatgcacag gtatccccaa 420 gttcaatctt acaacgtgca ggtggcgact accgactaca accaattcgc tatggtgttc 480 ttccgcaaaa caagcgagaa caagcagtat tttaaaatca ctctgtacgg tagaactaag 540 gagctgagcc ctgaacttaa ggagcggttc accagattcg ctaagtccct gggactgaag 600 gatgataata taatcttttc cgtccccacc gatcagtgta tcgataattc agcttggtca 660 catccccagt tcgagaaagg aggcggtgga tccatgcggg gtgagacacc aactcttcag 720 gattatgttc tggatctgca gccagaggcc acagatctgc actgttacga gcaattgcct 780 gattccagcg acgaggagga tgtcatcgat agccctgctg ggcaggccaa gccagacact 840 tcaaattaca acattgtaac gttttgttgt cagtgcgaat ccaccctcag gctttgcgtc 900 cagagcactc aggttgacat tcgaatactc caggagctgt tgatggggag ctttggaatc 960 gtgtgcccaa attgtagtac acgactgtga cggaccgcct ctccctccc 1009 <210> SEQ ID NO 66 <211> LENGTH: 1162 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-H6-murineScn-StrepII-GGGGS-E6.58 <400> SEQUENCE: 66 ctcgagacca tggagaccga cacgctcttg ttgtgggttc tcttgttgtg ggtgcctggg 60 tctacaggcg accaccacca tcatcaccac ctcgttccta gaggcagcca ggatagtacc 120 cagaatctta tcccagcacc atctttgctc acagtaccat tgcaacccga ctttcggtct 180 gatcaatttc ggggacgctg gtacgtggtt ggactggccg gcaatgctgt acagaaaaaa 240 acagagggca gtttcaccat gtactcaaca atctatgagc tccaagagaa taatagttac 300 aacgttacct ccatcttggt gagggaccag gatcagggat gtcgctactg gattcggaca 360 ttcgtaccaa gttctcgggc cggtcagttt actctgggca acatgcacag gtatccccaa 420 gttcaatctt acaacgtgca ggtggcgact accgactaca accaattcgc tatggtgttc 480 ttccgcaaaa caagcgagaa caagcagtat tttaaaatca ctctgtacgg tagaactaag 540 gagctgagcc ctgaacttaa ggagcggttc accagattcg ctaagtccct gggactgaag 600 gatgataata taatcttttc cgtccccacc gatcagtgta tcgataattc agcttggtca 660 catccccagt tcgagaaagg aggcggtgga tccatgtttc aggacgctga ggagaagccc 720 agaactctgc acgatctgtg tcaggccttg gagacgtctg tgcataaaat tgagcttaaa 780 tgtgtcgaat gtaagaagac actccagcgc agcgaagttt atgacttcgt gttcgcggat 840 ctgagaatcg tgtatcggga cggcaaccct tttgctgttt gcaaggtttg ccttaggctc 900 ctgtccaaaa ttagcgagta ccgccactat aactactctc tctacggtga tactctcgag 960 caaacactga agaagtgctt gaacgagatc ctgattagat gcatcatttg tcaaaggcca 1020 ctttgtccac aggagaagaa gaggcacgtg gacctgaata agcgctttca taacatctct 1080 ggcagatgga caggccgatg cgctgtatgt tggcgcccac ggagaaggca aacccaggtg 1140 tgacggaccg cctctccctc cc 1162 <210> SEQ ID NO 67 <211> LENGTH: 1009 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-H6-murineScn-StrepII-GGGGS-E7.58 <400> SEQUENCE: 67 ctcgagacca tggagaccga cacgctcttg ttgtgggttc tcttgttgtg ggtgcctggg 60 tctacaggcg accaccacca tcatcaccac ctcgttccta gaggcagcca ggatagtacc 120 cagaatctta tcccagcacc atctttgctc acagtaccat tgcaacccga ctttcggtct 180 gatcaatttc ggggacgctg gtacgtggtt ggactggccg gcaatgctgt acagaaaaaa 240 acagagggca gtttcaccat gtactcaaca atctatgagc tccaagagaa taatagttac 300 aacgttacct ccatcttggt gagggaccag gatcagggat gtcgctactg gattcggaca 360

ttcgtaccaa gttctcgggc cggtcagttt actctgggca acatgcacag gtatccccaa 420 gttcaatctt acaacgtgca ggtggcgact accgactaca accaattcgc tatggtgttc 480 ttccgcaaaa caagcgagaa caagcagtat tttaaaatca ctctgtacgg tagaactaag 540 gagctgagcc ctgaacttaa ggagcggttc accagattcg ctaagtccct gggactgaag 600 gatgataata taatcttttc cgtccccacc gatcagtgta tcgataattc agcttggtca 660 catccccagt tcgagaaagg aggcggtgga tccatgcggg ggaataaccc caccctgcgc 720 gagtacattc ttgacctgca cccagagcct acggatctgt tttgttacga acaactgtgc 780 gactcctccg acgaggatga gatcgggctg gatggcccag acgggcaggc acagcctgct 840 acagctaact actatattgt gacatgttgc tacacatgcg gaacgacggt cagactgtgc 900 attaatagca ctgccacaga cgtgcggacc ctgcagcaac tgctcatggg gacctgcact 960 attgtgtgtc cttcatgtgc gcagcaatga cggaccgcct ctccctccc 1009 <210> SEQ ID NO 68 <211> LENGTH: 319 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-sFLAG-H6-GGS-humanScn-GGS-ENLYFQ-GG-Adv2E3/19K <400> SEQUENCE: 68 Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Asp Tyr Lys Asp Glu His His His His His His Gly 20 25 30 Gly Ser Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser 35 40 45 Lys Val Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe Gln Gly Lys 50 55 60 Trp Tyr Val Val Gly Leu Ala Gly Asn Ala Ile Leu Arg Glu Asp Lys 65 70 75 80 Asp Pro Gln Lys Met Tyr Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys 85 90 95 Ser Tyr Asn Val Thr Ser Val Leu Phe Arg Lys Lys Lys Cys Asp Tyr 100 105 110 Trp Ile Arg Thr Phe Val Pro Gly Ser Gln Pro Gly Glu Phe Thr Leu 115 120 125 Gly Asn Ile Lys Ser Tyr Pro Gly Leu Thr Ser Tyr Leu Val Arg Val 130 135 140 Val Ser Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys Lys Val 145 150 155 160 Ser Gln Asn Arg Glu Tyr Phe Lys Ile Thr Leu Tyr Gly Arg Thr Lys 165 170 175 Glu Leu Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser 180 185 190 Leu Gly Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile Asp Gln 195 200 205 Cys Ile Asp Gly Gly Gly Ser Glu Asn Leu Tyr Phe Gln Gly Gly Ala 210 215 220 Lys Lys Val Glu Phe Lys Glu Pro Ala Cys Asn Val Thr Phe Lys Ser 225 230 235 240 Glu Ala Asn Glu Cys Thr Thr Leu Ile Lys Cys Thr Thr Glu His Glu 245 250 255 Lys Leu Ile Ile Arg His Lys Asp Lys Ile Gly Lys Tyr Ala Val Tyr 260 265 270 Ala Ile Trp Gln Pro Gly Asp Thr Asn Asp Tyr Asn Val Thr Val Phe 275 280 285 Gln Gly Glu Asn Arg Lys Thr Phe Met Tyr Lys Phe Pro Phe Tyr Glu 290 295 300 Met Cys Asp Ile Thr Met Tyr Met Ser Lys Gln Tyr Lys Leu Trp 305 310 315 <210> SEQ ID NO 69 <211> LENGTH: 704 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-sFLAG-H6-GGS-humanScn-GGS-ENLYFQ-GG-SF162gp120 <400> SEQUENCE: 69 Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Asp Tyr Lys Asp Glu His His His His His His Gly 20 25 30 Gly Ser Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser 35 40 45 Lys Val Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe Gln Gly Lys 50 55 60 Trp Tyr Val Val Gly Leu Ala Gly Asn Ala Ile Leu Arg Glu Asp Lys 65 70 75 80 Asp Pro Gln Lys Met Tyr Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys 85 90 95 Ser Tyr Asn Val Thr Ser Val Leu Phe Arg Lys Lys Lys Cys Asp Tyr 100 105 110 Trp Ile Arg Thr Phe Val Pro Gly Ser Gln Pro Gly Glu Phe Thr Leu 115 120 125 Gly Asn Ile Lys Ser Tyr Pro Gly Leu Thr Ser Tyr Leu Val Arg Val 130 135 140 Val Ser Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys Lys Val 145 150 155 160 Ser Gln Asn Arg Glu Tyr Phe Lys Ile Thr Leu Tyr Gly Arg Thr Lys 165 170 175 Glu Leu Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser 180 185 190 Leu Gly Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile Asp Gln 195 200 205 Cys Ile Asp Gly Gly Gly Ser Glu Asn Leu Tyr Phe Gln Gly Gly Trp 210 215 220 Val Thr Val Tyr Tyr Gly Val Pro Val Trp Lys Glu Ala Thr Thr Thr 225 230 235 240 Leu Phe Cys Ala Ser Asp Ala Lys Ala Tyr Asp Thr Glu Val His Asn 245 250 255 Val Trp Ala Thr His Ala Cys Val Pro Thr Asp Pro Asn Pro Gln Glu 260 265 270 Ile Val Leu Glu Asn Val Thr Glu Asn Phe Asn Met Trp Lys Asn Asn 275 280 285 Met Val Glu Gln Met His Glu Asp Ile Ile Ser Leu Trp Asp Gln Ser 290 295 300 Leu Lys Pro Cys Val Lys Leu Thr Pro Leu Cys Val Thr Leu His Cys 305 310 315 320 Thr Asn Leu Lys Asn Ala Thr Asn Thr Lys Ser Ser Asn Trp Lys Glu 325 330 335 Met Asp Arg Gly Glu Ile Lys Asn Cys Ser Phe Lys Val Thr Thr Ser 340 345 350 Ile Arg Asn Lys Met Gln Lys Glu Tyr Ala Leu Phe Tyr Lys Leu Asp 355 360 365 Val Val Pro Ile Asp Asn Asp Asn Thr Ser Tyr Lys Leu Ile Asn Cys 370 375 380 Asn Thr Ser Val Ile Thr Gln Ala Cys Pro Lys Val Ser Phe Glu Pro 385 390 395 400 Ile Pro Ile His Tyr Cys Ala Pro Ala Gly Phe Ala Ile Leu Lys Cys 405 410 415 Asn Asp Lys Lys Phe Asn Gly Ser Gly Pro Cys Thr Asn Val Ser Thr 420 425 430 Val Gln Cys Thr His Gly Ile Arg Pro Val Val Ser Thr Gln Leu Leu 435 440 445 Leu Asn Gly Ser Leu Ala Glu Glu Gly Val Val Ile Arg Ser Glu Asn 450 455 460 Phe Thr Asp Asn Ala Lys Thr Ile Ile Val Gln Leu Lys Glu Ser Val 465 470 475 480 Glu Ile Asn Cys Thr Arg Pro Asn Asn Asn Thr Arg Lys Ser Ile Thr 485 490 495 Ile Gly Pro Gly Arg Ala Phe Tyr Ala Thr Gly Asp Ile Ile Gly Asp 500 505 510 Ile Arg Gln Ala His Cys Asn Ile Ser Gly Glu Lys Trp Asn Asn Thr 515 520 525 Leu Lys Gln Ile Val Thr Lys Leu Gln Ala Gln Phe Gly Asn Lys Thr 530 535 540 Ile Val Phe Lys Gln Ser Ser Gly Gly Asp Pro Glu Ile Val Met His 545 550 555 560 Ser Phe Asn Cys Gly Gly Glu Phe Phe Tyr Cys Asn Ser Thr Gln Leu 565 570 575 Phe Asn Ser Thr Trp Asn Asn Thr Ile Gly Pro Asn Asn Thr Asn Gly 580 585 590 Thr Ile Thr Leu Pro Cys Arg Ile Lys Gln Ile Ile Asn Arg Trp Gln 595 600 605 Glu Val Gly Lys Ala Met Tyr Ala Pro Pro Ile Arg Gly Gln Ile Arg 610 615 620 Cys Ser Ser Asn Ile Thr Gly Leu Leu Leu Thr Arg Asp Gly Gly Lys 625 630 635 640 Glu Ile Ser Asn Thr Thr Glu Ile Phe Arg Pro Gly Gly Gly Asp Met 645 650 655 Arg Asp Asn Trp Arg Ser Glu Leu Tyr Lys Tyr Lys Val Val Lys Ile 660 665 670 Glu Pro Leu Gly Val Ala Pro Thr Lys Ala Lys Arg Arg Val Val Gln 675 680 685 Gln Gly Leu Asn Asp Ile Phe Glu Ala Gln Lys Ile Glu Trp His Glu 690 695 700 <210> SEQ ID NO 70 <211> LENGTH: 723 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-sFLAG-H6-GGS-humanScn-GGS-ENLYFQ-GG-QH0692gp120 <400> SEQUENCE: 70 Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15

Gly Ser Thr Gly Asp Tyr Lys Asp Glu His His His His His His Gly 20 25 30 Gly Ser Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser 35 40 45 Lys Val Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe Gln Gly Lys 50 55 60 Trp Tyr Val Val Gly Leu Ala Gly Asn Ala Ile Leu Arg Glu Asp Lys 65 70 75 80 Asp Pro Gln Lys Met Tyr Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys 85 90 95 Ser Tyr Asn Val Thr Ser Val Leu Phe Arg Lys Lys Lys Cys Asp Tyr 100 105 110 Trp Ile Arg Thr Phe Val Pro Gly Ser Gln Pro Gly Glu Phe Thr Leu 115 120 125 Gly Asn Ile Lys Ser Tyr Pro Gly Leu Thr Ser Tyr Leu Val Arg Val 130 135 140 Val Ser Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys Lys Val 145 150 155 160 Ser Gln Asn Arg Glu Tyr Phe Lys Ile Thr Leu Tyr Gly Arg Thr Lys 165 170 175 Glu Leu Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser 180 185 190 Leu Gly Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile Asp Gln 195 200 205 Cys Ile Asp Gly Gly Gly Ser Glu Asn Leu Tyr Phe Gln Gly Gly Trp 210 215 220 Val Thr Val Tyr Tyr Gly Val Pro Val Trp Lys Glu Ala Thr Thr Thr 225 230 235 240 Leu Phe Cys Ala Ser Asp Ala Lys Ala Tyr Glu Thr Glu Lys His Asn 245 250 255 Val Trp Ala Thr His Ala Cys Val Pro Thr Asp Pro Asn Pro Gln Glu 260 265 270 Val Val Leu Gly Asn Val Thr Glu Asn Phe Asn Met Trp Lys Asn Asn 275 280 285 Met Val Glu Gln Met His Glu Asp Ile Ile Ser Leu Trp Asp Glu Ser 290 295 300 Leu Lys Pro Cys Val Lys Leu Thr Pro Leu Cys Val Thr Leu Asn Cys 305 310 315 320 Thr Asp Glu Val Lys Thr Ser Tyr Ala Asn Lys Thr Ser Asn Glu Thr 325 330 335 Tyr Lys Thr Ser Asn Glu Thr Phe Gly Glu Ile Lys Asn Cys Ser Phe 340 345 350 Ser Val Pro Thr Gly Ile Lys Asp Lys Val Gln Asn Val Tyr Ala Leu 355 360 365 Phe Tyr Lys Leu Asp Val Ile Pro Ile Asp Asp Asn Asn Asn Ser Ser 370 375 380 Lys Asn Asn Asn Gly Ser Tyr Ser Ser Tyr Arg Leu Ile Asn Cys Asn 385 390 395 400 Thr Ser Val Ile Thr Gln Ala Cys Pro Lys Val Ser Phe Glu Pro Ile 405 410 415 Pro Ile His Tyr Cys Ala Pro Ala Gly Phe Ala Ile Leu Lys Cys Asn 420 425 430 Asn Lys Thr Phe Asn Gly Thr Gly Pro Cys Thr Asn Val Ser Thr Val 435 440 445 Gln Cys Thr His Gly Ile Arg Pro Val Val Ser Thr Gln Leu Leu Leu 450 455 460 Asn Gly Ser Leu Ala Glu Glu Glu Val Val Ile Arg Ser Glu Asn Phe 465 470 475 480 Thr Asn Asn Ala Lys Thr Ile Ile Val His Leu Lys Lys Ser Val Glu 485 490 495 Ile Asn Cys Thr Arg Pro Gly Asn Asn Thr Arg Lys Ser Ile His Ile 500 505 510 Gly Pro Gly Arg Ala Phe Tyr Ala Thr Gly Asp Ile Ile Gly Asp Ile 515 520 525 Arg Gln Ala His Cys Asn Leu Ser Ser Val Gln Trp Asn Asp Thr Leu 530 535 540 Lys Gln Ile Val Ile Lys Leu Gly Glu Gln Phe Gly Thr Asn Lys Thr 545 550 555 560 Ile Ala Phe Asn Gln Ser Ser Gly Gly Asp Pro Glu Ile Val Met His 565 570 575 Ser Phe Asn Cys Gly Gly Glu Phe Phe Tyr Cys Asn Thr Thr Gln Leu 580 585 590 Phe Asn Ser Thr Trp Glu Phe His Gly Asn Trp Thr Arg Ser Asn Phe 595 600 605 Thr Glu Ser Asn Ser Thr Thr Ile Thr Leu Pro Cys Arg Ile Lys Gln 610 615 620 Ile Val Asn Met Trp Gln Glu Val Gly Lys Ala Met Tyr Ala Pro Pro 625 630 635 640 Ile Arg Gly Gln Ile Arg Cys Ser Ser Asn Ile Thr Gly Leu Leu Leu 645 650 655 Thr Arg Asp Gly Gly Val Asn Gly Thr Arg Glu Thr Phe Arg Pro Gly 660 665 670 Gly Gly Asp Met Arg Asp Asn Trp Arg Ser Glu Leu Tyr Lys Tyr Lys 675 680 685 Val Val Lys Ile Glu Pro Leu Gly Val Ala Pro Thr Lys Ala Lys Arg 690 695 700 Arg Val Val Gln Gly Leu Asn Asp Ile Phe Glu Ala Gln Lys Ile Glu 705 710 715 720 Trp His Glu <210> SEQ ID NO 71 <211> LENGTH: 259 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-sFLAG-H6-GGS-humanScn-GGS-ENLYFQ-GG-ITPR-1 <400> SEQUENCE: 71 Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Asp Tyr Lys Asp Glu His His His His His His Gly 20 25 30 Gly Ser Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser 35 40 45 Lys Val Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe Gln Gly Lys 50 55 60 Trp Tyr Val Val Gly Leu Ala Gly Asn Ala Ile Leu Arg Glu Asp Lys 65 70 75 80 Asp Pro Gln Lys Met Tyr Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys 85 90 95 Ser Tyr Asn Val Thr Ser Val Leu Phe Arg Lys Lys Lys Cys Asp Tyr 100 105 110 Trp Ile Arg Thr Phe Val Pro Gly Ser Gln Pro Gly Glu Phe Thr Leu 115 120 125 Gly Asn Ile Lys Ser Tyr Pro Gly Leu Thr Ser Tyr Leu Val Arg Val 130 135 140 Val Ser Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys Lys Val 145 150 155 160 Ser Gln Asn Arg Glu Tyr Phe Lys Ile Thr Leu Tyr Gly Arg Thr Lys 165 170 175 Glu Leu Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser 180 185 190 Leu Gly Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile Asp Gln 195 200 205 Cys Ile Asp Gly Gly Gly Ser Glu Asn Leu Tyr Phe Gln Gly Gly Ser 210 215 220 Lys Cys Arg Val Phe Asn Thr Thr Glu Arg Asp Glu Gln Gly Ser Lys 225 230 235 240 Val Asn Asp Phe Phe Gln Gln Thr Glu Asp Leu Tyr Asn Glu Met Lys 245 250 255 Trp Gln Lys <210> SEQ ID NO 72 <211> LENGTH: 259 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-sFLAG-H6-GGS-humanScn-GGS-ENLYFQ-GG-ITPR-2 <400> SEQUENCE: 72 Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Asp Tyr Lys Asp Glu His His His His His His Gly 20 25 30 Gly Ser Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser 35 40 45 Lys Val Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe Gln Gly Lys 50 55 60 Trp Tyr Val Val Gly Leu Ala Gly Asn Ala Ile Leu Arg Glu Asp Lys 65 70 75 80 Asp Pro Gln Lys Met Tyr Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys 85 90 95 Ser Tyr Asn Val Thr Ser Val Leu Phe Arg Lys Lys Lys Cys Asp Tyr 100 105 110 Trp Ile Arg Thr Phe Val Pro Gly Ser Gln Pro Gly Glu Phe Thr Leu 115 120 125 Gly Asn Ile Lys Ser Tyr Pro Gly Leu Thr Ser Tyr Leu Val Arg Val 130 135 140 Val Ser Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys Lys Val 145 150 155 160 Ser Gln Asn Arg Glu Tyr Phe Lys Ile Thr Leu Tyr Gly Arg Thr Lys 165 170 175 Glu Leu Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser 180 185 190 Leu Gly Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile Asp Gln 195 200 205 Cys Ile Asp Gly Gly Gly Ser Glu Asn Leu Tyr Phe Gln Gly Gly Pro 210 215 220 Pro His Glu Leu Thr Glu Glu Glu Lys Gln Gln Ile Leu His Ser Glu 225 230 235 240

Glu Phe Leu Ser Phe Phe Asp His Ser Thr Arg Ile Val Glu Arg Ala 245 250 255 Leu Ser Glu <210> SEQ ID NO 73 <211> LENGTH: 259 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-sFLAG-H6-GGS-humanScn-GGS-ENLYFQ-GG-ITPR-3 <400> SEQUENCE: 73 Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Asp Tyr Lys Asp Glu His His His His His His Gly 20 25 30 Gly Ser Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser 35 40 45 Lys Val Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe Gln Gly Lys 50 55 60 Trp Tyr Val Val Gly Leu Ala Gly Asn Ala Ile Leu Arg Glu Asp Lys 65 70 75 80 Asp Pro Gln Lys Met Tyr Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys 85 90 95 Ser Tyr Asn Val Thr Ser Val Leu Phe Arg Lys Lys Lys Cys Asp Tyr 100 105 110 Trp Ile Arg Thr Phe Val Pro Gly Ser Gln Pro Gly Glu Phe Thr Leu 115 120 125 Gly Asn Ile Lys Ser Tyr Pro Gly Leu Thr Ser Tyr Leu Val Arg Val 130 135 140 Val Ser Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys Lys Val 145 150 155 160 Ser Gln Asn Arg Glu Tyr Phe Lys Ile Thr Leu Tyr Gly Arg Thr Lys 165 170 175 Glu Leu Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser 180 185 190 Leu Gly Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile Asp Gln 195 200 205 Cys Ile Asp Gly Gly Gly Ser Glu Asn Leu Tyr Phe Gln Gly Gly Pro 210 215 220 Pro Pro Arg Cys Ile Ser Thr Asn Lys Cys Thr Ala Pro Glu Val Glu 225 230 235 240 Asn Ala Ile Arg Val Pro Gly Asn Arg Ser Phe Phe Ser Leu Thr Glu 245 250 255 Ile Val Arg <210> SEQ ID NO 74 <211> LENGTH: 259 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-sFLAG-H6-GGS-humanScn-GGS-ENLYFQ-GG-ITPR-4 <400> SEQUENCE: 74 Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Asp Tyr Lys Asp Glu His His His His His His Gly 20 25 30 Gly Ser Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser 35 40 45 Lys Val Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe Gln Gly Lys 50 55 60 Trp Tyr Val Val Gly Leu Ala Gly Asn Ala Ile Leu Arg Glu Asp Lys 65 70 75 80 Asp Pro Gln Lys Met Tyr Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys 85 90 95 Ser Tyr Asn Val Thr Ser Val Leu Phe Arg Lys Lys Lys Cys Asp Tyr 100 105 110 Trp Ile Arg Thr Phe Val Pro Gly Ser Gln Pro Gly Glu Phe Thr Leu 115 120 125 Gly Asn Ile Lys Ser Tyr Pro Gly Leu Thr Ser Tyr Leu Val Arg Val 130 135 140 Val Ser Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys Lys Val 145 150 155 160 Ser Gln Asn Arg Glu Tyr Phe Lys Ile Thr Leu Tyr Gly Arg Thr Lys 165 170 175 Glu Leu Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser 180 185 190 Leu Gly Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile Asp Gln 195 200 205 Cys Ile Asp Gly Gly Gly Ser Glu Asn Leu Tyr Phe Gln Gly Gly Thr 210 215 220 Glu Arg Asp Glu Gln Gly Ser Lys Ile Asn Asp Phe Phe Leu Arg Ser 225 230 235 240 Glu Asp Leu Phe Asn Glu Met Asn Trp Gln Lys Lys Leu Arg Ala Gln 245 250 255 Pro Val Leu <210> SEQ ID NO 75 <211> LENGTH: 259 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-sFLAG-H6-GGS-humanScn-GGS-ENLYFQ-GG-ITPR-5 <400> SEQUENCE: 75 Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Asp Tyr Lys Asp Glu His His His His His His Gly 20 25 30 Gly Ser Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser 35 40 45 Lys Val Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe Gln Gly Lys 50 55 60 Trp Tyr Val Val Gly Leu Ala Gly Asn Ala Ile Leu Arg Glu Asp Lys 65 70 75 80 Asp Pro Gln Lys Met Tyr Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys 85 90 95 Ser Tyr Asn Val Thr Ser Val Leu Phe Arg Lys Lys Lys Cys Asp Tyr 100 105 110 Trp Ile Arg Thr Phe Val Pro Gly Ser Gln Pro Gly Glu Phe Thr Leu 115 120 125 Gly Asn Ile Lys Ser Tyr Pro Gly Leu Thr Ser Tyr Leu Val Arg Val 130 135 140 Val Ser Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys Lys Val 145 150 155 160 Ser Gln Asn Arg Glu Tyr Phe Lys Ile Thr Leu Tyr Gly Arg Thr Lys 165 170 175 Glu Leu Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser 180 185 190 Leu Gly Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile Asp Gln 195 200 205 Cys Ile Asp Gly Gly Gly Ser Glu Asn Leu Tyr Phe Gln Gly Gly Leu 210 215 220 Thr Glu Glu Thr Lys His Arg Leu Phe Thr Thr Thr Glu Gln Asp Glu 225 230 235 240 Gln Gly Ser Lys Val Ser Asp Phe Phe Asp Gln Ser Ser Phe Leu His 245 250 255 Asn Glu Met <210> SEQ ID NO 76 <211> LENGTH: 259 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-sFLAG-H6-GGS-humanScn-GGS-ENLYFQ-GG-ITPR-8 <400> SEQUENCE: 76 Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Asp Tyr Lys Asp Glu His His His His His His Gly 20 25 30 Gly Ser Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser 35 40 45 Lys Val Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe Gln Gly Lys 50 55 60 Trp Tyr Val Val Gly Leu Ala Gly Asn Ala Ile Leu Arg Glu Asp Lys 65 70 75 80 Asp Pro Gln Lys Met Tyr Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys 85 90 95 Ser Tyr Asn Val Thr Ser Val Leu Phe Arg Lys Lys Lys Cys Asp Tyr 100 105 110 Trp Ile Arg Thr Phe Val Pro Gly Ser Gln Pro Gly Glu Phe Thr Leu 115 120 125 Gly Asn Ile Lys Ser Tyr Pro Gly Leu Thr Ser Tyr Leu Val Arg Val 130 135 140 Val Ser Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys Lys Val 145 150 155 160 Ser Gln Asn Arg Glu Tyr Phe Lys Ile Thr Leu Tyr Gly Arg Thr Lys 165 170 175 Glu Leu Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser 180 185 190 Leu Gly Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile Asp Gln 195 200 205 Cys Ile Asp Gly Gly Gly Ser Glu Asn Leu Tyr Phe Gln Gly Gly Gly 210 215 220 Ala Gln Pro Pro Phe Asp Ala Gln Ser Pro Leu Asp Ser Gln Pro Gln 225 230 235 240 Pro Ser Gly Gln Pro Trp Asn Phe His Ala Ser Thr Ser Trp Tyr Trp 245 250 255 Arg Gln Ser <210> SEQ ID NO 77

<211> LENGTH: 488 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-sFLAG-H6-GGS-humanScn-GGS-ENLYFQ-GG-human HMOX1 <400> SEQUENCE: 77 Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Asp Tyr Lys Asp Glu His His His His His His Gly 20 25 30 Gly Ser Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser 35 40 45 Lys Val Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe Gln Gly Lys 50 55 60 Trp Tyr Val Val Gly Leu Ala Gly Asn Ala Ile Leu Arg Glu Asp Lys 65 70 75 80 Asp Pro Gln Lys Met Tyr Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys 85 90 95 Ser Tyr Asn Val Thr Ser Val Leu Phe Arg Lys Lys Lys Cys Asp Tyr 100 105 110 Trp Ile Arg Thr Phe Val Pro Gly Ser Gln Pro Gly Glu Phe Thr Leu 115 120 125 Gly Asn Ile Lys Ser Tyr Pro Gly Leu Thr Ser Tyr Leu Val Arg Val 130 135 140 Val Ser Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys Lys Val 145 150 155 160 Ser Gln Asn Arg Glu Tyr Phe Lys Ile Thr Leu Tyr Gly Arg Thr Lys 165 170 175 Glu Leu Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser 180 185 190 Leu Gly Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile Asp Gln 195 200 205 Cys Ile Asp Gly Gly Gly Ser Glu Asn Leu Tyr Phe Gln Gly Gly Met 210 215 220 Glu Arg Pro Gln Pro Asp Ser Met Pro Gln Asp Leu Ser Glu Ala Leu 225 230 235 240 Lys Glu Ala Thr Lys Glu Val His Thr Gln Ala Glu Asn Ala Glu Phe 245 250 255 Met Arg Asn Phe Gln Lys Gly Gln Val Thr Arg Asp Gly Phe Lys Leu 260 265 270 Val Met Ala Ser Leu Tyr His Ile Tyr Val Ala Leu Glu Glu Glu Ile 275 280 285 Glu Arg Asn Lys Glu Ser Pro Val Phe Ala Pro Val Tyr Phe Pro Glu 290 295 300 Glu Leu His Arg Lys Ala Ala Leu Glu Gln Asp Leu Ala Phe Trp Tyr 305 310 315 320 Gly Pro Arg Trp Gln Glu Val Ile Pro Tyr Thr Pro Ala Met Gln Arg 325 330 335 Tyr Val Lys Arg Leu His Glu Val Gly Arg Thr Glu Pro Glu Leu Leu 340 345 350 Val Ala His Ala Tyr Thr Arg Tyr Leu Gly Asp Leu Ser Gly Gly Gln 355 360 365 Val Leu Lys Lys Ile Ala Gln Lys Ala Leu Asp Leu Pro Ser Ser Gly 370 375 380 Glu Gly Leu Ala Phe Phe Thr Phe Pro Asn Ile Ala Ser Ala Thr Lys 385 390 395 400 Phe Lys Gln Leu Tyr Arg Ser Arg Met Asn Ser Leu Glu Met Thr Pro 405 410 415 Ala Val Arg Gln Arg Val Ile Glu Glu Ala Lys Thr Ala Phe Leu Leu 420 425 430 Asn Ile Gln Leu Phe Glu Glu Leu Gln Glu Leu Leu Thr His Asp Thr 435 440 445 Lys Asp Gln Ser Pro Ser Arg Ala Pro Gly Leu Arg Gln Arg Ala Ser 450 455 460 Asn Lys Val Gln Asp Ser Ala Pro Val Glu Thr Pro Arg Gly Lys Pro 465 470 475 480 Pro Leu Asn Thr Arg Ser Gln Ala 485 <210> SEQ ID NO 78 <211> LENGTH: 488 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-sFLAG-H6-GGS-humanScn-GGS-ENLYFQ-GG-murineHMOX1 <400> SEQUENCE: 78 Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Asp Tyr Lys Asp Glu His His His His His His Gly 20 25 30 Gly Ser Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser 35 40 45 Lys Val Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe Gln Gly Lys 50 55 60 Trp Tyr Val Val Gly Leu Ala Gly Asn Ala Ile Leu Arg Glu Asp Lys 65 70 75 80 Asp Pro Gln Lys Met Tyr Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys 85 90 95 Ser Tyr Asn Val Thr Ser Val Leu Phe Arg Lys Lys Lys Cys Asp Tyr 100 105 110 Trp Ile Arg Thr Phe Val Pro Gly Ser Gln Pro Gly Glu Phe Thr Leu 115 120 125 Gly Asn Ile Lys Ser Tyr Pro Gly Leu Thr Ser Tyr Leu Val Arg Val 130 135 140 Val Ser Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys Lys Val 145 150 155 160 Ser Gln Asn Arg Glu Tyr Phe Lys Ile Thr Leu Tyr Gly Arg Thr Lys 165 170 175 Glu Leu Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser 180 185 190 Leu Gly Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile Asp Gln 195 200 205 Cys Ile Asp Gly Gly Gly Ser Glu Asn Leu Tyr Phe Gln Gly Gly Met 210 215 220 Glu Arg Pro Gln Pro Asp Ser Met Pro Gln Asp Leu Ser Glu Ala Leu 225 230 235 240 Lys Glu Ala Thr Lys Glu Val His Ile Gln Ala Glu Asn Ala Glu Phe 245 250 255 Met Lys Asn Phe Gln Lys Gly Gln Val Ser Arg Glu Gly Phe Lys Leu 260 265 270 Val Met Ala Ser Leu Tyr His Ile Tyr Thr Ala Leu Glu Glu Glu Ile 275 280 285 Glu Arg Asn Lys Gln Asn Pro Val Tyr Ala Pro Leu Tyr Phe Pro Glu 290 295 300 Glu Leu His Arg Arg Ala Ala Leu Glu Gln Asp Met Ala Phe Trp Tyr 305 310 315 320 Gly Pro His Trp Gln Glu Ile Ile Pro Cys Thr Pro Ala Thr Gln His 325 330 335 Tyr Val Lys Arg Leu His Glu Val Gly Arg Thr His Pro Glu Leu Leu 340 345 350 Val Ala His Ala Tyr Thr Arg Tyr Leu Gly Asp Leu Ser Gly Gly Gln 355 360 365 Val Leu Lys Lys Ile Ala Gln Lys Ala Met Ala Leu Pro Ser Ser Gly 370 375 380 Glu Gly Leu Ala Phe Phe Thr Phe Pro Asn Ile Asp Ser Pro Thr Lys 385 390 395 400 Phe Lys Gln Leu Tyr Arg Ala Arg Met Asn Thr Leu Glu Met Thr Pro 405 410 415 Glu Val Lys His Arg Val Thr Glu Glu Ala Lys Thr Ala Phe Leu Leu 420 425 430 Asn Ile Glu Leu Phe Glu Glu Leu Gln Val Met Leu Thr Glu Glu His 435 440 445 Lys Asp Gln Ser Pro Ser Gln Met Ala Ser Leu Arg Gln Arg Pro Ala 450 455 460 Ser Leu Val Gln Asp Thr Ala Pro Ala Glu Thr Pro Arg Gly Lys Pro 465 470 475 480 Gln Ile Ser Thr Ser Ser Ser Gln 485 <210> SEQ ID NO 79 <211> LENGTH: 489 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: humanScn-humanHMOX1 <400> SEQUENCE: 79 Met Pro Leu Gly Leu Leu Trp Leu Gly Leu Ala Leu Leu Gly Ala Leu 1 5 10 15 His Ala Gln Ala Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro 20 25 30 Leu Ser Lys Val Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe Gln 35 40 45 Gly Lys Trp Tyr Val Val Gly Leu Ala Gly Asn Ala Ile Leu Arg Glu 50 55 60 Asp Lys Asp Pro Gln Lys Met Tyr Ala Thr Ile Tyr Glu Leu Lys Glu 65 70 75 80 Asp Lys Ser Tyr Asn Val Thr Ser Val Leu Phe Arg Lys Lys Lys Cys 85 90 95 Asp Tyr Trp Ile Arg Thr Phe Val Pro Gly Ser Gln Pro Gly Glu Phe 100 105 110 Thr Leu Gly Asn Ile Lys Ser Tyr Pro Gly Leu Thr Ser Tyr Leu Val 115 120 125 Arg Val Val Ser Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys 130 135 140 Lys Val Ser Gln Asn Arg Glu Tyr Phe Lys Ile Thr Leu Tyr Gly Arg 145 150 155 160 Thr Lys Glu Leu Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser 165 170 175 Lys Ser Leu Gly Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile 180 185 190

Asp Gln Cys Ile Asp Gly Gly Gly Ser Glu Asn Leu Tyr Phe Gln Gly 195 200 205 Gly Gly Met Glu Arg Pro Gln Pro Asp Ser Met Pro Gln Asp Leu Ser 210 215 220 Glu Ala Leu Lys Glu Ala Thr Lys Glu Val His Thr Gln Ala Glu Asn 225 230 235 240 Ala Glu Phe Met Arg Asn Phe Gln Lys Gly Gln Val Thr Arg Asp Gly 245 250 255 Phe Lys Leu Val Met Ala Ser Leu Tyr His Ile Tyr Val Ala Leu Glu 260 265 270 Glu Glu Ile Glu Arg Asn Lys Glu Ser Pro Val Phe Ala Pro Val Tyr 275 280 285 Phe Pro Glu Glu Leu His Arg Lys Ala Ala Leu Glu Gln Asp Leu Ala 290 295 300 Phe Trp Tyr Gly Pro Arg Trp Gln Glu Val Ile Pro Tyr Thr Pro Ala 305 310 315 320 Met Gln Arg Tyr Val Lys Arg Leu His Glu Val Gly Arg Thr Glu Pro 325 330 335 Glu Leu Leu Val Ala His Ala Tyr Thr Arg Tyr Leu Gly Asp Leu Ser 340 345 350 Gly Gly Gln Val Leu Lys Lys Ile Ala Gln Lys Ala Leu Asp Leu Pro 355 360 365 Ser Ser Gly Glu Gly Leu Ala Phe Phe Thr Phe Pro Asn Ile Ala Ser 370 375 380 Ala Thr Lys Phe Lys Gln Leu Tyr Arg Ser Arg Met Asn Ser Leu Glu 385 390 395 400 Met Thr Pro Ala Val Arg Gln Arg Val Ile Glu Glu Ala Lys Thr Ala 405 410 415 Phe Leu Leu Asn Ile Gln Leu Phe Glu Glu Leu Gln Glu Leu Leu Thr 420 425 430 His Asp Thr Lys Asp Gln Ser Pro Ser Arg Ala Pro Gly Leu Arg Gln 435 440 445 Arg Ala Ser Asn Lys Val Gln Asp Ser Ala Pro Val Glu Thr Pro Arg 450 455 460 Gly Lys Pro Pro Leu Asn Thr Arg Ser Gln Ala Gly Gly Leu Val Pro 465 470 475 480 Arg Gly Ser His His His His His His 485 <210> SEQ ID NO 80 <211> LENGTH: 387 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: humanScn-cTHAP4 <400> SEQUENCE: 80 Met Pro Leu Gly Leu Leu Trp Leu Gly Leu Ala Leu Leu Gly Ala Leu 1 5 10 15 His Ala Gln Ala Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro 20 25 30 Leu Ser Lys Val Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe Gln 35 40 45 Gly Lys Trp Tyr Val Val Gly Leu Ala Gly Asn Ala Ile Leu Arg Glu 50 55 60 Asp Lys Asp Pro Gln Lys Met Tyr Ala Thr Ile Tyr Glu Leu Lys Glu 65 70 75 80 Asp Lys Ser Tyr Asn Val Thr Ser Val Leu Phe Arg Lys Lys Lys Cys 85 90 95 Asp Tyr Trp Ile Arg Thr Phe Val Pro Gly Ser Gln Pro Gly Glu Phe 100 105 110 Thr Leu Gly Asn Ile Lys Ser Tyr Pro Gly Leu Thr Ser Tyr Leu Val 115 120 125 Arg Val Val Ser Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys 130 135 140 Lys Val Ser Gln Asn Arg Glu Tyr Phe Lys Ile Thr Leu Tyr Gly Arg 145 150 155 160 Thr Lys Glu Leu Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser 165 170 175 Lys Ser Leu Gly Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile 180 185 190 Asp Gln Cys Ile Asp Gly Gly Gly Ser Glu Asn Leu Tyr Phe Gln Gly 195 200 205 Gly Gly Pro Pro Lys Met Asn Pro Val Val Glu Pro Leu Ser Trp Met 210 215 220 Leu Gly Thr Trp Leu Ser Asp Pro Pro Gly Ala Gly Thr Tyr Pro Thr 225 230 235 240 Leu Gln Pro Phe Gln Tyr Leu Glu Glu Val His Ile Ser His Val Gly 245 250 255 Gln Pro Met Leu Asn Phe Ser Phe Asn Ser Phe His Pro Asp Thr Arg 260 265 270 Lys Pro Met His Arg Glu Cys Gly Phe Ile Arg Leu Lys Pro Asp Thr 275 280 285 Asn Lys Val Ala Phe Val Ser Ala Gln Asn Thr Gly Val Val Glu Val 290 295 300 Glu Glu Gly Glu Val Asn Gly Gln Glu Leu Cys Ile Ala Ser His Ser 305 310 315 320 Ile Ala Arg Ile Ser Phe Ala Lys Glu Pro His Val Glu Gln Ile Thr 325 330 335 Arg Lys Phe Arg Leu Asn Ser Glu Gly Lys Leu Glu Gln Thr Val Ser 340 345 350 Met Ala Thr Thr Thr Gln Pro Met Thr Gln His Leu His Val Thr Tyr 355 360 365 Lys Lys Val Thr Pro Gly Gly Leu Val Pro Arg Gly Ser His His His 370 375 380 His His His 385 <210> SEQ ID NO 81 <211> LENGTH: 295 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-sFLAG-H6-GGS-humanScn-GGS-ENLYFQ-GG-heptamer <400> SEQUENCE: 81 Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Asp Tyr Lys Asp Glu His His His His His His Gly 20 25 30 Gly Ser Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser 35 40 45 Lys Val Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe Gln Gly Lys 50 55 60 Trp Tyr Val Val Gly Leu Ala Gly Asn Ala Ile Leu Arg Glu Asp Lys 65 70 75 80 Asp Pro Gln Lys Met Tyr Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys 85 90 95 Ser Tyr Asn Val Thr Ser Val Leu Phe Arg Lys Lys Lys Cys Asp Tyr 100 105 110 Trp Ile Arg Thr Phe Val Pro Gly Ser Gln Pro Gly Glu Phe Thr Leu 115 120 125 Gly Asn Ile Lys Ser Tyr Pro Gly Leu Thr Ser Tyr Leu Val Arg Val 130 135 140 Val Ser Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys Lys Val 145 150 155 160 Ser Gln Asn Arg Glu Tyr Phe Lys Ile Thr Leu Tyr Gly Arg Thr Lys 165 170 175 Glu Leu Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser 180 185 190 Leu Gly Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile Asp Gln 195 200 205 Cys Ile Asp Gly Gly Gly Ser Glu Asn Leu Tyr Phe Gln Gly Gly Gly 210 215 220 Arg Ser Ala Gly Ala His Ala Gly Trp Glu Thr Pro Glu Gly Cys Glu 225 230 235 240 Gln Val Leu Thr Gly Lys Arg Leu Met Gln Cys Leu Pro Asn Pro Glu 245 250 255 Asp Val Lys Met Ala Leu Glu Val Tyr Lys Leu Ser Leu Glu Ile Glu 260 265 270 Gln Leu Glu Leu Gln Arg Asp Ser Ala Arg Gln Ser Thr Leu Asp Lys 275 280 285 Glu Leu Val Pro Arg Gly Ser 290 295 <210> SEQ ID NO 82 <211> LENGTH: 522 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-sFLAG-H6-GGS-humanScn-GGS-ENLYFQ-GG-CD80heptamer <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: (490)..(490) <223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid <400> SEQUENCE: 82 Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Asp Tyr Lys Asp Glu His His His His His His Gly 20 25 30 Gly Ser Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser 35 40 45 Lys Val Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe Gln Gly Lys 50 55 60 Trp Tyr Val Val Gly Leu Ala Gly Asn Ala Ile Leu Arg Glu Asp Lys 65 70 75 80 Asp Pro Gln Lys Met Tyr Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys 85 90 95 Ser Tyr Asn Val Thr Ser Val Leu Phe Arg Lys Lys Lys Cys Asp Tyr 100 105 110 Trp Ile Arg Thr Phe Val Pro Gly Ser Gln Pro Gly Glu Phe Thr Leu 115 120 125

Gly Asn Ile Lys Ser Tyr Pro Gly Leu Thr Ser Tyr Leu Val Arg Val 130 135 140 Val Ser Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys Lys Val 145 150 155 160 Ser Gln Asn Arg Glu Tyr Phe Lys Ile Thr Leu Tyr Gly Arg Thr Lys 165 170 175 Glu Leu Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser 180 185 190 Leu Gly Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile Asp Gln 195 200 205 Cys Ile Asp Gly Gly Gly Ser Glu Asn Leu Tyr Phe Gln Gly Gly Gly 210 215 220 Ile Ile Gln Val Asn Lys Thr Val Lys Glu Val Ala Val Leu Ser Cys 225 230 235 240 Asp Tyr Asn Ile Ser Thr Thr Glu Leu Met Lys Val Arg Ile Tyr Trp 245 250 255 Gln Lys Asp Asp Glu Val Val Leu Ala Val Thr Ser Gly Gln Thr Lys 260 265 270 Val Trp Ser Lys Tyr Glu Asn Arg Thr Phe Ala Asp Phe Thr Asn Asn 275 280 285 Leu Ser Ile Val Ile Met Ala Leu Arg Leu Ser Asp Asn Gly Lys Tyr 290 295 300 Thr Cys Ile Val Gln Lys Thr Glu Lys Arg Ser Tyr Lys Val Lys His 305 310 315 320 Met Thr Ser Val Met Leu Leu Val Arg Ala Asp Phe Pro Val Pro Ser 325 330 335 Ile Thr Asp Leu Gly Asn Pro Ser His Asp Ile Lys Arg Ile Met Cys 340 345 350 Ser Thr Ser Gly Gly Phe Pro Lys Pro His Leu Ser Trp Trp Glu Asn 355 360 365 Glu Glu Glu Leu Asn Ala Ala Asn Thr Thr Val Ser Gln Asp Pro Asp 370 375 380 Thr Glu Leu Tyr Thr Ile Ser Ser Glu Leu Asp Phe Asn Ile Thr Ser 385 390 395 400 Asn His Ser Phe Val Cys Leu Val Lys Tyr Gly Asp Leu Thr Val Ser 405 410 415 Gln Ile Phe Asn Trp Gln Lys Ser Val Glu Pro His Pro Pro Asn Asn 420 425 430 Ser Ala Trp Ser His Pro Gln Phe Glu Lys Gly Gly Ser Leu Val Pro 435 440 445 Arg Gly Ser Gly Ser Ala Gly Ala His Ala Gly Trp Glu Thr Pro Glu 450 455 460 Gly Cys Glu Gln Val Leu Thr Gly Lys Arg Leu Met Gln Cys Leu Pro 465 470 475 480 Asn Pro Glu Asp Val Lys Met Ala Leu Xaa Val Tyr Lys Leu Ser Leu 485 490 495 Glu Ile Glu Gln Leu Glu Leu Gln Arg Asp Ser Ala Arg Gln Ser Thr 500 505 510 Leu Asp Lys Glu Leu Val Pro Arg Gly Ser 515 520 <210> SEQ ID NO 83 <211> LENGTH: 279 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-sFLAG-H6-GGS-humanScn-GGS-ENLYFQ-GG-trimer <400> SEQUENCE: 83 Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Asp Tyr Lys Asp Glu His His His His His His Gly 20 25 30 Gly Ser Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser 35 40 45 Lys Val Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe Gln Gly Lys 50 55 60 Trp Tyr Val Val Gly Leu Ala Gly Asn Ala Ile Leu Arg Glu Asp Lys 65 70 75 80 Asp Pro Gln Lys Met Tyr Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys 85 90 95 Ser Tyr Asn Val Thr Ser Val Leu Phe Arg Lys Lys Lys Cys Asp Tyr 100 105 110 Trp Ile Arg Thr Phe Val Pro Gly Ser Gln Pro Gly Glu Phe Thr Leu 115 120 125 Gly Asn Ile Lys Ser Tyr Pro Gly Leu Thr Ser Tyr Leu Val Arg Val 130 135 140 Val Ser Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys Lys Val 145 150 155 160 Ser Gln Asn Arg Glu Tyr Phe Lys Ile Thr Leu Tyr Gly Arg Thr Lys 165 170 175 Glu Leu Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser 180 185 190 Leu Gly Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile Asp Gln 195 200 205 Cys Ile Asp Gly Gly Gly Ser Glu Asn Leu Tyr Phe Gln Gly Gly Gly 210 215 220 Arg Asn Leu Val Thr Ala Phe Ser Asn Met Asp Asp Met Leu Gln Lys 225 230 235 240 Ala His Leu Val Ile Glu Gly Thr Phe Ile Tyr Leu Arg Asp Ser Thr 245 250 255 Glu Phe Phe Ile Arg Val Arg Asp Gly Trp Lys Lys Leu Gln Leu Gly 260 265 270 Glu Leu Ile Pro Ile Pro Ala 275 <210> SEQ ID NO 84 <211> LENGTH: 506 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-sFLAG-H6-GGS-humanScn-GGS-ENLYFQ-GG-CD80trimer <400> SEQUENCE: 84 Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Asp Tyr Lys Asp Glu His His His His His His Gly 20 25 30 Gly Ser Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser 35 40 45 Lys Val Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe Gln Gly Lys 50 55 60 Trp Tyr Val Val Gly Leu Ala Gly Asn Ala Ile Leu Arg Glu Asp Lys 65 70 75 80 Asp Pro Gln Lys Met Tyr Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys 85 90 95 Ser Tyr Asn Val Thr Ser Val Leu Phe Arg Lys Lys Lys Cys Asp Tyr 100 105 110 Trp Ile Arg Thr Phe Val Pro Gly Ser Gln Pro Gly Glu Phe Thr Leu 115 120 125 Gly Asn Ile Lys Ser Tyr Pro Gly Leu Thr Ser Tyr Leu Val Arg Val 130 135 140 Val Ser Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys Lys Val 145 150 155 160 Ser Gln Asn Arg Glu Tyr Phe Lys Ile Thr Leu Tyr Gly Arg Thr Lys 165 170 175 Glu Leu Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser 180 185 190 Leu Gly Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile Asp Gln 195 200 205 Cys Ile Asp Gly Gly Gly Ser Glu Asn Leu Tyr Phe Gln Gly Gly Gly 210 215 220 Ile Ile Gln Val Asn Lys Thr Val Lys Glu Val Ala Val Leu Ser Cys 225 230 235 240 Asp Tyr Asn Ile Ser Thr Thr Glu Leu Met Lys Val Arg Ile Tyr Trp 245 250 255 Gln Lys Asp Asp Glu Val Val Leu Ala Val Thr Ser Gly Gln Thr Lys 260 265 270 Val Trp Ser Lys Tyr Glu Asn Arg Thr Phe Ala Asp Phe Thr Asn Asn 275 280 285 Leu Ser Ile Val Ile Met Ala Leu Arg Leu Ser Asp Asn Gly Lys Tyr 290 295 300 Thr Cys Ile Val Gln Lys Thr Glu Lys Arg Ser Tyr Lys Val Lys His 305 310 315 320 Met Thr Ser Val Met Leu Leu Val Arg Ala Asp Phe Pro Val Pro Ser 325 330 335 Ile Thr Asp Leu Gly Asn Pro Ser His Asp Ile Lys Arg Ile Met Cys 340 345 350 Ser Thr Ser Gly Gly Phe Pro Lys Pro His Leu Ser Trp Trp Glu Asn 355 360 365 Glu Glu Glu Leu Asn Ala Ala Asn Thr Thr Val Ser Gln Asp Pro Asp 370 375 380 Thr Glu Leu Tyr Thr Ile Ser Ser Glu Leu Asp Phe Asn Ile Thr Ser 385 390 395 400 Asn His Ser Phe Val Cys Leu Val Lys Tyr Gly Asp Leu Thr Val Ser 405 410 415 Gln Ile Phe Asn Trp Gln Lys Ser Val Glu Pro His Pro Pro Asn Asn 420 425 430 Ser Ala Trp Ser His Pro Gln Phe Glu Lys Gly Gly Ser Leu Val Pro 435 440 445 Arg Gly Ser Gly Asn Leu Val Thr Ala Phe Ser Asn Met Asp Asp Met 450 455 460 Leu Gln Lys Ala His Leu Val Ile Glu Gly Thr Phe Ile Tyr Leu Arg 465 470 475 480 Asp Ser Thr Glu Phe Phe Ile Arg Val Arg Asp Gly Trp Lys Lys Leu 485 490 495 Gln Leu Gly Glu Leu Ile Pro Ile Pro Ala 500 505 <210> SEQ ID NO 85 <211> LENGTH: 278 <212> TYPE: PRT

<213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-sFLAG-H6-GGS-humanScn-GGS-ENLYFQ-GG-pentamer <400> SEQUENCE: 85 Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Asp Tyr Lys Asp Glu His His His His His His Gly 20 25 30 Gly Ser Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser 35 40 45 Lys Val Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe Gln Gly Lys 50 55 60 Trp Tyr Val Val Gly Leu Ala Gly Asn Ala Ile Leu Arg Glu Asp Lys 65 70 75 80 Asp Pro Gln Lys Met Tyr Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys 85 90 95 Ser Tyr Asn Val Thr Ser Val Leu Phe Arg Lys Lys Lys Cys Asp Tyr 100 105 110 Trp Ile Arg Thr Phe Val Pro Gly Ser Gln Pro Gly Glu Phe Thr Leu 115 120 125 Gly Asn Ile Lys Ser Tyr Pro Gly Leu Thr Ser Tyr Leu Val Arg Val 130 135 140 Val Ser Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys Lys Val 145 150 155 160 Ser Gln Asn Arg Glu Tyr Phe Lys Ile Thr Leu Tyr Gly Arg Thr Lys 165 170 175 Glu Leu Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser 180 185 190 Leu Gly Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile Asp Gln 195 200 205 Cys Ile Asp Gly Gly Gly Ser Glu Asn Leu Tyr Phe Gln Gly Gly Gly 210 215 220 Arg Ser Ser Asn Ala Lys Trp Asp Gln Trp Ser Ser Asp Trp Gln Thr 225 230 235 240 Trp Asn Ala Lys Trp Asp Gln Trp Ser Asn Asp Trp Asn Ala Trp Arg 245 250 255 Ser Asp Trp Gln Ala Trp Lys Asp Asp Trp Ala Arg Trp Asn Gln Arg 260 265 270 Trp Asp Asn Trp Ala Thr 275 <210> SEQ ID NO 86 <211> LENGTH: 302 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-sFLAG-H6-GGS-humanScn-GGS-ENLYFQ-GG-ROR1Kringle <400> SEQUENCE: 86 Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Asp Tyr Lys Asp Glu His His His His His His Gly 20 25 30 Gly Ser Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser 35 40 45 Lys Val Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe Gln Gly Lys 50 55 60 Trp Tyr Val Val Gly Leu Ala Gly Asn Ala Ile Leu Arg Glu Asp Lys 65 70 75 80 Asp Pro Gln Lys Met Tyr Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys 85 90 95 Ser Tyr Asn Val Thr Ser Val Leu Phe Arg Lys Lys Lys Cys Asp Tyr 100 105 110 Trp Ile Arg Thr Phe Val Pro Gly Ser Gln Pro Gly Glu Phe Thr Leu 115 120 125 Gly Asn Ile Lys Ser Tyr Pro Gly Leu Thr Ser Tyr Leu Val Arg Val 130 135 140 Val Ser Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys Lys Val 145 150 155 160 Ser Gln Asn Arg Glu Tyr Phe Lys Ile Thr Leu Tyr Gly Arg Thr Lys 165 170 175 Glu Leu Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser 180 185 190 Leu Gly Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile Asp Gln 195 200 205 Cys Ile Asp Gly Gly Gly Ser Glu Asn Leu Tyr Phe Gln Gly Gly Cys 210 215 220 Tyr Asn Ser Thr Gly Val Asp Tyr Arg Gly Thr Val Ser Val Thr Lys 225 230 235 240 Ser Gly Arg Gln Cys Gln Pro Trp Asn Ser Gln Tyr Pro His Thr His 245 250 255 Thr Phe Thr Ala Leu Arg Phe Pro Glu Leu Asn Gly Gly His Ser Tyr 260 265 270 Cys Arg Asn Pro Gly Asn Gln Lys Glu Ala Pro Trp Cys Phe Thr Leu 275 280 285 Asp Glu Asn Phe Lys Ser Asp Leu Cys Asp Ile Pro Ala Cys 290 295 300 <210> SEQ ID NO 87 <211> LENGTH: 343 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-sFLAG-H6-GGS-humanScn-GGS-ENLYFQ-GG-CTLA4 <400> SEQUENCE: 87 Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Asp Tyr Lys Asp Glu His His His His His His Gly 20 25 30 Gly Ser Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser 35 40 45 Lys Val Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe Gln Gly Lys 50 55 60 Trp Tyr Val Val Gly Leu Ala Gly Asn Ala Ile Leu Arg Glu Asp Lys 65 70 75 80 Asp Pro Gln Lys Met Tyr Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys 85 90 95 Ser Tyr Asn Val Thr Ser Val Leu Phe Arg Lys Lys Lys Cys Asp Tyr 100 105 110 Trp Ile Arg Thr Phe Val Pro Gly Ser Gln Pro Gly Glu Phe Thr Leu 115 120 125 Gly Asn Ile Lys Ser Tyr Pro Gly Leu Thr Ser Tyr Leu Val Arg Val 130 135 140 Val Ser Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys Lys Val 145 150 155 160 Ser Gln Asn Arg Glu Tyr Phe Lys Ile Thr Leu Tyr Gly Arg Thr Lys 165 170 175 Glu Leu Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser 180 185 190 Leu Gly Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile Asp Gln 195 200 205 Cys Ile Asp Gly Gly Gly Ser Glu Asn Leu Tyr Phe Gln Gly Gly Met 210 215 220 His Val Ala Gln Pro Ala Val Val Leu Ala Ser Ser Arg Gly Val Ala 225 230 235 240 Ser Phe Val Cys Glu Tyr Gly Ser Ser Gly Asn Ala Ala Glu Val Arg 245 250 255 Val Thr Val Leu Arg Gln Ala Gly Ser Gln Met Thr Glu Val Cys Ala 260 265 270 Ala Thr Tyr Thr Val Glu Asp Glu Leu Ala Phe Leu Asp Asp Ser Thr 275 280 285 Cys Thr Gly Thr Ser Ser Gly Asn Lys Val Asn Leu Thr Ile Gln Gly 290 295 300 Leu Arg Ala Met Asp Thr Gly Leu Tyr Ile Cys Lys Val Glu Leu Met 305 310 315 320 Tyr Pro Pro Pro Tyr Tyr Val Gly Met Gly Asn Gly Thr Gln Ile Tyr 325 330 335 Val Ile Asp Pro Glu Pro Cys 340 <210> SEQ ID NO 88 <211> LENGTH: 788 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-sFLAG-H6-GGS-humanScn-GGS-ENLYFQ-GG-Imperatoxin <400> SEQUENCE: 88 ctcgagacca tggagacaga cacactcctg ctatgggtac tgctgctctg ggttccaggt 60 tccactggtg actacaagga cgagcatcac catcatcacc atggtggaag ccaggactcc 120 acctcagacc tgatcccagc cccacctctg agcaaggtcc ctctgcagca gaacttccag 180 gacaaccaat tccaggggaa gtggtatgtg gtaggcctgg cagggaatgc aattctcaga 240 gaagacaaag acccgcaaaa gatgtatgcc accatctatg agctgaaaga agacaagagc 300 tacaatgtca cctccgtcct gtttaggaaa aagaagtgtg actactggat caggactttt 360 gttccaggtt gccagcccgg cgagttcacg ctgggcaaca ttaagagtta ccctggatta 420 acgagttacc tcgtccgagt ggtgagcacc aactacaacc agcatgctat ggtgttcttc 480 aagaaagttt ctcaaaacag ggagtacttc aagatcaccc tctacgggag aaccaaggag 540 ctgacttcgg aactaaagga gaacttcatc cgcttctcca aatctctggg cctccctgaa 600 aaccacatcg tcttccctgt cccaatcgac cagtgtatcg acggcggagg tagcgaaaac 660 ctgtattttc agggaggcga ctgcctgccc cacctgagga ggtgcagggc cgacaacgac 720 tgctgcggca ggaggtgcag gaggaggggc accaacgccg agaggaggtg caggtaagct 780 aaggatcc 788 <210> SEQ ID NO 89 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE:

<223> OTHER INFORMATION: synthesized murine IgK light chain signal peptide <400> SEQUENCE: 89 Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly 20 <210> SEQ ID NO 90 <211> LENGTH: 60 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: coding sequence for synthesized murine IgK light chain signal peptide <400> SEQUENCE: 90 atggagacag acacactcct gctatgggta ctgctgctct gggttccagg ttccactggt 60 <210> SEQ ID NO 91 <211> LENGTH: 5 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: Shortened FLAG epitope <400> SEQUENCE: 91 Asp Tyr Lys Asp Glu 1 5 <210> SEQ ID NO 92 <211> LENGTH: 15 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: Shortened FLAG epitope coding <400> SEQUENCE: 92 gactacaagg acgag 15 <210> SEQ ID NO 93 <211> LENGTH: 6 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: 6xhistidine tag <400> SEQUENCE: 93 His His His His His His 1 5 <210> SEQ ID NO 94 <211> LENGTH: 18 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: 6xhistidine tag coding <400> SEQUENCE: 94 catcatcatc atcatcat 18 <210> SEQ ID NO 95 <211> LENGTH: 6 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: Tobacco Etch Virus Protease recognition site <400> SEQUENCE: 95 Glu Asn Leu Tyr Phe Gln 1 5 <210> SEQ ID NO 96 <211> LENGTH: 18 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: Coding sequencee for Tobacco Etch Virus Protease recognition site <400> SEQUENCE: 96 gagaatttat attttcag 18 <210> SEQ ID NO 97 <400> SEQUENCE: 97 000 <210> SEQ ID NO 98 <400> SEQUENCE: 98 000 <210> SEQ ID NO 99 <211> LENGTH: 8 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: furin cleavage site used for a BamHI site <400> SEQUENCE: 99 Arg Ala Arg Tyr Lys Arg Gly Ser 1 5 <210> SEQ ID NO 100 <211> LENGTH: 24 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: coding sequence for furin cleavage site used for a BamHI site <400> SEQUENCE: 100 cgggcccggt ataaacgggg atcc 24 <210> SEQ ID NO 101 <211> LENGTH: 6 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: furin cleavage site <400> SEQUENCE: 101 Arg Ala Arg Tyr Lys Arg 1 5 <210> SEQ ID NO 102 <211> LENGTH: 4 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: 4 amino acid residues of a siderocalin right before a cleavage site in a siderocalin fusion construct <400> SEQUENCE: 102 Cys Ile Asp Gly 1 <210> SEQ ID NO 103 <211> LENGTH: 198 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: a lipocalin fusion protein <400> SEQUENCE: 103 Met Pro Leu Gly Leu Leu Trp Leu Gly Leu Ala Leu Leu Gly Ala Leu 1 5 10 15 His Ala Gln Ala Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro 20 25 30 Leu Ser Lys Val Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe Gln 35 40 45 Gly Lys Trp Tyr Val Val Gly Leu Ala Gly Asn Ala Ile Leu Arg Glu 50 55 60 Asp Lys Asp Pro Gln Lys Met Tyr Ala Thr Ile Tyr Glu Leu Lys Glu 65 70 75 80 Asp Lys Ser Tyr Asn Val Thr Ser Val Leu Phe Arg Lys Lys Lys Cys 85 90 95 Asp Tyr Trp Ile Arg Thr Phe Val Pro Gly Cys Gln Pro Gly Glu Phe 100 105 110 Thr Leu Gly Asn Ile Lys Ser Tyr Pro Gly Leu Thr Ser Tyr Leu Val 115 120 125 Arg Val Val Ser Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys 130 135 140 Lys Val Ser Gln Asn Arg Glu Tyr Phe Lys Ile Thr Leu Tyr Gly Arg 145 150 155 160 Thr Lys Glu Leu Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser 165 170 175 Lys Ser Leu Gly Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile 180 185 190 Asp Gln Cys Ile Asp Gly 195 <210> SEQ ID NO 104 <211> LENGTH: 8 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: amino acid sequence in a light chain-siderocalin fusion <400> SEQUENCE: 104 Gly Arg Gly Gly Ser Gly Gly Ser 1 5 <210> SEQ ID NO 105 <211> LENGTH: 5 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: amino acid sequence in a siderocalin construct for downstream viral fusions <400> SEQUENCE: 105 Gly Gly Gly Gly Ser 1 5 <210> SEQ ID NO 106 <211> LENGTH: 287 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE:

<223> OTHER INFORMATION: IgK-SF-H6-GGS-lcn2C-GGS-ENLYFQ-GG-BubbleProtein amino acid sequence <400> SEQUENCE: 106 Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Asp Tyr Lys Asp Glu His His His His His His Gly 20 25 30 Gly Ser Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser 35 40 45 Lys Val Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe Gln Gly Lys 50 55 60 Trp Tyr Val Val Gly Leu Ala Gly Asn Ala Ile Leu Arg Glu Asp Lys 65 70 75 80 Asp Pro Gln Lys Met Tyr Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys 85 90 95 Ser Tyr Asn Val Thr Ser Val Leu Phe Arg Lys Lys Lys Cys Asp Tyr 100 105 110 Trp Ile Arg Thr Phe Val Pro Gly Cys Gln Pro Gly Glu Phe Thr Leu 115 120 125 Gly Asn Ile Lys Ser Tyr Pro Gly Leu Thr Ser Tyr Leu Val Arg Val 130 135 140 Val Ser Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys Lys Val 145 150 155 160 Ser Gln Asn Arg Glu Tyr Phe Lys Ile Thr Leu Tyr Gly Arg Thr Lys 165 170 175 Glu Leu Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser 180 185 190 Leu Gly Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile Asp Gln 195 200 205 Cys Ile Asp Gly Gly Gly Ser Glu Asn Leu Tyr Phe Gln Gly Gly Asp 210 215 220 Thr Cys Gly Ser Gly Tyr Asn Val Asp Gln Arg Arg Thr Asn Ser Gly 225 230 235 240 Cys Lys Ala Gly Asn Gly Asp Arg His Phe Cys Gly Cys Asp Arg Thr 245 250 255 Gly Val Val Glu Cys Lys Gly Gly Lys Trp Thr Glu Val Gln Asp Cys 260 265 270 Gly Ser Ser Ser Cys Lys Gly Thr Ser Asn Gly Gly Ala Thr Cys 275 280 285 <210> SEQ ID NO 107 <211> LENGTH: 281 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-SF-H6-GGS-lcn2C-GGS-ENLYFQ-GG-Attractin amino acid sequence <400> SEQUENCE: 107 Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Asp Tyr Lys Asp Glu His His His His His His Gly 20 25 30 Gly Ser Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser 35 40 45 Lys Val Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe Gln Gly Lys 50 55 60 Trp Tyr Val Val Gly Leu Ala Gly Asn Ala Ile Leu Arg Glu Asp Lys 65 70 75 80 Asp Pro Gln Lys Met Tyr Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys 85 90 95 Ser Tyr Asn Val Thr Ser Val Leu Phe Arg Lys Lys Lys Cys Asp Tyr 100 105 110 Trp Ile Arg Thr Phe Val Pro Gly Cys Gln Pro Gly Glu Phe Thr Leu 115 120 125 Gly Asn Ile Lys Ser Tyr Pro Gly Leu Thr Ser Tyr Leu Val Arg Val 130 135 140 Val Ser Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys Lys Val 145 150 155 160 Ser Gln Asn Arg Glu Tyr Phe Lys Ile Thr Leu Tyr Gly Arg Thr Lys 165 170 175 Glu Leu Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser 180 185 190 Leu Gly Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile Asp Gln 195 200 205 Cys Ile Asp Gly Gly Gly Ser Glu Asn Leu Tyr Phe Gln Gly Gly Asp 210 215 220 Gln Asn Cys Asp Ile Gly Asn Ile Thr Ser Gln Cys Gln Met Gln His 225 230 235 240 Lys Asn Cys Glu Asp Ala Asn Gly Cys Asp Thr Ile Ile Glu Glu Cys 245 250 255 Lys Thr Ser Met Val Glu Arg Cys Gln Asn Gln Glu Phe Glu Ser Ala 260 265 270 Ala Gly Ser Thr Thr Leu Gly Pro Gln 275 280 <210> SEQ ID NO 108 <211> LENGTH: 245 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-SF-H6-GGS-lcn2C-GGS-ENLYFQ-GG-Hefutoxin amino acid sequence <400> SEQUENCE: 108 Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Asp Tyr Lys Asp Glu His His His His His His Gly 20 25 30 Gly Ser Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser 35 40 45 Lys Val Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe Gln Gly Lys 50 55 60 Trp Tyr Val Val Gly Leu Ala Gly Asn Ala Ile Leu Arg Glu Asp Lys 65 70 75 80 Asp Pro Gln Lys Met Tyr Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys 85 90 95 Ser Tyr Asn Val Thr Ser Val Leu Phe Arg Lys Lys Lys Cys Asp Tyr 100 105 110 Trp Ile Arg Thr Phe Val Pro Gly Cys Gln Pro Gly Glu Phe Thr Leu 115 120 125 Gly Asn Ile Lys Ser Tyr Pro Gly Leu Thr Ser Tyr Leu Val Arg Val 130 135 140 Val Ser Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys Lys Val 145 150 155 160 Ser Gln Asn Arg Glu Tyr Phe Lys Ile Thr Leu Tyr Gly Arg Thr Lys 165 170 175 Glu Leu Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser 180 185 190 Leu Gly Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile Asp Gln 195 200 205 Cys Ile Asp Gly Gly Gly Ser Glu Asn Leu Tyr Phe Gln Gly Gly Gly 210 215 220 His Ala Cys Tyr Arg Asn Cys Trp Arg Glu Gly Asn Asp Glu Glu Thr 225 230 235 240 Cys Lys Glu Arg Cys 245 <210> SEQ ID NO 109 <211> LENGTH: 258 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-SF-H6-GGS-lcn2C-GGS-ENLYFQ-GG-Hanatoxin amino acid sequence <400> SEQUENCE: 109 Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Asp Tyr Lys Asp Glu His His His His His His Gly 20 25 30 Gly Ser Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser 35 40 45 Lys Val Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe Gln Gly Lys 50 55 60 Trp Tyr Val Val Gly Leu Ala Gly Asn Ala Ile Leu Arg Glu Asp Lys 65 70 75 80 Asp Pro Gln Lys Met Tyr Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys 85 90 95 Ser Tyr Asn Val Thr Ser Val Leu Phe Arg Lys Lys Lys Cys Asp Tyr 100 105 110 Trp Ile Arg Thr Phe Val Pro Gly Cys Gln Pro Gly Glu Phe Thr Leu 115 120 125 Gly Asn Ile Lys Ser Tyr Pro Gly Leu Thr Ser Tyr Leu Val Arg Val 130 135 140 Val Ser Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys Lys Val 145 150 155 160 Ser Gln Asn Arg Glu Tyr Phe Lys Ile Thr Leu Tyr Gly Arg Thr Lys 165 170 175 Glu Leu Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser 180 185 190 Leu Gly Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile Asp Gln 195 200 205 Cys Ile Asp Gly Gly Gly Ser Glu Asn Leu Tyr Phe Gln Gly Gly Glu 210 215 220 Cys Arg Tyr Leu Phe Gly Gly Cys Lys Thr Thr Ser Asp Cys Cys Lys 225 230 235 240 His Leu Gly Cys Lys Phe Arg Asp Lys Tyr Cys Ala Trp Asp Phe Thr 245 250 255 Phe Ser <210> SEQ ID NO 110 <211> LENGTH: 259 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION:

IgK-SF-H6-GGS-lcn2C-GGS-ENLYFQ-GG-Chymotrypsin Inhibitor amino acid sequence <400> SEQUENCE: 110 Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Asp Tyr Lys Asp Glu His His His His His His Gly 20 25 30 Gly Ser Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser 35 40 45 Lys Val Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe Gln Gly Lys 50 55 60 Trp Tyr Val Val Gly Leu Ala Gly Asn Ala Ile Leu Arg Glu Asp Lys 65 70 75 80 Asp Pro Gln Lys Met Tyr Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys 85 90 95 Ser Tyr Asn Val Thr Ser Val Leu Phe Arg Lys Lys Lys Cys Asp Tyr 100 105 110 Trp Ile Arg Thr Phe Val Pro Gly Cys Gln Pro Gly Glu Phe Thr Leu 115 120 125 Gly Asn Ile Lys Ser Tyr Pro Gly Leu Thr Ser Tyr Leu Val Arg Val 130 135 140 Val Ser Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys Lys Val 145 150 155 160 Ser Gln Asn Arg Glu Tyr Phe Lys Ile Thr Leu Tyr Gly Arg Thr Lys 165 170 175 Glu Leu Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser 180 185 190 Leu Gly Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile Asp Gln 195 200 205 Cys Ile Asp Gly Gly Gly Ser Glu Asn Leu Tyr Phe Gln Gly Gly Glu 210 215 220 Ile Ser Cys Glu Pro Gly Lys Thr Phe Lys Asp Lys Cys Asn Thr Cys 225 230 235 240 Arg Cys Gly Ala Asp Gly Lys Ser Ala Ala Cys Thr Leu Lys Ala Cys 245 250 255 Pro Asn Gln <210> SEQ ID NO 111 <211> LENGTH: 260 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-SF-H6-GGS-lcn2C-GGS-ENLYFQ-GG-ToxinK amino acid sequence <400> SEQUENCE: 111 Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Asp Tyr Lys Asp Glu His His His His His His Gly 20 25 30 Gly Ser Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser 35 40 45 Lys Val Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe Gln Gly Lys 50 55 60 Trp Tyr Val Val Gly Leu Ala Gly Asn Ala Ile Leu Arg Glu Asp Lys 65 70 75 80 Asp Pro Gln Lys Met Tyr Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys 85 90 95 Ser Tyr Asn Val Thr Ser Val Leu Phe Arg Lys Lys Lys Cys Asp Tyr 100 105 110 Trp Ile Arg Thr Phe Val Pro Gly Cys Gln Pro Gly Glu Phe Thr Leu 115 120 125 Gly Asn Ile Lys Ser Tyr Pro Gly Leu Thr Ser Tyr Leu Val Arg Val 130 135 140 Val Ser Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys Lys Val 145 150 155 160 Ser Gln Asn Arg Glu Tyr Phe Lys Ile Thr Leu Tyr Gly Arg Thr Lys 165 170 175 Glu Leu Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser 180 185 190 Leu Gly Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile Asp Gln 195 200 205 Cys Ile Asp Gly Gly Gly Ser Glu Asn Leu Tyr Phe Gln Gly Gly Val 210 215 220 Cys Arg Asp Trp Phe Lys Glu Thr Ala Cys Arg His Ala Lys Ser Leu 225 230 235 240 Gly Asn Cys Arg Thr Ser Gln Lys Tyr Arg Ala Asn Cys Ala Lys Thr 245 250 255 Cys Glu Leu Cys 260 <210> SEQ ID NO 112 <211> LENGTH: 269 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-SF-H6-GGS-lcn2C-GGS-ENLYFQ-GG-EGFepiregulin Core amino acid sequence <400> SEQUENCE: 112 Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Asp Tyr Lys Asp Glu His His His His His His Gly 20 25 30 Gly Ser Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser 35 40 45 Lys Val Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe Gln Gly Lys 50 55 60 Trp Tyr Val Val Gly Leu Ala Gly Asn Ala Ile Leu Arg Glu Asp Lys 65 70 75 80 Asp Pro Gln Lys Met Tyr Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys 85 90 95 Ser Tyr Asn Val Thr Ser Val Leu Phe Arg Lys Lys Lys Cys Asp Tyr 100 105 110 Trp Ile Arg Thr Phe Val Pro Gly Cys Gln Pro Gly Glu Phe Thr Leu 115 120 125 Gly Asn Ile Lys Ser Tyr Pro Gly Leu Thr Ser Tyr Leu Val Arg Val 130 135 140 Val Ser Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys Lys Val 145 150 155 160 Ser Gln Asn Arg Glu Tyr Phe Lys Ile Thr Leu Tyr Gly Arg Thr Lys 165 170 175 Glu Leu Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser 180 185 190 Leu Gly Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile Asp Gln 195 200 205 Cys Ile Asp Gly Gly Gly Ser Glu Asn Leu Tyr Phe Gln Gly Gly Val 210 215 220 Ser Ile Thr Lys Cys Ser Ser Asp Met Asn Gly Tyr Cys Leu His Gly 225 230 235 240 Gln Cys Ile Tyr Leu Val Asp Met Ser Gln Asn Tyr Cys Arg Cys Glu 245 250 255 Val Gly Tyr Thr Gly Val Arg Cys Glu His Phe Phe Leu 260 265 <210> SEQ ID NO 113 <211> LENGTH: 253 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-SF-H6-GGS-lcn2C-GGS-ENLYFQ-GG-Circulin amino acid sequence <400> SEQUENCE: 113 Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Asp Tyr Lys Asp Glu His His His His His His Gly 20 25 30 Gly Ser Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser 35 40 45 Lys Val Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe Gln Gly Lys 50 55 60 Trp Tyr Val Val Gly Leu Ala Gly Asn Ala Ile Leu Arg Glu Asp Lys 65 70 75 80 Asp Pro Gln Lys Met Tyr Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys 85 90 95 Ser Tyr Asn Val Thr Ser Val Leu Phe Arg Lys Lys Lys Cys Asp Tyr 100 105 110 Trp Ile Arg Thr Phe Val Pro Gly Cys Gln Pro Gly Glu Phe Thr Leu 115 120 125 Gly Asn Ile Lys Ser Tyr Pro Gly Leu Thr Ser Tyr Leu Val Arg Val 130 135 140 Val Ser Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys Lys Val 145 150 155 160 Ser Gln Asn Arg Glu Tyr Phe Lys Ile Thr Leu Tyr Gly Arg Thr Lys 165 170 175 Glu Leu Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser 180 185 190 Leu Gly Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile Asp Gln 195 200 205 Cys Ile Asp Gly Gly Gly Ser Glu Asn Leu Tyr Phe Gln Gly Gly Gly 210 215 220 Ile Pro Cys Gly Glu Ser Cys Val Trp Ile Pro Cys Ile Ser Ala Ala 225 230 235 240 Leu Gly Cys Ser Cys Lys Asn Lys Val Cys Tyr Arg Asn 245 250 <210> SEQ ID NO 114 <211> LENGTH: 277 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-SF-H6-GGS-lcn2C-GGS-ENLYFQ-GG-Brazzein amino acid sequence <400> SEQUENCE: 114 Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro

1 5 10 15 Gly Ser Thr Gly Asp Tyr Lys Asp Glu His His His His His His Gly 20 25 30 Gly Ser Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser 35 40 45 Lys Val Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe Gln Gly Lys 50 55 60 Trp Tyr Val Val Gly Leu Ala Gly Asn Ala Ile Leu Arg Glu Asp Lys 65 70 75 80 Asp Pro Gln Lys Met Tyr Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys 85 90 95 Ser Tyr Asn Val Thr Ser Val Leu Phe Arg Lys Lys Lys Cys Asp Tyr 100 105 110 Trp Ile Arg Thr Phe Val Pro Gly Cys Gln Pro Gly Glu Phe Thr Leu 115 120 125 Gly Asn Ile Lys Ser Tyr Pro Gly Leu Thr Ser Tyr Leu Val Arg Val 130 135 140 Val Ser Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys Lys Val 145 150 155 160 Ser Gln Asn Arg Glu Tyr Phe Lys Ile Thr Leu Tyr Gly Arg Thr Lys 165 170 175 Glu Leu Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser 180 185 190 Leu Gly Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile Asp Gln 195 200 205 Cys Ile Asp Gly Gly Gly Ser Glu Asn Leu Tyr Phe Gln Gly Gly Gln 210 215 220 Asp Lys Cys Lys Lys Val Tyr Glu Asn Tyr Pro Val Ser Lys Cys Gln 225 230 235 240 Leu Ala Asn Gln Cys Asn Tyr Asp Cys Lys Leu Asp Lys His Ala Arg 245 250 255 Ser Gly Glu Cys Phe Tyr Asp Glu Lys Arg Asn Leu Gln Cys Ile Cys 260 265 270 Asp Tyr Cys Glu Tyr 275 <210> SEQ ID NO 115 <211> LENGTH: 259 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: amino acid sequence for IgK-SF-H6-GGS-lcn2C-GGS-ENLYFQ-GG-fusion construct <400> SEQUENCE: 115 Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Asp Tyr Lys Asp Glu His His His His His His Gly 20 25 30 Gly Ser Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser 35 40 45 Lys Val Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe Gln Gly Lys 50 55 60 Trp Tyr Val Val Gly Leu Ala Gly Asn Ala Ile Leu Arg Glu Asp Lys 65 70 75 80 Asp Pro Gln Lys Met Tyr Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys 85 90 95 Ser Tyr Asn Val Thr Ser Val Leu Phe Arg Lys Lys Lys Cys Asp Tyr 100 105 110 Trp Ile Arg Thr Phe Val Pro Gly Cys Gln Pro Gly Glu Phe Thr Leu 115 120 125 Gly Asn Ile Lys Ser Tyr Pro Gly Leu Thr Ser Tyr Leu Val Arg Val 130 135 140 Val Ser Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys Lys Val 145 150 155 160 Ser Gln Asn Arg Glu Tyr Phe Lys Ile Thr Leu Tyr Gly Arg Thr Lys 165 170 175 Glu Leu Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser 180 185 190 Leu Gly Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile Asp Gln 195 200 205 Cys Ile Asp Gly Gly Gly Ser Glu Asn Leu Tyr Phe Gln Gly Gly Met 210 215 220 Cys Met Pro Cys Phe Thr Thr Asp His Gln Met Ala Arg Lys Cys Asp 225 230 235 240 Asp Cys Cys Gly Gly Lys Gly Arg Gly Lys Cys Tyr Gly Pro Gln Cys 245 250 255 Leu Cys Arg <210> SEQ ID NO 116 <211> LENGTH: 7 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: idealized furin cut site <400> SEQUENCE: 116 Arg Ala Arg Tyr Lys Arg Ser 1 5 <210> SEQ ID NO 117 <211> LENGTH: 266 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-SF-H6-GGS-lcn2C-GGS-ENLYFQ-GS-MIDKINE amino acid sequence <400> SEQUENCE: 117 Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Asp Tyr Lys Asp Glu His His His His His His Gly 20 25 30 Gly Ser Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser 35 40 45 Lys Val Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe Gln Gly Lys 50 55 60 Trp Tyr Val Val Gly Leu Ala Gly Asn Ala Ile Leu Arg Glu Asp Lys 65 70 75 80 Asp Pro Gln Lys Met Tyr Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys 85 90 95 Ser Tyr Asn Val Thr Ser Val Leu Phe Arg Lys Lys Lys Cys Asp Tyr 100 105 110 Trp Ile Arg Thr Phe Val Pro Gly Cys Gln Pro Gly Glu Phe Thr Leu 115 120 125 Gly Asn Ile Lys Ser Tyr Pro Gly Leu Thr Ser Tyr Leu Val Arg Val 130 135 140 Val Ser Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys Lys Val 145 150 155 160 Ser Gln Asn Arg Glu Tyr Phe Lys Ile Thr Leu Tyr Gly Arg Thr Lys 165 170 175 Glu Leu Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser 180 185 190 Leu Gly Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile Asp Gln 195 200 205 Cys Ile Asp Gly Gly Gly Ser Glu Asn Leu Tyr Phe Gln Ser Asp Cys 210 215 220 Lys Tyr Lys Phe Glu Asn Trp Gly Ala Cys Asp Gly Gly Thr Gly Thr 225 230 235 240 Lys Val Arg Gln Gly Thr Leu Lys Lys Ala Arg Tyr Asn Ala Gln Cys 245 250 255 Gln Glu Thr Ile Arg Val Thr Lys Pro Cys 260 265 <210> SEQ ID NO 118 <211> LENGTH: 250 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-SF-H6-GGS-lcn2C-GGS-ENLYFQ-GG-Violacin A amino acid sequence <400> SEQUENCE: 118 Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Asp Tyr Lys Asp Glu His His His His His His Gly 20 25 30 Gly Ser Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser 35 40 45 Lys Val Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe Gln Gly Lys 50 55 60 Trp Tyr Val Val Gly Leu Ala Gly Asn Ala Ile Leu Arg Glu Asp Lys 65 70 75 80 Asp Pro Gln Lys Met Tyr Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys 85 90 95 Ser Tyr Asn Val Thr Ser Val Leu Phe Arg Lys Lys Lys Cys Asp Tyr 100 105 110 Trp Ile Arg Thr Phe Val Pro Gly Cys Gln Pro Gly Glu Phe Thr Leu 115 120 125 Gly Asn Ile Lys Ser Tyr Pro Gly Leu Thr Ser Tyr Leu Val Arg Val 130 135 140 Val Ser Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys Lys Val 145 150 155 160 Ser Gln Asn Arg Glu Tyr Phe Lys Ile Thr Leu Tyr Gly Arg Thr Lys 165 170 175 Glu Leu Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser 180 185 190 Leu Gly Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile Asp Gln 195 200 205 Cys Ile Asp Gly Gly Gly Ser Glu Asn Leu Tyr Phe Gln Gly Gly Ser 210 215 220 Ala Ile Ser Cys Gly Glu Thr Cys Phe Lys Phe Lys Cys Tyr Thr Pro 225 230 235 240 Arg Cys Ser Cys Ser Tyr Pro Val Cys Lys 245 250 <210> SEQ ID NO 119 <211> LENGTH: 234

<212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-SF-H6-GGS-lcn2C-GGS-ENLYFQ-GG-Lambda Toxin amino acid sequence <400> SEQUENCE: 119 Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Asp Tyr Lys Asp Glu His His His His His His Gly 20 25 30 Gly Ser Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser 35 40 45 Lys Val Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe Gln Gly Lys 50 55 60 Trp Tyr Val Val Gly Leu Ala Gly Asn Ala Ile Leu Arg Glu Asp Lys 65 70 75 80 Asp Pro Gln Lys Met Tyr Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys 85 90 95 Ser Tyr Asn Val Thr Ser Val Leu Phe Arg Lys Lys Lys Cys Asp Tyr 100 105 110 Trp Ile Arg Thr Phe Val Pro Gly Cys Gln Pro Gly Glu Phe Thr Leu 115 120 125 Gly Asn Ile Lys Ser Tyr Pro Gly Leu Thr Ser Tyr Leu Val Arg Val 130 135 140 Val Ser Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys Lys Val 145 150 155 160 Ser Gln Asn Arg Glu Tyr Phe Lys Ile Thr Leu Tyr Gly Arg Thr Lys 165 170 175 Glu Leu Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser 180 185 190 Leu Gly Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile Asp Gln 195 200 205 Cys Ile Asp Gly Gly Gly Ser Glu Asn Leu Tyr Phe Gln Gly Gly Val 210 215 220 Cys Cys Gly Tyr Lys Leu Cys His Pro Cys 225 230 <210> SEQ ID NO 120 <211> LENGTH: 236 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-SF-H6-GGS-lcn2C-GGS-ENLYFQ-GG-Lambda Toxin NG amino acid sequence <400> SEQUENCE: 120 Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Asp Tyr Lys Asp Glu His His His His His His Gly 20 25 30 Gly Ser Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser 35 40 45 Lys Val Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe Gln Gly Lys 50 55 60 Trp Tyr Val Val Gly Leu Ala Gly Asn Ala Ile Leu Arg Glu Asp Lys 65 70 75 80 Asp Pro Gln Lys Met Tyr Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys 85 90 95 Ser Tyr Asn Val Thr Ser Val Leu Phe Arg Lys Lys Lys Cys Asp Tyr 100 105 110 Trp Ile Arg Thr Phe Val Pro Gly Cys Gln Pro Gly Glu Phe Thr Leu 115 120 125 Gly Asn Ile Lys Ser Tyr Pro Gly Leu Thr Ser Tyr Leu Val Arg Val 130 135 140 Val Ser Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys Lys Val 145 150 155 160 Ser Gln Asn Arg Glu Tyr Phe Lys Ile Thr Leu Tyr Gly Arg Thr Lys 165 170 175 Glu Leu Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser 180 185 190 Leu Gly Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile Asp Gln 195 200 205 Cys Ile Asp Gly Gly Gly Ser Glu Asn Leu Tyr Phe Gln Gly Gly Asn 210 215 220 Gly Val Cys Cys Gly Tyr Lys Leu Cys His Pro Cys 225 230 235 <210> SEQ ID NO 121 <211> LENGTH: 262 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: IgK-SF-H6-GGS-lcn2C-GGS-ENLYFQ-GG-Potato Carboxypeptidase Inhibitor amino acid sequence <400> SEQUENCE: 121 Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Asp Tyr Lys Asp Glu His His His His His His Gly 20 25 30 Gly Ser Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser 35 40 45 Lys Val Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe Gln Gly Lys 50 55 60 Trp Tyr Val Val Gly Leu Ala Gly Asn Ala Ile Leu Arg Glu Asp Lys 65 70 75 80 Asp Pro Gln Lys Met Tyr Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys 85 90 95 Ser Tyr Asn Val Thr Ser Val Leu Phe Arg Lys Lys Lys Cys Asp Tyr 100 105 110 Trp Ile Arg Thr Phe Val Pro Gly Cys Gln Pro Gly Glu Phe Thr Leu 115 120 125 Gly Asn Ile Lys Ser Tyr Pro Gly Leu Thr Ser Tyr Leu Val Arg Val 130 135 140 Val Ser Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys Lys Val 145 150 155 160 Ser Gln Asn Arg Glu Tyr Phe Lys Ile Thr Leu Tyr Gly Arg Thr Lys 165 170 175 Glu Leu Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser 180 185 190 Leu Gly Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile Asp Gln 195 200 205 Cys Ile Asp Gly Gly Gly Ser Glu Asn Leu Tyr Phe Gln Gly Gly Gln 210 215 220 Gln His Ala Asp Pro Ile Cys Asn Lys Pro Cys Lys Thr His Asp Asp 225 230 235 240 Cys Ser Gly Ala Trp Phe Cys Gln Ala Cys Trp Asn Ser Ala Arg Thr 245 250 255 Cys Gly Pro Tyr Val Gly 260 <210> SEQ ID NO 122 <211> LENGTH: 191 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: sequence of an oligonucleotide coding for a knottin variant in a libary vector <400> SEQUENCE: 122 ctgtaacctg atcctgctag cgggtctcaa ggtggatcca tgtgcatgcc gtgcttcacc 60 accgataacg aaatggcggc gaactgcgat cgctgctgcg gtggccgtgg ccgtggccgc 120 tgctatggcc cgcagtgcct gtgccgctaa tgcggccgct agtgagaccg cttgcatggc 180 tagtacctac g 191 <210> SEQ ID NO 123 <211> LENGTH: 191 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: sequence of an oligonucleotide coding for a knottin variant in a libary vector <400> SEQUENCE: 123 ctgtaacctg atcctgctag cgggtctcaa ggtggatcca tgtgcatgcc gtgcttcacc 60 accgataacg atatggcgga tgaatgcgat cgctgctgcg gtggccgtgg ccgtggccgc 120 tgctatggcc cgcagtgcct gtgccgctaa tgcggccgct agtgagaccg cttgcatggc 180 tagtacctac g 191 <210> SEQ ID NO 124 <211> LENGTH: 36 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: unique tryptic peptide of a knottin <220> FEATURE: <221> NAME/KEY: MISC_FEATURE <222> LOCATION: (21)..(27) <223> OTHER INFORMATION: Xaa can be any amino acid <220> FEATURE: <221> NAME/KEY: MISC_FEATURE <222> LOCATION: (29)..(32) <223> OTHER INFORMATION: Xaa can be any amino acid <220> FEATURE: <221> NAME/KEY: MISC_FEATURE <222> LOCATION: (34)..(34) <223> OTHER INFORMATION: Xaa can be any amino acid <220> FEATURE: <221> NAME/KEY: MISC_FEATURE <222> LOCATION: (36)..(36) <223> OTHER INFORMATION: Xaa can be any amino acid <400> SEQUENCE: 124 Met Cys Met Pro Cys Phe Thr Thr Asp Asn Glu Met Ala Ala Asn Cys 1 5 10 15 Asp Arg Cys Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa 20 25 30 Cys Xaa Cys Xaa 35 <210> SEQ ID NO 125 <211> LENGTH: 36 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: unique tryptic peptide of a knottin

<220> FEATURE: <221> NAME/KEY: MISC_FEATURE <222> LOCATION: (21)..(27) <223> OTHER INFORMATION: Xaa can be any amino acid <220> FEATURE: <221> NAME/KEY: MISC_FEATURE <222> LOCATION: (29)..(32) <223> OTHER INFORMATION: Xaa can be any amino acid <220> FEATURE: <221> NAME/KEY: MISC_FEATURE <222> LOCATION: (34)..(34) <223> OTHER INFORMATION: Xaa can be any amino acid <220> FEATURE: <221> NAME/KEY: MISC_FEATURE <222> LOCATION: (36)..(36) <223> OTHER INFORMATION: Xaa can be any amino acid <400> SEQUENCE: 125 Met Cys Met Pro Cys Phe Thr Thr Asp Asn Asp Met Ala Asp Glu Cys 1 5 10 15 Asp Arg Cys Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa 20 25 30 Cys Xaa Cys Xaa 35 <210> SEQ ID NO 126 <211> LENGTH: 112 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: sequence of an oligonucleotide coding for a knottin variant in a libary vector <400> SEQUENCE: 126 atgtgcatgc cgtgcttcac caccgataac gaaatggcgg cgaactgcga tcgctgctgc 60 ggtggccgtg gccgtggccg ctgctatggc ccgcagtgcc tgtgccgcta at 112 <210> SEQ ID NO 127 <211> LENGTH: 36 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: unique tryptic peptide of a knottin <220> FEATURE: <221> NAME/KEY: MISC_FEATURE <222> LOCATION: (21)..(27) <223> OTHER INFORMATION: Xaa can be any amino acid <220> FEATURE: <221> NAME/KEY: MISC_FEATURE <222> LOCATION: (29)..(32) <223> OTHER INFORMATION: Xaa can be any amino acid <220> FEATURE: <221> NAME/KEY: MISC_FEATURE <222> LOCATION: (34)..(34) <223> OTHER INFORMATION: Xaa can be any amino acid <400> SEQUENCE: 127 Met Cys Met Pro Cys Phe Thr Thr Asp Asn Glu Met Ala Ala Asn Cys 1 5 10 15 Asp Arg Cys Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa 20 25 30 Cys Xaa Cys Arg 35 <210> SEQ ID NO 128 <211> LENGTH: 38 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: representative sequence from a cloned knottin library <400> SEQUENCE: 128 Gly Ser Glu Ile Ser Cys Glu Pro Gly Arg Thr Phe Arg Asp Arg Cys 1 5 10 15 Asn Gln Cys Phe Cys Gly Phe Asp Gly Arg Arg Ala Ala Cys Thr Ile 20 25 30 Arg Ala Cys Pro Asn Gln 35 <210> SEQ ID NO 129 <211> LENGTH: 38 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: representative sequence from a cloned knottin library <400> SEQUENCE: 129 Gly Ser Glu Ile His Cys Gln Pro Gly Arg Thr Phe Arg Asp Arg Cys 1 5 10 15 Asn Thr Cys Tyr Cys Gly Trp Tyr Gly Arg Ser Ala Ala Cys Thr Leu 20 25 30 Arg Ala Cys Pro Asn Gln 35 <210> SEQ ID NO 130 <211> LENGTH: 38 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: representative sequence from a cloned knottin library <400> SEQUENCE: 130 Gly Ser Glu Ile Ser Cys Glu Pro Gly Gly Thr Phe Glu Asp Arg Cys 1 5 10 15 Asn Val Cys Arg Cys Gly Ala Asp Gly Arg Ser Ala Gly Cys Thr Leu 20 25 30 Arg Ala Cys Pro Asn Gln 35 <210> SEQ ID NO 131 <211> LENGTH: 38 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: representative sequence from a cloned knottin library <400> SEQUENCE: 131 Gly Ser Arg Ile Asp Cys Arg Pro Gly Arg Thr Phe Arg Asp Arg Cys 1 5 10 15 Asn Thr Cys Met Cys Gly Trp Thr Gly His Ser Ala Ala Cys Thr Leu 20 25 30 Arg Ala Cys Pro Asn Gln 35 <210> SEQ ID NO 132 <211> LENGTH: 38 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: representative sequence from a cloned knottin library <400> SEQUENCE: 132 Gly Ser Glu Ile Ser Cys Glu Pro Gly Arg Thr Phe Arg Asp Arg Cys 1 5 10 15 Asn Thr Cys His Cys Trp Ala Asp Gly Arg Gly Ala Ala Cys Thr Glu 20 25 30 Arg Ala Cys Pro Asn Gln 35 <210> SEQ ID NO 133 <211> LENGTH: 38 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: representative sequence from a cloned knottin library <400> SEQUENCE: 133 Gly Ser Glu Ser Ser Cys Glu Pro Gly Ala Thr Trp Arg Asp Arg Cys 1 5 10 15 Asn Thr Cys Arg Cys Arg Ala Asp Gly Arg Ser Ala Ala Cys Thr Val 20 25 30 Arg Gln Cys Pro Asn Gln 35 <210> SEQ ID NO 134 <211> LENGTH: 38 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: representative sequence from a cloned knottin library <400> SEQUENCE: 134 Gly Ser Glu Ile Phe Cys Ile Pro Gly Arg Thr Phe Arg Asp Arg Cys 1 5 10 15 Asn Thr Cys Arg Cys Gly Arg Arg Gly Ile Ser Ala Ala Cys Thr Leu 20 25 30 Arg Ala Cys Pro Asn Gln 35 <210> SEQ ID NO 135 <211> LENGTH: 38 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: representative sequence from a cloned knottin library <400> SEQUENCE: 135 Gly Ser Glu Ile Ser Cys Glu Pro Gly Arg Thr Phe Arg Asp Arg Cys 1 5 10 15 Asn Thr Cys Arg Cys Gly Ala Asp Gly Arg Ser Ala Ala Cys Thr Leu 20 25 30 Phe Asp Cys Ser Leu Gln 35 <210> SEQ ID NO 136 <211> LENGTH: 38 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: representative sequence from a cloned knottin library <400> SEQUENCE: 136 Gly Ser Glu Ile Ser Cys Glu Pro Gly Arg Thr Ser Arg Asp Arg Cys 1 5 10 15 Asn Thr Cys Arg Cys Gly Ala Asp Gly Arg Ser Ala Ala Cys Thr Leu 20 25 30

Ile Asp Cys Pro Gly Gln 35 <210> SEQ ID NO 137 <211> LENGTH: 38 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: representative sequence from a cloned knottin library <400> SEQUENCE: 137 Gly Ser Glu Ile Ser Cys Glu Pro Gly Arg Thr Phe Arg Asp Arg Cys 1 5 10 15 Asn Thr Cys Arg Cys Gly Ala Asp Gly Arg Asp Ala Ala Cys Thr Leu 20 25 30 Gly His Cys Phe Phe Tyr 35 <210> SEQ ID NO 138 <211> LENGTH: 38 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: representative sequence from a cloned knottin library <400> SEQUENCE: 138 Gly Ser Glu Ile Ser Cys Glu Pro Gly Phe Thr Glu Gln Asp Arg Cys 1 5 10 15 Asn Thr Cys Arg Cys Gly Ala Ile Gly Arg Ser Ala Ala Cys Thr Leu 20 25 30 Arg Ala Cys Pro Asn Gln 35 <210> SEQ ID NO 139 <211> LENGTH: 38 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: representative sequence from a cloned knottin library <400> SEQUENCE: 139 Gly Ser Glu Ile Ser Cys Glu Pro Tyr Ser Thr Phe Arg Asp Arg Cys 1 5 10 15 Asn Thr Cys Ser Cys Gly Ala Asp Gly Arg Gly Ala Ala Cys Thr Met 20 25 30 Arg Ala Cys Pro Asn Gln 35 <210> SEQ ID NO 140 <211> LENGTH: 38 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: representative sequence from a cloned knottin library <400> SEQUENCE: 140 Gly Ser Glu Ile Ser Cys Glu Pro Gly Arg Thr Phe Arg Asp Arg Cys 1 5 10 15 Asn Thr Cys Arg Cys Gly Ala Asp Gly Arg Ser Ala Ala Cys Thr Leu 20 25 30 Val Ala Cys Leu Ile Thr 35 <210> SEQ ID NO 141 <211> LENGTH: 38 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: representative sequence from a cloned knottin library <400> SEQUENCE: 141 Gly Ser Glu Ile Phe Cys Ile Pro Gly Val Thr Phe Arg Phe Arg Cys 1 5 10 15 Asn Thr Cys Arg Cys Gly Met Asp Gly Arg Ser Ala Ala Cys Thr Leu 20 25 30 Arg Ala Cys Pro Asn Gln 35 <210> SEQ ID NO 142 <211> LENGTH: 38 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: representative sequence from a cloned knottin library <400> SEQUENCE: 142 Gly Ser Glu Asn Asp Cys His Pro Gly Thr Thr Phe Arg Asp Arg Cys 1 5 10 15 Asn Thr Cys Arg Cys Gly Gly Glu Gly Arg Ser Ala Ala Cys Thr Leu 20 25 30 Arg Ala Cys Pro Asn Gln 35 <210> SEQ ID NO 143 <211> LENGTH: 38 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: representative sequence from a cloned knottin library <400> SEQUENCE: 143 Gly Ser Gln Arg Ser Cys Glu Pro Gly Arg Thr Phe Arg Asp Arg Cys 1 5 10 15 Asn Thr Cys Arg Cys Gly Ala Asp Gly Arg Ser Ala Ala Cys Thr Leu 20 25 30 Phe Ile Cys Pro Phe Gln 35 <210> SEQ ID NO 144 <211> LENGTH: 38 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: representative sequence from a cloned knottin library <400> SEQUENCE: 144 Gly Ser Glu Ile Ser Cys Glu Pro Gly Arg Thr Phe Arg Asp Arg Cys 1 5 10 15 Asn Thr Cys Arg Cys Gly Ala Asp Gly Arg Ser Ala Ala Cys Thr Leu 20 25 30 Phe Leu Cys Gly Phe Ile 35 <210> SEQ ID NO 145 <211> LENGTH: 38 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: representative sequence from a cloned knottin library <400> SEQUENCE: 145 Gly Ser Glu Ile Ser Cys Glu Pro Asp Ser Thr Thr Arg Asp Arg Cys 1 5 10 15 Asn Ser Cys Arg Cys Gly Asn Asp Gly Arg Ser Ala Ala Cys Thr Leu 20 25 30 Arg Ala Cys Pro Asn Gln 35 <210> SEQ ID NO 146 <211> LENGTH: 38 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: representative sequence from a cloned knottin library <400> SEQUENCE: 146 Gly Ser Glu Ile Ser Cys Glu Pro Gly Arg Thr Phe Arg Asp Arg Cys 1 5 10 15 Asn Thr Cys Arg Cys Gly Ala Asp Gly Arg Ser Glu Ala Cys Thr Leu 20 25 30 His Asn Cys Arg Glu Gln 35 <210> SEQ ID NO 147 <211> LENGTH: 38 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: representative sequence from a cloned knottin library <400> SEQUENCE: 147 Gly Ser Asp Ile Ser Cys Glu Pro Gly Ser Thr His Arg Asp Arg Cys 1 5 10 15 Asn Thr Cys Arg Cys Ser Ala Asp Gly Arg Ser Arg Ala Cys Thr Leu 20 25 30 Arg Ala Cys Pro Asn Gln 35 <210> SEQ ID NO 148 <211> LENGTH: 38 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: representative sequence from a cloned knottin library <400> SEQUENCE: 148 Gly Ser Glu Asp Ser Cys Glu Pro Gly Trp Thr Gln Arg Met Arg Cys 1 5 10 15 Asn Thr Cys Arg Cys Thr Ala Asp Gly Arg Ser Ala Ala Cys Thr Leu 20 25 30 Arg Ala Cys Pro Asn Gln 35 <210> SEQ ID NO 149 <211> LENGTH: 38 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: representative sequence from a cloned knottin library

<400> SEQUENCE: 149 Gly Ser Glu Ile Ser Cys Glu Pro Gly Arg Thr Phe Arg Asp Arg Cys 1 5 10 15 Asn Thr Cys Arg Cys Gly Ala Asp Gly Arg Ser Ala Ala Cys Thr Leu 20 25 30 His His Cys Ile Tyr Trp 35 <210> SEQ ID NO 150 <211> LENGTH: 38 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: representative sequence from a cloned knottin library <400> SEQUENCE: 150 Gly Ser Glu Val Ser Cys Glu Pro Gly Arg Thr Phe Arg Ser Arg Cys 1 5 10 15 Asn Asp Cys Val Cys Gly Ala Asp Gly Arg His Ala Ala Cys Thr Ile 20 25 30 Arg Ala Cys Pro Asn Gln 35 <210> SEQ ID NO 151 <211> LENGTH: 38 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: representative sequence from a cloned knottin library <400> SEQUENCE: 151 Gly Ser Glu Ile Ser Cys Glu Pro Gly Arg Thr Phe Arg Asp Arg Cys 1 5 10 15 Asn Thr Cys Arg Cys Gly Ala Asp Gly Arg Ser Ala Ala Cys Thr Leu 20 25 30 Val Phe Cys His Glu Asp 35 <210> SEQ ID NO 152 <211> LENGTH: 38 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: representative sequence from a cloned knottin library <400> SEQUENCE: 152 Gly Ser Glu Ile Ser Cys Glu Pro Trp Arg Thr Phe Arg Asp Arg Cys 1 5 10 15 Asn Thr Cys Arg Cys Gly Ala Asp Gly Arg Gly Ala Ala Cys Thr Leu 20 25 30 Val Ile Cys Gly Met Gln 35 <210> SEQ ID NO 153 <211> LENGTH: 38 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: representative sequence from a cloned knottin library <400> SEQUENCE: 153 Gly Ser Glu Ile Ser Cys Glu Pro Gly Arg Thr Phe Arg Asp Arg Cys 1 5 10 15 Asn Met Cys Gly Cys Gly Ala Asp Gly Arg Trp Ala Arg Cys Thr Arg 20 25 30 Arg Ala Cys Pro Asn Gln 35 <210> SEQ ID NO 154 <211> LENGTH: 38 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: representative sequence from a cloned knottin library <400> SEQUENCE: 154 Gly Ser Glu Ile Ser Cys Glu Pro Gly Arg Thr Phe Arg Asp Arg Cys 1 5 10 15 Asn Thr Cys Arg Cys Gly Ala Asp Gly Arg Ser Ala Ala Cys Thr Leu 20 25 30 Phe Thr Cys Thr Tyr Phe 35 <210> SEQ ID NO 155 <211> LENGTH: 38 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: representative sequence from a cloned knottin library <400> SEQUENCE: 155 Gly Ser Glu Ile Ser Cys Glu Pro Gly Arg Thr Trp Arg Asp Arg Cys 1 5 10 15 Asn Thr Cys Arg Cys Gly Ala Asp Gly Arg Ser Ala Ala Cys Thr Leu 20 25 30 Asn Gly Cys Leu Leu Gln 35 <210> SEQ ID NO 156 <211> LENGTH: 38 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: representative sequence from a cloned knottin library <400> SEQUENCE: 156 Gly Ser Glu Ile Ser Cys Glu Pro Gly Arg Thr Phe Arg Asp Arg Cys 1 5 10 15 Asn Thr Cys Arg Cys Gly Ala Asp Gly Arg Ser Ala Ala Cys Thr Leu 20 25 30 Ala Asn Cys Phe Phe Ala 35 <210> SEQ ID NO 157 <211> LENGTH: 178 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 157 Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser Lys Val 1 5 10 15 Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe Gln Gly Lys Trp Tyr 20 25 30 Val Val Gly Leu Ala Gly Asn Ala Ile Leu Arg Glu Asp Lys Asp Pro 35 40 45 Gln Lys Met Tyr Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys Ser Tyr 50 55 60 Asn Val Thr Ser Val Leu Phe Arg Lys Lys Lys Cys Asp Tyr Trp Ile 65 70 75 80 Arg Thr Phe Val Pro Gly Cys Gln Pro Gly Glu Phe Thr Leu Gly Asn 85 90 95 Ile Lys Ser Tyr Pro Gly Leu Thr Ser Tyr Leu Val Arg Val Val Ser 100 105 110 Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys Lys Val Ser Gln 115 120 125 Asn Arg Glu Tyr Phe Lys Ile Thr Leu Tyr Gly Arg Thr Lys Glu Leu 130 135 140 Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser Leu Gly 145 150 155 160 Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile Asp Gln Cys Ile 165 170 175 Asp Gly <210> SEQ ID NO 158 <211> LENGTH: 178 <212> TYPE: PRT <213> ORGANISM: Pan troglodytes <400> SEQUENCE: 158 Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser Lys Val 1 5 10 15 Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe Gln Gly Lys Trp Tyr 20 25 30 Val Val Gly Leu Ala Gly Asn Ala Ile Leu Arg Glu Asp Lys Asp Pro 35 40 45 Gln Lys Met Tyr Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys Ser Tyr 50 55 60 Asn Val Thr Ser Val Leu Phe Arg Lys Lys Lys Cys Asp Tyr Trp Ile 65 70 75 80 Arg Thr Phe Val Pro Gly Arg Gln Pro Gly Glu Phe Thr Leu Gly Asn 85 90 95 Ile Lys Ser Tyr Pro Gly Leu Thr Ser Tyr Leu Val Arg Val Val Ser 100 105 110 Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys Lys Val Ser Gln 115 120 125 Asn Arg Glu Tyr Phe Lys Ile Thr Leu Tyr Gly Arg Thr Lys Glu Leu 130 135 140 Thr Ser Glu Leu Gln Glu Asn Phe Ile Arg Phe Ser Lys Ser Leu Gly 145 150 155 160 Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile Asp Gln Cys Ile 165 170 175 Asp Gly <210> SEQ ID NO 159 <211> LENGTH: 180 <212> TYPE: PRT <213> ORGANISM: Gorilla gorilla <400> SEQUENCE: 159 Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser Lys Val 1 5 10 15 Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe Gln Gly Lys Trp Tyr 20 25 30

Val Val Gly Leu Ala Gly Asn Ala Ile Leu Arg Glu Asp Lys Asp Pro 35 40 45 Gln Lys Met Tyr Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys Ser Tyr 50 55 60 Asn Val Thr Ser Val Leu Phe Arg Glu Lys Ala Gln Lys Cys Asp Tyr 65 70 75 80 Trp Ile Arg Thr Phe Val Pro Gly Ser Gln Pro Gly Glu Phe Thr Leu 85 90 95 Gly Asn Ile Lys Ser Tyr Pro Gly Leu Thr Ser Tyr Leu Val Arg Val 100 105 110 Val Ser Thr Asn Tyr Asn Gln His Ala Met Val Phe Phe Lys Lys Val 115 120 125 Ser Gln Asn Arg Glu Tyr Phe Lys Ile Thr Leu Tyr Gly Arg Thr Lys 130 135 140 Glu Leu Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser 145 150 155 160 Leu Gly Leu Pro Glu Asn His Ile Val Phe Pro Val Pro Ile Asp Gln 165 170 175 Cys Ile Asp Gly 180 <210> SEQ ID NO 160 <211> LENGTH: 178 <212> TYPE: PRT <213> ORGANISM: Pongo pygmaeus <400> SEQUENCE: 160 Gln Asp Ser Thr Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser Lys Val 1 5 10 15 Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe Gln Gly Lys Trp Tyr 20 25 30 Val Val Gly Leu Ala Gly Asn Ala Ile Arg Arg Glu Asp Lys Asp Ser 35 40 45 Gln Lys Met Tyr Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys Ser Tyr 50 55 60 Asn Val Thr Ser Val Leu Phe Arg Lys Lys Lys Cys Asp Tyr Trp Ile 65 70 75 80 Arg Thr Phe Val Pro Gly Ser Gln Pro Gly Glu Phe Thr Leu Gly Asn 85 90 95 Thr Lys Gly Tyr Pro Gly Leu Thr Ser Tyr Leu Val Arg Val Val Ser 100 105 110 Thr Asn Tyr Asn Gln Tyr Ala Met Val Phe Phe Lys Lys Val Ser Gln 115 120 125 Asn Arg Glu Tyr Phe Lys Ile Thr Leu Tyr Gly Arg Thr Lys Glu Leu 130 135 140 Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser Leu Gly 145 150 155 160 Leu Pro Glu Asn His Ile Val Phe Pro Ala Pro Ile Asp Gln Cys Ile 165 170 175 Asp Gly <210> SEQ ID NO 161 <211> LENGTH: 178 <212> TYPE: PRT <213> ORGANISM: Macaca mulatta <400> SEQUENCE: 161 Gln Asp Ser Ser Ser Asp Leu Ile Pro Ala Pro Pro Leu Ser Lys Val 1 5 10 15 Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe Gln Gly Lys Trp Tyr 20 25 30 Val Val Gly Leu Ser Gly Asn Ala Val Gly Arg Lys Asp Glu Ala Pro 35 40 45 Leu Lys Met Tyr Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys Ser Tyr 50 55 60 Asn Val Thr Ser Ile Leu Phe Arg Lys Glu Lys Cys Asp Tyr Trp Ile 65 70 75 80 Arg Thr Phe Val Pro Gly Ser Gln Pro Gly Glu Phe Thr Leu Gly Asn 85 90 95 Ile Gln Asn His Pro Gly Leu Thr Ser Tyr Val Val Arg Val Val Ser 100 105 110 Thr Asn Tyr Lys Gln Tyr Ala Met Val Phe Phe Lys Lys Val Ser Gln 115 120 125 Asn Lys Glu Tyr Phe Lys Ile Thr Leu Tyr Gly Arg Thr Lys Glu Leu 130 135 140 Thr Ser Glu Leu Lys Glu Asn Phe Ile Arg Phe Ser Lys Ser Leu Gly 145 150 155 160 Leu Pro Glu Asn His Ile Val Phe Ser Val Pro Ile Asp Gln Cys Ile 165 170 175 Asn Gly <210> SEQ ID NO 162 <211> LENGTH: 179 <212> TYPE: PRT <213> ORGANISM: Callithrix jacchus <400> SEQUENCE: 162 Gln Asp Ser Pro Ser Pro Leu Ile Pro Ala Pro Pro Leu Ser Lys Val 1 5 10 15 Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe Gln Gly Lys Trp Tyr 20 25 30 Val Val Gly Leu Ala Gly Asn Ala Ile Arg Arg Glu Asp Gln Asp Ser 35 40 45 Leu Lys Met Tyr Ala Thr Ile Tyr Glu Leu Lys Glu Asp Lys Ser Tyr 50 55 60 Asn Val Thr Ser Val Leu Phe Arg Lys Ala Gln Lys Cys Asp Tyr Trp 65 70 75 80 Ile Arg Thr Phe Val Pro Ser Ser Arg Pro Gly Glu Phe Lys Leu Gly 85 90 95 Asn Ile Glu Ser His Pro Gly Leu Thr Ser Tyr Ile Val Arg Val Val 100 105 110 Asn Thr Asp Tyr Lys Gln His Ala Met Val Phe Phe Met Lys Ala Ser 115 120 125 His Asn Arg Lys Tyr Phe Lys Val Thr Leu Tyr Gly Arg Thr Lys Glu 130 135 140 Leu Thr Ser Asp Leu Lys Glu Asn Phe Thr Ser Phe Ser Lys Ser Leu 145 150 155 160 Gly Leu Thr Glu Asn His Ile Ile Phe Pro Val Pro Ile Asp Gln Cys 165 170 175 Ile Asp Gly <210> SEQ ID NO 163 <211> LENGTH: 180 <212> TYPE: PRT <213> ORGANISM: Mus musculus <400> SEQUENCE: 163 Gln Asp Ser Thr Gln Asn Leu Ile Pro Ala Pro Ser Leu Leu Thr Val 1 5 10 15 Pro Leu Gln Pro Asp Phe Arg Ser Asp Gln Phe Arg Gly Arg Trp Tyr 20 25 30 Val Val Gly Leu Ala Gly Asn Ala Val Gln Lys Lys Thr Glu Gly Ser 35 40 45 Phe Thr Met Tyr Ser Thr Ile Tyr Glu Leu Gln Glu Asn Asn Ser Tyr 50 55 60 Asn Val Thr Ser Ile Leu Val Arg Asp Gln Asp Gln Gly Cys Arg Tyr 65 70 75 80 Trp Ile Arg Thr Phe Val Pro Ser Ser Arg Ala Gly Gln Phe Thr Leu 85 90 95 Gly Asn Met His Arg Tyr Pro Gln Val Gln Ser Tyr Asn Val Gln Val 100 105 110 Ala Thr Thr Asp Tyr Asn Gln Phe Ala Met Val Phe Phe Arg Lys Thr 115 120 125 Ser Glu Asn Lys Gln Tyr Phe Lys Ile Thr Leu Tyr Gly Arg Thr Lys 130 135 140 Glu Leu Ser Pro Glu Leu Lys Glu Arg Phe Thr Arg Phe Ala Lys Ser 145 150 155 160 Leu Gly Leu Lys Asp Asp Asn Ile Ile Phe Ser Val Pro Thr Asp Gln 165 170 175 Cys Ile Asp Asn 180 <210> SEQ ID NO 164 <211> LENGTH: 178 <212> TYPE: PRT <213> ORGANISM: Rattus norvegicus <400> SEQUENCE: 164 Gln Asp Ser Thr Gln Asn Leu Ile Pro Ala Pro Pro Leu Ile Ser Val 1 5 10 15 Pro Leu Gln Pro Gly Phe Trp Thr Glu Arg Phe Gln Gly Arg Trp Phe 20 25 30 Val Val Gly Leu Ala Ala Asn Ala Val Gln Lys Glu Arg Gln Ser Arg 35 40 45 Phe Thr Met Tyr Ser Thr Ile Tyr Glu Leu Gln Glu Asp Asn Ser Tyr 50 55 60 Asn Val Thr Ser Ile Leu Val Arg Gly Gln Gly Cys Arg Tyr Trp Ile 65 70 75 80 Arg Thr Phe Val Pro Ser Ser Arg Pro Gly Gln Phe Thr Leu Gly Asn 85 90 95 Ile His Ser Tyr Pro Gln Ile Gln Ser Tyr Asp Val Gln Val Ala Asp 100 105 110 Thr Asp Tyr Asp Gln Phe Ala Met Val Phe Phe Gln Lys Thr Ser Glu 115 120 125 Asn Lys Gln Tyr Phe Lys Val Thr Leu Tyr Gly Arg Thr Lys Gly Leu 130 135 140 Ser Asp Glu Leu Lys Glu Arg Phe Val Ser Phe Ala Lys Ser Leu Gly 145 150 155 160 Leu Lys Asp Asn Asn Ile Val Phe Ser Val Pro Thr Asp Gln Cys Ile 165 170 175 Asp Asn <210> SEQ ID NO 165 <211> LENGTH: 181 <212> TYPE: PRT

<213> ORGANISM: Ochotona princeps <400> SEQUENCE: 165 Gln Glu Leu Thr Thr Asp Leu Ile Pro Val Pro Ser Leu Arg Lys Ile 1 5 10 15 His Val Gln Lys Asn Phe Gln Ser Asp Gln Phe Gln Gly Lys Trp Tyr 20 25 30 Val Val Gly Leu Ala Gly Asn Asn Ile His Asn Ser Asp Gln Glu His 35 40 45 Gln Gln Met Tyr Ser Thr Thr Tyr Glu Leu Lys Glu Asp Gly Ser Tyr 50 55 60 Asn Val Thr Ser Thr Leu Leu Arg Gln Arg Asn Gln Gln Cys Asp His 65 70 75 80 Trp Ile Arg Thr Phe Val Pro Gly Ser Lys Leu Gly His Phe Asn Leu 85 90 95 Gly Asn Ile Lys Ser Tyr Pro Thr Leu Lys Ser Tyr Leu Ile Arg Val 100 105 110 Val Thr Thr Asp Tyr Asn Gln Phe Ala Ile Val Phe Phe Arg Lys Val 115 120 125 Tyr Lys Asn Asn Lys Lys Phe Phe Lys Ile Val Leu Tyr Gly Arg Thr 130 135 140 Lys Glu Leu Ser Pro Glu Leu Arg Gly Arg Phe Thr Ser Phe Ala Lys 145 150 155 160 Thr Leu Gly Leu Thr Asp Asn His Ile Val Phe Pro Ala Pro Ile Gly 165 170 175 Gln Cys Ile Asp Asp 180 <210> SEQ ID NO 166 <211> LENGTH: 178 <212> TYPE: PRT <213> ORGANISM: Oryctolagus cuniculus <400> SEQUENCE: 166 Gln Asp Pro Thr Pro Lys Leu Ile Pro Ala Pro Ser Leu Arg Arg Val 1 5 10 15 Pro Leu Gln Arg Asn Phe Gln Asp Glu Gln Phe Gln Gly Lys Trp Tyr 20 25 30 Val Val Gly Leu Ala Gly Asn Ala Val Gln Lys Arg Glu Glu Gly Gln 35 40 45 Glu Pro Met Tyr Ser Thr Thr Tyr Glu Leu Asn Glu Asp Arg Ser Phe 50 55 60 Asn Val Thr Ser Thr Leu Leu Arg Asp Gln Arg Cys Asp His Trp Ile 65 70 75 80 Arg Thr Phe Val Pro Thr Ser Arg Pro Gly Gln Tyr Asn Leu Gly Asn 85 90 95 Ile Lys Ser Tyr Pro Gly Val Lys Asn Tyr Ile Val Arg Val Val Ala 100 105 110 Thr Asp Tyr Ser Gln Tyr Ala Met Met Phe Phe Arg Lys Gly Ser Arg 115 120 125 Asn Lys Gln Phe Phe Lys Thr Thr Leu Tyr Gly Arg Thr Lys Glu Leu 130 135 140 Ser Pro Glu Leu Arg Glu Arg Phe Thr Arg Phe Ala Lys Ser Leu Gly 145 150 155 160 Leu Pro Asp Asp Arg Ile Val Phe Pro Thr Pro Ile Asp Gln Cys Ile 165 170 175 Asp Asp <210> SEQ ID NO 167 <211> LENGTH: 179 <212> TYPE: PRT <213> ORGANISM: Bos taurus <400> SEQUENCE: 167 Arg Ser Ser Ser Ser Arg Leu Leu Arg Ala Pro Pro Leu Ser Arg Ile 1 5 10 15 Pro Leu Gln Pro Asn Phe Gln Ala Asp Gln Phe Gln Gly Lys Trp Tyr 20 25 30 Thr Val Gly Val Ala Gly Asn Ala Ile Lys Lys Glu Glu Gln Asp Pro 35 40 45 Leu Lys Met Tyr Ser Ser Asn Tyr Glu Leu Lys Glu Asp Gly Ser Tyr 50 55 60 Asn Val Thr Ser Ile Leu Leu Lys Asp Asp Leu Cys Asp Tyr Trp Ile 65 70 75 80 Arg Thr Phe Val Pro Ser Ser Gln Pro Gly Gln Phe Thr Leu Gly Asn 85 90 95 Ile Lys Ser Tyr Arg Gly Ile Arg Ser Tyr Thr Val Arg Val Val Asn 100 105 110 Thr Asp Tyr Asn Gln Phe Ala Ile Val Tyr Phe Lys Lys Val Gln Arg 115 120 125 Lys Lys Thr Tyr Phe Lys Ile Thr Leu Tyr Gly Arg Thr Lys Glu Leu 130 135 140 Thr Pro Glu Val Arg Glu Asn Phe Ile Asn Phe Ala Lys Ser Leu Gly 145 150 155 160 Leu Thr Asp Asp His Ile Val Phe Thr Val Pro Ile Asp Arg Cys Ile 165 170 175 Asp Asp Gln <210> SEQ ID NO 168 <211> LENGTH: 179 <212> TYPE: PRT <213> ORGANISM: Sus scrofa <400> SEQUENCE: 168 Gln Gly Thr Ile Pro Asn Trp Ile Pro Ala Pro Pro Leu Ser Lys Val 1 5 10 15 Pro Leu Gln Pro Asn Phe Gln Ala Asp Gln Phe Gln Gly Lys Trp Tyr 20 25 30 Val Val Gly Leu Ala Gly Asn Ala Val Lys Lys Glu Glu Gln Gly Arg 35 40 45 Phe Lys Met Tyr Thr Thr Thr Tyr Glu Leu Lys Glu Asp Gly Ser Tyr 50 55 60 Asn Val Ile Ser Thr Leu Leu Arg Gly Gln Leu Cys Asp Asn Trp Ile 65 70 75 80 Arg Thr Phe Val Pro Ser Leu Gln Pro Gly Gln Phe Lys Leu Gly Asp 85 90 95 Ile Lys Lys Tyr Ser Gly Leu Gln Ser Tyr Val Val Arg Val Val Ser 100 105 110 Thr Asn Tyr Ser Gln Phe Ala Ile Val Phe Phe Lys Lys Val Ser Asn 115 120 125 Asn Gln Glu Tyr Phe Lys Thr Thr Leu Tyr Gly Arg Thr Lys Val Leu 130 135 140 Ser Pro Glu Leu Lys Glu Asn Phe Val Arg Phe Ala Lys Ser Leu Gly 145 150 155 160 Leu Ser Asp Asp Asn Ile Ile Phe Pro Val Ala Ile Asp Gln Cys Ile 165 170 175 Asp Gly Gln <210> SEQ ID NO 169 <211> LENGTH: 181 <212> TYPE: PRT <213> ORGANISM: Tursiops truncatus <400> SEQUENCE: 169 Gln Asp Ser Thr Pro Asn Leu Ile Pro Ala Pro Pro Leu Phe Arg Val 1 5 10 15 Pro Leu Gln Pro Asn Phe Gln Pro Asp Gln Phe Gln Gly Lys Trp Tyr 20 25 30 Ile Val Gly Leu Ala Gly Asn Ala Phe Lys Lys Glu Lys Gln Gly Gln 35 40 45 Phe Lys Met Tyr Ala Thr Thr Tyr Glu Leu Lys Glu Asp Arg Ser Tyr 50 55 60 Asn Val Thr Ser Ala Leu Leu Arg Gly Lys Thr Gln Arg Cys Asp His 65 70 75 80 Trp Ile Arg Thr Phe Val Pro Ser Ser Arg Pro Gly Gln Phe Thr Leu 85 90 95 Gly Asn Ile Lys Gly Phe Pro Gly Val Gln Ser Tyr Thr Val Arg Val 100 105 110 Ala Thr Thr Asn Tyr Asn Gln Phe Ala Ile Val Tyr Phe Lys Lys Val 115 120 125 Tyr Lys Asn Gln Glu Tyr Phe Lys Thr Thr Leu Tyr Gly Arg Thr Lys 130 135 140 Glu Leu Thr Pro Gln Leu Lys Glu Asn Phe Ile His Phe Ala Lys Ser 145 150 155 160 Leu Gly Leu Thr Asp Glu Tyr Ile Leu Phe Pro Val Pro Ile Asp Lys 165 170 175 Cys Ile Asp Asp Gln 180 <210> SEQ ID NO 170 <211> LENGTH: 179 <212> TYPE: PRT <213> ORGANISM: Equus caballus <400> SEQUENCE: 170 Arg Asp Pro Ala Pro Lys Leu Ile Pro Ala Pro Pro Leu Asp Arg Val 1 5 10 15 Pro Leu Gln Pro Asp Phe Lys Asp Asp Gln Phe Gln Gly Lys Trp Tyr 20 25 30 Val Val Gly Val Ala Gly Asn Ala Phe Lys Lys Glu Glu Gln Gly Gln 35 40 45 Phe Thr Met Tyr Thr Thr Thr Tyr Glu Leu Lys Glu Asp His Ser Tyr 50 55 60 Asn Val Thr Ser Ile Leu Leu Arg Asp Gln Asn Cys Asp His Trp Ile 65 70 75 80 Arg Thr Phe Ile Pro Ser Ser Gln Pro Gly Gln Phe Asn Leu Gly Asp 85 90 95 Ile Lys Arg Tyr Phe Gly Val Gln Ser Tyr Ile Val Arg Val Ala Asp 100 105 110 Thr Asp Tyr Asn Gln Phe Ala Ile Val Phe Phe Arg Lys Val Tyr Lys 115 120 125 Asn Gln Glu Tyr Phe Lys Thr Thr Leu Tyr Arg Arg Thr Lys Glu Leu 130 135 140 Thr Pro Glu Leu Arg Glu Lys Phe Ile Ser Phe Ala Lys Ser Leu Gly 145 150 155 160

Leu Thr Asp Asp His Ile Ile Phe Pro Val Pro Ile Asp Gln Cys Ile 165 170 175 Asp Glu Glu <210> SEQ ID NO 171 <211> LENGTH: 178 <212> TYPE: PRT <213> ORGANISM: Microcebus murinus <400> SEQUENCE: 171 Gln Asp Ser Lys Glu Lys Leu Ile Pro Ala Pro Pro Leu Leu Arg Val 1 5 10 15 Pro Leu Gln Pro Asp Phe Gln Asp Asp Gln Phe Arg Glu Thr Ser Trp 20 25 30 Pro Arg Gly Ser Lys Met Lys Glu Thr Pro Ala Gly Ser Arg Asp Ala 35 40 45 Gly Thr Gly Trp Ala Thr Thr Tyr Glu Leu Lys Asp His Ser Tyr Asn 50 55 60 Val Thr Ser Thr Leu Leu Arg Gln Asn Gly Lys Cys Asp Tyr Trp Ile 65 70 75 80 Arg Thr Phe Val Leu Thr Ser Gln Pro Gly Gln Phe Ala Leu Gly Asn 85 90 95 Ile Asn Arg Tyr Pro Gly Ile Gln Ser Tyr Thr Val Arg Val Val Thr 100 105 110 Thr Asn Tyr Asn Gln Phe Ala Ile Val Phe Phe Lys Lys Val Ser Glu 115 120 125 Asn Lys Glu Tyr Phe Lys Thr Thr Leu Tyr Gly Arg Thr Lys Glu Leu 130 135 140 Pro Pro Glu Leu Lys Glu Asn Phe Ile Arg Phe Ala Lys Ser Leu Gly 145 150 155 160 Leu Thr Glu Asp His Ile Ile Tyr Pro Val Pro Ile Asp Gln Cys Ile 165 170 175 Asp Asp <210> SEQ ID NO 172 <211> LENGTH: 178 <212> TYPE: PRT <213> ORGANISM: Loxodonta africana <400> SEQUENCE: 172 Gln Thr His Ser Pro Thr Leu Ile Pro Ala Pro Pro Leu Leu Arg Val 1 5 10 15 Pro Leu Gln Pro Asp Phe Gln Asp Asp Lys Phe Gln Gly Lys Trp Tyr 20 25 30 Val Ile Gly Leu Ala Gly Asn Ala Val Glu Lys Lys Glu Gln Gly Gln 35 40 45 Phe Lys Met Tyr Thr Thr Thr Tyr Glu Leu Lys Glu Asp Gly Ser Tyr 50 55 60 Asn Val Thr Ser Thr Leu Leu Gln Glu Asp Gly Lys Cys Ser Tyr Trp 65 70 75 80 Ile Arg Thr Phe Val Pro Ser Phe Gln Pro Gly Gln Phe Asn Leu Gly 85 90 95 Asn Ile Lys Asn Phe Pro Gly Leu Gln Ser Tyr Thr Val Arg Val Thr 100 105 110 Ala Thr Asn Tyr Asn Gln Phe Ala Ile Val Phe Phe Lys Lys Val Ser 115 120 125 Lys Asn Gly Glu Tyr Phe Lys Thr Thr Leu Tyr Gly Arg Thr Lys Glu 130 135 140 Leu Thr Pro Glu Leu Lys Glu Arg Phe Ile Arg Phe Ala Lys Ser Leu 145 150 155 160 Gly Leu Ser Asp His Ile Ile Phe Pro Val Pro Ile Asp Arg Cys Ile 165 170 175 Asp Asp <210> SEQ ID NO 173 <211> LENGTH: 179 <212> TYPE: PRT <213> ORGANISM: Procavia capensis <400> SEQUENCE: 173 Gln Glu Pro Thr Pro Thr Leu Ile Pro Ala Pro Pro Leu Ser Ser Ile 1 5 10 15 Pro Leu Lys Pro Asn Phe His Asn Asp Lys Phe Gln Gly Lys Trp Tyr 20 25 30 Val Val Gly Val Ala Gly Asn Ala Ile Thr Lys Glu Lys Asp Pro Ser 35 40 45 Leu Met Tyr Thr Thr Thr Tyr Glu Leu Arg Asp Asp Gly Ser Tyr Asn 50 55 60 Val Thr Ser Thr Gln Phe Arg Glu Lys Ile Asn Cys Thr His Trp Thr 65 70 75 80 Arg Thr Phe Val Pro Thr Ser Gln Pro Gly Gln Phe Ser Leu Gly Asn 85 90 95 Ile Asp Lys Tyr Pro His Leu Ser Ser Tyr Thr Val Arg Val Thr Ala 100 105 110 Thr Asn Tyr Asn Tyr Phe Ala Ile Val Tyr Phe Lys Lys Val Ser Lys 115 120 125 Asn Gln Glu Tyr Phe Lys Thr Thr Leu Tyr Lys Arg Ile Lys Lys Leu 130 135 140 Thr His Gly Leu Lys Lys His Phe Ile Gln Phe Ala Lys Ser Leu Gly 145 150 155 160 Leu Pro Asp Asn His Ile Thr Phe Leu Val Pro Thr Asp Arg Cys Ile 165 170 175 Asp Asp Ala <210> SEQ ID NO 174 <211> LENGTH: 178 <212> TYPE: PRT <213> ORGANISM: Canis familiaris <400> SEQUENCE: 174 Gln Asp Ser Thr Pro Ser Leu Ile Pro Ala Pro Pro Pro Leu Lys Val 1 5 10 15 Pro Leu Gln Pro Asp Phe Gln His Asp Gln Phe Gln Gly Lys Trp Tyr 20 25 30 Val Ile Gly Ile Ala Gly Asn Ile Leu Lys Lys Glu Gly His Gly Gln 35 40 45 Leu Lys Met Tyr Thr Thr Thr Tyr Glu Leu Lys Asp Asp Gln Ser Tyr 50 55 60 Asn Val Thr Ser Thr Leu Leu Arg Asn Glu Arg Cys Asp Tyr Trp Asn 65 70 75 80 Arg Asp Phe Val Pro Ser Phe Gln Pro Gly Gln Phe Ser Leu Gly Asp 85 90 95 Ile Gln Leu Tyr Pro Gly Val Gln Ser Tyr Leu Val Gln Val Val Ala 100 105 110 Thr Asn Tyr Asn Gln Tyr Ala Leu Val Tyr Phe Arg Lys Val Tyr Lys 115 120 125 Ser Gln Glu Tyr Phe Lys Ile Thr Leu Tyr Gly Arg Thr Lys Glu Leu 130 135 140 Pro Leu Glu Leu Lys Lys Glu Phe Ile Arg Phe Ala Lys Ser Ile Gly 145 150 155 160 Leu Thr Glu Asp His Ile Ile Phe Pro Val Pro Ile Asp Gln Cys Ile 165 170 175 Asp Glu <210> SEQ ID NO 175 <211> LENGTH: 427 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: amino acid sequence of a light chain antibody fusion with Scn <400> SEQUENCE: 175 Met Asp Phe Gln Val Gln Ile Phe Ser Phe Leu Leu Ile Ser Ala Ser 1 5 10 15 Val Ile Met Ser Arg Gly Asp Ile Val Met Thr Gln Ala Ala Pro Ser 20 25 30 Val Pro Val Thr Pro Gly Glu Ser Val Ser Ile Ser Cys Arg Ser Thr 35 40 45 Lys Ser Leu Leu His Ser Asn Gly Asn Thr Tyr Leu Tyr Trp Phe Leu 50 55 60 Gln Arg Pro Gly Gln Ser Pro Gln Arg Leu Ile Tyr Tyr Met Ser Asn 65 70 75 80 Leu Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Arg Gly Ser Gly Thr 85 90 95 Asp Phe Thr Leu Arg Ile Ser Arg Val Glu Ala Glu Asp Ala Gly Val 100 105 110 Tyr Tyr Cys Met Gln Ser Leu Glu Tyr Pro Tyr Thr Phe Gly Gly Gly 115 120 125 Thr Lys Leu Glu Ile Lys Arg Ala Asp Ala Ala Pro Thr Val Ser Ile 130 135 140 Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly Gly Ala Ser Val Val 145 150 155 160 Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile Asn Val Lys Trp Lys 165 170 175 Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu Asn Ser Trp Thr Asp 180 185 190 Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser Ser Thr Leu Thr Leu 195 200 205 Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr Thr Cys Glu Ala Thr 210 215 220 His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser Phe Asn Arg Asn Glu 225 230 235 240 Cys Gly Arg Gly Gly Ser Gly Gly Ser Gln Asp Ser Thr Ser Asp Leu 245 250 255 Ile Pro Ala Pro Pro Leu Ser Lys Val Pro Leu Gln Gln Asn Phe Gln 260 265 270 Asp Asn Gln Phe Gln Gly Lys Trp Tyr Val Val Gly Leu Ala Gly Asn 275 280 285 Ala Ile Leu Arg Glu Asp Lys Asp Pro Gln Lys Met Tyr Ala Thr Ile 290 295 300 Tyr Glu Leu Lys Glu Asp Lys Ser Tyr Asn Val Thr Ser Val Leu Phe 305 310 315 320 Arg Lys Lys Lys Cys Asp Tyr Trp Ile Arg Thr Phe Val Pro Gly Ser 325 330 335

Gln Pro Gly Glu Phe Thr Leu Gly Asn Ile Lys Ser Tyr Pro Gly Leu 340 345 350 Thr Ser Tyr Leu Val Arg Val Val Ser Thr Asn Tyr Asn Gln His Ala 355 360 365 Met Val Phe Phe Lys Lys Val Ser Gln Asn Arg Glu Tyr Phe Lys Ile 370 375 380 Thr Leu Tyr Gly Arg Thr Lys Glu Leu Thr Ser Glu Leu Lys Glu Asn 385 390 395 400 Phe Ile Arg Phe Ser Lys Ser Leu Gly Leu Pro Glu Asn His Ile Val 405 410 415 Phe Pro Val Pro Ile Asp Gln Cys Ile Asp Gly 420 425 <210> SEQ ID NO 176 <211> LENGTH: 46 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: sequence showing NotI cut for SEQ ID NO: 1 <400> SEQUENCE: 176 aacctgtatt ttcagggagg cgctaaggat cccggaccgc ctctcc 46

Claims

1. A method for producing a fusion protein, the method comprising expressing, in a cell, a fusion protein, the fusion protein comprising human siderocalin and trastuzumab or a fragment thereof.

2. A method of claim 1, wherein the expressing utilizes the parental cloning construct of SEQ ID NO: 37.

3. A method of claim 1, wherein the fusion protein comprises trastuzumab.

4. A method of claim 1, wherein the fusion protein comprises a fragment of trastuzumab.

5. A method of claim 4, wherein the fragment is a Fab fragment.

6. A method of claim 1, further comprising associating the human siderocalin with a radionuclide.

7. A method of claim 5, wherein the radionuclide is selected from Sc-47, Ga-67, Y-90, Ag-111, In-111, Sm-153, Tb-166, Lu-177, Bi-213, Ac-225, Cu-64, Cu-67, Pd-109, Ag-111, Re-186, Re-188, Pt-197, Bi-212, Bi-213, Pb-212 or Ra-223.

8. A fusion protein produced by the method of claim 1.

9. A fusion protein of claim 7, wherein the fusion protein comprises trastuzumab.

10. A fusion protein of claim 7, wherein the fusion protein comprises a fragment of trastuzumab.

11. A fusion protein of claim 10, wherein the fragment is a Fab fragment.

12. A fusion protein of claim 7, wherein the human siderocalin is associated with a radionuclide.

13. A fusion protein of claim 12, wherein the radionuclide is selected from Sc-47, Ga-67, Y-90, Ag-111, In-111, Sm-153, Tb-166, Lu-177, Bi-213, Ac-225, Cu-64, Cu-67, Pd-109, Ag-111, Re-186, Re-188, Pt-197, Bi-212, Bi-213, Pb-212 or Ra-223.

14. A method for producing a fusion protein, the method comprising expressing, in a cell, a fusion protein, the fusion protein comprising human siderocalin and infliximab or a fragment thereof, adalimumab or a fragment thereof, OKT3 or a fragment thereof, or Fc.

15. A method of claim 14, wherein the expressing utilizes the parental cloning construct of SEQ ID NO: 37.

16. A method of claim 14, wherein the fusion protein comprises infliximab, adalimumab, OKT3, or Fc.

17. A method of claim 14, wherein the fusion protein comprises a fragment of infliximab, a fragment of adalimumab, or a fragment of OKT3.

18. A method of claim 17, wherein the fragment is a Fab fragment.

19. A method of claim 14, further comprising associating the human siderocalin with a radionuclide.

20. A method of claim 19, wherein the radionuclide is selected from Sc-47, Ga-67, Y-90, Ag-111, In-111, Sm-153, Tb-166, Lu-177, Bi-213, Ac-225, Cu-64, Cu-67, Pd-109, Ag-111, Re-186, Re-188, Pt-197, Bi-212, Bi-213, Pb-212 or Ra-223.